Review the data at the 2023 ASH Annual Meeting & Exposition.

THERE’S SO MUCH TO DISCOVER

Come visit us December 9-12 at booth #1033 or visit DARZALEXHCP.com
Call for Editor Nominations
ASH Seeks Inaugural Editor-in-Chief for a New Journal

ASH has begun the process of selecting an inaugural editor to lead a new open access journal focused on global hematology, recently approved for addition to the Society's peer-reviewed Blood journals portfolio beginning in 2024.

Blood Global Hematology is a new open access, peer-reviewed journal which aims to publish high-quality research, local adaptations of clinical guidelines, and opinion articles that improve the lives of patients in low- and middle-income countries. It will offer an online, rapid publishing venue for research focused on hematology-specific healthcare delivery in local or regional settings conducted in or focused on low- and middle-income countries and/or with a global reach and applicability. As part of the Blood journals portfolio, Blood Global Hematology will connect to the ASH mission of educating hematologists worldwide to improve patient care.

The inaugural editor-in-chief will begin work in the Spring of 2024 and will help establish the initial editorial team and peer review procedures. Candidates must have significant editorial experience, preferably as an editor of a peer-reviewed journal; a distinguished research record; broad and comprehensive knowledge of basic, translational, and clinical research; and a record of leadership in the community. Successful candidates should have an interest in developing innovative new content, knowledge of ASH programs and initiatives, experience coordinating international collaborations, and familiarity with international experts in the field to solicit relevant, high-quality articles.

Candidates must be ASH members in good standing with an MD, MD/PhD, or equivalent degree. The term is five years with the potential for one five-year extension. An honorarium will be provided.

ASH members may self-nominate for this position by submitting a cover letter, a CV, a brief description of previous editorial experience, and a vision statement for the journal. Nominations from international members are encouraged. Members are also welcome to nominate a colleague by submitting a brief informal endorsement. ASH will confirm the nominee's membership status and request submission of additional materials to complete the nomination. ASH prohibits members employed by a pharmaceutical or biomedical company from serving in an editorial position.

All submissions should be sent to EditorSearch@hematology.org by the deadline of 11:59 P.M. EST on December 20, 2023.
### Table of Contents

#### About ASH

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>ASH Executive and Program Committees</td>
<td>5</td>
</tr>
<tr>
<td>Reviewers of Abstracts and <em>Hematology 2023</em></td>
<td>8</td>
</tr>
<tr>
<td>Corporate Acknowledgements</td>
<td>11</td>
</tr>
<tr>
<td>Recipients of Awards</td>
<td>15</td>
</tr>
</tbody>
</table>

#### Guide to Navigating the Meeting

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>General Information</td>
<td>23</td>
</tr>
<tr>
<td>Diversity, Equity, and Inclusion at ASH</td>
<td>35</td>
</tr>
<tr>
<td>Non-CME Sessions</td>
<td>37</td>
</tr>
</tbody>
</table>

#### Meeting Schedule

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Day-At-A-Glance</td>
<td>41</td>
</tr>
</tbody>
</table>

#### Invited Speaker Sessions

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>General Sessions</td>
<td>65</td>
</tr>
<tr>
<td>Special Interest Sessions</td>
<td>67</td>
</tr>
<tr>
<td>Trainee Activities (Open to Trainees Only)</td>
<td>75</td>
</tr>
</tbody>
</table>

*continued on next page*
## Education Program

<table>
<thead>
<tr>
<th>Session Type</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Education Sessions</td>
<td>83</td>
</tr>
<tr>
<td>Education Spotlight Sessions</td>
<td>93</td>
</tr>
<tr>
<td>How I Treat: Bringing Science to Clinical Dilemmas (Ticketed Sessions)</td>
<td>95</td>
</tr>
</tbody>
</table>

## Scientific Program

<table>
<thead>
<tr>
<th>Session Type</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Scientific Sessions</td>
<td>101</td>
</tr>
<tr>
<td>Scientific Symposia</td>
<td>107</td>
</tr>
<tr>
<td>Scientific Spotlight Sessions</td>
<td>109</td>
</tr>
<tr>
<td>Scientific Workshops</td>
<td>113</td>
</tr>
<tr>
<td>ASH Poster Walks</td>
<td>117</td>
</tr>
<tr>
<td>Meet the Scientist (Ticketed Sessions)</td>
<td>119</td>
</tr>
</tbody>
</table>

## Abstract Sessions

<table>
<thead>
<tr>
<th>Session Type</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Scientific Categories</td>
<td>121</td>
</tr>
<tr>
<td>Oral Abstract Sessions</td>
<td>125</td>
</tr>
<tr>
<td>Poster Presentations</td>
<td>133</td>
</tr>
</tbody>
</table>

## Exhibitors

<table>
<thead>
<tr>
<th>Type of Exhibitor</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Satellite Symposia</td>
<td>139</td>
</tr>
<tr>
<td>Product Theaters</td>
<td>151</td>
</tr>
<tr>
<td>Industry Theaters</td>
<td>157</td>
</tr>
<tr>
<td>Company Showcases</td>
<td>159</td>
</tr>
<tr>
<td>Exhibitor Directory</td>
<td>161</td>
</tr>
</tbody>
</table>
AMERICAN SOCIETY OF HEMATOLOGY
EXECUTIVE COMMITTEE

STAFF LIAISONS:
Martha Liggett, Esq., mliggett@hematology.org
Matthew Gertzog, MBA, CAE, mgertzog@hematology.org
LaFaundra Neville Ingram, CAP, lneville@hematology.org

OFFICERS:
President: Robert A. Brodsky, MD
President-Elect: Mohandas Narla, DSc
Vice President: Belinda Avalos, MD
Secretary: Cynthia E. Dunbar, MD
Treasurer: Joseph Mikhael, MD, FRCP, MEd

COUNCILLORS:
Christopher R. Flowers, MD, MSc ('26)
Alison Loren, MD ('23)
Bob Löwenberg, MD, PhD ('23)
Charlotte Marie Niemeyer, MD ('26)
Sarah H. O’Brien, MD ('25)
Betty Pace, MD ('24)
Jamile M. Shammo, MD ('24)
Wendy Stock, MD ('25)
PROGRAM COMMITTEE

STAFF LIAISON:
Ana Velarde
E-mail: avelarde@hematology.org

Robert A. Brodsky, MD ('23) - Chairperson, President
Mohandas Narla, DSc ('23) - Ex-Officio: President-Elect
Joseph Mikhail, MD, FRCPC, MEd ('23) - Ex-Officio: Treasurer
Cynthia E. Dunbar, MD ('24) - Ex-Officio: Secretary
Belinda Avalos ('25) - Ex-Officio: Vice President
Nancy Berliner, MD ('24) - Liaison, Editor-in-Chief, Blood
Catherine M. Bollard, MD ('26) - Liaison, Blood Advances Editor-in-Chief
Jennifer R. Brown, MD, PhD ('23) - Liaison, Chair, Committee on Educational Affairs
Hetty Carraway, MD ('24) - Liaison, Chair, Committee on Training
Adam Cuker, MD ('23) - Liaison, Chair, Committee on Quality
Chancellor E. Donald, MD ('23) - Liaison, Chair, Committee on Practice
Aaron T. Gerds, MD, MS ('23) - Liaison, Editor-in-Chief, ASH Clinical News
Judith Kleinerman, MD ('23) - Liaison, Chair, CME Accreditation Committee
Shaji Kunnathu Kumar, MD ('25) - Liaison, Editor-in-Chief, The Hematologist
Eduardo Magalhães Rego, MD, PhD ('23) - Liaison, Chair, International Members Committee
Andrew W. Roberts, MBBS, PhD ('24) - Liaison, Deputy Editor, Blood
Mikkael A. Sekeres, MD ('22) - Liaison, Chair, Committee on Communications
Andrew S. Weyrich, PhD ('26) - Liaison, Blood Advances Deputy Editor
Allison Walker, MD, MPH, MBA – Liaison, Chair, Committee on Diversity, Equity and Inclusion
Alisa Wolberg, PhD ('24) - Liaison, Chair, Committee on Scientific Affairs
STAFF LIAISON:
Ana Velarde
E-mail: avelarde@hematology.org

Jean M. Connors, MD ('23) - 2023 Education Program Co-Chair
Amy E. DeZern, MD ('23) - 2023 Education Program Co-Chair
Kojo Elenitoba-Johnson, MD ('23) - 2023 Scientific Program Co-Chair
Elizabeta Nemeth, PhD ('23) - 2023 Scientific Program Co-Chair

John Koreth, MD, PhD ('24) - 2024 Education Program Co-Chair
Rakhi Naik, MD, MHS ('24) - 2024 Education Program Co-Chair
Sant Rayn Pasricha, MBBS, MPH, PhD ('24) – 2024 Scientific Program Co-Chair
Jennifer Trowbridge, PhD ('24) – 2024 Scientific Program Co-Chair
Hanny Al-Samkari, MD ('24) - Editor, Hematology
Suneet Agarwal, MD, PhD ('23) - Appointed Member
Alice Bertaina, MD, PhD ('24) – Appointed Member
Steven Fein, MD ('23) – Appointed Member
Francesca Gay, MD, PhD ('23) – Appointed Member
Andreas Greinacher, MD ('23) – Appointed Member
Betty Hamilton, MD ('23) – Appointed Member
Manali Kamdar, MD ('23) – Appointed Member
Richard M. Kaufman, MD ('23) - Appointed Member
Judith Kleinerman, MD ('23) - Liaison, Chair, CME Accreditation Committee
Dipti Patel Donnelly, MD ('23) – Appointed Member
Kristen Pettit, MD ('23) - Appointed Member
David Sallman, MD ('23) - Appointed Member
Sharon Savage, MD ('23) – Appointed Member
Clifford Takemoto, MD ('23) - Appointed Member
Justin Taylor, MD ('23) - Appointed Member
The Society gratefully acknowledges the time and effort of the following individuals who served as reviewers of abstracts for this meeting and of Hematology 2023, the ASH Education Program.

2023 REVIEWERS

ASH ABSTRACTS COORDINATING REVIEWERS

Maureen Okam Achebe
Diego Adriazzen Herrera
Joseph Ahnstrom
Juan Alderuccio
Immacolata Andolfo
Anthony Audino
Karen Ballen
Joao Barata
Roger Belizaire
Adam Binder
Robert Bowman
Hetty Carraway
Namrata Chandhok
Shanmuganathan Chandrakasan
Shruti Chaturvedi
David Coffey
Rachel Cook
Raul Cordoba
Emily Curran
Susan DeWolff
Meghan Drayton Jackson
Martin Dreyling
Delfim Duarte
Barbara Elchhorst
Tarec Christoffer El-Galaly
Carmen Fava
Jonathan Flanagan
Lucy Fox
Miguel Ganuza Fernandez
Ulrich Geringer
Mark Geyer
Arnab Ghosh
James Godfrey
Kandace Gollomp
Damian Green
Emma Groarke
Boglarka Gyurkoza
Tanja Hartmann
Rong He
Alex Herrera
Michael Heuser
Kyle Hewitt
Matthew Hsieh
Andrew Intlekofer
Singmoo Jeong
Courtney Jones
Swetha Kambhampati
Shaji Kumar
Catherine Lai
Catherine Lee
Jessica Leonard
Sheng Li
Richard Little
Rui Lu
Nadim Mahmoud
Enrica Marchi
Kathy McGraw
Maximilian Merz
Lehka Mikilineni
Ghulam Rehman Mohyuddin
Florence Nguyen-Khac
Grzegorz Nowakowski
Olubusola Oluwolfe
Sung-Yun Pai
Freda Passam
Fabiana Perna
Bethan Psaila
Muna Qayed
Patrick Reagan
Andreas Reiter
Kerry Rogers
Jacob Rowe
Elna Saah
Bethany Samuelson Bannow
Jordan Schaefer
David Scott
Urvi Shah
Kenneth Shain
Kristin Shimano
Melody Smith
Anna Maria Sureda Balari
Natasha Szuber
Ali Taher
Douglas Tremblay
Cindy Varga

ASH ABSTRACTS REVIEWERS

Yasmin Abaza
Oussama Abla
Jeremy Abramson
Melissa Acquazzino
Lionel Ades
Catherine Aftandilian
Imo Akpan
Ibrahim Aldoss
Alvaro Alencar
Lapo Alinari
Jacob Appelbaum
Jane Apperley
Caroline Arber
Alberto Arribas
Kenneth Ataga
Ehab Atallah
Andishe Attarbaschi
Yesim Aydinok
Melissa Azul
Asihsh Bajel
Pere Barba
Paul Barr
Jose Maria Bastida
Taha Bat
Kiran Batta
Anna Beaudin
Wendy Béguelin
Meral Bekssac
Pavan Bendapudi
N. Nora Benshani
Maria Ester Bernardo
Ofrat Beyer Katz
Neha Bhasin
Rukhmi Bhat
Nabanita Bhunia
Giada Bianchi
James Biekerc
Melinda Ann Biernacki
Andrea Biondi
Lionel Blanc
Judith Boer
Kelly Bolton
Claire Booth
Mercedes Borge
Prithviraj Bose
Marita Bosticardo
Alexander Boucher
Jeanne Boudreaux
Andrew Branagan
Thorsten Braun
Marc Braunstein
Annamaria Brioli
Jennifer Brudno
Andrew Brunner
Emily Bryer
Barbara Buldini
Lambert Busque
Craig Byersdorfer
Anna Candoni
Antonino Carbone
Jennifer Carew
Shannon Carpenter
Luciano Costac
Francesca Cottinic
Angelo D'Alessandroc
Alexey Danilov
Faith Davies
Blachy Davila Saldana
Kara Davis
Lucia De Franceschic
Maria Eugenia de la Morena-Barrico
Laurence de Leval
Erich De Paula
Thomas Deloughery
Karl Deshoc
Ani Deshpander
Robertta Di Blasid
Anita D'Souzae
Sarah Ducamp
Jarrod Dudakov
Amy Duffield
Carlo Dufour
Remy Dulery
Amy Dunn
Walter Dzik
Karen Effinger
Firas El Chaer
Najla El Jurdii
Shannon Elf
Patrick Ellsworth
Miriam Erlacher
Jason Farrar
Jonathan Feld
Francisca Ferrer Marin
Simone Ferrerod
Lynda Foltz
Lisa Forbes Satter
Henrik Frederiksen
Sylvia Freeman
Matthew Frigaut
Hideohako Fujiiwarao
David Gailan
Radhika Gangerajau
Sylvain Garcia
Moshe Gatt
Valter Gatei
Aaron Gerds
Irene Ghabriao
David Gibly
Eva Gine
Domenico Girellic
Nicola Giulanid
Benjamin Goldensond
Andres Gomez-De Leon
Michael Green
Philipp Greif
Hildegarde Greinix
Nicole Grieselhuber
Kira Gritsman
Tanja Gruber
Sonia Gueday
Fabio Guolo
Carmelo Gurnaric
Reviewers

2023 REVIEWERS

Alejandro Gutierrez
Fernanda Gutierrez-Rodrigues
Monica Guzman
Claudia Haferlach
Roman Hajek
Stephanie Halene
Mehdi Hamadani
Betty Hamilton
Doris Hansen
Eliza Hawkes
Caroline Heckman
Ute Hegenbart
Florian Heidel
Olaf Heidenreich
Jens Hillengass
Devendra Hiwase
Gabriela Hobbs
Toril Holien
Junshik Hong
Alessandro Isidori
Raphael Itzykson
Shai Izraeli
Elias Jabbour
Salvia Jain
Sakshi Jasra
Reena Jayani
Mats Jerkeman
Patrick Connor Johnson
Wojciech Jurczak
Jonas Jutzi
Martin Kaiser
Matko Kalac
Maggie Kalev-Zylinska
Christopher Kanakry
Reem Kassim
Adetola Kassim
Malgorzata Kassim
Fernanda Gutierrez-Rodrigues

2023 REVIEWERS

Izidore Lossos
Alison Loren
Richard Lock
Cheryl Lobo
Betty Hamilton
Doris Hansen
Eliza Hawkes
Caroline Heckman
Ute Hegenbart
Florian Heidel
Olaf Heidenreich
Jens Hillengass
Devendra Hiwase
Gabriela Hobbs
Toril Holien
Junshik Hong
Alessandro Isidori
Raphael Itzykson
Shai Izraeli
Elias Jabbour
Salvia Jain
Sakshi Jasra
Reena Jayani
Mats Jerkeman
Patrick Connor Johnson
Wojciech Jurczak
Jonas Jutzi
Martin Kaiser
Matko Kalac
Maggie Kalev-Zylinska
Christopher Kanakry
Reem Kassim
Adetola Kassim
Malgorzata Kassim
Fernanda Gutierrez-Rodrigues

2023 REVIEWERS

Linda Resar
Rebecca Richards
Ingo Ringshausen
Antonio Risitano
Jason Romancik
Rizwan Romee
Marlies Rossman
Harvey Roweth
Sergio Rutella
Russell Ryan
Zohar Sachs
Neeraj Saini
R. Leo Sakemura
Ben Samelson-Jones
Jose Sandvoal-Sus
Kristen Sanfilippo
Jolanda Sarno
Prakash Satwani
Tim Sauer
Caner Saygin
Alexandra Schifferli
Fredrik Schjesvold
Sol Schulman
Lora Michal Schulz
Eduard Schulz
Jan Jacob Schuringa
Juliana Schwaab
Juerg Schwaller
Marie Scully
Mikkael Sekeres
Valentina Serafin
Brian Shaffer
Nishi Shah
Jamile Sharnoff
Naraine Shambuchan
Noha Sharafeldin
Joseph Shaw
Geoffrey Shouse
Elizabeth Shpall
Tanya Siddiqi
David Siegel
Robert Signer
Wellington Silva
Laura Silvestri
Sharon Singh
Pratibha Singh
Ankur Singh
Shireen Sirhan
Julia Skokowa
Luke Smart
Andrew Snow
Simona Soverini
Adam Sperling
Maximilian Stahl
Joseph Stanek
Kimberly Stengel
Laurie Steiner
Paolo Strati
Jonathan Strefford
Christopher Su
Senthil Sukumar
Prithu Sundd
Agoston Gyula Szabo
Owen Tamplin
Yvette Tanhehco
Benoit Tessoulin
Suzanne Thibodeaux
Meghan Thompson
Courtney Thornburg
Sigrun Thorsteinsdottir
Swapna Thota
Brian Till
Zuzana Tothova
Jan Trka

ASH REVIEWERS

Steven Tsai
Mazie Tsang
Venee Tubman
Lucie Turcotte
Dimitrios Tzachanis
Masumi Ueda Oshima
Bert Van der Reijden
Antoipi Varelias
Anant Vatsayan
Leandro Venturutti
Sangeetha Venugopal
Amit Verma
Vip Viprakasit
Linus Voelker
Bastian von Tresckow
Ajay Vora
Radovan Vrhovac
Vladan Vucinic
Franziska Wachter
Aman Wadhwa
Nina Wagner-Johnston
Johannes Waldschmidt
Alison Walker
Roland Walter
Anthony Washington
Jonathan Webster
Lachelle Weeks
Andrew Wei
Jeffrey Weitz
Jason Westin
Joseph Wiemels
Adrian Wiestner
Lindsay Wilde
Jennifer Wilkes
Eric Winer
Eric Wong
Chuanfeng Wu
Ana Xavier
Stephanie Xie
Victor Yazbeck
Andrew Yee
Jonathan Yen
Guy Young
Neil Zakai
Emanuele Zucca
Jeffrey Zwicker

ASH REVIEWERS

Jeffrey Zwicker
Emanuele Zucca
Jeffrey Zwicker
HEMATOLOGY 2023 REVIEWERS

Jeremy S. Abramson
Catherine Aftandilian
Suneet Agarwal
Haris Ali
Pamela Blair Allen
Andrew S. Artz
Michael Auerbach
Nizar J. Bahlis
Brian J. Ball
Kenneth A. Bauer
Pavan K. Bendapudi
Alice Bertaina
Bhavana Bhatnagar
Neel S. Bhatt
Javier Bolaños-Meade
Prithviraj Bose
Robert A. Brodsky
Jennifer N. Brudno
Patricia A.R. Brunker
Andrew M. Brunner
John M. Burke
James B. Bussel
Scott Canna
Maria Dominica Cappellini
Hetty E. Carraway
Marc Carrier
Shruti Chaturvedi
Luke Y.C. Chen
Yi-Bin Chen
Jacques Chiorioni
Satheesh Chonat
Douglas B. Cines
Nathan T. Connell
Mhairi Copland
Jorge Cortes
Luciano J. Costa
Anita D’Souza
Alexey V. Danilov
Thomas G. DeLoughery
Amy E. DeZern
Yvonne A. Efereha
Hesham Eissa
Andrew M. Evens
Lorenzo Falchi
Steven Fein
Courtney Fitzhugh
Courtney D. Fitzhugh
Radhika Gangaraju
David A. Garcia
Valentin Garcia-Gutierrez
Francesca Gay
Nilanjan Ghosh
Andreas Glenthøj
Ajay K. Gopal
Jed B. Gorlin
Rachael F. Grace
Tara Graff
Elizabeth A. Griffiths
Emma M. Groarke
Monique Hartley-Brown
David Henry
Gabriela Hobbs
Christopher S. Hourigan
Amanda Jacobson-Kelly
Nitin Jain
Siddhartha Jaiswal
Murali Janakiram
Martin F. Kaiser
Theodosia A. Kalfa
Manali Kamdar
Julie Kanter
Richard M Kaufman
Sioban B. Keel
Steve Kitchen
Adam S. Kittai
Jan-Henning Klusmann
Paul Knoebel
Peter Koudes
Taxiarchis V. Kourelis
Nicolaus Kröger
Amrita Y. Krishnan
Rebecca Kruse-Jarres
Nicole Kucine
Stephan Ladisch
Michele P. Lambert
Rebecca Karp Leaf
Jerrold H. Levy
Howard Allen Liebman
Tara L. Lin
Ton Lisman
Frederick L. Locke
Sagar Lonial
Tiffany L. Lucas
Marlise R. Lukin
Leo Luznik
Ryan C. Lynch
Stephen MacDonald
Katerina Machova Polakova
John P. Manis
Deepa Manwani
Camila Masias
Jennifer McNeer
Robert T. Means
Matthew G. Mei
Reid W. Merryman
Saskia Middeldorp
Tamara P. Miller
Alice S. Mims
Alison J. Moskowitz
Fionnuala B. Ni Ainle
Swati Naik
Eneida R. Nemecek
Cindy E. Neunert
Marena Rebekka Niewisch
Sven R. Olson
Timothy S. Olson
Giovanna Palladini
Jeanne M. Palmer
Anand A. Patel
Dipti Patel-Donnelly
Steven Z. Pavletic
Françoise Pirenne
Allyson Pishko
Daniel A. Pollyea
Keith W. Pratz
Muna Qayed
Christian Récher
Jean-Antoine Ribeil
Lara N. Roberts
David A. Saltman
Bethany T. Samuelson Bannow
Sharon A. Savage
Bipin N. Savani
Jordan K. Schaefer
Zbigniew Macdonald
Szczepiorkowski
Gary J. Schiller
Jecko Thachil
Alvin H. Schmaier
Alexis A. Thompson
Kirk R. Schultz
Andreas Tiede
Roger E.G. Schutgens
Chaitra Ujjani
Mikkael A. Sekeres
Rolf T. Urbanus
Nirali N. Shah
Celalettin Ustun
Uri A. Shah
Jurjen Versluis
Naranie Shanmuganathan
Jeff P. Sharan
Joseph J. Shatzel
Akiko Shimamura
Michelle Sholzberg
Roni Shouval
Deborah M. Siegal
Leslie Skeith
Heather J. Symons
Zbigniew Macdonald
Szczepiorkowski
Jecko Thachil
Alexis A. Thompson
Andreas Tiede
Chaitra Ujjani
Rolf T. Urbanus
Celalettin Ustun
Jurjen Versluis
Adrianna Vlachos
Alison R. Walker
Alan S. Wayne
Jason R. Westin
Joshua F. Zeidner
Jeffrey A. Zonder
2023 ASH Annual Meeting Foundation Run/Walk Supporters

**PREMIER**
- Acrotech Biopharma, Inc.
- AstraZeneca
- Biomea Fusion, Inc.
- Editas Medicine
- Gilead and Kite Oncology
- GSK
- Regeneron
- Syndax Pharmaceuticals

**LEAD**
- AbbVie
- Blueprint Medicines
- Seagen Inc.

**SUPPORTING**
- Freeman
- Novartis
- Ono Pharmaceuticals

2023 ASH Annual Meeting Education Supporters

*ASH would like to acknowledge the following companies for the educational grants provided in support of the 2023 ASH Annual Meeting:*

**Hematology 2023: The Education Program**
- AstraZeneca
- GlaxoSmithKline
- Incyte Corporation
- Jazz Pharmaceuticals
- Merck Sharp & Dohme Corp.
- Novartis Pharmaceuticals Corporation

**General Education Grant**
- AbbVie
- AstraZeneca
- GlaxoSmithKline
- Incyte Corporation
- Lilly USA, LLC
- Merck Sharp & Dohme Corp.
- Novartis Pharmaceuticals Corporation
- Pfizer Inc.
- Seagen
- Syndax Pharmaceuticals Inc.
2023 ASH Independent Medical Education Supporters

ASH would like to acknowledge the following companies for their support:

- Agios Pharmaceuticals Inc.
- Astellas Pharma US, Inc.
- Bristol Myers Squibb
- CRISPR Therapeutics, Inc.
- Daiichi Sankyo, Inc.
- GlaxoSmithKline
- Johnson & Johnson Innovative Medicine
- Kite Pharma Inc.
- Novartis Pharmaceuticals
- Pfizer Inc.
- Syneos Health
- Vertex Pharmaceuticals

2023 ASH Award Supporters

ASH would like to acknowledge and thank the following companies for supporting the ASH Bridge Grant, Minority Recruitment Initiative and Scholar Award programs:

- AstraZeneca
- Novartis Pharmaceuticals

2023 Annual Meeting Corporate Supporters

ASH would like to acknowledge the following companies for their support of the 2022 Annual Meeting:

- AbbVie
- Ash Red
- AstraZeneca
- Exhibit Hall Aisle Signs
- Daiichi Sankyo, Inc.
- PosterCast
- Gilead and Kite Oncology
- Internet Stations and Wi-Fi
- GSK
- ASH Hotel Door Drop Bag
- Mobile Device Charging Stations
- Incyte
- Hydration Stations
- Johnson & Johnson
- Hand Sanitizing Stations
- Headshot Alley
- Mobile Device Charging Stations
- Loxo@Lilly
- Photo Zone and Social Media Wall
- NMDP
- ASH-a-Palooza – Gold Level Supporter
- Sanofi
- ASH Park @ the Plaza
- Hand Sanitizing Stations
- Mobile Device Charging Stations (Marriott Marquis San Diego Marina)
- Spark Therapeutics
- ASH-a-Palooza – Silver Level Supporter
- ASH-a-Palooza – Photo Zone
- Syndax Pharmaceuticals
- Mobile App
2023 ASH Global Initiatives

ASH would like to acknowledge and thank the following companies and foundation for supporting ASH’s international consortia:

Consortium on Newborn Screening in Africa
Bristol-Myers Squibb
Novartis
Revvity

International Consortium on Acute Leukemia
Torsten Haferlach Leukemia Diagnostics Foundation
Illumina

2023 ASH Corporate Friends

ASH Corporate Friends are dedicated partners of the Society and their support to advance hematology research, education, training, and advocacy throughout the year is sincerely appreciated. ASH is grateful for the generous support of the following companies:

Premier Circle
- GSK
- Pfizer
- Regeneron

Partner Circle
- AstraZeneca
- Bristol-Myers Squibb
- Kite
- Lilly
- Novartis
- Vertex

Advocate Circle
- Agios
- Amgen
- Astellas
- Beigene
- Genentech
- Genmab
- Johnson & Johnson Innovative Medicine
- Merck
- Novo Nordisk
- Sanofi

Insider Circle
- Bluebird Bio
- Kura Oncology
- Orca Bio
- Rigel
- Syndax

2023 ASH Health Equity Collective

The Health Equity Collective represents a cooperative enterprise of support opportunity areas for organizations seeking to help stop the trajectory and minimize the impact of health care inequality. Building on ASH’s work over the last 20 years to combat health inequity, and through the support of partnering organizations, participating members of the Collective have taken tangible steps to dismantle inequitable practices within the health care community. ASH is grateful for the support and recognizes the inaugural members for their laudable work:

- Bristol-Myers Squibb
- Genentech
- GSK
- Johnson & Johnson Innovative Medicine
- Lilly
- Merck
- Novartis
- Pfizer
- Sanofi
- Vertex
8th Edition ASH-SAP Self-Assessment Program

- 25 New & Updated Chapters – covering malignant and classical (non-malignant) disorders
- 17 New & Updated Multi-Media features for key topics
- 260 NEW Questions in the Question and Answer Book
- 75 – CME/MOC Credits

The Question and Answer Book allows for preparation for the CME/MOC Test featuring:
- Laboratory Hematology & Cellular Therapy
- Consultative Hematology
- Anemia, Iron Physiology, and Iron Disorders
- Thrombosis & Hemostasis
- Myeloid Diseases
- Lymphoid Disorders

ORDER TODAY AT:
ASH Store on-site | hematology.org/store
RECIPIENTS OF AWARDS

WALLACE H. COULTER AWARD FOR LIFETIME ACHIEVEMENT IN HEMATOLOGY

- 2023 Blanche P. Alter
- 2022 Irving Weissman
- 2021 Harvey Lodish
- 2020 Mohandas Narla
- 2019 Richard H. Aster
- 2018 Victor Hoffbrand

- 2017 Marshall A. Lichtman
- 2016 Thalia Papayannopoulou
- 2015 Aaron Marcus
- 2014 Kanti Rai
- 2013 Sir David John Weatherall
- 2012 James George

- 2011 David G. Nathan
- 2010 Volker Diehl
- 2009 H. Franklin Bunn
- 2008 Robert Kyle
- 2007 Ernest Beutler

ERNEST BEUTLER LECTURE AND PRIZE

- 2023 Taakeisa Kitazawa and Johnny Mahlangu
- 2022 John Atkinson and Peter Hillmen
- 2021 Margaret Shipp and Stephen Ansell
- 2020 Courtney DiNardo and Ari Melnick
- 2019 Srim Krishnaswamy and Jeffrey I. Weitz

- 2018 Alan D'Andrea and Neal Young
- 2017 Luigi Naldini and Marina Cavazzana
- 2016 Hugues de Thé and Zhu Chen
- 2015 Alfred Goldberg and Paul Richardson
- 2014 Michael R. DeBaun and Robert P. Hebbel

- 2013 Kenneth Kaushansky and David J. Kuter
- 2012 Bruce R. Blazar and Carl H. June

E. DONNALL THOMAS LECTURE AND PRIZE

- 2023 Katy Rezvani
- 2022 Bruce Blazar
- 2021 Connie Westhoff
- 2020 Toshio Suda
- 2019 Philip D. Greenberg

- 2018 Connie J. Eaves
- 2017 James R. Downing
- 2016 David Scadden
- 2015 Barbara C. Furie and Bruce Furie
- 2014 Tomas Ganz

- 2013 Katherine A. High
- 2012 Timothy J. Ley
- 2011 George Q. Daley
- 2010 Leonard I. Zon
- 2009 John E. Dick

- 2008 Neal S. Young
- 2007 Hal Broxmeyer
- 2006 E. Richard Stanley
- 2005 Rainer Storb
- 2004 Donald Metcalf

- 2003 Ernest Beutler
- 2002 Kenneth Mann
- 2001 Janet D. Rowley and Brian J. Druker
- 2000 David Ginsburg
- 1999 Irving Weissman

- 1998 Stuart H. Orkin
- 1997 Robert Rosenberg
- 1996 Stanley Korsmeyer
- 1995 Charles Esmon
- 1994 Thomas P. Stossel

- 1993 Thomas P. Stossel
- 1992 Stuart Kornfeld

WILLIAM DAMESHEK PRIZE

- 2023 Omar Abdel-Wahab
- 2022 Irene Gobrial
- 2021 Elizabeth Nemeth
- 2020 Adolfo Ferrando
- 2019 Emmanuelle Passegué

- 2018 Ross L. Levine
- 2017 Benjamin L. Ebert
- 2016 Charles Mullighan
- 2015 John Byrd
- 2014 Scott Armstrong

- 2013 Andrew Weyrich
- 2012 Margaret A. Goodell
- 2011 Christoph Klein
- 2010 David T. Scadden
- 2009 Louis M. Staudt

- 2008 Kenneth Anderson
- 2007 William Vainchenker
- 2006 Riccardo Dalla-Favera
- 2005 John Dick
- 2004 Ronald Levy

- 2003 Gary Gilliland
- 2002 Catherine Verfaillie
- 2001 Brian Druker
- 2000 David A. Williams
- 1999 Salvador Moncada

- 1998 J. Evan Sadler
- 1997 Björn Dahlbäck
- 1996 Kenneth Kaushansky
- 1995 James Ihle
- 1994 George J. Broze, Jr.

- 1993 Owen Witte
- 1992 Richard D. Klausner
- 1991 Makio Ogawa
- 1990 Thalia Papayannopoulou and George Stamatoyannopoulos

- 1989 Samuel E. Lux IV
- 1988 Theodore S. Zimmerman
- 1987 Charles Sherr
- 1986 Stuart Orkin
- 1985 Thomas F. Deuel

- 1984 Barbara C. and Bruce Furie
- 1983 Thomas P. Stossel
- 1982 Janet D. Rowley
- 1981 Philip W. Majerus
- 1979 Yuet Wai Kan

- 1978 Robert D. Rosenberg
- 1977 Yale Nemerson
- 1976 Robert I. Weed
- 1975 Charlotte Friend
- 1974 Robert C. Gallo
ASH AWARD FOR LEADERSHIP IN PROMOTING DIVERSITY

2023 Alexis A. Thompson
2022 James Gavin and David Wilkes
2021 Deepika Darbari

HENRY M. STRATTON MEDAL

2023 Rodger McEver and James B. Bussel
2022 Timothy Ley and Robert Montgomery
2021 Kwaku Ohene-Frempong and Denisa Wagner
2020 Maria Domenica Cappellini and Michelle Le Beau
2019 William Allen Eaton and Richard A. Larson
2018 Brunangelo Falini and Freda K. Stevenson
2017 Josef Tomas Prchal and Sherrill J. Slichter
2016 J. Evan Sadler and Ayalew Tefferi


1991 Ralph L. Nachman
1990 Malcolm Moore
1989 Aaron J. Marcus
1988 Robert S. Schwartz
1987 Robert C. Gallo
1986 Bernard Babior
1985 Vincent DeVita
1984 Samuel Rapaport

HENRY M. STRATTON AWARD

1995 E. Donnall Thomas
1994 Ernest Beutler
1993 Albert S. Gordon
1992 Oscar D. Ratnoff
1991 H.G. Kunkel
1990 W.R. Bruce

ASH MENTOR AWARD

2023 Stephen Sallan and Helen Heslop
2022 Michael Caligiuri and Christopher Flowers
2021 Anthony Goldstone and Jonathan Licht
2020 Judith Gasson and Wendy Stock
2019 Michael R. DeBaun and Leonard I. Zon
2018 John E. Dick and Reed E. Drews
2017 Ronald Hoffman and Oliver W. Press

ASH AWARD FOR LEADERSHIP IN PROMOTING DIVERSITY

2020 Edward J. Benz Jr.
2019 Griffin P. Rodgers
2018 Cage S. Johnson and José A. López
2017 Betty Pace

HENRY M. STRATTON MEDAL

2015 Nancy Speck and Karl Welte
2014 Geraldine Schechter and Timothy Springer
2013 Nancy Andrews and Elaine Jaffe
2012 Richard Aster and David Ginsburg
2011 Ching-Hon Pui
2010 Sanford Shattil
2009 Connie Eaves
2008 Clara Bloomfield
2007 Carlo Croce
2006 Jack Hirsh
2005 Barry Coller
2004 Stanley Korsmeyer

ASH MENTOR AWARD

2010 Mary M. Horowitz and Harvey F. Lodish
2009 Arthur Nienhuis and Stuart H. Orkin
2008 George R. Buchanan and Timothy J. Ley
2007 Edward J. Benz Jr and Harold R. Roberts
2006 Samuel E. Lux and Deane F. Mosher

ASH OUTSTANDING ABSTRACT ACHIEVEMENT AWARDS

The American Society of Hematology is pleased to recognize the following abstract presenters who received the highest ranking in their categories of undergraduate student, medical student, graduate student, resident physician, and post-doctoral fellow.

UNDERGRADUATE STUDENT
Rajagopalan Subramaniam
Indian Institute of Technology (IIT)

GRADUATE STUDENT
Zhaozeng Zheng
Institute of Hematology & Blood

POST-DOCTORAL FELLOW
Mirca Sauty-Seeurunghen, PhD
Weill Cornell Medicine

MEDICAL STUDENT
Anagha Sheth, BSc
University of Colorado School of Medicine

RESIDENT PHYSICIAN
Moritz Fürstenau, MD
University of Cologne

ABSTRACT ACHIEVEMENT AWARDS
ASH-BRITISH SOCIETY OF HEMATOLOGY ABSTRACT ACHIEVEMENT AWARD

This annual award in partnership with the British Society of Hematology (BSH) is granted to up to three British trainees (undergraduate student, medical student, graduate student, resident physician, or post-doctoral (MD or PhD) fellow) who are the first-or-senior author and presenter of the most meritorious submitted abstract. Recipients of this award must be a member of BSH and reside in the United Kingdom.

I-Jun Lau, DPhil, BMBCCh
University of Oxford

Maryam Subhan
University College London

Nikolaos Sousos, MD, MSc, PGCert, DPhil
Oxford University Hospitals

ASH-HEMATOLOGY SOCIETY OF AUSTRALIA AND NEW ZEALAND ABSTRACT ACHIEVEMENT AWARD

This annual award in partnership with the Haematology Society of Australia and New Zealand (HSANZ) is granted to up to two Australian or New Zealander trainees (undergraduate student, medical student, graduate student, resident physician, or post-doctoral (MD or PhD) fellow) who are the first or senior author and presenter of the most meritorious submitted abstract. Recipients of this award must be a member of HSANZ and reside in Australia or New Zealand.

James Kuzich, MBBS, FRACP, FRCPA
Peter MacCallum Cancer Centre

ASH-JAPANESE SOCIETY OF HEMATOLOGY ABSTRACT ACHIEVEMENT AWARD

This annual award in partnership with the Japanese Society of Hematology (JSH) is granted to up to three Japanese trainees (undergraduate student, medical student, graduate student, resident physician, or post-doctoral (MD or PhD) fellow) who are the first or senior author and presenter of the most meritorious submitted abstract. Recipients of this award must be members of JSH and reside in Japan.

Kenki Saito
Nara Medical University

Satoshi Kaito, MD, PhD
The University of Tokyo

Rurika Okuda, MSc,BS
Kyoto University

ASH-SOCIETY ITALIANA DI EMATOLOGIA ABSTRACT ACHIEVEMENT AWARD

This annual award in partnership with the Society Italiana di Ematologia (SIE) is granted to up to two Italian two trainees (undergraduate student, medical student, graduate student, resident physician, or post-doctoral (MD or PhD) fellow) who are the first or senior author and presenter of the most meritorious submitted abstract. Recipients of this award must be a member of SIE and reside in Italy.

Enrico Attardi, MD
University of Rome Tor Vergata

Luca Lanino, MD
IRCCS

ASH-IPIG ABSTRACT ACHIEVEMENT AWARD FOR PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)

This annual award in partnership with the Japanese Society of Hematology (JSH) is granted to up to three Japanese trainees (undergraduate student, medical student, graduate student, resident physician, or post-doctoral (MD or PhD) fellow) who are the first or senior author and presenter of the most meritorious submitted abstract. Recipients of this award must be members of JSH and reside in Japan.

Carlos Bravo-Perez, MD
Cleveland Clinic

Hiroki Mizumaki, MD, PhD
National Institutes of Health

JOANNE LEVY, MD, MEMORIAL AWARD FOR OUTSTANDING ACHIEVEMENT

This award was established in 2006 to recognize the current ASH Scholar with the highest scoring abstract for the ASH annual meeting. This award is given in honor of a past Scholar Award recipient and distinguished member of ASH, Joanne Levy, who passed away in 2004. This annual award is made possible by the Levy family to continue her legacy and promote excellence in hematology research.

Matthew Frank, MD, PhD
Stanford University
MARY RODES GIBSON MEMORIAL AWARD IN HEMOSTASIS AND THROMBOSIS

This award was established to recognize the trainee (undergraduate student, medical student, graduate student, resident physician, or post-doctoral fellow) who is the first author and presenter of the highest-scoring abstract submitted in the field of hemostasis and thrombosis. This annual award is made possible by the Mary Rodes Gibson Hemostasis-Thrombosis Foundation to continue the legacy of Mary Rodes Gibson who suffered from severe, type 3 von Willebrand’s disease.

Lucas Van Gorder
Children’s Hospital of Philadelphia

ASH-FRANK TOOHEY ABSTRACT ACHIEVEMENT AWARD FOR MYELODYSPLASTIC SYNDROMES

This award was established to recognize the trainee (undergraduate student, medical student, graduate student, resident physician, or post-doctoral fellow) who is the first author and presenter of the highest-scoring abstract submitted in the field of MDS, with a preference for highly rated abstracts related to older populations. This annual award is made possible by donations from Mary McGrane in memory of Frank Toohey.

Cristina Astrid Tentori, MD
IRCCS

MINORITY GRADUATE STUDENT ABSTRACT ACHIEVEMENT AWARD

Each year, the American Society of Hematology offers merit-based Minority Graduate Student Abstract Achievement Awards to select graduate students to acknowledge the accomplishments of and recruit and retain minority graduate students in the field of hematology.

Charles Ayemoba
University of Illinois at Chicago

Corbin Azucenas
Cincinnati Children’s Hospital Medical Center

Ginette Balbin-Cuesta
University of Michigan Medical School

Claudia Cabrera
Washington University School of Medicine

Daisy Diaz Rohena
The University of Texas MD Anderson Cancer Center

Ariel Leyte-Vidal
University of California

Francisco Marchi
University of Florida

Richard Marrero
University of Florida

Jonny Mendoza-Castrejon
Washington University School of Medicine

Fathima Mohamed
University of Minnesota

Justin Thomas
Fred Hutchinson Cancer Center

Eudorah Vital
Georgia Institute of Technology and Emory University

ASH ABSTRACT ACHIEVEMENT AWARDS

Each year, the American Society of Hematology offers merit-based Abstract Achievement Awards to select individuals to acknowledge the accomplishments of hematologists-in-training. This year’s Abstract Achievement Awards recognize undergraduate students, medical students, graduate students, resident physicians, and post-doctoral fellows who are both first author and presenter of an abstract.

Dor Abelman
Yazan Abu-Shihab
Adebimpe Adelaja
Jele Adimora
Margo Aertgeerts
Mike Agius
Louise Ahlgren
Guirayz Ahmed
Roberto Aiolfi
Abigail Ajanel Gomez
Yu Akahoshi
Theresia Akhlaghi
Emmanuelle Alawode
Jean-Baptiste Alberge
Mohammad Alhomoud
Konstantinos Aliazis
Stefan Alig
Cecily Allen
Diana Al-Sarayfi
Othman Al-Sawaf
Sultan Alsulaibani
Zhuo-Yu An
Michael Andersen
Mathew Angelos
Kaitlin Annunzio
Tomohiro Aoki
Michelle Aranha
Mutlu Arat
Mya Arellano
Christopher Arends
Ruby Arora
Sankalp Arora
Esteban Arrieta-Bolanos
Khetwasan Arunphong
Aghavan Ashouri
Frida Bugge Askeland
Ferdowsi Atiq
Himachandana Atturi
Franziska Auer
Matias Autio
Edward Ayoub
Irfan Azaman
Stefanie Bachl
Maximilian Bader
Marc-Andrea Baertsch
Jie Bai
Zhiliang Bai
Firas Baidoun
Shovik Bandypadhyay
Subham Bandypadhyay
Lauren Banner
Mei Bao
Juan Barajas
Sergio Barajas
Manpreet Barihana
Aditya Barve
Fahmin Bashir
Naseer Basma
Salman Basrai
Alex Bataller
Benjamin Bateman
Habin Bea
Francisco Beas
Isabelle Becker
J. Beeler
Manali Begur
Salina Benbarche
Philipp Berning
Kalay Bertulfo
Jan Philipp Bewersdorf
Alicia Beyou
Anand Bhagwat
Dipabarna Bhattacharya
Honghao Bi
Viktoria Blumenberg
Prajwal Boddhu
Marta Bortolotti
Jonas Bouhol
Ruya da Boul
Molly Brakhane
Kelsey Bria
Charlotte Brierley
Robert Briski
Pamela Brito
Maura Bueno
Marco Buttigieg
Madeline Caduc
Xuan Cai
Steven Callori
Virginia Camacho
Wenjing Cao
Bria Carrithers
<table>
<thead>
<tr>
<th>Name</th>
<th>Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>William Lee</td>
<td>Yoonkyu Lee</td>
</tr>
<tr>
<td>Julien Legrand</td>
<td>Allison Lehanka</td>
</tr>
<tr>
<td>Andrew Leo Lemerquis</td>
<td>Thomas Lew</td>
</tr>
<tr>
<td>Lisa Leypoldt</td>
<td>Chen Li</td>
</tr>
<tr>
<td>Lixia Li</td>
<td>Menglin Li</td>
</tr>
<tr>
<td>Na Li</td>
<td>Qin Li</td>
</tr>
<tr>
<td>Qing Li</td>
<td>Xueqi Li</td>
</tr>
<tr>
<td>Yang Li</td>
<td>Yiwen Li</td>
</tr>
<tr>
<td>Zhengping Li</td>
<td>Zhenlong Li</td>
</tr>
<tr>
<td>Ziming Li</td>
<td>Emily Li</td>
</tr>
<tr>
<td>Nora Liebers</td>
<td>Katie Lien</td>
</tr>
<tr>
<td>Raphael Lievin</td>
<td>Elizabeth Lightbody</td>
</tr>
<tr>
<td>Kenneth Lim</td>
<td>Guanglan Lin</td>
</tr>
<tr>
<td>William Lin</td>
<td>Zesen Lin</td>
</tr>
<tr>
<td>Bingyu Liu</td>
<td>Boya Liu</td>
</tr>
<tr>
<td>Jie Liu</td>
<td>Yingyue Liu</td>
</tr>
<tr>
<td>Yu Liu</td>
<td>Yuchen Liu</td>
</tr>
<tr>
<td>Alison Livada</td>
<td>Amaya Llorente-Chavez</td>
</tr>
<tr>
<td>Marissa Locastro</td>
<td>Alexa Loncharich</td>
</tr>
<tr>
<td>Zhangbiao Long</td>
<td>Izabela Lopes</td>
</tr>
<tr>
<td>Diego Lopez</td>
<td>Yadith Karina Lopez-Garcia</td>
</tr>
<tr>
<td>Joseph Lownik</td>
<td>John Lozada</td>
</tr>
<tr>
<td>Bin Lu</td>
<td>Tiange Lu</td>
</tr>
<tr>
<td>Ling Lu</td>
<td>Danny Luan</td>
</tr>
<tr>
<td>Alexander Lubin</td>
<td>Johannes Lubke</td>
</tr>
<tr>
<td>Ahmed Ludvigsen Al-Mashhadi</td>
<td>Sofia Luna</td>
</tr>
<tr>
<td>Hanzhi Luo</td>
<td>Yingyu Luo</td>
</tr>
<tr>
<td>Feat Ruttwak</td>
<td>Xiurui Lv</td>
</tr>
<tr>
<td>Maria Lysandrou</td>
<td>Maria M.Hosseini</td>
</tr>
<tr>
<td>Rui Ma</td>
<td>Shengling Ma</td>
</tr>
<tr>
<td>Eduardo Magalhaes</td>
<td>Tylan Magnussson</td>
</tr>
<tr>
<td>Himil Mahadevia</td>
<td>Kiran Majeti</td>
</tr>
<tr>
<td>Bilal Malik</td>
<td>Erica Mamaug</td>
</tr>
<tr>
<td>Paola Manara</td>
<td>Srija Manchankanti</td>
</tr>
<tr>
<td>Aashray Mandala</td>
<td>Sacha Bellinda Mapombo Choupa</td>
</tr>
<tr>
<td>Alfredo Marchetti</td>
<td>Josue Marquez</td>
</tr>
<tr>
<td>Alexander Marr</td>
<td>Tanner Martinez</td>
</tr>
<tr>
<td>Esperanza Martin-Sanchez</td>
<td>Shinichiro Matsu</td>
</tr>
<tr>
<td>Meghana Matur</td>
<td>Katie Maurer</td>
</tr>
<tr>
<td>Michael McCONVILLE</td>
<td>Dustin McCurry</td>
</tr>
<tr>
<td>Danielle McQuinn</td>
<td>Rabea Mecklenbrauck</td>
</tr>
<tr>
<td>Jose Mejias</td>
<td>Megan Melody</td>
</tr>
<tr>
<td>Max Mendez-Lopez</td>
<td>Ana Menezes</td>
</tr>
<tr>
<td>Gao Mengge</td>
<td>Lea Meriranta</td>
</tr>
<tr>
<td>Lauren Meyer</td>
<td>Xiaodi Mi</td>
</tr>
<tr>
<td>Maria Mikhaileva</td>
<td>Michelle Millions</td>
</tr>
<tr>
<td>Jelena Milosevic</td>
<td>Charles Milrod</td>
</tr>
<tr>
<td>Rahul Mishra</td>
<td>Jayna Mistry</td>
</tr>
<tr>
<td>Safa Mohammad</td>
<td>Anna Montanaro</td>
</tr>
<tr>
<td>Adnan Mookhtiar</td>
<td>Analy Mora</td>
</tr>
<tr>
<td>Luz Moreno Rueda</td>
<td>Kristina Mott</td>
</tr>
<tr>
<td>Junil Mou</td>
<td>Jan Mueller</td>
</tr>
<tr>
<td>Umarl Munawar</td>
<td>Lauren Murphy</td>
</tr>
<tr>
<td>Jurik Mutter</td>
<td>Greggory Myers</td>
</tr>
<tr>
<td>Keiichi Nakata</td>
<td>Henna Nam</td>
</tr>
<tr>
<td>Ahmad Nanaa</td>
<td>Anna Naqi</td>
</tr>
<tr>
<td>Anna Navarro Figueroedo</td>
<td>Kit Neikirk</td>
</tr>
<tr>
<td>Niraj Neupane</td>
<td>Lok Lam Ngai</td>
</tr>
<tr>
<td>Chi Nguyen</td>
<td>Daniel Nguyen</td>
</tr>
<tr>
<td>Nam Nguyen</td>
<td>Madeline Niederkorn</td>
</tr>
<tr>
<td>Sandra Novoa Jauregui</td>
<td>Andres Noyola-Perez</td>
</tr>
<tr>
<td>Timothy O’Connor</td>
<td>Yaa Ofori-Marfoh</td>
</tr>
<tr>
<td>Olisaemeka Ogbue</td>
<td>Denis Ohlstrom</td>
</tr>
<tr>
<td>Sylvia Okonofu</td>
<td>Runika Okuda</td>
</tr>
<tr>
<td>Fathia Oladiupo</td>
<td>Aina Oliver-Caldes</td>
</tr>
<tr>
<td>Jon Thorir Oskarsson</td>
<td>Anna Ossami Saidy</td>
</tr>
<tr>
<td>Julia Paczkowska</td>
<td>Andrew Palmer</td>
</tr>
<tr>
<td>Darren Pan</td>
<td>Lii PAN</td>
</tr>
<tr>
<td>Nilesh Pandey</td>
<td>Marios Papadimitriou</td>
</tr>
<tr>
<td>Julien Papoin</td>
<td>Durien Pastoors</td>
</tr>
<tr>
<td>Ruchi Patel</td>
<td>Akshay Patwardhan</td>
</tr>
<tr>
<td>Jean Pegliasco</td>
<td>Diego Pereira-Martins</td>
</tr>
<tr>
<td>Cristina Perez</td>
<td>Kristen Peterson</td>
</tr>
<tr>
<td>Alexander Pichler</td>
<td>Alexander Pike</td>
</tr>
<tr>
<td>Alfredo Pinedo-Rodriguez</td>
<td>Michael Poeschla</td>
</tr>
<tr>
<td>Laura Polcik</td>
<td>Kanagaraju Ponnusamy</td>
</tr>
<tr>
<td>Marianna Ponzo</td>
<td>Mansour Poorebrahim</td>
</tr>
<tr>
<td>Vera Poort</td>
<td>Bogdan Popescu</td>
</tr>
<tr>
<td>Patrizia Porazzi</td>
<td>Lakshmi Bhavani Potluri</td>
</tr>
<tr>
<td>Narges Pourmandi</td>
<td>Yuelun Qi</td>
</tr>
<tr>
<td>Laura Quiullen</td>
<td>Laura Raggi</td>
</tr>
<tr>
<td>Kathrine Rallis</td>
<td>Giulia Petra Rappa</td>
</tr>
<tr>
<td>Christian Rausch</td>
<td>Molly Reed</td>
</tr>
<tr>
<td>Kai Rejeski</td>
<td>Hongwei Ren</td>
</tr>
<tr>
<td>Kehan Ren</td>
<td>Fausto Alfredo Rios Olais</td>
</tr>
<tr>
<td>Malte Ritter</td>
<td>Sofia Riarolava</td>
</tr>
<tr>
<td>Santiago Riviello-Goya</td>
<td>Pauline Robbe</td>
</tr>
<tr>
<td>Karl Roberts</td>
<td>Alyssa Rodriguez</td>
</tr>
<tr>
<td>Juan Jose Rodriguez Sevilla</td>
<td>Sergio Rodriguez-Rodriguez</td>
</tr>
<tr>
<td>Alberto Rodriguez-Sanchez</td>
<td>Saemundur Rognvaldsson</td>
</tr>
<tr>
<td>Gregory Roloff</td>
<td>Laurel Romano</td>
</tr>
<tr>
<td>James Ropa</td>
<td>Sterling Rosqvist</td>
</tr>
<tr>
<td>Paula Rothamell</td>
<td>Paula Ruckdeschel</td>
</tr>
<tr>
<td>Leo Ruhinke</td>
<td>Zuzanna Rydzynska</td>
</tr>
<tr>
<td>Ludovic Saba</td>
<td>Kelsey Sack</td>
</tr>
<tr>
<td>Yasutaka Sadaga</td>
<td>Aditi Saha</td>
</tr>
<tr>
<td>Omran Saifi</td>
<td>Noah Salama</td>
</tr>
<tr>
<td>Suruchig Salgar</td>
<td>Christopher Sande</td>
</tr>
<tr>
<td>Junya Sango</td>
<td>Hanaisa Sant’Anna</td>
</tr>
<tr>
<td>Martina Sarchi</td>
<td>Nurefsan Sariipek</td>
</tr>
<tr>
<td>Samuel Sassine</td>
<td>Ahmed Sayed</td>
</tr>
<tr>
<td>Ayman Sayed</td>
<td>Nastassja Scheidegger</td>
</tr>
<tr>
<td>Sven Schimanski</td>
<td>Tessa Schmachtel</td>
</tr>
<tr>
<td>Ann-Kristin Schmalter</td>
<td>Caitlin Schneider</td>
</tr>
<tr>
<td>Constanze Schneider</td>
<td>Marissa Schranner</td>
</tr>
<tr>
<td>Jan Schroder</td>
<td>Daniel Schoors-Martín</td>
</tr>
<tr>
<td>Christian Schütze-Florey</td>
<td>Laurianne Scouric</td>
</tr>
<tr>
<td>Inbal Sdayor</td>
<td>Yuichiro Somba</td>
</tr>
<tr>
<td>Rushil Shah</td>
<td>Jinxi Shan</td>
</tr>
<tr>
<td>Hanqing Shang</td>
<td>Vignesh Shanmugam</td>
</tr>
<tr>
<td>Priyanka Sharma</td>
<td>Koustubh Shekar</td>
</tr>
<tr>
<td>Jaclyn Shelton</td>
<td>Shal Shimot</td>
</tr>
<tr>
<td>Young Jun Shim</td>
<td>Melissa Shyian</td>
</tr>
<tr>
<td>Shai Shimony</td>
<td>Jasmeet Sidhu</td>
</tr>
<tr>
<td>Silvia Sighinolfi</td>
<td>Martha Sim</td>
</tr>
<tr>
<td>Florian Simon</td>
<td>Haley Simpson</td>
</tr>
<tr>
<td>Aakanksha Singh</td>
<td>Apeksha Singh</td>
</tr>
<tr>
<td>Maria Sireno</td>
<td>Abigail Skidmore</td>
</tr>
<tr>
<td>Sarah Skuli</td>
<td>Febe Smits</td>
</tr>
<tr>
<td>Yang Song</td>
<td>Nikolaos Spyrou</td>
</tr>
<tr>
<td>Andrew Srissuwananukorn</td>
<td>Ankita Srivastava</td>
</tr>
<tr>
<td>Livia Stanger</td>
<td>Fabio Steffen</td>
</tr>
<tr>
<td>Noaen Subramanian</td>
<td>Torsten Steinbrunn</td>
</tr>
<tr>
<td>Takehi Sugio</td>
<td>Andrew Stiff</td>
</tr>
<tr>
<td>Adam Suleman</td>
<td>Sophia Stock</td>
</tr>
<tr>
<td>Naveen Subramanian</td>
<td></td>
</tr>
</tbody>
</table>
ABSTRACT ACHIEVEMENT AWARDS

Fumou Sun
Jing Sun
Ruifeng Sun
Ryan Sun
Wenyue Sun
Xueyan Sun
Teodora Supeanu
Keito Suto
Andrew Ta
Jesse Tai
Amanda Tajik
Yuki Takeuchi
Joanne Tan
Megane Tanguay
Matthew Tanner
Isham Tatakare
Dylan Tatterton
Samuel Taylor
Ana Cristina Tejada Vasquez
Semaje Testamark
Erik Thiele Orberg
Zanshe Thompson
Sigrun Thorsteinsdottir
Kirsten Thus
Zheng Tian
Elizabeth Titova
Hunter Tolison
Seda Tolu
Monika Toma
Zehra Tombul
Ahmet Toprak
Dicte Træden
Marissa Traets
Jennifer Tran
Iva Trsova
Billy Truong
Serhan Unlu
Daniela Urueta Portillo
Marc Usart
Camille Vaganay
Arti Vaishnav
Sergio Vallejo
Yannis Valtis
Niek Van Der Maas
Jort Van Der Schans
Myrthe van Dijk
Karolina Vanickova
Hector Alejandro Vaquera Alfaro
Giulia Veltri
Rathnam Venkat
Eric Vick
Junia Vieira dos Santos
Laura Volta
Sydney Wade
Joseph Walden
Christina Waldron
Sarah Waldvogel
Janek Walker
Bo Wan
Visanu Wanchai
Amy Wang
Dandan Wang
Daniel Wang
Helen Wang
Jacqueline Wang
Junyu Wang
Moran Wang
Pan Wang
Shichong Wang
Song Wang
Ximi Wang
Xin Wang
Yu-Hung Wang
Yun Wang
Zhifa Wang
Mustafa Wasifuddin
Isabel Weinhaeuser
Alisha Weiss-Haug
Tobias Wertheimer
William Wesson
Jonas Wilkirkchen
Maggie Wong
Ping Chun Wu
Xia Wu
Ye-Jun Wu
Michael Wysota
Serene Xavier
Sera Xie
Tingting Xie
Jane Xu
Ruohao Xu
Yaqun Xu
Chitresh Yadav
Kyoko Yamaguchi
Li-Ping Yang
Sen Yang
Tingting Yang
Chun En Yau
Rashmi Yawalkar
Yongjun Yi
Charles Yin
Takao Yogo
Justin You
Masanori Yoshida
Satoshi Yoshimura
Chenqi Yu
Zhuoya Yu
Zhuoya Yu
Junyun Yuan
Yin Yuan
Saurabh Zanwar
Clare Zarka
Martha Zarou
Chi Zhang
Ellen Zhang
Jingliao Zhang
Lei Zhang
Menglu Zhang
Michelle Zhang
Ningning Zhang
Xiao-shuai Zhang
Yaping Zhang
Yi Zhang
Peng Zhao
Hao Zheng
Xinhui Zheng
Chen Zhou
Jianying Zhou
Xiang Zhou
Xinyue Zhou
Yichao Zhou
Yifan Zhou
Hongming Zhu
Xinyu Zhu
Katherine Zhuo
Bachisio Ziccheddu
Fu Ziyu
Becky Zion
Adi Zoref-Lorenz
Luciana Zuccherato
Ines Zugasti
Call for Papers

NEW FROM ASH®

Blood Vessels, Thrombosis & Hemostasis seeks to publish high-quality manuscripts focused on clinical and mechanistic aspects of normal and abnormal hemostasis and vascular function. These will include inherited and acquired bleeding and thrombotic disorders, including those involving platelets, as well as disorders involving the venous, arterial, and microvasculature. We seek novel and innovative studies that will have a significant aspect on translational and basic science as well as clinical care. The journal is open for submissions.

With a long publishing history that exemplifies superior quality and reach, the Blood Journals portfolio, anchored by our high-impact flagship, Blood, is a natural home for research in specialty areas of hematology.

WHY SUBMIT?
Blood Vessels, Thrombosis & Hemostasis helps place your research within the reputable and highly visible Blood Journals portfolio. By publishing within these journals, you align your research with the long-trusted ASH and Blood brands.

BENEFITS TO AUTHORS:
• ASH & Blood Portfolio Visibility
• Fast Peer Review
• Seamless Transfers
• Speed to Publication
• Open Science

ASH is the home for hematology. Long embraced by the hematology community, Blood Journals are a sought-after platform for researchers to advance their work. Expansion gives more authors an opportunity to be published in a Blood journal.

Submit your paper now

Keith McCrae, MD
Editor-in-Chief
Cleveland Clinic
Lerner Research Institute

Blood Vessels, Thrombosis & Hemostasis Joins the Blood Journals Portfolio
PUPPOSE OF ASH SCIENTIFIC AND EDUCATIONAL MEETINGS

The mission of the American Society of Hematology (ASH) is to foster high-quality, equitable care, transformative research, and innovative education to improve the lives of patients with blood and bone marrow disorders. In accordance with this mission, the primary purpose of scientific meetings organized by ASH, including the Society’s annual meeting, is to facilitate the global exchange of scientific information and clinical results related to the field of hematology. Another important goal of ASH-organized meetings is to assist physicians and scientists in developing and maintaining academic collaborations that will generate new knowledge, ultimately benefiting patients.

At this year’s annual meeting, ASH will continue to offer an inclusive environment for all participants, including a focus on making the in-person meeting in San Diego and the virtual meeting platform as accessible as possible for attendees with disabilities. ASH will offer mobility, vision, hearing, and other resources as needed. For more information or for questions regarding these services, please contact disabilities@hematology.org.

TWO WAYS TO ATTEND THE 65TH ASH ANNUAL MEETING

ASH is pleased to continue to offer the 65th ASH Annual Meeting and Exposition as a hybrid experience where participants can decide to attend in person in San Diego or participate using ASH's virtual meeting platform. All participants, regardless of location, will have access to the virtual meeting platform built for learning, collaboration, and networking. Most sessions offered at the in-person meeting will be broadcast simultaneously on the virtual meeting platform, and attendees will have the ability to ask questions and participate in real time.

REGISTRATION

ASH is offering multiple registration options for the annual meeting. Both in-person and virtual registration packages include access to sessions, Q&A, networking, CME/MOC, exhibit halls, and more. If an attendee chooses to participate in person, they will also receive complimentary access to the virtual meeting platform through January 1, 2024.

Registration is available now at hematology.org/meetings/annual-meeting/registration-information. Those who have previously registered may upgrade their subscription to extend their access to the meeting’s virtual platform at any time by contacting the Registration Center.

IN-PERSON MEETING

When you register for the in-person meeting, you will receive complimentary access to the virtual meeting platform through January 1, 2024. In-person registrants have the option to extend their access to the virtual meeting platform for an additional fee.

VIRTUAL ACCESS REGISTRATION PACKAGE OPTIONS

The virtual meeting packages were designed to give attendees maximum flexibility. Most sessions offered at the in-person meeting will be broadcast simultaneously on the virtual platform, and attendees will have the ability to ask questions and participate in real time. The platform will also include on-demand recordings of all sessions (unless otherwise noted), as well as access to networking opportunities, exhibits, and more.

- **Real-Time Experience: Access through January 1, 2024**
  Provides access during peak dates and hours of the meeting with the largest number of participants at a given time, maximizing opportunities for interactions and networking. CME/MOC credits can be claimed through April 12, 2024 by viewing the qualifying sessions on the virtual meeting platform.

- **Extended Flexibility: Access through February 1, 2024**
  Provides ongoing access to continue watching on-demand sessions after the meeting ends. CME/MOC credits can be claimed through April 12, 2024 by viewing qualifying sessions on the virtual meeting platform.

- **Best Value: Access through March 1, 2024**
  Provides maximum flexibility to continue accessing on-demand sessions at the best price per day of access. CME/MOC credits can be claimed through April 12, 2024 by viewing qualifying sessions on the virtual meeting platform.
LATE PURCHASE REGISTRATION FEES (BEGINNING OCTOBER 26)

<table>
<thead>
<tr>
<th>Registration Category</th>
<th>In-Person or Real-Time Experience (Virtual access through January 1, 2024)</th>
<th>Extended Flexibility (Virtual access through February 1, 2024)</th>
<th>Best Value (Virtual access through March 1, 2024)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Member (Active and International)</td>
<td>$850</td>
<td>$950</td>
<td>$1,050</td>
</tr>
<tr>
<td>Non-Member</td>
<td>$1,500</td>
<td>$1,600</td>
<td>$1,700</td>
</tr>
<tr>
<td>Associate or International Member</td>
<td>$150</td>
<td>$175</td>
<td>$200</td>
</tr>
<tr>
<td>Medical Student, Graduate Student, or Resident Member</td>
<td>$150</td>
<td>$175</td>
<td>$200</td>
</tr>
<tr>
<td>Non-Member in Training</td>
<td>$250</td>
<td>$275</td>
<td>$300</td>
</tr>
<tr>
<td>Allied Health Professional</td>
<td>$750</td>
<td>$850</td>
<td>$950</td>
</tr>
<tr>
<td>Spouse/Guest (in person only)</td>
<td>$150</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Honorary/Emeritus (before 1/1/15)</td>
<td>$0</td>
<td>$50</td>
<td>$100</td>
</tr>
<tr>
<td>Honorary/Emeritus (after 1/1/15)</td>
<td>$150</td>
<td>$175</td>
<td>$200</td>
</tr>
<tr>
<td>Non-Profit Patient Advocacy Organization Representative</td>
<td>$0</td>
<td>$0</td>
<td>$0</td>
</tr>
</tbody>
</table>

BADGE COLORS

Each badge holder at the ASH annual meeting is color-coded for easy identification of participants:

- Member ........................................ Red
- Non-Member .................................... Green
- Associate Member ............................. Blue
- International Associate Member .......... Blue
- Non-Member in Training ....................... Blue
- Graduate/Medical Student Member ......... Blue
- Resident Member .............................. Blue
- Honorary/Emeritus Member .................... White
- Allied Health Professional ................. Purple
- Exhibitor Booth Personnel ................. Black
- Spouses/Guest .................................. Yellow
- Media............................................. Orange

BADGES

Returning this year, badges will be mailed in advance of the meeting to North American attendees only. International attendees may pick up their badge at one of several registration locations in San Diego, including at the San Diego International Airport. Your name badge contains a barcode that stores your name and address provided at the time of registration. It can be used by the exhibitors, with your consent, to register your visit to their booths and to send you additional information on their products and services. Your name badge also provides the information you require to access CME stations or receipt stations.
OVERVIEW OF THE MEETING SCHEDULE
PREVIEW DAYS: DECEMBER 6-7, 2023

Beginning December 6, 2023, the ASH annual meeting virtual platform will be available to all registered participants at annualmeeting.hematology.org

All registered attendees are encouraged to log in early to get acquainted with the site’s navigation. To log into the platform, you will need your ASH username and password used to register for the meeting.

WHO TO CONTACT

If you are having difficulty accessing the meeting’s virtual platform, please contact the ASH Customer Service department by emailing customerservice@hematology.org or calling 866-828-1231 (U.S. toll free) or 001-202-776-0544 (for International callers), Monday through Friday, from 8:30 a.m. to 5:00 p.m. Eastern time.

If you have successfully accessed the meeting’s virtual platform but are having difficulty with one of its features, please use the online support form feature within the platform for technical assistance.

FRIDAY-ONLY PROGRAMMING: December 8, 2023

There are pre-meeting activities scheduled on Friday, December 8, 2023.

• Friday Satellite Symposia

• ASH-a-Palooza

• Scientific Workshops

Refer to schedule at-a-glance or the mobile app for specific session times.

OFFICIAL MEETING DAYS: December 9-12, 2023

The 65th ASH Annual Meeting and Exposition will take place December 9-12, 2023 in San Diego, California, and on the meeting’s virtual platform. All times listed reflect the Pacific time zone.

Saturday, December 9

Refer to schedule-at-a-glance or the mobile app for specific session times

Sunday, December 10

Refer to schedule-at-a-glance or the mobile app for specific session times

Monday, December 11

Refer to schedule-at-a-glance or the mobile app for specific session times

Tuesday, December 12

All sessions will occur in the general session room beginning at 8:45 a.m. The meeting concludes at 2:15 p.m.

All sessions will be presented at the in-person meeting in San Diego, and unless otherwise noted all events will stream simultaneously on the virtual platform. Session recordings will be available on demand on the virtual platform for the duration of your registration package. Scientific Workshops will be available until December 16, 2023.
GENERAL INFORMATION

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

CATCH UP DAYS: December 13-14, 2023

After the official dates of the annual meeting, ASH Poster Walks will be held on Wednesday and Thursday, December 13-14, on the meeting’s virtual platform.

BINGE WATCHING—CATCH UP ON CONTENT

Participants will also be able to watch presentation recordings on demand for sessions and posters that were presented earlier in the meeting from December 13 through the end of their virtual meeting registration package.

NETWORKING

ASH understands that connecting with colleagues is one of the most important reasons that people love attending the ASH annual meeting. In San Diego, small gathering and seating areas will be available indoors and outdoors to informally meet with colleagues.

ASH’s virtual meeting platform makes connecting with colleagues in San Diego and all around the world easy. On the meeting’s virtual platform click on Networking to connect with your peers.

ASH SOCIAL MEDIA WALLS

Take a break from the science and visit the ASH Social Media Walls located on the meeting’s virtual platform and throughout the convention center to view and contribute to a real-time scientific conversation and engage with colleagues on a variety of topics. This year, the Walls will feature a daily leaderboard ranking of the top 10 most prolific tweeters who use the featured annual meeting hashtags (#ASH23, #ASHRunWalk, #ASHKudos, and #ASHHaiku). The leaderboard will reset each day, giving you ample opportunity to join the online discourse.

SPEAKER INFORMATION

SPEAKER READY ROOM

The Speaker Ready Room will be located in ASH Central in the Sails Pavilion at the San Diego Convention Center. All times are in Pacific time.

Speaker Ready Room Hours

Thursday, December 7 . . . . 3:00 p.m. – 6:00 p.m.
Friday, December 8 . . . . . 7:00 a.m. – 6:00 p.m.
Saturday, December 9 . . . . 7:00 a.m. – 6:00 p.m.
Sunday, December 10 . . . . 7:00 a.m. – 6:00 p.m.
Monday, December 11 . . . 7:00 a.m. – 6:00 p.m.
Tuesday, December 12 . . . . 7:00 a.m. – 11:00 a.m.

All speakers should bring a copy of their presentation to the Speaker Ready Room on a CD-R, DVD-R, or USB flash drive (memory stick, jump drive, etc.). A professional audio-visual (AV) technician will be available to consult with you on any of the guidelines and to make certain your slides are properly identified for your specific session. Please turn in your presentation to the Speaker Ready Room according to the following guidelines:

24 hours before your presentation if you would like the AV technician to assist you in formatting your presentation to ensure clear and readable images.

6 hours before your presentation, if your PowerPoint presentation was prepared on an Apple computer.

At least 6 hours before your presentation if your presentation contains movies or other videos.

At least 4 hours before your presentation is final and requires no modifications.

CONFLICT-OF-INTEREST POLICY

ASH is committed to providing quality, objective, balanced, and scientifically rigorous continuing medical education activities that are free from commercial and non-commercial bias. In accordance with the rules of the Accreditation Council for Continuing Medical Education (ACCME), all meeting session chairs, speakers, and moderators are required to disclose in writing any financial relationships they may have prior to the meeting. All poster presenters are required to disclose in writing any financial relationships they may have prior to the meeting and display their disclosures as a part of their poster presentation. If bias, actual or perceived, occurs during the presentations, session attendees are encouraged to address such bias during the question-and-answer periods following the presentations.

All ASH annual meeting presenters (including chairs, speakers, and moderators) are asked to disclose any relationships of the following types: Employment, Consultancy, Equity Ownership, Research Funding, Honoraria, Patents & Royalties, Speakers Bureau, Membership on an entity’s Board of Directors or advisory committee, and any other financial relationship.

Any questions about this policy or concerns regarding disclosures should be directed to CME@hematology.org.
GENERAL INFORMATION

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

CONTINUING MEDICAL EDUCATION INFORMATION

EDUCATIONAL OBJECTIVES

Upon completion of this educational activity, participants should be able to:

- Employ the knowledge gained regarding the diagnosis and treatment of classical and malignant hematologic disorders to improve patient care;
- Discuss state-of-the-art research in hematology; and
- Analyze the potential contribution of novel, not-yet-approved modalities of therapy to current evidence-based management of hematologic disorders.

ACCREDITATION

The American Society of Hematology (ASH) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The American Society of Hematology designates this Other [blended live and on-demand content] activity for a maximum of 80 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with their participation in the live activity.

CME CERTIFICATE ELIGIBILITY

ASH is accredited to provide AMA PRA Category 1 Credits™ to physicians only. The American Medical Association (AMA) defines physicians as those individuals who have obtained an MD, DO, or equivalent medical degree from another country.

Physicians not licensed in the United States who participate in this CME activity are also eligible for AMA PRA Category 1 Credits™.

HOW TO OBTAIN A CME CERTIFICATE

A processing fee of $30 will be charged for CME certificates. Attendees must complete the Annual Meeting Evaluation Surveys to claim their CME credits and print their CME certificates through the ASH website (www.hematology.org) by clicking the CME link on the homepage. The online process for claiming CME credits and printing a CME certificate for the 65th ASH Annual Meeting must be completed no later than April 12, 2024.

ABIM MOC

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 80 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Attendees will earn MOC points equivalent to the amount of CME credits claimed for the activity. In addition to completing the evaluation survey, attendees must submit a reflective statement on how they intend to change their practice based on the knowledge gained from participation in the meeting. Attendees must also provide their ABIM number and date of birth. Upon review and approval of the reflective statement, points will be submitted to the ACCME by ASH and will appear in the ABIM Physician Portal within 48 hours. Points will only be submitted if all the steps are completed. To receive ABIM MOC points for the 65th ASH Annual Meeting, the online process for claiming CME/ABIM MOC credits must be completed by April 12, 2024.

CERTIFICATE OF PARTICIPATION

Non-physicians and other health-care professionals attending the meeting may print a Certificate of Participation after completing the Annual Meeting Evaluation Surveys through the ASH website (www.hematology.org) beginning Saturday, December 9, 2023. The online process of filling out the annual meeting survey and printing the certificate must be completed no later than April 12, 2024. There is no charge to meeting registrants for this service.

EUROPEAN BOARD OF ACCREDITATION IN HEMATOLOGY CME CREDIT

ASH is applying for accreditation with the European Board of Accreditation in Hematology (EBAH). If you plan to claim EBAH-CME credit for attending the meeting, please check the appropriate box during the registration process or after the meeting in the online evaluation site. There is no fee required in order to be eligible for EBAH-CME Credit Points. For additional information about EBAH-CME Credit points, visit the EBAH website (http://ebah.org). For information about claiming EBAH CME for the 65th ASH Annual Meeting email cme@hematology.org.

QUALIFYING ACCREDITED SESSIONS

Attendees can claim CME for viewing qualifying sessions as they are broadcast in-person and on the virtual platform. Credit can also be claimed for viewing qualifying sessions on the platform after they have concluded.
ASH CENTRAL

ASH Central, a place where hematologists can gather to collaborate, is located in the Sails Pavilion at the San Diego Convention Center. Within ASH Central, you can learn about ASH membership, purchase ASH products at the ASH Store, or make a donation to the ASH Foundation. The following resources are also offered at ASH Central: the ASH Health Equity Studio, fASHion boutique for the hematologist with style, ASH Live: Remote Session Viewing, ASH Store, Collaboration Rooms, Headshot Alley, Photo Zone, Power Nap @ ASH, Trainee Lounge, and the ASH Wellness Studio. Additional seating and charging areas are also offered in ASH Central.

ASH Health Equity Studio

As part of ASH’s commitment to promoting and nurturing a diverse and inclusive hematology community, the ASH Health Equity Studio will once again be located in ASH Central. This brave space is designed to help attendees recognize inequities in health care and provide tools to make change in their institutions. Plan to attend these sessions to learn more about the root causes of health inequities, strategies to overcome disparities in patient care and career development, and ways to improve diversity and inclusion in hematology. These sessions will include a short expert commentary followed by facilitated conversations about actions that can be taken to address health inequities at your institution. These micro-sessions will also be available on the virtual meeting platform.

ASH Live: Remote Session Viewing Area

A designated seating area that will enable attendees to experience select sessions in progress elsewhere without having to navigate through the building. This viewing area will have television monitors/screens displaying the slides from a selection of sessions. Participants will be provided with a set of headphones so they may listen to the selected session’s speakers. Note: Not all sessions will be broadcast into the remote session viewing area. Check the annual meeting mobile app or ASH News Daily for more information on which sessions are available remotely.

ASH Store

ASH offers a variety of products to aid hematologists in their professional development. Stop by to peruse the latest ASH educational products, which will be available for a discounted on-site rate. These items will also be available for purchase in the online ASH Store at (www.hematology.org/Store).

ASH Wellness Studio

In between sessions and throughout the day, ASH will feature informal micro-learning workshops on various aspects of resiliency and wellness in the ASH Wellness Studio, where there will be short presentations and stand-up audience participation. Topics in the studio will be geared towards helping professionals attain a balanced, productive, and healthy work life balance through wellness.

Collaboration Rooms

Small conference rooms will be available for attendees to meet and collaborate in a more private setting. These small conference rooms, equipped with a table, chairs, flat screen monitor, and a cable to connect your own laptop to the monitor, can accommodate groups of up to 20 people and are free to reserve for up to 45 minutes. Each reservation starts at the top of the hour and lasts 45 minutes and each attendee will be limited to one 45-minute reservation per day. For the courtesy of all attendees, multiple, back-to-back reservations cannot be accommodated. Outside food and beverage and/or additional audiovisual equipment may not be brought into a Collaboration Room. Visit the ASH website (www.hematology.org) via the mobile application or the Collaboration Room Help Desk in the Sails Pavilion to reserve a Collaboration Room.

ASH ATTENDEE TECHNOLOGY TO ENHANCE YOUR EXPERIENCE

Ask Red

ASH is continuing the use of AI technology in the form of “Red,” your virtual chatbot assistant who helps attendees by answering ASH-specific questions. Red will also be able to connect you with “live” customer service agents that are available to answer questions. Here are some example questions you can ask Red:

- When do the shuttle buses operate?
- Where is ASH Central located?
- Does ASH offer child care?
GENERAL INFORMATION

Interactive Technology in Sessions
Second screen technology through Conferences i/o enables attendees to view session slides in real time from most personal devices, including smartphones, tablets, and laptop computers. Conferences i/o allows for better viewing of images that can be difficult to see from the back of the session room and allows the audience to submit questions to the moderators virtually. Some sessions will use this technology for audience polls.

Attendees in participating sessions will be given a unique URL via QR code, which will grant access to view the slides for that session only. The QR code will be displayed at the beginning of the session but may also be found by navigating to the session within the mobile app.

Mobile App
ASH's mobile application will provide program and exhibitor information, messaging capability, and general information happening with the 2023 annual meeting. The application includes the full text of the abstracts and the articles available in Hematology 2023 (the ASH Education Program). The application will allow users to add a session to their device's calendar which will build their itinerary for the meeting. A login is no longer required to view application content; a login is only required to contact other attendees and view Education Program articles.

PosterCast
While you are in the poster hall, use the free PosterCast app to view five-minute video presentations by the author. This tool is especially useful when away from your computer, laptop or desk, or for viewing posters while the author is not present in the in-person poster hall.

Download the app on your smartphone by searching for "PosterCast" in the App Store or by visiting the PosterCast website and signing in with your ASH credentials.

To use the app, scan the QR code on a participating poster or use the keypad to enter the poster number. You will then be able to view a five-minute video describing the poster’s content while you view the poster. A link to the PosterCast recording will also appear within the mobile app for the poster description.

ASH FOUNDATION DONOR LOUNGE
Gifts of all amounts to the ASH Foundation are always helpful and appreciated. With cumulative annual giving of $250 or more, you can access the ASH Foundation Donor Lounge during the annual meeting. Please visit the ASH Foundation page for more information. The Donor Lounge will be located in the Tides Restaurant on Level 1 of the San Diego Convention Center. The Tides Restaurant is located adjacent to Hall A and can be accessed from the Hall A Lobby.

ASH MANAGEMENT OFFICE
The ASH Staff Office is located in Room 15A on the Mezzanine level of the San Diego Convention Center.

ASH PARK @ THE PLAZA
ASH Park @ the Plaza will be located in Park Plaza at the San Diego Convention Center. This area will feature early morning yoga, life-sized games, and lounge furniture. There will also be ample seating and tables outdoors for those who wish to take a break and enjoy the San Diego sunshine.

BUSINESS CENTER
The San Diego Convention Center has a FedEx Office that provides full-service business needs for your convenience located on the ground level across from Hall D. FedEx Office provides attendees with photocopying, faxing, computer workstations, and printing services. Office supplies are also available for purchase.

CHILD CARE ROOM
ASH has, once again, made arrangements with KiddieCorp to provide child-care services for children ranging in age from six months to 12 years at the meeting. KiddieCorp has been caring for children at the ASH annual meeting for 24 years and offers a wide range of activities to keep children entertained while you attend the ASH sessions. KiddieCorp staff come prepared with age-appropriate games, souvenir arts and crafts projects, toys, and entertainment. KiddieCorp staff members are bonded and trained childcare specialists. Additionally, KiddieCorp utilizes a photo identification system to check your child in and out of the room. There will also be a refrigerator in this room for nursing mothers to store milk after using the lactation room. The deadline for reserving space for your child is November 17. The cost for child-care service is completely free and is subsidized by ASH, however a cancellation penalty will be assessed if you cancel after the November 17 pre-registration deadline. Snacks, light meals, and beverages will be provided each day. Pre-registration is recommended to ensure participation. This service will be available from Monday, December 8, through Tuesday, December 12.

The child-care room is located in Room 16 on the Mezzanine Level at the San Diego Convention Center.

Child Care Room Hours
- Friday, December 8: 6:30 a.m. – 7:30 p.m.
- Saturday, December 9: 6:30 a.m. – 7:30 p.m.
- Sunday, December 10: 6:30 a.m. – 8:00 p.m.
- Monday, December 11: 6:30 a.m. – 8:00 p.m.
- Tuesday, December 12: 7:30 a.m. – 3:00 p.m.

COAT/BAG CHECK
Complimentary coat and bag check is available on the Ground Level of the San Diego Convention Center in Box Office A and Hall H Lobby as well as in the East Lobby Lounge of the Marriott Marquis San Diego Marina and the Seaport Foyer at the Manchester Grand Hyatt. Electronic items will not be accepted.

Coat/Bag Check Hours
- Friday, December 8: 7:00 a.m. – 8:30 p.m.
- Saturday, December 9: 7:00 a.m. – 8:00 p.m.
- Sunday, December 10: 7:00 a.m. – 8:00 p.m.
- Monday, December 11: 7:00 a.m. – 8:30 p.m.
- Tuesday, December 12: 7:00 a.m. – 3:30 p.m.

FRIENDS OF BILL W.
A meeting room for the Friends of Bill W. is located in Conference Room 2 at the Marriott Marquis San Diego Marina in South Tower Level 3.

HEMATOLOGY MEETUPS
To encourage interaction among attendees, “Hematology Meet Up” areas consisting of public meeting spaces with couches, chairs, and tables will be placed in the convention center. Where possible and permissible, portable concession carts will be located nearby offering coffee and quick grab-and-go food. These locations will be indicated on the campus maps so that...
All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

GENERAL INFORMATION

INTERNET STATIONS
Internet Stations are placed throughout the San Diego Convention Center. Attendees can utilize the Internet and do any of the following at all Internet Stations:

- Check email
- Print a boarding pass
- Print a registration receipt
- Access ASH Job Center
- View the Annual Meeting Program online
- Complete the Meeting Evaluation
- Obtain a Certificate of Attendance
- Register for the ASH Foundation Run/Walk
  (up to 6:00 p.m. on Saturday night)

LOST AND FOUND
Contact the ASH Security Main Office for all lost items and inquiries. The ASH Security Main Office is located in Room 14A on the Mezzanine Level of the San Diego Convention Center.

NURSING MOTHERS’ LOUNGES
Dedicated lounges will be available for nursing mothers in safe, accessible areas throughout the San Diego Convention Center, Hilton San Diego Bayfront, Marriott Marquis San Diego Marina, and Manchester Grand Hyatt. Each nursing mothers’ lounge will provide a private, comfortable area equipped with lockable doors, furniture, and power outlets to use for pumping sessions during the ASH annual meeting.

There is also a complimentary refrigerator located in the Child Care Room, Room 16 at the San Diego Convention Center.

Nursing Mothers’ Lounges Locations
San Diego Convention Center:
- Hall E Lobby
- Hall B1 Lobby
- Mezzanine Level
Manchester Grand Hyatt:
- Show Office 6
Hilton San Diego Bayfront:
- Aqua Level
Marriott Marquis San Diego Marina:
- Pacific Ballroom Registration Desk

QUIET ROOMS
Two quiet rooms are located in San Diego Convention Center. Show Office G is designated as the Female Quiet Room and Show Office H is designated as the Male Quiet Room.

PRESS COMPLEX
The Press Complex, open to registered members of the media, is located on the third Level of the Seaport Tower at the Manchester Grand Hyatt.

Press Room Hours
- Friday, December 8: 9:00 a.m. – 5:00 p.m.
- Saturday, December 9: 7:00 a.m. – 6:00 p.m.
- Sunday, December 10: 7:00 a.m. – 6:00 p.m.
- Monday, December 11: 7:00 a.m. – 6:00 p.m.
- Tuesday, December 12: 7:00 a.m. – 1:00 p.m.

RESTAURANTS/CONCESSIONS
Sodexo Live at the San Diego Convention Center offers a wide variety of dining options, including concessions in the Exhibit Hall and numerous food outlets featuring variety of cuisines. A variety of restaurants are also located near the San Diego Convention Center.

TRAVEL INFORMATION AND OFFICIAL SHUTTLE SERVICE

VISITOR SAFETY
To stay safe during your visit to San Diego, please follow the tips provided below:

- Never hand your phone to someone else (i.e. handing to an Uber or Taxi driver to show them directions or asking a stranger to take your photo).
- Always lock your front and/or patio doors in your hotel room. Use the safety chain/lock for security.
- Never open your room door unless you know who is there. If you did not call for the hotel service offered by the person at the door, call hotel security or the front desk to see if they have sent someone to your room.
- Place valuables in a safety deposit box in your room or at the hotel office. Do not leave valuables in your car.
- When checking into a hotel, consult the floor plan on the back of your room door to familiarize yourself with fire and emergency exits.

When driving, keep all car doors locked.

SHUTTLE SERVICE
ASH will be providing complimentary shuttle service for more than 70 hotels; additionally, 15 hotels are within walking distance of the San Diego Convention Center.

Shuttle Boarding Locations
Routes 1-2
- Marriott Marquis Pacific Ballroom
Routes 3-8
- SDCC Halls A-C
- SDCC Halls F-H
Routes 9-16
- Park Blvd. (Near ASH Park @ the Plaza)
Shuttle Hours
Thursday, December 7 . . . . No shuttle service
Friday, December 8 . . . . . 6:30 a.m. – 10:30 p.m.
Saturday, December 9 . . . . 6:30 a.m. – 9:30 p.m.
Sunday, December 10 . . . . 6:30 a.m. – 9:30 p.m.
Monday, December 11 . . . . 6:30 a.m. – 9:30 p.m.
Tuesday, December 12 . . . . 6:30 a.m. – 3:15 p.m.
Service frequency will vary throughout the day. Look for detailed shuttle bus schedules in each hotel lobby.

Service will not be provided for the following hotels, located within walking distance of the San Diego Convention Center:
• Courtyard San Diego Gaslamp/Convention Center
• Embassy Suites San Diego Bay Downtown
• Hard Rock Hotel San Diego
• Hilton San Diego Bayfront
• Hilton San Diego Gaslamp Quarter
• Horton Grand Hotel
• Hotel Indigo San Diego Gaslamp Quarter
• Hotel Z
• Manchester Grand Hyatt
• Margaritaville Hotel San Diego Gaslamp Quarter
• Marriott Marquis San Diego Marina
• Marriott San Diego Gaslamp Quarter
• Omni San Diego
• Pendry San Diego
• Residence Inn San Diego Downtown/Gaslamp Quarter

AIRPORT SHUTTLE INFORMATION
The official shuttle provider, Kushner & Associates, will offer one-way direct shuttle service every 30 minutes between the San Diego Convention Center and the San Diego International Airport during the days and times indicated below.
Tickets are sold on site at the ASH Airport Shuttle Desk in the Hall C Lobby, Ground Level of the San Diego Convention Center. Tickets cost $25.

Tickets Sales Hours
Monday, December 11 . . . . 9:00 a.m. - 7:00 p.m.
Tuesday, December 12 . . . . 7:00 a.m. - 2:45 p.m.

Shuttle Hours
Monday, December 11 . . . . 12:00 noon - 6:00 p.m.
Tuesday, December 12 . . . . 9:00 a.m. - 3:00 p.m.

Departure Location: San Diego Convention Center, Buses load outside curbside in front of Hall C Lobby. Level 1

PARKING
On-site private vehicle parking is available at the San Diego Convention Center as well as nearby parking options that serve the Downtown San Diego area. For detailed parking information, visit https://www.visitsandiego.com/parking.

GETTING AROUND
The area's public transportation system - MTS - has routes servicing the San Diego Convention Center with connections to the San Diego International Airport and downtown San Diego. To plan your journey and obtain the latest fares, visit https://www.sdmts.com/.

Taking the MTS Trolley is one of the most convenient and least expensive ways to explore the downtown area and the San Diego Convention Center. For maps and fare information, visit the MTS Trolley website, https://www.sdmts.com/transit-services/trolley.

FRED: Free Ride Everywhere Downtown is a unique form of transport in San Diego. These electric, open-air vehicles offer completely free rides within their service area throughout downtown San Diego. Service works through a mobile app and can be a great option if the pick-up times align with your schedule. Download the Ride Circuit app to request a ride. Hours of operation can be found at ridecircuit.com/fred.

Taxis in San Diego are billed using a base fare of $3 with a charge of $3.30 per mile.

EXPOSITION
Nearly 300 pharmaceutical companies, medical suppliers, clinical diagnostic and research-based companies, publishers, and nonprofit organizations will be participating in the 65th ASH Annual Meeting and Exposition. The state-of-the-art exhibit hall will feature the latest technology and research as well as a wide range of products and services. The exposition will be held in Halls B-F in the San Diego Convention Center. Badges will be required for entrance. For safety and liability reasons, ASH does not permit children 12 years of age or younger at any time in the exhibit areas. During move-in or move-out, NO ONE under the age of 18 will be permitted within the exhibit areas.

Exhibit Hours
Saturday, December 9 . . . . 11:00 a.m. – 5:00 p.m.
Sunday, December 10 . . . . 10:00 a.m. – 5:00 p.m.
Monday, December 11 . . . . 10:00 a.m. – 2:00 p.m.

LUNCH AVAILABLE SUNDAY AND MONDAY
Your "ticket" for lunch is encoded in your badge, which will be scanned for entry into the “ticketed” event. Simply present your badge to access the complimentary light lunch offered on Sunday and Monday in the Exhibit Hall. Lunch will be served from the ASH Café areas located in the back of the exhibit hall.

Lunch Hours
Sunday, December 10 . . . . 11:00 a.m. – 12:30 p.m.
Monday, December 11 . . . . 12:00 noon – 1:30 p.m.
**ASH BOOTH (#1215) – YOUR GATEWAY TO ALL ASH HAS TO OFFER**

ASH is more than just an annual meeting; it is the premier hematology organization in the world. ASH is proud to offer its members many valuable resources. Come say hello and see what the Society has to offer at the ASH Booth (#1215). Get the latest information on grants and awards, publications, educational materials, and ASH meetings and find out how you can help move hematology forward with a contribution to ASH Foundation programs. Be sure to pick up the most recent issues of Blood, see what materials are available to hematologists around the world, and discover free online ASH resources. Our friendly staff will be glad to answer any questions and hear your feedback about the annual meeting or the Society. Consider this an open invitation to visit the booth Saturday, Sunday, and Monday to see how ASH can do more for you. Be sure to pick up a small giveaway as a token of our appreciation for attending the annual meeting.

**CORPORATE PRESENTATIONS**

Corporate Presentations include Product Theaters, Industry Theaters, and Company Showcases, which feature new research findings, company overviews, and products presented to small groups of annual meeting attendees (no more than 150). All corporate presentations will take place on the Upper Level of the San Diego Convention Center (Rooms 1-5). Check the mobile app for the specific room number of the presentation you wish to attend. The sessions offered at the times listed below will be solely promotional in nature; therefore, continuing medical education credits will not be offered.

**Theater Hours**

**Saturday, December 9**
11:30 a.m. – 12:30 p.m.
1:30 p.m. – 1:45 p.m.
3:30 p.m. – 3:45 p.m.

**Sunday, December 10**
8:00 a.m. – 9:00 a.m.
11:30 a.m. – 12:30 p.m.
4:00 p.m. – 4:15 p.m.

**Monday, December 11**
8:00 a.m. – 9:00 a.m.
12:15 p.m. – 1:15 p.m.

Please see page 139 for detailed Corporate Presentation program information.

**POSTER SESSIONS**

Poster sessions are held in Halls G-H of the San Diego Convention Center. Receptions are scheduled for Saturday, Sunday, and Monday evening during the poster sessions, and badges will be required for entrance.

**Saturday, December 9**
9:00 a.m. – 7:30 p.m. Poster Session I – Viewing
5:30 p.m. – 7:30 p.m. Poster Session I – Presentations

**Sunday, December 10**
9:00 a.m. – 8:00 p.m. Poster Session II – Viewing
6:00 p.m. – 8:00 p.m. Poster Session II – Presentations

**Monday, December 11**
9:00 a.m. – 8:00 p.m. Poster Session III – Viewing
6:00 p.m. – 8:00 p.m. Poster Session III – Presentations

**SOCIAL EVENTS**

**POSTER HALL RECEPTIONS**

Saturday, December 9 ........... 5:30 p.m. – 7:30 p.m.
Sunday, December 10 ........... 6:00 p.m. – 8:00 p.m.
Monday, December 11 ........... 6:00 p.m. – 8:00 p.m.

Abstracts selected for poster presentations feature new advancements in hematologic research and are considered among the best of the thousands submitted for the 2023 ASH Annual Meeting. ASH invites meeting attendees to take advantage of these special opportunities to meet the abstract authors, discuss their research, and ask them questions. Light snacks and beverages will be provided.

**ASH FOUNDATION RUN/WALK**

**Sunday, December 10, 2023, 7:00 a.m. – 9:00 a.m.**

Fifth Avenue Landing (on the Embarcadero and marina side of the convention center toward the Hilton San Diego Bayfront Hotel)

Begin your day in a fun, healthy, and philanthropic way by participating in the 10th annual ASH Foundation Run/Walk before attending the sessions on Sunday, December 10. Participants may run or walk through the designated event course in scenic San Diego, choosing either a 3K or 5K route. Not attending in person this year? Don’t worry! You can still support the Foundation by choosing your own virtual 3K or 5K route.

Proceeds from all individual and group registration fees as well as additional individual donations will benefit the ASH Minority Recruitment Initiative Fund. ASH and the ASH Foundation may opt to designate a portion of, or all corporate sponsorship revenues associated with the run/walk to help support the cost of administering the event. Learn more and register at https://www.hematology.org/foundation/run-walk
GENERAL INFORMATION

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

MEETING RULES AND REGULATIONS

CODE OF CONDUCT

ASH is committed to providing a welcoming meeting environment for all attendees. This Code of Conduct applies to all in-person and virtual participants, including members, volunteers, guests, exhibitors, vendors, staff, and any other attendee.

All attendees will conduct themselves in a collegial and respectful manner, free from any form of discrimination, harassment, or retaliation. Attendees will commit to creating a safe, inclusive, and professional atmosphere. Inappropriate conduct, including but not limited to harassment; threatening physical or verbal actions; or disorderly or disruptive conduct, will not be tolerated.

If you or anyone you know is being treated inappropriately, feels unsafe, and/or witnesses any unacceptable behavior, please contact customerservice@hematology.org as soon as possible. ASH will do its best to respond in a timely manner and determine the appropriate next steps.

MEETING AND SESSION PARTICIPATION

Admission to all official ASH events will require a proper display of registration badges. Badges should always be worn and are non-transferable. False certification of individuals as paid ASH meeting attendees, misuse of badges, any method of assisting unauthorized persons to gain access to any in-person or virtual meeting event, or inappropriate conduct, including but not limited to harassment, threatening physical or verbal actions, or disorderly or disruptive conduct, will not be tolerated and will be just cause for repossessing badges of any individuals involved and/or revoking access to the meeting or virtual meeting platform. As a result, ASH reserves the right to expel all parties and/or revoking access to the meeting or virtual meeting just cause for repossessing badges of any individuals involved and/or revoking access to the meeting or virtual meeting platform. As a result, ASH reserves the right to expel all parties involved and has no obligation to refund registration fees paid.

Below are the policies that all in-person participants of the annual meeting will be required to acknowledge and agree to as part of the badge pick-up process at the San Diego Convention Center:

1. I AM AN ADULT OVER THE AGE OF 18, AND I KNOWINGLY AND VOLUNTARILY ASSUME ANY AND ALL RISKS AND DANGERS THAT MAY OCCUR PURSUANT TO MY ATTENDANCE AND PARTICIPATION IN THE ASH ANNUAL MEETING, INCLUDING THE RISK OF ILLNESS, INJURY, DEATH, OR PROPERTY DAMAGE AND I RELEASE ASH AND THE SAN DIEGO CONVENTION CENTER FROM ANY AND ALL SUCH LIABILITY. I agree, for myself and any heirs, not to sue ASH or the San Diego Convention Center or otherwise assert any claim for damages arising out of any illness (including COVID-19 or other communicable disease or illness), personal injury, temporary or permanent disability, death, damages, liabilities, or expenses I or they may sustain arising out of my attendance and participation in the ASH Annual Meeting.

2. I agree that I will not pass my registration badge to another individual, or otherwise allow anyone else to use my badge, since the recipient would not have completed the requirement to show proof of vaccination to ASH before a badge is issued. I understand that violating this requirement will result in immediate revocation of my access to the meeting, and possibly future meetings.

PARTICIPATION OF FINANCIAL PROFESSIONALS

Financial professionals and other individuals whose principal reason for attending the meeting is to seek business opportunities or obtain information affecting investment positions are welcome to register for the meeting. However, the educational and scientific aspects of the meeting are always top priority. Financial professionals are required to identify themselves when speaking with presenters, particularly when asking questions for which the answers may have implications for corporate valuation or positions in equity markets. Speakers and moderators are also asked to give preference to questioners with scientific or clinical inquiries.

ANNUAL MEETING DATA COLLECTION

As a participant of the meeting, you have read and agreed to the following privacy policies and/or terms of service:

American Society of Hematology
- Privacy Policy (hematology.org/about/privacy-policy)
- Terms of Service (hematology.org/about/terms-of-service)

SPARGO (ASH Registration and Housing provider)
- Privacy Policy (https://spargoinc.com/privacy-statement)
- Terms of Service (https://spargoinc.com/terms/)

Attendees who have questions or concerns can contact ashregistration@spargoinc.com.

PROHIBITED SESSION ROOM BEHAVIOR

In crowded sessions, please honor the instructions provided by ASH staff. You may be told not to stand against the walls in these rooms or not to block the aisles. Please note that if a room reaches full capacity, you may be denied entry, as ASH must obey the guidelines established by the Fire Marshal.

CHILDREN

For safety reasons, children under the age of 12 (including infants in carriers and strollers, or hand-carried infants and toddlers) are not permitted the exhibit hall or poster sessions. Additionally, ASH prohibits all children and infants in the sessions, as they may distract the speakers and disrupt other attendees. Attendees should contact ASH for assistance with childcare options in advance of the meeting.

RADIO FREQUENCY IDENTIFICATION (RFID) BADGE SCANNING IN USE

As part of ASH’s ongoing efforts to improve the member experience, RFID-enabled badges will be used at the ASH annual meeting. No identifying personal information will be stored in the RFID badge, only an ID number. Data collected will only be used for program planning purposes and will not be shared or sold to other entities. Attendees who have questions or concerns can contact ashregistration@spargoinc.com.
PHOTOGRAPHY AND RECORDING OF COPYRIGHTED MATERIAL AT THE ASH ANNUAL MEETING

A. General

Materials presented at the American Society of Hematology ("ASH") annual meeting, including all slides, written and oral presentations, posters, and other materials displayed, shown, or otherwise published during the ASH annual meeting (the "Meeting Materials"), are protected by copyright and may not be publicly displayed or republished (including social media) without the express written consent of the copyright owner, ASH, or (in the case of the slides and posters) the presenter or author except as expressly provided in this Policy.

B. Photographs and Audio Recording

Limited Right to Share: Except as provided in Sections A and B.2 of this Policy (hematology.org/meetings/annual-meeting/attendee-resources/photography-and-recording#b2), attendees of the ASH annual meeting may take photographs and make audio recordings (but no video recordings or live-streaming) of Meeting Materials for personal, non-commercial use, which are licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International license (available in its entirety at http://creativecommons.org/licenses/by-nc-nd/4.0/legalcode). This means that, except as provided in Sections A and B.2 of this Policy, attendees may share a limited number of photographs or short audio recordings of the Meeting Materials in a reasonable manner, as determined by ASH, in any medium or format subject to the following terms:

Attribution: an attendee must give appropriate credit to the original author, and may not in any way suggest that the original author endorses the attendee or his or her use;

Non-Commercial: an attendee may not use the Meeting Materials for commercial purposes; and

No Derivatives: if an attendee remixes, transforms, or builds upon the Meeting Material, he or she may not distribute or publish the modified material.

Poster and Exhibit Hall Presentations: Attendees of the ASH annual meeting may take photographs and make recordings of Meeting Materials associated with Poster and Exhibit Hall presentations and displays for personal, non-commercial, use only. Attendees are strictly prohibited from sharing Meeting Materials associated with Poster Presentations or exhibit hall displays without the express consent of the presenter or exhibitor, respectively, and the copyright owner of such Meeting Materials.

C. No Disruptive Recordings or Photos

Attendees taking photos or audio recording of meeting materials must do so in a non-disruptive manner so as not to disturb the presenter and other attendees. Flash photography is strictly prohibited.

D. No Video Recording, Live Audio, or Video Streaming

Sharing any recordings of meeting materials, including live streaming audio or video recordings, is strictly prohibited.

E. Violators

Violators of this Policy may be asked to leave the room or session and may be escorted and barred from the ASH meeting. Repeat violators may have their ASH meeting badges and/or virtual meeting access revoked and not be allowed to return to attend the remainder of the ASH meeting.

F. Disclaimer

ASH will have professional photographers present at the meeting, and portions of the meeting will be recorded. Any photographs or recordings taken during the meeting may be used in future ASH publications, online, or in other ASH materials. Attendance or participation in the meeting constitutes an agreement with ASH by the registrant for the Society to use and distribute the registrant's image or voice in photographs, videotapes, audiotapes, or other electronic media pertaining to the ASH annual meeting events and activities.
As a global hematology community, ASH understands the importance of having individuals with diverse perspectives and experiences in all areas of the field. Through various ASH programs and committees, ASH continues its long-standing commitment to combating inequities in hematology, supporting scientists and clinicians from backgrounds underrepresented in medicine, and embracing diverse voices across the patient and health care communities. ASH’s efforts in diversity, equity, and inclusion apply to everyone, regardless of race, ethnicity, religion, age, sexual orientation, gender identity or expression, ability, national origin, or other attributes. Join us for the following events at the 65th ASH Annual Meeting to help improve diversity, equity, and inclusion in medical research on hematologic diseases and disorders and in the practice of hematology.

### ASH HEALTH EQUITY STUDIO

**Saturday, Sunday, Monday**

**Sails Pavilion, San Diego Convention Center**

As part of our commitment to promoting and nurturing a diverse and inclusive hematology community, the American Society of Hematology (ASH) is offering the ASH Health Equity Studio, located in ASH Central. This brave space is designed to help attendees recognize inequities in health care and provide tools to make change in their institutions. Plan to attend these sessions to learn more about the root causes of health inequities, strategies to overcome disparities in patient care and career development, and ways to improve diversity and inclusion in hematology. These sessions will include a short expert commentary followed by facilitated conversations about actions that can be taken to address health inequities at your institution.

### PROMOTING MINORITIES IN HEMATOLOGY ORAL PRESENTATIONS AND RECEPTION (FOR IN-PERSON PARTICIPANTS)

**Saturday 6:30 p.m. – 9:00 p.m.**

**Marina Ballroom G, Marriott Marquis San Diego Marina**

ASH invites all interested meeting attendees to this event, which will showcase training and research opportunities geared toward increasing the diversity of scholars in the field of hematology. The highlight of the session will be scientific presentations from the ASH Minority Medical Student Award, Minority Resident Hematology Award, ASH Minority Graduate Award, and the ASH Minority Fellowship Award program participants. A special reception will follow the presentations to mark the 20th anniversary of the ASH Minority Recruitment Initiative.

### MATERNAL HEALTH – FERTILITY PRESERVATION IN HEMATOLOGY CARE

**Sunday 9:30 a.m. – 11:00 a.m.**

**Ballroom 20AB, San Diego Convention Center**

Both patients with hematologic conditions and their hematologists face a complex set of challenges when considering options for fertility preservation. With new technologies available and a broader understanding of the need for fertility preservation, there are more opportunities available. This session will explore why there has been such a marked increase in demand for these options, what exactly the options and techniques available are and what both hematologists and their patients need to expect in success rates, complications and demands on their already busy schedules.

### SPECIAL SCIENTIFIC SESSION ON RACE AND SCIENCE

**Sunday 9:30 a.m. – 11:00 a.m.**

**Hall A, San Diego Convention Center**

Race and Science: Bench to Bedside to the Community. Will address DEI as it relates to basic through clinical research. The following two questions will be the core focus of the discussion: (1) How do we ensure that research is generalizable; and (2) What are the critical DEI questions that need to be addressed in the different domains of research (basic, translational, and clinical).
### Health Equity Rounds Lunch (for In-Person Participants)

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sunday</td>
<td>11:15 a.m. – 12:15 p.m.</td>
<td>Sapphire Ballroom CD, Hilton San Diego Bayfront</td>
</tr>
</tbody>
</table>

The Health Equity Rounds are interactive in-person, case-based discussions with interdisciplinary panels, including hematologists, health equity/public health experts, patients, and patient advocates, to discuss health equity issues within hematology.

### Wake Up to DEI Networking Breakfast (for In-Person Participants)

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Monday</td>
<td>7:00 a.m. – 8:30 a.m.</td>
<td>Marina Ballroom, Marriott Marquis San Diego Marina</td>
</tr>
</tbody>
</table>

This will be a networking gathering to allow the communities that fall within the Diversity, Equity, and Inclusion (DEI) umbrella a space to gather across communities and get to know each other. The event will include remarks from a member of the ASH Committee on Diversity, Equity, and Inclusion.

### AI in Hematology: Where Do You Stand in 2023?

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Monday</td>
<td>10:30 a.m. – 12:00 p.m.</td>
<td>Room 11, San Diego Convention Center</td>
</tr>
</tbody>
</table>

Artificial intelligence (AI) and related technologies are rapidly gaining traction in a variety of industries, including healthcare. The integration of AI and machine learning (ML) has the potential to revolutionize the way we approach research and patient care in hematology, from diagnosis to prognosis and treatment selection. This session will delve into the current state of AI and ML in diagnostic hematology and clinical research. It will highlight the various ways in which AI and ML are being used in hematology, such as developing diagnostic tools and novel drug targets. Additionally, the session will discuss the use of AI and ML in prognostic models, which can help predict the outcome of a patient’s disease, as well as personalized treatment plans. Finally, the session will discuss the complexity and the importance of AI ethics.

### Women in Hematology Networking Reception (for In-Person Participants)

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Monday</td>
<td>7:30 p.m. – 9:30 p.m.</td>
<td>Coronado Ballroom &amp; Terrace, Manchester Grand Hyatt San Diego</td>
</tr>
</tbody>
</table>

The networking reception provides a space where all can gather in an informal environment, interact with peers, connect with role models and potential mentors, and become inspired and empowered to overcome the challenges women face in hematology.
NON-CME SESSIONS

ASH is committed to continuously re-evaluating our policies and processes to ensure that they align with the Accreditation Council for Continuing Medical Education’s (AACME) increasingly stringent standards. The ACCME defines Ineligible Companies (IC), also known as commercial interests, as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Pharmaceutical and biotechnology companies, including biomedical startups and diagnostic laboratories with proprietary products, are classified as ineligible companies and, per ACCME, any presentation given by employees of industry is considered to be promotional in nature and therefore ineligible to be accredited.

There are a number of programs and sessions in the program that are not accredited for CME. Please note that oral and poster abstracts are no longer included in the accredited programming.

The final list of Non-CME sessions is subject to change. Accredited sessions will be labeled on the virtual platform and an up-to-date list of sessions will also be available.

Non-CME Sessions
Due to stricter ACCME guidelines regarding who may be allowed to control/present accredited content, the following sessions will not be certified for CME credit.

General Sessions
- Best of ASH
- Ernest Beutler Lecture and Prize
- Late-Breaking Abstracts Session
- Plenary Scientific Session

Scientific Program Sessions
- The Evolution of Multiple Myeloma: From Inside-Out
- Next Generation of Gene-Based Therapies for Bleeding Disorders
- JOINT SESSION: Genome Engineering for Enhanced Blood Cancer Immunotherapy

Special Interest Sessions
- ASH and the ASH Research Collaborative: Advancing Progress in Sickle Cell Disease
- ASH Foundation Run/Walk
- Blood Advances Meet the Editors
- Blood Advances Presents: How to Peer Review a Scientific Paper
- Blood and Beyond
- Blood Presents: How to Get Published in a Peer Review Journal

Health Equity Rounds Lunch
Hemostasis and Thrombosis Community Networking Reception
Meet the Blood Editors
Promoting Minorities in Hematology: Presentations and Reception
Women in Hematology Networking Dinner
Wake up to DEI Networking Breakfast

Spotlight Sessions
- The Evolution of Multiple Myeloma: From Inside-Out
- Next Generation of Gene-Based Therapies for Bleeding Disorders

Non-CME Programs
All sessions in the following programs are not accredited for CME credit:
- ASH Health Equity Studio
- ASH Poster Walks
- ASH Wellness Studio
- ASH-a-Palooza Events
- Company Showcases
- Industry Theaters
- Oral and Poster Abstracts
- Scientific Workshops
- Product Theaters
- Trainee Activities and Services

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.
For your patients

Learn more about dosing information for KEYTRUDA® (pembrolizumab)

For more information, visit keytrudahcp.com/dosing
AMERICAN SOCIETY OF HEMATOLOGY
65TH ASH® ANNUAL MEETING
AND EXPOSITION

DAY-AT-A-GLANCE

Friday, December 8, 2023

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

THURSDAY, DECEMBER 7, 2023

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>5:30 a.m.-10:00 p.m.</td>
<td>Registration at the Airport (for in-person participants)</td>
</tr>
<tr>
<td>San Diego International Airport</td>
<td></td>
</tr>
<tr>
<td>3:00 p.m.-7:00 p.m.</td>
<td>Registration at the Convention Center (for in-person participants)</td>
</tr>
<tr>
<td>Ballroom 20 Lobby</td>
<td></td>
</tr>
</tbody>
</table>

FRIDAY, DECEMBER 8, 2023

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>5:30 a.m.-10:00 p.m.</td>
<td>Registration at the Airport (for in-person participants)</td>
</tr>
<tr>
<td>San Diego International Airport</td>
<td></td>
</tr>
<tr>
<td>7:00 a.m.-6:00 p.m.</td>
<td>Learn, Engage, and Relax in ASH Central (for in-person participants)</td>
</tr>
<tr>
<td>Sails Pavilion</td>
<td></td>
</tr>
<tr>
<td>7:00 a.m.-6:00 p.m.</td>
<td>Registration at the Convention Center (for in-person participants)</td>
</tr>
<tr>
<td>Ballroom 20 Lobby</td>
<td></td>
</tr>
<tr>
<td>3:00 p.m.-7:00 p.m.</td>
<td>Registration at the Grand Hyatt (for in-person participants)</td>
</tr>
<tr>
<td>Manchester Grand Hyatt San Diego, Hotel Main Lobby</td>
<td></td>
</tr>
<tr>
<td>7:00 a.m.-6:00 p.m.</td>
<td>Registration at the Marriott Marquis (for in-person participants)</td>
</tr>
<tr>
<td>Marriott Marquis San Diego Marina, East Lobby Lounge</td>
<td></td>
</tr>
<tr>
<td>9:00 a.m.-12:00 p.m.</td>
<td>Training Program Directors Workshop (for in-person participants)</td>
</tr>
<tr>
<td>Hilton San Diego Bayfront, Indigo 204</td>
<td></td>
</tr>
</tbody>
</table>

BEYOND THE GUIDELINES: Clinical Investigator Perspectives on the Management of Patients with Follicular, Mantle Cell and Hodgkin Lymphoma (Part 1 of a 4-part CME-accredited Symposia Series)
Omni San Diego, Grand Ballroom 4
Exploring Unmarked Territory in MDS: Taking Command and Enhancing Care with Team-Based Diagnosis and Treatment for Lower- and Higher-Risk Disease
Ballroom 20C
Medical Crossfire®: Novel BTKi Strategies Transforming Aggressive and Indolent B-Cell Malignancies
Room 6B
Myelodysplastic Syndromes 2023: What’s New?
Marriott Marquis San Diego Marina, San Diego Ballroom AB
Overcoming Racial Disparities in Multiple Myeloma Outcomes and Clinical Trials: How We are Moving Care Forward Today
Room 6A
Raising the BCMA Standard in Multiple Myeloma: Strategies for Enhanced Care with Potent CAR-T and Bispecific Options
Marriott Marquis San Diego Marina, Pacific Ballroom Salons 15-17

9:00 a.m.-12:00 p.m.  | Training Program Directors Workshop (for in-person participants)         |
| Hilton San Diego Bayfront, Indigo 204 |

11:00 a.m.-2:00 p.m.   | Satellite Symposia                                                   |

A Master Class in Personalized Myelofibrosis Care: Applying New Evidence and Novel Therapeutic Strategies to Improve Outcomes
Marriott Marquis San Diego Marina, San Diego Ballroom AB
An MCL Quiz Game: Experts Review New and Emerging Therapies to Optimize Clinical Outcomes
Marriott Marquis San Diego Marina, Pacific Ballroom Salons 21-22

Advances in the Treatment Paradigm of Myeloid Malignancies: From Biology to Clinical Practice
Room 6C

Applying the Latest Evidence and NCCN Guideline Recommendations in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Marriott Marquis San Diego Marina, Pacific Ballroom Salons 21-22
BEYOND THE GUIDELINES: Clinical Investigator Perspectives on the Management of Patients with Diffuse Large B-Cell Lymphoma (Part 2 of a 4-part CME-accredited Symposia Series)
Omni San Diego, Grand Ballroom

CAR T-Cell Therapies in Relapsed/Refractory Multiple Myeloma: Evaluating the Evidence for Optimal Integration
Room 30 A-E

Controlling and Conquering CLL: Guidance on Modern Targeted Options, Innovative Combinations, and Sequential Management
Ballroom 20CD

Experts Address the Hottest Topics in AML: Considerations on FLT3, IDH1/2, TP53, Maintenance, Novel Combinations and Beyond!
Room 6A

Hitting the Mark? Targeted Antibody-Based Therapy for Diffuse Large B-cell Lymphoma
Room 6DE

Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?
Marriott Marquis San Diego Marina, Pacific Ballroom Salons 24-26

Medical Crossfire: Bridging Expert Guidance and Evidence-Based Recommendations in the Treatment of AYA and Adult ALL
Marriott Marquis San Diego Marina, Marriott Grand Ballroom 11-13

More Than a Disease: Exploring the Patient Journey for Chronic Immune Thrombocytopenia
Marriott Marquis San Diego Marina, Marriott Grand Ballroom 2-4

Multiple Myeloma: Clinical Challenges for the Community Clinician
Marriott Marquis San Diego Marina, Marriott Grand Ballroom 5-6

Optimizing Myelofibrosis Management with Current and Emerging Therapies
Marriott Marquis San Diego Marina, Marriott Grand Ballroom 8-9

Reimagining Outcomes in Hemophilia: Improving Efficacy and Reducing Treatment Burden with High-Sustained Factor and Non-Factor Replacement Therapies
Marriott Marquis San Diego Marina, Pacific Ballroom Salons 18-19

Show Me the Data™: How Do We Navigate the Latest Evidence on Novel Therapies, Combinations, and Clinical Trials Across MPN Care in the Context of Current Treatment Algorithms?
Room 6B

Untangling Amyloidosis 2023: Diagnosis, Prognosis, Selection of Individualized Therapy, and Management of Difficult Clinical Complications
Ballroom 20AB

12:45 p.m.-5:00 p.m. ASH-a-Palooza (Open to Trainees Only)
Petco Park
Opening Song and Welcome
ASH Talks
Blood Drops
Blood Buddies

1:00 p.m.-1:20 p.m. ASH-a-Palooza (Open to Trainees Only)
ASH Talk #1 - Imposter Syndrome/DEI/Pay Disparities
Petco Park, Sections 112 and 114

2:00 p.m.-5:00 p.m. Scientific Workshops
Scientific Workshop on Defining Goals and Utilizing Tools for Enhancing Diversity, Equity and Inclusion (DEI) in Clinical Trials in Hematology
Room 33

Scientific Workshop on Diagnostic Techniques in Classical and Malignant Hematology
Room 28 A-D

Background to Scientific Workshop on Germline Predisposition to Hematopoietic Malignancies and Bone Marrow Failure
Room 29

Scientific Workshop on Hematology and Aging
Room 11

Scientific Workshop on the Interplay between Coagulation and Malignancy
Room 25

Scientific Workshop on Mitochondria and Metabolism in Blood Cancer - From Worms to Patients
Room 24

Scientific Workshop on Myeloid Development
Room 6CF

Scientific Workshop on Therapy Resistance Mechanisms in Blood Malignancies
Room 7

Scientific Workshop on Viruses in Hematology: Emerging Challenges and Therapeutic Vulnerabilities
Room 8

2:10 p.m.-2:30 p.m. ASH-a-Palooza (Open to Trainees Only)
ASH Talk #2 - Approaches to Team Management
Petco Park, Sections 112 and 114

3:00 p.m.-6:00 p.m. Satellite Symposia
A Rare Day in the Community Hematology Clinic: Interesting Cases in Classical Hematology
Marriott Marquis San Diego Marina, Marriott Grand Ballroom 11-13

Achieving “Next-Level” Care in AML: Conversations on Targeted Platforms, Emerging Immunotheerapies, and Implications for Precision Medicine
Marriott Marquis San Diego Marina, Pacific Ballroom Salons 15-17

Advances in Autoimmune Hemolytic Anemia: Targeting the Complement Cascade in Cold Agglutinin Disease
Marriott Marquis San Diego Marina, San Diego Ballroom AB

Advances in Precision Medicine for Relapsed/Refractory Diffuse Large B-Cell Lymphoma Care
Room 30 A-E

Advancing cTTP Care Through Integration of the Latest Clinical Evidence
Ballroom 20AB

AL Amyloidosis: Advancements and Future Trends on Diagnosis and Individualized Treatment Approaches
Marriott Marquis San Diego Marina, Pacific Ballroom Salons 21-22
All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

**DAY-AT-A-GLANCE**

**FRIDAY, DECEMBER 8, 2023**

**Room 6DE**

**Amplying New and Emerging Clinical Evidence in the Treatment and Management of Myelodysplastic Syndrome**

**Marriott Marquis San Diego Marina, Pacific Ballroom Salons 18-19**

**BEYOND THE GUIDELINES: Clinical Investigator Perspectives on the Management of Patients with Chronic Lymphocytic Leukemia (Part 3 of a 4-part CME-accredited Symposia Series)**

**Omni San Diego, Grand Ballroom**

**Case Challenges in Myelofibrosis for the Community Clinician**

**Marriott Marquis San Diego Marina, Marriott Grand Ballroom 5-6**

**Changing the Path of Myelofibrosis: Envisioning a Brighter Future for Our Patients**

**Marriott Marquis San Diego Marina, Marriott Grand Ballroom B-9**

**Comprehensive Approaches to Creating Successful Sickle Cell Management Plans Across Patients’ Lifespans**

**Room 6B**

**Putting Your Stamp on the Next Generation of Care in CML – Improving Outcomes from Frontline to R/R Treatment Settings**

**Marriott Marquis San Diego Marina, Pacific Ballroom Salons 24-26**

**Real-World Applications of Asparaginase Formulations in ALL and LBL from Pediatric/AYA to Adult Treatment: Maximizing Clinical Benefits Through Multidisciplinary Care**

**Room 6A**

**SATURDAY, DECEMBER 9, 2023**

**7:00 a.m.-7:45 a.m.**

**ASH Wellness Studio**

(for in-person participants)

**ASH Yoga**

**ASH Park @ The Plaza**

**7:00 a.m.-6:00 p.m.**

**Learn, Engage, and Relax in ASH Central**

(for in-person participants)

**Sails Pavilion**

**7:00 a.m.-6:00 p.m.**

**Registration at the Convention Center**

(for in-person participants)

**Ballroom 20 Lobby**

**7:00 a.m.-6:00 p.m.**

**Registration at the Grand Hyatt**

(for in-person participants)

**Manchester Grand Hyatt San Diego, Hotel Main Lobby**

**7:00 a.m.-6:00 p.m.**

**Registration at the Marriott Marquis**

(for in-person participants)

**Marriott Marquis San Diego Marina, East Lobby Lounge**

**8:00 a.m.-9:00 a.m.**

**Coffee and Collaboration in ASH Central**

(for in-person participants)

**Sails Pavilion**

**Day-At-A-Glance**

**8:00 a.m.-9:00 a.m.**

**How I Treat: Bringing Science to Clinical Dilemmas**

(Ticketed Sessions, for in-person participants)

**Acquired Hemophilia A Diagnosis and Management**

**Hilton San Diego Bayfront, Aqua Salon AB**

**Adolescent and Young Adult (AYA) Patients with Acute Lymphoblastic Leukemia (ALL)**

**Hilton San Diego Bayfront, Aqua Salon F**

**Advances in Myeloproliferative Neoplasms Affecting Management**

**Hilton San Diego Bayfront, Aqua Salon D**

**Hematologists and the Care of Pregnant Women**

**Hilton San Diego Bayfront, Aqua 310**

**Patients with Acute Myeloid Leukemia**

**Hilton San Diego Bayfront, Aqua Salon C**

**8:00 a.m.-9:00 a.m.**

**Meet the Scientist**

(Ticketed Sessions, for in-person participants)

**Co-Operativity in the Pathogenesis of Myeloid Malignancies**

**Hilton San Diego Bayfront, Aqua Salon E**

**Improving Outcomes for Individuals with Sickle Cell Disease: Are We Moving the Needle**

**Hilton San Diego Bayfront, Aqua 313**

**Iron and Heme in Stem Cell Maintenance and Erythropoiesis**

**Hilton San Diego Bayfront, Aqua 311**

**Toward a Brighter Future for Preventing COVID-19 in Patients With Hematologic Malignancies: Leveraging the Power of Current Strategies and Next-Generation Agents**

**Ballroom 20CD**

**3:20 p.m.-3:30 p.m.**

**ASH-a-Poolza: President’s Remarks**

(Open to Trainees Only)

**Petcio Park, Sections 112 and 114**

**3:30 p.m.-4:15 p.m.**

**ASH-a-Palooza: Blood Wars - Jeopardy!**

(Open to Trainees Only)

**Petcio Park, Sections 112 and 114**

**5:00 p.m.-7:00 p.m.**

**Trainee Welcome Reception**

(Open to Trainees Only)

**Petcio Park, Left Field**

**7:00 p.m.-10:00 p.m.**

**Satellite Symposia**

**BEYOND THE GUIDELINES: Clinical Investigator Perspectives on the Management of Patients with Multiple Myeloma (Part 4 of a 4-part CME-accredited Symposia Series)**

**Omni San Diego, Grand Ballroom**

**Evolving Paradigms: Novel Approaches and Best Practices for Hodgkin Lymphoma**

**Marriott Marquis San Diego Marina, Marriott Grand Ballroom 11-13**

**How Do We Treat GvHD Today... And Tomorrow? Treatment Algorithms for Key Decision Points in Prophylaxis Care, Acute, and Chronic Disease**

**Marriott Marquis San Diego Marina, Pacific Ballroom Salons 24-26**

**8:00 a.m.-9:00 a.m.**

**How I Treat: Bringing Science to Clinical Dilemmas**

(Ticketed Sessions, for in-person participants)

**Acquired Hemophilia A Diagnosis and Management**

**Hilton San Diego Bayfront, Aqua Salon AB**

**Adolescent and Young Adult (AYA) Patients with Acute Lymphoblastic Leukemia (ALL)**

**Hilton San Diego Bayfront, Aqua Salon F**

**Advances in Myeloproliferative Neoplasms Affecting Management**

**Hilton San Diego Bayfront, Aqua Salon D**

**Hematologists and the Care of Pregnant Women**

**Hilton San Diego Bayfront, Aqua 310**

**Patients with Acute Myeloid Leukemia**

**Hilton San Diego Bayfront, Aqua Salon C**

**8:00 a.m.-9:00 a.m.**

**Meet the Scientist**

(Ticketed Sessions, for in-person participants)

**Co-Operativity in the Pathogenesis of Myeloid Malignancies**

**Hilton San Diego Bayfront, Aqua Salon E**

**Improving Outcomes for Individuals with Sickle Cell Disease: Are We Moving the Needle**

**Hilton San Diego Bayfront, Aqua 313**

**Iron and Heme in Stem Cell Maintenance and Erythropoiesis**

**Hilton San Diego Bayfront, Aqua 311**
Day-At-A-Glance

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

Saturday 09 Dec 2023

Genome Engineering for Enhanced Blood Cancer Immunotherapy
Hilton San Diego Bayfront, Aqua 313

Lymphomagenesis - What Normal Immunology, Abnormal Immunology and Genomics Can Teach Us About Lymphoma Biology and Novel Therapeutic Strategies
Hilton San Diego Bayfront, Aqua 300

9:00 a.m.-9:30 a.m.  Coffee Break in Poster Hall (for in-person participants)

Halls G-H

9:00 a.m.-9:30 a.m.  Health Equity Studio

Outcome Disparities in Hematologic Diseases: The Importance of Social Determinants of Health
Sails Pavilion - ASH Health Equity Studio

9:00 a.m.-9:30 a.m.  Poster Session I - Viewing

Halls G-H

9:05 a.m.-9:15 a.m.  ASH Wellness Studio (for in-person participants)

What’s Restoring You?
Sails Pavilion - ASH Wellness Studio

9:15 a.m.-9:25 a.m.  ASH Wellness Studio (for in-person participants)

An Oasis in Chaos
Sails Pavilion - ASH Wellness Studio

9:30 a.m.-10:45 a.m.  Education Sessions

Acquired Hemophilia A Diagnosis and Management
Room 28 A-D

Are We Personalizing MDS Therapy in 2023?
Marriott Marquis San Diego Marina, Marriott Grand Ballroom 5-6

CAR T Cells in ALL: Bridge or Definitive Therapy?
Room 6B

How Do We Calibrate Cellular Therapy for Lymphoma in 2023?
Room 6CF

What are Treatment Options for Patients with Relapsed, Refractory or Persistent AML?
Marriott Marquis San Diego Marina, Pacific Ballroom Salons 15-17

9:30 a.m.-10:45 a.m.  Scientific Sessions

Mechanisms of Genetic Rescue in Inherited Bone Marrow Failure Syndromes
Room 7

Next Generation of Gene-Based Therapies for Bleeding Disorders
Room 31

The Evolution of Multiple Myeloma: From Inside-Out
Manchester Grand Hyatt San Diego, Grand Hall C

9:30 a.m.-11:00 a.m.  Oral Abstract Sessions

Room 25

113. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias: Basic and Translational: Emerging Therapies for Sickle Cell Disease
Room 29

321. Coagulation and Fibrinolysis: Basic and Translational: Coagulation Protein: Molecular Insights and Molecular Therapies
Room 33

322. Disorders of Coagulation or Fibrinolysis: Clinical and Epidemiological: Out of the Box: Acquired, Vascular and Other Neglected Bleeding Disorders
Room 30

501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis: Basic and Translational: Inflammation, Metabolism, and Stress
Room 24

603. Lymphoid Oncogenesis: Basic: Mechanisms of Acute Lymphoblastic Leukemia Development and Progression
Marriott Marquis San Diego Marina, Marriott Grand Ballroom 11-13

604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Personalized and Combinatorial Approaches to Target Vulnerabilities in Myeloid Malignancies
Ballroom 20CD

605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Novel Therapeutic Approaches in Lymphoma and Multiple Myeloma
Manchester Grand Hyatt San Diego, Grand Hall D

Marriott Marquis San Diego Marina, Pacific Ballroom Salons 21-22

617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Risk Refinement and Therapy Response
Marriott Marquis San Diego Marina, Pacific Ballroom Salons 24-26

627. Aggressive Lymphomas: Clinical and Epidemiological: Real World Data on Outcomes and Treatment-Related Toxicity in B Cell NHL
Manchester Grand Hyatt San Diego, Seaport Ballroom EFGH

634. Myeloproliferative Syndromes: Clinical and Epidemiological: Rare Myeloproliferative Neoplasms: Unveiling Promising Pathways and Novel Therapies
Ballroom 20AB

641. Chronic Lymphocytic Leukemias: Basic and Translational: Molecular Determinants of CLL and Richter Transformation
Manchester Grand Hyatt San Diego, Grand Hall B

651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Spatial Dissection and Multiomics Analysis of the Multiple Myeloma Tumor and Immune Microenvironment
Manchester Grand Hyatt San Diego, Harbor Ballroom

652. Multiple Myeloma: Clinical and Epidemiological: T Cell Redirecting Therapy Outcomes and Associated Complications
Manchester Grand Hyatt San Diego, Seaport Ballroom ABCD

703. Cellular Immunotherapies: Basic and Translational: Overcoming Challenges in CAR-T Therapies Through Biological Insights
Room 6DE
All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

**9:30 a.m.-11:00 a.m.** Special Session on Sickle Cell Disease Centers

**11:00 a.m.-11:00 a.m.** Blood Journals Studio (for in-person participants)

Meet the Blood Advances Editors

**11:00 a.m.-11:30 a.m.** Health Equity Studio

Community Partnerships: An Essential Component to Advance Health Equity

**11:00 a.m.-12:30 p.m.** Live Music and Outdoor Lunch Seating (for in-person participants)

ASH Park @ The Plaza

**11:00 a.m.-12:30 p.m.** Open Time for Lunch

**11:00 a.m.-5:00 p.m.** Exhibits Open

**11:05 a.m.-11:15 a.m.** ASH Wellness Studio (for in-person participants)

**11:15 a.m.-12:15 p.m.** Blood Presents: How to get Published in a Peer Review Journal (for in-person participants)

**11:15 a.m.-12:15 p.m.** ASH Grassroots Network Lunch (for in-person participants)

Marriott Marquis San Diego Marina, Marina Ballroom DE

**11:15 a.m.-12:15 p.m.** Career Development Lunch (Open to Trainees Only)

Hilton San Diego Bayfront, Sapphire Ballroom ABCD

**11:20 a.m.-11:30 a.m.** ASH Wellness Studio (for in-person participants)

**11:30 a.m.-12:30 p.m.** Industry Theaters

BTK Mutations and the Emergence of Treatment Resistance: Changing the CLL Landscape

**11:30 a.m.-12:30 p.m.** Product Theaters

Frontline Treatment of Newly Diagnosed, Transplant-Ineligible Multiple Myeloma Across Patient Types

**11:35 a.m.-11:45 a.m.** ASH Wellness Studio (for in-person participants)

**12:30 p.m.-1:30 p.m.** Ham-Wasserman Lecture

Day-At-A-Glance
### Saturday

**09 Dec 2023**

*All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.*

<table>
<thead>
<tr>
<th>Time</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:30 p.m.-1:45 p.m.</td>
<td>Company Showcases</td>
</tr>
<tr>
<td>1:30 p.m.-1:45 p.m.</td>
<td>Galapagos’ 7 Day Vein-to-Vein Point-of-Care CAR-T Manufacturing Model</td>
</tr>
<tr>
<td>1:30 p.m.-2:00 p.m.</td>
<td>Coffee Break in Exhibit Hall (for in-person participants)</td>
</tr>
<tr>
<td>1:30 p.m.-2:00 p.m.</td>
<td>Health Equity Studio (for in-person participants)</td>
</tr>
<tr>
<td>1:35 p.m.-1:45 p.m.</td>
<td>ASH Wellness Studio (for in-person participants)</td>
</tr>
<tr>
<td>2:00 p.m.-3:15 p.m.</td>
<td>Scientific Symposia</td>
</tr>
<tr>
<td>2:00 p.m.-3:15 p.m.</td>
<td>Education Program</td>
</tr>
<tr>
<td>2:00 p.m.-3:15 p.m.</td>
<td>Scientific Sessions</td>
</tr>
</tbody>
</table>

#### Company Showcases
- Showcases on Galapagos’, a multi-cancer early detection test | Room 5B

#### Coffee Break in Exhibit Hall
- For in-person participants | Halls B-F

#### Health Equity Studio
- How to Support LGBTQIA Patients, Trainees, and Colleagues: A Whole Person Perspective | Sails Pavilion - ASH Health Equity Studio

#### ASH Wellness Studio
- Finding Stillness in the Busyness | Sails Pavilion - ASH Wellness Studio
- The Real Purpose of Your Purpose | Sails Pavilion - ASH Wellness Studio

#### Scientific Symposia
- Alternative Immune Effector Cells | Room 6DE
- Co-Operativity in the Pathogenesis of Myeloid Malignancies
  Marriott Marquis San Diego Marina, Marriott Grand Ballroom 11-13
  Emerging Methodologies to Investigate Platelet Biology | Room 25
- Spatial Genomic & Epigenomic Profiling in Hematology
  Marriott Marquis San Diego Marina, Marriott Grand Ballroom 8-9

#### Education Program
- How Do We Extend Survival for Patients with Chronic Lymphocytic Leukemia (CLL) in 2023?
  Ballroom 20CD
- Inherited Bone Marrow Failure Syndromes - From Pediatrics to Adult | Room 24
- Ongoing Challenges in the Management of VTE | Room 29
- Transfusion Support in Sickle Cell Disease | Room 28 A-D

#### Scientific Sessions
- Co-Operativity in the Pathogenesis of Myeloid Malignancies
  Marriott Marquis San Diego Marina, Marriott Grand Ballroom 11-13
- Emerging Methodologies to Investigate Platelet Biology | Room 25
- Spatial Genomic & Epigenomic Profiling in Hematology
  Marriott Marquis San Diego Marina, Marriott Grand Ballroom 8-9

#### Distinguished Abstract Achievement Awards Ceremony
- Halls G-H - Blood Journals Studio

#### Oral Abstract Sessions
- 101. Red Cells and Erythropoiesis, Excluding Iron: Red Cells: Erythropoiesis in Stress and Disease | Room 33
- 114. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: Hot Topics in Clinical Care and Genomic Factors | Room 31
- 203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: Decoding the Complex Landscape of Human Immunity: Insights From Genetic Mutations to Cellular Heterogeneity | Marriott Marquis San Diego Marina, San Diego Ballroom AB
- 616. Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Novel Uses of Approved Therapeutic Agents | Room 6A
- 617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Biomarkers and Therapeutics | Marriott Marquis San Diego Marina, Pacific Ballroom Salons 24-26
- 621. Lymphomas: Translational: Molecular and Genetic: Microenvironment and Methylome in Lymphoma and Misc. | Ballroom 20AB
- 622. Lymphomas: Translational: Non-Genetic: Illuminating the Tumor Microenvironment and Immune Landscape in Lymphoma | Manchester Grand Hyatt San Diego, Seaport Ballroom ABCD
- 627. Aggressive Lymphomas: Clinical and Epidemiological: Diagnostic and Prognostic Implications in the Care of Patients with Aggressive Lymphomas | Manchester Grand Hyatt San Diego, Grand Ballroom C
- 653. Multiple Myeloma: Prospective Therapeutic Trials: Smoldering and Newly Diagnosed Myeloma | Manchester Grand Hyatt San Diego, Harbor Ballroom
- 704. Cellular Immunotherapies: Early Phase and Investigational Therapies: Expanding Disease Targets for CAR-T Cell Therapies | Room 6B
09 Dec 2023

Day-At-A-Glance

**All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.**

- **705. Cellular Immunotherapies: Late Phase and Commercially Available Therapies: Translational Data and Prognostic Factors**
  - Marriott Marquis San Diego Marina, Marriott Grand Ballroom 5-6

- **721. Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities: Optimizing Conditioning Regimens for Lymphoid Malignancies and Fanconi Anemia**
  - Marriott Marquis San Diego Marina, Marriott Grand Ballroom 5-6

- **723. Allogeneic Transplantation: Long-Term Follow-Up and Disease Recurrence: Long-Term Survival and Survivorship from Clinical Trials And Observations**
  - Room 7

- **803. Emerging Tools, Techniques and Artificial Intelligence in Hematology: Emerging Technologies for Understanding Benign and Malignant Hematology**
  - Room 7

- **901. Health Services and Quality Improvement: Non-Malignant Conditions: Sickle Cell Disease Across the Spectrum**
  - Marriott Marquis San Diego Marina, Pacific Ballroom Salons 15-17

- **902. Health Services and Quality Improvement: Lymphoid Malignancies: Innovative Care in CAR-T Therapy**
  - Marriott Marquis San Diego Marina, Marriott Grand Ballroom 2-4

- **903: Health Services and Quality Improvement: Myeloid Malignancies: From Blood to Bombs: Identifying and Addressing Barriers to Care for Myeloid Malignancies**
  - Hall A

- **905. Outcomes Research: Lymphoid Malignancies: Outcomes Research in Lymphoma/CLL: Biomarkers, Dosing Strategies, and Big-Data**
  - Marriott Marquis San Diego Marina, Pacific Ballroom Salons 21-22

**Saturday**

- **3:45 p.m.-3:55 p.m.**
  - ASH Wellness Studio (for in-person participants)

  *Eating With a Full Mind or Mindfully*
  - Sails Pavilion - ASH Wellness Studio

- **4:00 p.m.-5:00 p.m.**
  - ASH Poster Walks (for in-person participants)

  *ASH Poster Walk on Hemostasis and Thrombosis hosted by Blood VTH*
  - Halls G-H - Blood Journals Studio

- **4:00 p.m.-5:15 p.m.**
  - Education Program

  *Graft Versus Host Disease: Is an Ounce of Prevention Worth a Pound of Cure?*
  - Marriott Marquis San Diego Marina, San Diego Ballroom AB

  *Hematologic Toxicity of Immunotherapies*
  - Room 6DE

  *How is the Management Paradigm Evolving for Hodgkin Lymphoma in 2023?*
  - Ballroom 20CD

  *Why Am I Getting Paged at 2AM? Microangiopathic Emergencies*
  - Room 29

- **3:00 p.m.-3:15 p.m.**

  *Special Symposium on Quality - Identifying and Addressing Underuse in Hematologic Care*
  - Room 11

- **3:30 p.m.-3:45 p.m.**

  *Company Showcases*
  - Room 11

  *Genetic Engineering of T Cells and CD34+ HSPCs using RNA-Lipid Nanoparticle for Cell and Gene Therapies*
  - Room 5B

  *Reimagining Cancer Care at Syndax: Clinical Development of Targeted Therapies*
  - Room 5A

- **3:30 p.m.-4:00 p.m.**

  *Coffee Break in Exhibit Hall (for in-person participants)*
  - Halls B-F

- **3:30 p.m.-4:00 p.m.**

  *Health Equity Studio (for in-person participants)*
  - Room 5A

  *Using Research to Advance Equity in the LGBTQIA+ Space*
  - Sails Pavilion - ASH Health Equity Studio

- **3:35 p.m.-3:45 p.m.**

  *ASH Wellness Studio (for in-person participants)*
  - Sails Pavilion - ASH Wellness Studio

*Workday Tension Timeout*
All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

615. Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies
616. Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies
617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis
618. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis
621. Lymphomas: Translational: Molecular and Genetic
622. Lymphomas: Translational: Non-Genetic
623. Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological
624. Hodgkin Lymphomas and T/NK Cell Lymphomas: Clinical and Epidemiological
626. Aggressive Lymphomas: Prospective Therapeutic Trials
627. Aggressive Lymphomas: Clinical and Epidemiological
631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational
632. Chronic Myeloid Leukemia: Clinical and Epidemiological
634. Myeloproliferative Syndromes: Clinical and Epidemiological
636. Myelodysplastic Syndromes: Basic and Translational
637. Myelodysplastic Syndromes: Clinical and Epidemiological
641. Chronic Lymphocytic Leukemia: Basic and Translational
642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological
651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational
652. Multiple Myeloma: Clinical and Epidemiological
653. Multiple Myeloma: Prospective Therapeutic Trials
654. MGUS, Amyloidosis and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological
701. Experimental Transplantation: Basic and Translational
705. Cellular Immunotherapies: Late Phase and Commercially Available Therapies
711. Cell Collection and Processing
721. Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities
722. Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution
723. Allogeneic Transplantation: Long-Term Follow-Up and Disease Recurrence
731. Autologous Transplantation: Clinical and Epidemiological
732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies
801. Gene Therapies
802. Chemical Biology and Experimental Therapeutics
803. Emerging Tools, Techniques and Artificial Intelligence in Hematology
901. Health Services and Quality Improvement: Non-Malignant Conditions
902. Health Services and Quality Improvement: Lymphoid Malignancies
903. Health Services and Quality Improvement: Myeloid Malignancies
904. Outcomes Research: Non-Malignant Conditions
905. Outcomes Research: Lymphoid Malignancies
906. Outcomes Research: Myeloid Malignancies

6:30 p.m.-8:00 p.m. Promoting Minorities in Hematology (PMH) Oral Presentations (for in-person participants)
Marriott Marquis San Diego Marina, Marina Ballrooms D-F

8:00 p.m.-9:00 p.m. Promoting Minorities in Hematology (PMH) MRI Anniversary Reception (for in-person participants)
Marriott Marquis San Diego Marina, Marina Ballroom G

SUNDAY, DECEMBER 10, 2023

7:00 a.m.-9:00 a.m. ASH Foundation Run/Walk
San Diego Bayfront Park and South Embarcadero

7:00 a.m.-5:00 p.m. Registration at the Convention Center (for in-person participants)
Ballroom 20 Lobby

7:00 a.m.-6:00 p.m. Learn, Engage, and Relax in ASH Central (for in-person participants)
Sails Pavilion

7:30 a.m.-9:30 a.m. Medical Educators Symposium
Hilton San Diego Bayfront, Sapphire Ballroom AB

8:00 a.m.-9:00 a.m. Coffee and Collaboration in ASH Central (for in-person participants)

8:00 a.m.-9:00 a.m. How I Treat: Bringing Science to Clinical Dilemmas (Ticketed sessions, for in-person participants)

Cellular Therapy for Lymphoma
Hilton San Diego Bayfront, Aqua Salon D
Early Management of Acute Promyelocytic Leukemia (APML)
Hilton San Diego Bayfront, Aqua Salon F
Ongoing Challenges in the Management of VTE
Hilton San Diego Bayfront, Aqua Salon AB
T-Cell Redirection Therapy for Multiple Myeloma
Hilton San Diego Bayfront, Aqua Salon E
<table>
<thead>
<tr>
<th>Time</th>
<th>Location</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 a.m.-9:00 a.m.</td>
<td>Industry Theaters</td>
<td><strong>Classical Hematology: Looking into the Future</strong>&lt;br&gt;Room 1B&lt;br&gt;The disease burden of transfusion dependent beta-thalassemia and approaches to cell and genetic therapy&lt;br&gt;Room 1A</td>
</tr>
<tr>
<td>8:00 a.m.-9:00 a.m.</td>
<td>Product Theaters</td>
<td><strong>A Treatment Option for Relapsed or Refractory Multiple Myeloma from Pfizer</strong>&lt;br&gt;Room 2&lt;br&gt;APHEXDA (motixafortide): Learn about this new FDA approved treatment option&lt;br&gt;Room 3&lt;br&gt;Could there be a Link Between Autoimmune Cytopenias, Lymphadenopathy, and Splenomegaly? A Physician’s Perspective and a Patient’s Experience&lt;br&gt;Room 4&lt;br&gt;Exploring Time Off Treatment with a BCL-2 Inhibitor&lt;br&gt;Room 5B&lt;br&gt;Unveiling a Subcutaneous Therapy for 3L+ DLBCL&lt;br&gt;Room 5A</td>
</tr>
<tr>
<td>8:00 a.m.-9:00 a.m.</td>
<td>Hilton San Diego Bayfront, Aqua 300</td>
<td><strong>Lymphomagenesis - What Normal Immunology, Abnormal Immunology and Genomics Can Teach Us About Lymphoma Biology and Novel Therapeutic Strategies (For In-person Participants)</strong></td>
</tr>
<tr>
<td></td>
<td>Hilton San Diego Bayfront, Aqua 314</td>
<td><strong>Mechanisms of Genetic Rescue in Inherited Bone Marrow Failure Syndromes</strong></td>
</tr>
<tr>
<td></td>
<td>Hilton San Diego Bayfront, Aqua 300</td>
<td><strong>Natural Killer Cells: A New Frontier for Cancer Immunotherapy</strong></td>
</tr>
<tr>
<td></td>
<td>Hilton San Diego Bayfront, Aqua 313</td>
<td><strong>Research in Complications Sickle Cell Disease</strong></td>
</tr>
<tr>
<td></td>
<td>Hilton San Diego Bayfront, Aqua 311</td>
<td><strong>The Long Non-Coding Road, RNA and Signaling, and Regulation of Globin Gene Expression</strong></td>
</tr>
<tr>
<td>9:05 a.m.-9:15 a.m.</td>
<td>ASH Wellness Studio</td>
<td><strong>How to Quiet the Mind Chatter</strong>&lt;br&gt;Sails Pavilion - ASH Wellness Studio</td>
</tr>
<tr>
<td>9:15 a.m.-9:25 a.m.</td>
<td>ASH Wellness Studio</td>
<td><strong>Family First - 7 Steps to Living Well</strong>&lt;br&gt;Sails Pavilion - ASH Wellness Studio</td>
</tr>
<tr>
<td>9:30 a.m.-10:45 a.m.</td>
<td>Hilton San Diego Bayfront, Aqua 300</td>
<td><strong>The Impact of the Microbiota on Immunotherapy of Hematological Malignancies</strong>&lt;br&gt;Room 25&lt;br&gt;Understanding Sickle Cell Pathophysiology&lt;br&gt;Room 33</td>
</tr>
<tr>
<td>9:30 a.m.-10:45 a.m.</td>
<td>ASH Wellness Studio</td>
<td><strong>Goldilocks and Transplant Timing in Inherited Marrow Failure Syndromes: Too Early, Too Late, Just Right?</strong>&lt;br&gt;Room 11&lt;br&gt;Hemostasis in Patients With Severe Liver Disease&lt;br&gt;Room 31&lt;br&gt;How Do We Enhance Results in Rare Hematologic Malignancies?&lt;br&gt;Room 29&lt;br&gt;How Do We Improve Outcomes in Relapsed and Refractory Multiple Myeloma in 2023?&lt;br&gt;Manchester Grand Hyatt San Diego, Seaport Ballroom EFGH&lt;br&gt;The Iron Revolution!&lt;br&gt;Room 28 A-D&lt;br&gt;What Are the Advances in Myeloproliferative Neoplasms Affecting Management?&lt;br&gt;Marriott Marquis San Diego Marina, Marriott Grand Ballroom 5-6</td>
</tr>
<tr>
<td>9:00 a.m.-9:30 a.m.</td>
<td>Coffee Break in Poster Hall (for in-person participants)</td>
<td></td>
</tr>
<tr>
<td>9:00 a.m.-9:30 a.m.</td>
<td>Health Equity Studio (for in-person participants)</td>
<td><strong>Systemic Racism in Hematology</strong>&lt;br&gt;Sails Pavilion - ASH Health Equity Studio</td>
</tr>
<tr>
<td>9:00 a.m.-6:00 p.m.</td>
<td>Poster Session II - Viewing</td>
<td><strong>Poster Session II - Viewing</strong>&lt;br&gt;Halls G-H</td>
</tr>
<tr>
<td>10 Dec 2023</td>
<td></td>
<td><strong>Day-At-A-Glance</strong>&lt;br&gt;All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.</td>
</tr>
</tbody>
</table>
All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

**9:30 a.m.-11:05 a.m.**  | **Scientific Sessions**
---|---
**Scientific Committee on Immunology and Host Defense**| **Scientific Committee on Transplantation Biology & Cellular Therapies:**
**Joint Session: Genome Engineering for Enhanced Blood Cancer Immunotherapy**| **Room 6CF**

**10:00 a.m.-11:00 a.m.**  | **Meet the Blood Editors**
---|---
**Halls G-H - Blood Journals Studio** |  

**10:00 a.m.-5:00 p.m.**  | **Exhibits Open**
---|---
**Halls B-F** |  

**11:00 a.m.-11:30 a.m.**  | **Health Equity Studio**
---|---
**(for in-person participants)** |  

**Legally Intentional: Microlearning Session on Systemic Racism** | **Sails Pavilion - ASH Health Equity Studio**

**11:00 a.m.-12:30 p.m.**  | **Complimentary Light Lunch in the Exhibit Hall (for in-person participants)**
---|---
**Halls B-F** |  

**11:00 a.m.-12:30 p.m.**  | **Live Music and Outdoor Lunch Seating (for in-person participants)**
---|---
**ASH Park @ The Plaza** |  

**11:05 a.m.-11:15 a.m.**  | **ASH Wellness Studio**
---|---
**(for in-person participants)** |  

**The Real Purpose of Your Purpose** | **Sails Pavilion - ASH Wellness Studio**

**11:15 a.m.-12:15 p.m.**  | **Blood Advances Presents: How to Peer Review a Scientific Paper**
---|---
**Room 24** |  

**11:15 a.m.-12:15 p.m.**  | **Health Equity Rounds Lunch (for in-person participants)**
---|---
**Hilton San Diego Bayfront, Sapphire Ballroom CD** |  

**11:15 a.m.-12:15 p.m.**  | **Trainee Didactic Session: The International Trainee Journey (Open to Trainees Only)**
---|---
**Room 33** |  

**11:15 a.m.-12:15 p.m.**  | **Trainee Didactic Session: A Road Less Traveled - Careers Outside of Academia (Open to Trainees Only)**
---|---
**Room 31** |  

**11:15 a.m.-12:30 p.m.**  | **ASH Clinicians in Practice (ACIP) Lunch - How Can We Provide Sustainable Care to Hematology Patients?**
---|---
**Marriott Marquis San Diego Marina, Marina Ballroom DE** |  

617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Minimal Residual Disease and Therapy Response  
**Marriott Marquis San Diego Marina, Marriott Grand Ballroom 8-9**

**Manchester Grand Hyatt San Diego, Grand Hall C**

626. Aggressive Lymphomas: Prospective Therapeutic Trials: Novel Therapies For Relapsed/Refractory Aggressive Lymphoma  
**Manchester Grand Hyatt San Diego, Seaport Ballroom ABCD**

627. Aggressive Lymphomas: Clinical and Epidemiological: Treatment to Best Outcomes: Find the Right Therapy for the Right Patient  
**Manchester Grand Hyatt San Diego, Grand Hall D**

632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Treatment-Free Remission and Prognostication  
**Marriott Marquis San Diego Marina, Pacific Ballroom Salons 21-22**

701. Experimental Transplantation: Basic and Translational: T Cells in GVHD, Thymus Regeneration, and Immune Reconstitution  
**Room 6B**

703. Cellular Immunotherapies: Basic and Translational: Novel Approaches for Next Generation Cellular Immunotherapies  
**Room 6A**

**Marriott Marquis San Diego Marina, Pacific Ballroom Salons 18-19**

722. Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Emerging Insights in GVHD Immunobiology  
**Marriott Marquis San Diego Marina, Marriott Grand Ballroom 2-4**

801. Gene Therapies: New Approaches From Bench to Bedside  
**Ballroom 20CD**

904. Outcomes Research: Non-Malignant Conditions: What to Know: Management Costs and Outcomes in Various Non-Malignant Disorders  
**Marriott Marquis San Diego Marina, Pacific Ballroom Salons 15-17**

905. Outcomes Research: Lymphoid Malignancies: Factors That Affect Outcomes in Patients With Leukemia-Beyond the Biology  
**Marriott Marquis San Diego Marina, San Diego Ballroom AB**

9:30 a.m.-11:00 a.m.  | **2023 ASH Guideline Implementation Champions**
---|---
**Room 7** |  

9:30 a.m.-11:00 a.m.  | **Maternal Health: Fertility Preservation in Hematology Care**
---|---
**Ballroom 20AB** |  

9:30 a.m.-11:00 a.m.  | **Special Scientific Session on Race and Science: Bench to Bedside to the Community**
---|---
**Hall A** |  

Day-At-A-Glance
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:20 a.m.-11:30 a.m.</td>
<td>ASH Wellness Studio (for in-person participants)</td>
<td>Sails Pavilion - ASH Wellness Studio</td>
</tr>
<tr>
<td>11:30 a.m.-12:30 p.m.</td>
<td>A Complement Inhibitor for PNH</td>
<td>Room 5B</td>
</tr>
<tr>
<td>11:30 a.m.-12:30 p.m.</td>
<td>A Discussion on a Treatment Option for Sickle Cell Disease</td>
<td>Room 5A</td>
</tr>
<tr>
<td>11:35 a.m.-11:45 a.m.</td>
<td>Stress Doesn’t Exist</td>
<td>Sails Pavilion - ASH Wellness Studio</td>
</tr>
<tr>
<td>12:00 p.m.-1:30 p.m.</td>
<td>Announcement of Awards: Wallace H. Coulter Award for Lifetime Achievement in Hematology, ASH Mentor Awards, ASH Award for Leadership in Promoting Diversity, ASH Outstanding Service Award, and ASH Public Service Award</td>
<td>Marriott Marquis San Diego Marina, Marriott Grand Ballroom 2-4</td>
</tr>
<tr>
<td>12:30 p.m.-1:30 p.m.</td>
<td>Announcement of Awards: Wallace H. Coulter Award for Lifetime Achievement in Hematology, ASH Mentor Awards, ASH Award for Leadership in Promoting Diversity, ASH Outstanding Service Award, and ASH Public Service Award</td>
<td>Marriott Marquis San Diego Marina, Marriott Grand Ballroom 11-13</td>
</tr>
<tr>
<td>1:30 p.m.-2:00 p.m.</td>
<td>Health Equity Studio (for in-person participants)</td>
<td>Hall A</td>
</tr>
<tr>
<td>1:30 p.m.-4:00 p.m.</td>
<td>Simulcast of Announcement of Awards and Plenary Scientific Session (for in-person participants)</td>
<td>Room 28 A-D</td>
</tr>
<tr>
<td>1:30 p.m.-4:00 p.m.</td>
<td>Simulcast of Announcement of Awards and Plenary Scientific Session (for in-person participants)</td>
<td>Marriott Marquis San Diego Marina, San Diego Ballroom AB</td>
</tr>
<tr>
<td>2:00 p.m.-4:00 p.m.</td>
<td>Plenary Scientific Session</td>
<td>Hall A</td>
</tr>
<tr>
<td>4:00 p.m.-4:15 p.m.</td>
<td>Company Showcases</td>
<td>Hall A</td>
</tr>
</tbody>
</table>

**Day-At-A-Glance**

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>4:00 p.m.-4:30 p.m.</td>
<td>Coffee Break in Exhibit Hall (for in-person participants)</td>
<td>Halls B-F</td>
</tr>
<tr>
<td>4:00 p.m.-4:30 p.m.</td>
<td>Health Equity Studio (for in-person participants)</td>
<td>Sails Pavilion - ASH Health Equity Studio</td>
</tr>
<tr>
<td>4:05 p.m.-4:15 p.m.</td>
<td>ASH Wellness Studio (for in-person participants)</td>
<td>Sails Pavilion - ASH Wellness Studio</td>
</tr>
<tr>
<td>4:15 p.m.-4:25 p.m.</td>
<td>Fix the Way You Sit (for in-person participants)</td>
<td>Sails Pavilion - ASH Wellness Studio</td>
</tr>
<tr>
<td>4:30 p.m.-5:30 p.m.</td>
<td>ASH Poster Walks (for in-person participants)</td>
<td>Halls G-H - Blood Journals Studio</td>
</tr>
<tr>
<td>4:30 p.m.-5:45 p.m.</td>
<td>Education Sessions</td>
<td>Room 6CF</td>
</tr>
<tr>
<td>4:30 p.m.-5:45 p.m.</td>
<td>Education Spotlight Sessions</td>
<td>Room 29</td>
</tr>
<tr>
<td>4:30 p.m.-5:45 p.m.</td>
<td>Scientific Spotlight Sessions</td>
<td>Room 6A</td>
</tr>
</tbody>
</table>

**Oral Abstract Sessions**

<table>
<thead>
<tr>
<th>4:30 p.m.-6:00 p.m.</th>
<th>Oral Abstract Sessions</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>112. Thalassemia and Globin Gene Regulation: Finding New Pathways to Treat Thalassemia</td>
<td>Room 31</td>
<td></td>
</tr>
<tr>
<td>113. Sickle Cell Disease, Sickled Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias: Basic and Translational Pathophysiology of Sickled Hemoglobinopathies: From Mice to Humans</td>
<td>Room 33</td>
<td></td>
</tr>
<tr>
<td>332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Clonal Hematopoiesis of Indeterminate Potential (CHIP) and Cancer Associated Thrombosis (CAT): Understanding Risk as a Potential Means to Improve Patient Care</td>
<td>Room 28 A-D</td>
<td></td>
</tr>
<tr>
<td>508. Bone Marrow Failure: Acquired: Unraveling the Future of PNH Therapy From Clinical Trials</td>
<td>Room 7</td>
<td></td>
</tr>
<tr>
<td>604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Therapeutic Implications of Leukemia Stem Cells and Differentiation in Myeloid Malignancies</td>
<td>Marriott Marquis San Diego Marina, Pacific Ballroom Salons 18-19</td>
<td></td>
</tr>
<tr>
<td>613. Acute Myeloid Leukemias: Clinical and Epidemiological: Real World Outcomes and Treatment Approaches</td>
<td>Marriott Marquis San Diego Marina, Pacific Ballroom Salons 24-26</td>
<td></td>
</tr>
<tr>
<td>618. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Targeted Therapies and The Immune Microenvironment</td>
<td>Manchester Grand Hyatt San Diego, Grand Hall D</td>
<td></td>
</tr>
<tr>
<td>623. Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Immunotherapy</td>
<td>Manchester Grand Hyatt San Diego, Grand Hall C</td>
<td></td>
</tr>
<tr>
<td>634. Myeloproliferative Syndromes: Clinical and Epidemiological: Charting The Future Of MPN Therapies</td>
<td>Ballroom 20CD</td>
<td></td>
</tr>
<tr>
<td>642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Frontline Treatment With Targeted Agents in Patients With Chronic Lymphocytic Leukemia</td>
<td>Manchester Grand Hyatt San Diego, Seaport Ballroom ABCD</td>
<td></td>
</tr>
<tr>
<td>651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Molecular Characterization of MM and Precursor Disease States</td>
<td>Manchester Grand Hyatt San Diego, Harbor Ballroom</td>
<td></td>
</tr>
<tr>
<td>652. Multiple Myeloma: Clinical and Epidemiological: Novel Biomarkers for Treatment Guidance in Multiple Myeloma</td>
<td>Manchester Grand Hyatt San Diego, Seaport Ballroom EFGH</td>
<td></td>
</tr>
</tbody>
</table>

**All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.**
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>4:30 p.m.-6:00 p.m.</td>
<td>Blood and Beyond: Un-Walling Health and Well-Being: Shared Destinies at the San Diego-Tijuana Border</td>
</tr>
<tr>
<td>4:30 p.m.-6:30 p.m.</td>
<td>Systems-Based Hematology Education and Networking Session: Hematology E-Consultation</td>
</tr>
<tr>
<td>5:30 p.m.-6:00 p.m.</td>
<td>Meet the Blood Neoplasia Editor-in-Chief (for in-person participants)</td>
</tr>
<tr>
<td>6:00 p.m.-8:00 p.m.</td>
<td>Poster Session II - Presentations (for in-person participants)</td>
</tr>
</tbody>
</table>

**Marriott Marquis San Diego Marina, Marriott Grand Ballroom 8-9**

**Marriott Marquis San Diego Marina, Pacific Ballroom Salons 15-17**

**Marriott Marquis San Diego Marina, Marriott Grand Ballroom 2-4**

**Halls G-H - Blood Journals Studio**

**Halls G-H**

- Red Cells and Erythropoiesis, Excluding Iron Poster II
- Iron Homeostasis and Biology Poster II
- Thalassemia and Globin Gene Regulation Poster II
- Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias: Basic and Translational Poster II
- Sickle cell disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological Poster II
- Granulocytes, Monocytes, and Macrophages Poster II
- Lymphocytes and Acquired or Congenital Immunodeficiency Disorders Poster II
- Vasculature, Endothelium, Thrombosis and Platelets: Basic and Translational Poster II
- Disorders of Platelet Number or Function: Clinical and Epidemiological Poster II
- Coagulation and Fibrinolysis: Basic and Translational Poster II
- Disorders of Coagulation or Fibrinolysis: Clinical and Epidemiological Poster II
- Thrombotic Microangiopathies/Thrombocytopenias and COVID-19-related Thrombotic/Vascular Disorders: Clinical and Epidemiological Poster II
- Thrombosis and Anticoagulation: Clinical and Epidemiological Poster II
- Blood Transfusion Poster II
- Hematopoietic Stem and Progenitor Cells and Hematopoiesis: Basic and Translational Poster II
- Clonal Hematopoiesis, Aging and Inflammation Poster II
- Bone Marrow Microenvironment Poster II
- Bone Marrow Failure: Acquired Poster II
- Bone Marrow Failure and Cancer Predisposition Syndromes: Congenital Poster II
- Myeloid Oncogenesis: Basic Poster II
- Lymphoid Oncogenesis: Basic Poster II
- Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms Poster II
- Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms Poster II
- Acute Lymphoblastic Leukemias: Clinical and Epidemiological Poster II
- Acute Myeloid Leukemias: Clinical and Epidemiological Poster II
- Multiple Myeloma: Prospective Therapeutic Trials Poster II
- Acute Lymphoblastic Leukemias: Therapies, Excluding Transplantation and Cellular Immunotherapies Poster II
- Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies Poster II
- Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies Poster II
- Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Poster II
- Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Poster II
- Lymphomas: Translational: Molecular and Genetic Poster II
- Lymphomas: Translational: Non-Genetic Poster II
- Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological Poster II
- Hodgkin Lymphomas and T/NK cell Lymphomas: Clinical and Epidemiological I
- Aggressive Lymphomas: Prospective Therapeutic Trials Poster II
- Aggressive Lymphomas: Clinical and Epidemiological Poster II
- Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational Poster III
- Chronic Myeloid Leukemia: Clinical and Epidemiological Poster II
- Myelodysplastic Syndromes: Clinical and Epidemiological Poster II
- Myelodysplastic Syndromes : Basic and Translational Poster II
- Chronic Lymphocytic Leukemias: Basic and Translational Poster II
- Chronic Lymphocytic Leukemia: Clinical and Epidemiological Poster II
- Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational Poster II
- Multiple Myeloma: Clinical and Epidemiological Poster II
- MGUS, Amyloidosis and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological Poster II
- Experimental Transplantation: Basic and Translational Poster II
- Cellular Immunotherapies: Basic and Translational Poster II
- Cellular Immunotherapies: Early Phase and Investigational Therapies Poster II
- Cellular Immunotherapies: Late Phase and Commercially Available Therapies Poster II
- Cell Collection and Processing Poster II
MONDAY, DECEMBER 11, 2023

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00 a.m.-7:45 a.m.</td>
<td>ASH Wellness Studio (for in-person participants)</td>
</tr>
<tr>
<td>7:00 a.m.-8:30 a.m.</td>
<td>Wake Up To DEI Networking Breakfast (for in-person participants)</td>
</tr>
<tr>
<td>7:00 a.m.-5:00 p.m.</td>
<td>Registration at the Convention Center (for in-person participants)</td>
</tr>
<tr>
<td>8:00 a.m.-9:00 a.m.</td>
<td>Coffee and Collaboration in ASH Central (for in-person participants)</td>
</tr>
<tr>
<td>8:00 a.m.-9:00 a.m.</td>
<td>Product Theaters</td>
</tr>
<tr>
<td>8:15 a.m.-8:45 a.m.</td>
<td>Health Equity Studio (for in-person participants)</td>
</tr>
<tr>
<td>9:00 a.m.-10:00 a.m.</td>
<td>E. Donnall Thomas Lecture and Prize</td>
</tr>
<tr>
<td>9:00 a.m.-8:00 p.m.</td>
<td>Poster Session III - Viewing</td>
</tr>
<tr>
<td>10:00 a.m.-10:30 a.m.</td>
<td>Coffee Break in Exhibit Hall (for in-person participants)</td>
</tr>
<tr>
<td>10:00 a.m.-11:00 a.m.</td>
<td>Meet the Blood Advances Editors (for in-person participants)</td>
</tr>
<tr>
<td>10:05 a.m.-10:15 a.m.</td>
<td>ASH Wellness Studio (for in-person participants)</td>
</tr>
<tr>
<td>10:15 a.m.-10:25 a.m.</td>
<td>ASH Wellness Studio (for in-person participants)</td>
</tr>
<tr>
<td>10:30 a.m.-11:45 a.m.</td>
<td>Education Sessions</td>
</tr>
<tr>
<td>9:00 a.m.-10:00 a.m.</td>
<td>E. Donnall Thomas Lecture and Prize</td>
</tr>
<tr>
<td>9:00 a.m.-8:00 p.m.</td>
<td>Poster Session III - Viewing</td>
</tr>
<tr>
<td>10:00 a.m.-10:30 a.m.</td>
<td>Coffee Break in Exhibit Hall (for in-person participants)</td>
</tr>
<tr>
<td>10:00 a.m.-11:00 a.m.</td>
<td>Meet the Blood Advances Editors (for in-person participants)</td>
</tr>
<tr>
<td>10:05 a.m.-10:15 a.m.</td>
<td>ASH Wellness Studio (for in-person participants)</td>
</tr>
<tr>
<td>10:15 a.m.-10:25 a.m.</td>
<td>ASH Wellness Studio (for in-person participants)</td>
</tr>
<tr>
<td>10:30 a.m.-11:45 a.m.</td>
<td>Education Sessions</td>
</tr>
<tr>
<td>8:00 a.m.-9:00 a.m.</td>
<td>Coffee and Collaboration in ASH Central (for in-person participants)</td>
</tr>
<tr>
<td>8:00 a.m.-9:00 a.m.</td>
<td>Product Theaters</td>
</tr>
<tr>
<td>8:15 a.m.-8:45 a.m.</td>
<td>Health Equity Studio (for in-person participants)</td>
</tr>
<tr>
<td>9:00 a.m.-10:00 a.m.</td>
<td>E. Donnall Thomas Lecture and Prize</td>
</tr>
<tr>
<td>9:00 a.m.-8:00 p.m.</td>
<td>Poster Session III - Viewing</td>
</tr>
<tr>
<td>10:00 a.m.-10:30 a.m.</td>
<td>Coffee Break in Exhibit Hall (for in-person participants)</td>
</tr>
<tr>
<td>10:00 a.m.-11:00 a.m.</td>
<td>Meet the Blood Advances Editors (for in-person participants)</td>
</tr>
<tr>
<td>10:05 a.m.-10:15 a.m.</td>
<td>ASH Wellness Studio (for in-person participants)</td>
</tr>
<tr>
<td>10:15 a.m.-10:25 a.m.</td>
<td>ASH Wellness Studio (for in-person participants)</td>
</tr>
<tr>
<td>10:30 a.m.-11:45 a.m.</td>
<td>Education Sessions</td>
</tr>
</tbody>
</table>

**Day At A Glance**

- **All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.**

- **721. Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities Poster II**
- **722. Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution Poster II**
- **723. Allogeneic Transplantation: Long-term Follow-up and Disease Recurrence Poster II**
- **731. Autologous Transplantation: Clinical and Epidemiological Poster II**
- **732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies Poster II**
- **801. Gene Therapies Poster II**
- **802. Chemical Biology and Experimental Therapeutics Poster II**
- **803. Emerging Tools, Techniques and Artificial Intelligence in Hematology Poster II**
- **901. Health Services and Quality Improvement: Non-Malignant Conditions Poster II**
- **902. Health Services and Quality Improvement: Lymphoid Malignancies Poster II**
- **903. Health Services and Quality Improvement: Myeloid Malignancies Poster II**
- **904. Outcomes Research: Non-Malignant Conditions Poster II**
- **905. Outcomes Research: Lymphoid Malignancies Poster II**
- **906. Outcomes Research: Myeloid Malignancies Poster II**
### DAY-AT-A-GLANCE

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30 a.m.-11:45 a.m.</td>
<td><strong>Scientific Sessions</strong>&lt;br&gt;Pre- and Post-Thrombus: Risk Factors of Clotting and Post-Thrombosis Syndrome</td>
<td>Room 31</td>
</tr>
<tr>
<td>10:30 a.m.-11:45 a.m.</td>
<td><strong>Scientific Spotlight Sessions</strong>&lt;br&gt;(for in-person participants)</td>
<td></td>
</tr>
<tr>
<td>10:30 a.m.-12:00 p.m.</td>
<td><strong>Oral Abstract Sessions</strong></td>
<td></td>
</tr>
<tr>
<td>201. Granulocytes, Monocytes, and Macrophages: Granulocytes, Monocytes and Disorders of Histocytes</td>
<td>Room 24</td>
<td></td>
</tr>
<tr>
<td>301. Vasculature, Endothelium, Thrombosis and Platelets: Basic and Translational: Targeting platelet reactivity in thrombosis</td>
<td>Room 30</td>
<td></td>
</tr>
<tr>
<td>311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Innovative Treatments for Immune Thrombocytopenia</td>
<td>Hall A</td>
<td></td>
</tr>
<tr>
<td>401. Blood Transfusion: Advances in Transfusion Medicine</td>
<td>Room 33</td>
<td></td>
</tr>
<tr>
<td>508. Bone Marrow Failure: Acquired: Immune AA and VEXAS : Biology, Diagnosis and Treatment</td>
<td>Room 6DE</td>
<td></td>
</tr>
<tr>
<td>613. Acute Myeloid Leukemias: Clinical and Epidemiological: Innovations in Prognostication</td>
<td>Room 6B</td>
<td></td>
</tr>
<tr>
<td>615. Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies: Long-Term Outcomes for Children and Adults Diagnosed With AML/APL</td>
<td>Room 6A</td>
<td></td>
</tr>
<tr>
<td>623. Mantle Cell, Follicular and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Prospective Clinical Trials in Mantle Cell Lymphoma Incorporating Novel Agents</td>
<td>Manchester Grand Hyatt San Diego, Grand Hall B</td>
<td></td>
</tr>
<tr>
<td>631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Stromal-Immune and Signaling Context</td>
<td>Ballroom 20AB</td>
<td></td>
</tr>
<tr>
<td>634. Myeloproliferative Syndromes: Clinical and Epidemiological: Treatment and Outcomes in MPNs</td>
<td>Ballroom 20CD</td>
<td></td>
</tr>
<tr>
<td>651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Advancing Therapies in Multiple Myeloma and Waldenström’s Macroglobulinemia</td>
<td>Manchester Grand Hyatt San Diego, Harbor Ballroom</td>
<td></td>
</tr>
<tr>
<td>652. Multiple Myeloma: Clinical and Epidemiological: Immunological Effects of Sustained Responses in Multiple Myeloma</td>
<td>Manchester Grand Hyatt San Diego, Seaport Ballroom EFGH</td>
<td></td>
</tr>
<tr>
<td>704. Cellular Immunotherapies: Early Phase and Investigational Therapies: Novel Approaches to Enhance Cellular Therapies and Immune Responses in Leukemias and Lymphomas</td>
<td>Room 6CF</td>
<td></td>
</tr>
<tr>
<td>901. Health Services and Quality Improvement: Non-Malignant Conditions: Improving Care in Sickle Cell Disease Via Technologies and Medical Education</td>
<td>Marriott Marquis San Diego Marina, Marriott Grand Ballroom 2-4</td>
<td></td>
</tr>
<tr>
<td>10:30 a.m.-11:45 a.m.</td>
<td><strong>Scientific Sessions</strong>&lt;br&gt;How Do We Apply T-Cell Redirection Therapy for Multiple Myeloma? CAR T-Cells and Bispecific Antibodies</td>
<td>Manchester Grand Hyatt San Diego, Seaport Ballroom ABCD</td>
</tr>
<tr>
<td>10:30 a.m.-11:45 a.m.</td>
<td><strong>Scientific Spotlight Sessions</strong>&lt;br&gt;(for in-person participants)</td>
<td></td>
</tr>
<tr>
<td>10:30 a.m.-12:00 p.m.</td>
<td><strong>Oral Abstract Sessions</strong></td>
<td></td>
</tr>
</tbody>
</table>

**Monday, 11 Dec 2023**
### 11 Dec 2023

**Day-At-A-Glance**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:00 p.m.-1:30 p.m.</td>
<td>Complimentary Light Lunch in the Exhibit Hall (for in-person participants)</td>
</tr>
<tr>
<td>Halls B-F</td>
<td></td>
</tr>
<tr>
<td>12:00 p.m.-1:30 p.m.</td>
<td>Live Music and Outdoor Lunch Seating (for in-person participants)</td>
</tr>
<tr>
<td>ASH Park @ The Plaza</td>
<td></td>
</tr>
<tr>
<td>12:05 p.m.-12:15 p.m.</td>
<td>ASH Wellness Studio (for in-person participants)</td>
</tr>
<tr>
<td><strong>Feel Better in Your Body</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Sails Pavilion - ASH Wellness Studio</strong></td>
<td></td>
</tr>
<tr>
<td>12:15 p.m.-1:15 p.m.</td>
<td>Emerging AstraZeneca Hematology Pipeline Room 5B</td>
</tr>
<tr>
<td><strong>Gilead and Kite Oncology Pipeline</strong></td>
<td>Room 1A</td>
</tr>
<tr>
<td>In Pursuit of Healthier Red Blood Cells: The RISE UP Phase 2/3 Clinical Trial of Mitapivat in Sickle Cell Disease</td>
<td>Room 5A</td>
</tr>
<tr>
<td>12:15 p.m.-1:15 p.m.</td>
<td>Industry Theaters</td>
</tr>
<tr>
<td><strong>ASH Wellness Studio</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Product Theaters</strong></td>
<td></td>
</tr>
<tr>
<td>An FDA approved treatment option for anemia in LR-MDS Room 3</td>
<td></td>
</tr>
<tr>
<td><strong>CARVYKTI® Product Summary for Healthcare Providers</strong></td>
<td>Room 1B</td>
</tr>
<tr>
<td>Outcomes and Economic Impact of Treatment with CABLIVI® (caplacizumab-yhdp) Room 4</td>
<td></td>
</tr>
<tr>
<td>12:15 p.m.-1:15 p.m.</td>
<td>ASH Choosing Wisely® Campaign: 2023 ASH Choosing Wisely Champions Room 7</td>
</tr>
<tr>
<td>12:15 p.m.-1:15 p.m.</td>
<td>Trainee Didactic Session: Show Me the Money - Funding Your Research (Open to Trainees Only) Room 31</td>
</tr>
<tr>
<td>12:15 p.m.-1:15 p.m.</td>
<td>Trainee Didactic Session: What to Ask For in an Interview (Open to Trainees Only) Room 33</td>
</tr>
<tr>
<td>12:20 p.m.-12:30 p.m.</td>
<td>ASH Wellness Studio (for in-person participants)</td>
</tr>
<tr>
<td><strong>Workday Tension Timeout</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Sails Pavilion - ASH Wellness Studio</strong></td>
<td></td>
</tr>
<tr>
<td>12:35 p.m.-12:45 p.m.</td>
<td>ASH Wellness Studio (for in-person participants)</td>
</tr>
<tr>
<td>1:00 p.m.-1:30 p.m.</td>
<td>Health Equity Studio</td>
</tr>
<tr>
<td><strong>Legally Intentional: Microlearning Session on Systemic Racism</strong></td>
<td>Sails Pavilion - ASH Health Equity Studio</td>
</tr>
<tr>
<td>1:30 p.m.-2:30 p.m.</td>
<td>Ernest Beutler Lecture and Prize Hall A</td>
</tr>
<tr>
<td>2:30 p.m.-2:45 p.m.</td>
<td>Coffee Break in Poster Hall (for in-person participants)</td>
</tr>
<tr>
<td><strong>Protective Power of Plants</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Sails Pavilion - ASH Wellness Studio</strong></td>
<td></td>
</tr>
<tr>
<td>2:45 p.m.-4:00 p.m.</td>
<td>Scientific Symposia</td>
</tr>
<tr>
<td>Multi-Omics Driven Precision Hematology Room 30</td>
<td></td>
</tr>
<tr>
<td>2:45 p.m.-4:00 p.m.</td>
<td>Education Sessions</td>
</tr>
<tr>
<td>Not Kids Anymore and Not Adults Yet: How Do We Treat Adolescent and Young Adult (AYA) Patients With ALL? Manchester Grand Hyatt San Diego, Grand Hall B</td>
<td></td>
</tr>
<tr>
<td>2:45 p.m.-4:00 p.m.</td>
<td>Scientific Sessions</td>
</tr>
<tr>
<td>Interplay of Coagulation and Complement in Transfusion Medicine Room 29</td>
<td></td>
</tr>
<tr>
<td>2:45 p.m.-4:00 p.m.</td>
<td>Education Spotlight Sessions (for in-person participants)</td>
</tr>
<tr>
<td>Managing Previvorship in Hematology: Clinical Approaches to CCUS and MBL Room 7</td>
<td></td>
</tr>
<tr>
<td>2:45 p.m.-4:00 p.m.</td>
<td></td>
</tr>
<tr>
<td>What is a “Normal” Neutrophil Count? The Duffy Red Cell Antigen, Ancestry, Genetics and Evolution Hall A</td>
<td></td>
</tr>
<tr>
<td>2:45 p.m.-4:00 p.m.</td>
<td></td>
</tr>
<tr>
<td>Who are the Alternatives for Cellular Therapies? Engineering and Retargeting Other Effector Lymphocytes Room 11</td>
<td></td>
</tr>
</tbody>
</table>
### Scientific Spotlight Session (for in-person participants)

**Room 31**

**2:45 p.m.-4:00 p.m.**

**The Mysteries of Factor XI**

**3:15 p.m.-3:30 p.m.**

**Oral Abstract Sessions**

**Room 28 A-D**

**2:45 p.m.-4:15 p.m.**

114. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: Advances in Clinical Care and Implementation

**Room 25**

311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Thrombocytopenia in Special Populations

**Room 33**


**Room 24**

503. Clonal Hematopoiesis, Aging and Inflammation: From Omics to Discoveries

**Room 25**

613. Acute Myeloid Leukemias: Clinical and Epidemiological: AML: De Novo and Myelodysplasia-Related

**Manchester Grand Hyatt San Diego, Pacific Ballroom Salons 24-26**

614. Acute Lymphoblastic Leukemias: Therapies, Excluding Transplantation and Cellular Immunotherapies: Optimal Frontline Treatment for ALL

**Manchester Grand Hyatt San Diego, Grand Hall C**

615. Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies: Refining Chemotherapy Regimens Plus/Minus MRD Evaluation to Optimize Outcomes in AML

**Marriott Marquis San Diego Marina, San Diego Ballroom AB**

617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Deciphering Risk by Genetic and Epigenetic Features

**Marriott Marquis San Diego Marina, Pacific Ballroom Salons 15-17**

618. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Novel Disease Subclassifications and Clinical Prognosis

**Manchester Grand Hyatt San Diego, Grand Hall D**

621. Lymphomas: Translational: Molecular and Genetic: Insights into Lymphoma: Unraveling the Molecular Complexity for Precision Diagnostics and Therapeutics

**Room 6DE**

626. Aggressive Lymphomas: Prospective Therapeutic Trials: Initial treatment strategies in aggressive B Cell lymphomas

**Merchant Grand Hyatt San Diego, Seaport Ballroom ABCD**

631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Lineage Tracing and Novel Target Discovery

**Marriott Marquis San Diego Marina, Pacific Ballroom Salons 21-22**

632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Novel Therapeutic Approaches

**Marriott Marquis San Diego Marina, Pacific Ballroom Salons 18-19**

651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Multiple Myeloma Circulating Tumor Cells, Novel Mechanisms, and Immune Interactions

**Manchester Grand Hyatt San Diego, Harbor Ballroom**

652. Multiple Myeloma: Clinical and Epidemiological: Molecular and Biological Signatures and Predictors of Outcomes

**Manchester Grand Hyatt San Diego, Seaport Ballroom EFGH**


**Room 6B**

704. Cellular Immunotherapies: Early Phase and Investigational Therapies: Improving CAR-T Therapies for B Cell Malignancies

**Room 6A**

732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Modern Challenges in Transplantation

**Ballroom 20CD**

803. Emerging Tools, Techniques and Artificial Intelligence in Hematology: Image-Based Machine Learning in Hematology

**Room 6CF**

902. Health Services and Quality Improvement: Lymphoid Malignancies: Improving Processes and Outcomes in Plasma Cell Dyscrasias

**Marriott Marquis San Diego Marina, Marriott Grand Ballroom 2-4**

906. Outcomes Research: Myeloid Malignancies: Symptom Burden and Supportive Therapies

**Marriott Marquis San Diego Marina, Marriott Grand Ballroom 8-9**

**Meet the *Blood* Editors (for in-person participants)**

**Halls G-H - Blood Journals Studio**

**4:30 p.m.-5:45 p.m.**

**Education Sessions**

**Room 11**

Alphabet Soup - Challenging Consults on the Pediatric Units

**Marriott as Lifesavers: Inpatient Hematology Emergencies**

**Marriott Marquis San Diego Marina, Marriott Grand Ballroom 5-6**

How Can We Manage High-Risk Hematologic Malignancies in the Community?

**Manchester Grand Hyatt San Diego, Grand Hall B**

Improving Outcomes for Individuals With Sickle Cell Disease: Are We Moving the Needle?

**Room 29**

**4:30 p.m.-6:00 p.m.**

**Scientific Symposia**

Special Symposium on the Basic Science in Hemostasis and Thrombosis

**Room 30**

**4:30 p.m.-6:00 p.m.**

**Oral Abstracts Sessions**

102. Iron Homeostasis and Biology: Exploring Molecular Mechanisms and Therapeutic Options in Iron Homeostasis

**Room 25**

114. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: Sickle Cell Treatment: Present and Future

**Room 31**
### Day-At-A-Glance

**11 Dec 2023**

**Monday**

<table>
<thead>
<tr>
<th>Event</th>
<th>Time</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>201. Granulocytes, Monocytes, and Macrophages: New Insights into Inherited and Acquired Neutropenias</strong></td>
<td>Room 33</td>
<td>6:00 p.m.-8:00 p.m.</td>
</tr>
<tr>
<td><strong>503. Clonal Hematopoiesis, Aging and Inflammation: Translational Innovations</strong></td>
<td>Room 24</td>
<td>6:00 p.m.-8:00 p.m.</td>
</tr>
<tr>
<td><strong>509. Bone Marrow Failure and Cancer Predisposition Syndromes: Congenital and Misc.</strong></td>
<td>Room 7</td>
<td>6:00 p.m.-8:00 p.m.</td>
</tr>
<tr>
<td><strong>602. Myeloid Oncogenesis: Basic: Mechanisms and Models of Myeloid Malignancy</strong></td>
<td>Marriott Marquis San Diego Marina, Marriott Grand Ballroom 11-13</td>
<td>6:00 p.m.-8:00 p.m.</td>
</tr>
<tr>
<td><strong>613. Acute Myeloid Leukemias: Clinical and Epidemiological: AML: Molecular Targets, Ethnicity, and AI</strong></td>
<td>Marriott Marquis San Diego Marina, Pacific Ballroom Salons 24-26</td>
<td>6:00 p.m.-8:00 p.m.</td>
</tr>
<tr>
<td><strong>614. Acute Lymphoblastic Leukemias: Therapies, Excluding Transplantation and Cellular Immunotherapies: Novel Therapies for ALL</strong></td>
<td>Manchester Grand Hyatt San Diego, Grand Hall D</td>
<td>6:00 p.m.-8:00 p.m.</td>
</tr>
<tr>
<td><strong>615. Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies: Improving Intensive Chemotherapy Regimens for Treatment of AML</strong></td>
<td>Marriott Marquis San Diego Marina, San Diego Ballroom AB</td>
<td>6:00 p.m.-8:00 p.m.</td>
</tr>
<tr>
<td><strong>617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Response Predictors to Targeted Therapies and Transplant</strong></td>
<td>Marriott Marquis San Diego Marina, Pacific Ballroom Salons 15-17</td>
<td>6:00 p.m.-8:00 p.m.</td>
</tr>
<tr>
<td><strong>623. Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Targeted Therapy</strong></td>
<td>Manchester Grand Hyatt San Diego, Grand Hall C</td>
<td>6:00 p.m.-8:00 p.m.</td>
</tr>
<tr>
<td><strong>627. Aggressive Lymphomas: Clinical and Epidemiological: Uncommon Aggressive NHL</strong></td>
<td>Manchester Grand Hyatt San Diego, Harbor Ballroom</td>
<td>6:00 p.m.-8:00 p.m.</td>
</tr>
<tr>
<td><strong>631. Myelodysplastic Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Oncogenic Drivers and Genetic Models</strong></td>
<td>Marriott Marquis San Diego Marina, Pacific Ballroom Salons 21-22</td>
<td>6:00 p.m.-8:00 p.m.</td>
</tr>
<tr>
<td><strong>637. Myelodysplastic Syndromes: Clinical and Epidemiological: Genomic Classification and Prognostication of MDS</strong></td>
<td>Marriott Marquis San Diego Marina, Pacific Ballroom Salons 18-19</td>
<td>6:00 p.m.-8:00 p.m.</td>
</tr>
<tr>
<td><strong>652. Multiple Myeloma: Clinical and Epidemiological: Predicting Outcome and Side Effects of Novel Immunotherapies in Multiple Myeloma</strong></td>
<td>Manchester Grand Hyatt San Diego, Seaport Ballroom EFGH</td>
<td>6:00 p.m.-8:00 p.m.</td>
</tr>
<tr>
<td><strong>653. Multiple Myeloma: Prospective Therapeutic Trials: Relapsed and Refractory Myeloma</strong></td>
<td>Manchester Grand Hyatt San Diego, Seaport Ballroom ABCD</td>
<td>6:00 p.m.-8:00 p.m.</td>
</tr>
<tr>
<td><strong>703. Cellular Immunotherapies: Basic and Translational: Evaluating Strategies to Enhance Cellular Immunotherapies</strong></td>
<td>Room 6B</td>
<td>6:00 p.m.-8:00 p.m.</td>
</tr>
<tr>
<td><strong>704. Cellular Immunotherapies: Early Phase and Investigational Therapies: CAR-T Cell Therapies for Multiple Myeloma and B Cell Lymphomas</strong></td>
<td>Room 6A</td>
<td>6:00 p.m.-8:00 p.m.</td>
</tr>
<tr>
<td><strong>705. Cellular Immunotherapies: Late Phase and Commercially Available Therapies: Cellular Therapy for Multiple Myeloma, B-cell Acute Lymphoblastic Leukemia and B Cell Lymphomas: Clinical Trial and Real World Evidence</strong></td>
<td>Room 6CF</td>
<td>6:00 p.m.-8:00 p.m.</td>
</tr>
<tr>
<td><strong>711. Cell Collection and Processing: Hematopoietic Stem/Progenitor Cells Graft and Immune Effector Cells</strong></td>
<td>Room 6DE</td>
<td>6:00 p.m.-8:00 p.m.</td>
</tr>
<tr>
<td><strong>721. Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities: Expanding the Donor Pool</strong></td>
<td>Ballroom 20AB</td>
<td>6:00 p.m.-8:00 p.m.</td>
</tr>
<tr>
<td><strong>732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Donor and Conditioning Regimen Selection</strong></td>
<td>Ballroom 20CD</td>
<td>6:00 p.m.-8:00 p.m.</td>
</tr>
<tr>
<td><strong>801. Gene Therapies: The Long and the Short of Clinical Trials in Blood Disorders</strong></td>
<td>Hall A</td>
<td>6:00 p.m.-8:00 p.m.</td>
</tr>
<tr>
<td><strong>904. Outcomes Research: Non-Malignant Conditions: Blending the Old With the New: Traditional and Innovative Approaches to Determining Outcomes in Patients With Sickle Cell Disease</strong></td>
<td>Marriott Marquis San Diego Marina, Marriott Grand Ballroom 8-9</td>
<td>6:00 p.m.-8:00 p.m.</td>
</tr>
<tr>
<td><strong>905. Outcomes Research: Lymphoid Malignancies: Balancing Efficacy, Safety and Tolerability, and Quality of Life in Patients With Multiple Myeloma</strong></td>
<td>Marriott Marquis San Diego Marina, Marriott Grand Ballroom 2-4</td>
<td>6:00 p.m.-8:00 p.m.</td>
</tr>
</tbody>
</table>

**Poster Session III - Presentations**

**Room 28 A-D**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:00 p.m.-7:30 p.m.</td>
<td>ASH Hemostasis and Thrombosis Community Networking Reception (for in-person participants)</td>
</tr>
<tr>
<td>6:00 p.m.-8:00 p.m.</td>
<td>Poster Hall Reception (for in-person participants)</td>
</tr>
</tbody>
</table>

**Halls G-H**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:00 p.m.-7:30 p.m.</td>
<td>Poster Hall Reception (for in-person participants)</td>
</tr>
</tbody>
</table>

**Halls G-H**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:00 p.m.-8:00 p.m.</td>
<td>Poster Session III - Presentations</td>
</tr>
</tbody>
</table>

**Halls G-H**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:00 p.m.-8:00 p.m.</td>
<td>Poster Session - Presentations</td>
</tr>
</tbody>
</table>

**Halls G-H**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:00 p.m.-8:00 p.m.</td>
<td>Poster Session - Presentations</td>
</tr>
</tbody>
</table>

**Halls G-H**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:00 p.m.-8:00 p.m.</td>
<td>Poster Session - Presentations</td>
</tr>
</tbody>
</table>

**Halls G-H**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:00 p.m.-8:00 p.m.</td>
<td>Poster Session - Presentations</td>
</tr>
</tbody>
</table>

**Halls G-H**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:00 p.m.-8:00 p.m.</td>
<td>Poster Session - Presentations</td>
</tr>
</tbody>
</table>

**Halls G-H**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:00 p.m.-8:00 p.m.</td>
<td>Poster Session - Presentations</td>
</tr>
</tbody>
</table>

**Halls G-H**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:00 p.m.-8:00 p.m.</td>
<td>Poster Session - Presentations</td>
</tr>
</tbody>
</table>

**Halls G-H**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:00 p.m.-8:00 p.m.</td>
<td>Poster Session - Presentations</td>
</tr>
</tbody>
</table>

**Halls G-H**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:00 p.m.-8:00 p.m.</td>
<td>Poster Session - Presentations</td>
</tr>
</tbody>
</table>
### TUESDAY, DECEMBER 12, 2023

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00 a.m.-1:30 p.m.</td>
<td>Registration at the Convention Center (for in-person participants)</td>
</tr>
<tr>
<td>Ballroom 20 Lobby</td>
<td></td>
</tr>
<tr>
<td>7:00 a.m.-6:00 p.m.</td>
<td>Learn, Engage, and Relax in ASH Central (for in-person participants)</td>
</tr>
<tr>
<td>Sails Pavilion</td>
<td></td>
</tr>
</tbody>
</table>

---

### Room 28E & Plaza Terrace

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:00 p.m.-8:00 p.m.</td>
<td>ASH and the ASH Research Collaborative: Advancing Progress in Sickle Cell Disease (for in-person participants)</td>
</tr>
</tbody>
</table>

---

### Manchester Grand Hyatt San Diego, Coronado Ballroom & Terrace

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:30 p.m.-9:30 p.m.</td>
<td>Women In Hematology Networking Event (for in-person participants)</td>
</tr>
</tbody>
</table>

---

### Day-At-A-Glance

222. Disorders of Coagulation or Fibrinolysis: Clinical and Epidemiological Poster III
332. Thrombosis and Anticoagulation: Clinical and Epidemiological Poster III
401. Blood Transfusion Poster III
501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis: Basic and Translational Poster III
503. Clonal Hematopoiesis, Aging and Inflammation Poster III
506. Bone Marrow Microenvironment Poster III
508. Bone Marrow Failure: Acquired Poster III
509. Bone Marrow Failure and Cancer Predisposition Syndromes: Congenital Poster III
602. Myeloid Oncogenesis: Basic Poster III
603. Lymphoid Oncogenesis: Basic Poster III
604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms Poster III
605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms Poster III
612. Acute Lymphoblastic Leukemias: Clinical and Epidemiological Poster III
613. Acute Myeloid Leukemias: Clinical and Epidemiological Poster III
614. Acute Lymphoblastic Leukemias: Therapies, Excluding Transplantation and Cellular Immunotherapies Poster III
615. Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies Poster III
616. Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies Poster III
617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Poster III
618. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Poster III
621. Lymphomas: Translational: Molecular and Genetic Poster III
622. Lymphomas: Translational: Non-Genetic Poster III
623. Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological Poster III
624. Hodgkin Lymphomas and T/NK cell Lymphomas: Clinical and Epidemiological Poster III
626. Aggressive Lymphomas: Prospective Therapeutic Trials Poster III
627. Aggressive Lymphomas: Clinical and Epidemiological Poster III
631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational Poster III
632. Chronic Myeloid Leukemia: Clinical and Epidemiological Poster III
634. Myeloproliferative Syndromes: Clinical and Epidemiological Poster III
636. Myelodysplastic Syndromes: Basic and Translational Poster III
637. Myelodysplastic Syndromes: Clinical and Epidemiological Poster III
641. Chronic Lymphocytic Leukemias: Basic and Translational Poster III
642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological Poster III
643. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational Poster III
644. Multiple Myeloma: Prospective Therapeutic Trials Poster III
645. MGUS, Amyloidosis and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological Poster III
701. Experimental Transplantation: Basic and Translational Poster III
703. Cellular Immunotherapies: Basic and Translational Poster III
704. Cellular Immunotherapies: Early Phase and Investigational Therapies Poster III
705. Cellular Immunotherapies: Late Phase and Commercially Available Therapies Poster III
711. Cell Collection and Processing Poster III
731. Autologous Transplantation: Clinical and Epidemiological Poster III
732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies Poster III
801. Gene Therapies Poster III
802. Chemical Biology and Experimental Therapeutics Poster III
803. Emerging Tools, Techniques and Artificial Intelligence in Hematology Poster III
901. Health Services and Quality Improvement - Non-Malignant Conditions Poster III
902. Health Services and Quality Improvement - Lymphoid Malignancies Poster III
903. Health Services and Quality Improvement: Myeloid Malignancies Poster III
904. Outcomes Research : Non-Malignant Conditions Poster III
905. Outcomes Research: Lymphoid Malignancies Poster III
906. Outcomes Research: Myeloid Malignancies Poster III

---

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.
### DAY-AT-A-GLANCE

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

#### Tuesday–Thursday

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:15 a.m.-11:30 a.m.</td>
<td>Coffee and Late-Breaking Abstracts</td>
<td>Hall A</td>
</tr>
<tr>
<td>8:45 a.m.-9:00 a.m.</td>
<td>Announcement of Awards: William Dameshek Prize and Henry M. Stratton Medals</td>
<td>Hall A</td>
</tr>
<tr>
<td>9:00 a.m.-10:30 a.m.</td>
<td>Coffee Available in General Session Room (for in-person participants)</td>
<td>Hall A</td>
</tr>
<tr>
<td>9:00 a.m.-10:30 a.m.</td>
<td>Late-Breaking Abstracts Session</td>
<td>Hall A</td>
</tr>
<tr>
<td>11:00 a.m.-12:30 p.m.</td>
<td>Presidential Symposium</td>
<td>Hall A</td>
</tr>
<tr>
<td>12:30 p.m.-2:00 p.m.</td>
<td>Best of ASH</td>
<td>Hall A</td>
</tr>
<tr>
<td>2:00 p.m.-2:15 p.m.</td>
<td>Business Meeting</td>
<td>Hall A</td>
</tr>
</tbody>
</table>

#### Wednesday, December 13, 2023

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00 a.m.-11:00 a.m.</td>
<td>ASH Poster Walks (Virtual Program)</td>
<td>Virtual Program</td>
</tr>
<tr>
<td>5:00 p.m.-6:00 p.m.</td>
<td>ASH Poster Walk on Genetic Mutations in Myeloma and Leukemia</td>
<td>Virtual Program</td>
</tr>
<tr>
<td>5:00 p.m.-6:00 p.m.</td>
<td>ASH Poster Walk on What's Hot in Sickle Cell Disease Clinical Research in 2023</td>
<td>Virtual Program</td>
</tr>
</tbody>
</table>

#### Thursday, December 14, 2023

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00 a.m.-11:00 a.m.</td>
<td>ASH Poster Walks (Virtual Program)</td>
<td>Virtual Program</td>
</tr>
<tr>
<td>5:00 p.m.-6:00 p.m.</td>
<td>ASH Poster Walk on Time to Examine Time Toxicity in Hematology</td>
<td>Virtual Program</td>
</tr>
</tbody>
</table>

**Day-At-A-Glance**

61
BLOOD AND BEYOND

UN-WALLING HEALTH AND WELL-BEING: SHARED DESTINIES AT THE SAN DIEGO-TIJUANA BORDER

The editors of the Blood journal take this opportunity to highlight the intersection of hematology and the humanities in a session entitled Blood and Beyond. For this year, in complement to the celebration of the 20th anniversary of ASH’s Minority Recruitment Initiative, the session: Un-walling Health and Well-Being: Shared destinies at the San Diego-Tijuana Border will be presented by Teddy Cruz and Fonna Forman and will consider the intersection of diversity, equity and inclusion, migration and social policy.

ASH® 2023 Annual Meeting in San Diego
Sunday, December 10, 2023
4:30 PM – 6:00 PM
SDCC, Room 24

Register to attend this session in-person, or via the Virtual Platform/Webcast*
hematology.org/annual-meeting

*Requires ASH 2023 registration or webcast purchase

Teddy Cruz and Fonna Forman are principals in Estudio Teddy Cruz + Fonna Forman, a research-based political and architectural practice in San Diego transgressing conventional boundaries between theory and practice, and merging the fields of architecture and urbanism, political theory, and urban policy.

SPEAKERS:
Teddy Cruz (MDes Harvard), Professor, Public Culture and Urbanism, Visual Arts Department, University of California, San Diego
Fonna Forman (JD, PhD Chicago), Professor, Political Science and Founding Director of the Center on Global Justice, University of California, San Diego

CO-CHAIRS:
Nancy Berliner, MD, Brigham and Women’s Hospital, Boston, MA
Alison Walker, MD, MPH, MBA, Moffet Cancer Center, Tampa, FL
Join our panels of LEADING EXPERTS FOR ENGAGING DISCUSSIONS at the Friday Satellite Symposia on December 8!

TURN OVER TO EXPLORE OUR FRIDAY SATELLITE SYMPOSIA!

MAKE A DIFFERENCE!
For each in-person attendee, we will be donating $10 to Make-A-Wish Foundation

To learn more visit gotoper.com/friday23
EXPLORE OUR FRIDAY SATELLITE SYMPOSIA!

<table>
<thead>
<tr>
<th>BREAKFAST SERVED AT 6:30 AM PT</th>
<th>HAPPY HOUR SERVED AT 2:30 PM PT</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>BTKi</strong>&lt;br&gt;Medical Crossfire®: Novel BTKi Strategies Transforming Aggressive and Indolent B-Cell Malignancies&lt;br&gt;Overcoming Racial Disparities in Multiple Myeloma Outcomes and Clinical Trials: How We Are Moving Care Forward Today</td>
<td><strong>CML</strong>&lt;br&gt;Putting Your Stamp on the Next Generation of Care in CML — Improving Outcomes From Frontline to R/R&lt;br&gt;<strong>ALL LBL</strong>&lt;br&gt;Real-World Applications of Asparaginase Formulations in ALL and LBL From Pediatric/AYA to Adult Treatment: Maximizing Clinical Benefits Through Multidisciplinary Care&lt;br&gt;<strong>SCD</strong>&lt;br&gt;Comprehensive Approaches to Creating Successful Sickle Cell Management Plans Across Patients’ Life Spans</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>BRUNCH SERVED AT 10:30 AM PT</th>
<th>DINNER SERVED AT 6:30 PM PT</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ALL</strong>&lt;br&gt;Medical Crossfire: Bridging Expert Guidance and Evidence-Based Recommendations in the Treatment of AYA and Adult ALL&lt;br&gt;<strong>IDA</strong>&lt;br&gt;Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients With Cancer-Related Anemia?&lt;br&gt;<strong>MPN</strong>&lt;br&gt;Show Me the Data®: How Do We Navigate the Latest Evidence on Novel Therapies, Combinations, and Clinical Trials Across MPN Care in the Context of Current Treatment Algorithms?&lt;br&gt;<strong>AML</strong>&lt;br&gt;Experts Address the Hottest Topics in AML: Considerations on FLT3, IDH1/2, TP53, Maintenance, Novel Combinations, and Beyond!</td>
<td><strong>GvHD</strong>&lt;br&gt;How Do We Treat GvHD Today...And Tomorrow? Treatment Algorithms for Key Decision Points in Prophylaxis Care, Acute, and Chronic Disease</td>
</tr>
</tbody>
</table>

SCAN HERE TO LEARN MORE
GENERAL SESSIONS

These signature sessions are designed to be of interest to a broad and diverse audience and include the prestigious Plenary Scientific Session, Best of ASH, and the Presidential Symposium. Many of the General Sessions also honor distinguished leaders in the field through awards and special lectures.

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

SATURDAY

Ham-Wasserman Lecture

Saturday 12:30 p.m. – 1:30 p.m.
Hall A

Thrombocytopenia Due to Platelet Activation Syndromes: HIT and Beyond

Chair: ROBERT BRODSKY, MD, President, American Society of Hematology, Johns Hopkins University, Baltimore, MD

Speakers: ANDREAS GREINACHER, MD, University of Greifswald, Greifswald, Germany

SUNDAY

ASH-EHA Joint Symposium

Sunday 12:30 p.m. – 1:30 p.m.
Hall A

Stem Cell Transcriptomics in the Niche

Co-Chairs: ROBERT BRODSKY, MD, President, American Society of Hematology, Johns Hopkins University, Baltimore, MD
ANTONIO MEDINA ALMEIDA, MD, PhD, President, European Hematology Association Universidade Catolica Portuguesa, Rio de Mouro, Portugal Hospital da Luz Lisboa, Lisbon, Portugal

Speakers: ALEXANDER MEDVINSKY, PhD, The University of Edinburgh, Edinburgh, Scotland, UK
LINHENG LI, PhD, Stowers Institute for Medical Research, Kansas City, MO

Announcement of Awards: Wallace H. Coulter Award for Lifetime Achievement in Hematology, ASH Mentor Awards, ASH Award for Leadership in Promoting Diversity, ASH Outstanding Service Award, and ASH Public Service Award

Sunday 1:30 p.m. – 2:00 p.m.
Hall A

Chair: ROBERT BRODSKY, MD, President, American Society of Hematology, Johns Hopkins University, Baltimore, MD

Plenary Scientific Session

Sunday 2:00 p.m. – 4:00 p.m.
Hall A

Co-Chairs: ROBERT BRODSKY, MD, President, American Society of Hematology, Johns Hopkins University, Baltimore, MD
NARLA MOHANDAS, DSc, New York Blood Center, New York, NY
### MONDAY

**E. Donnall Thomas Lecture and Prize**

<table>
<thead>
<tr>
<th>Day</th>
<th>Time</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Monday</td>
<td>9:00 a.m. – 10:00 a.m.</td>
<td>Hall A</td>
</tr>
</tbody>
</table>

**Chair:**
ROBERT BRODSKY, MD, President, American Society of Hematology, Johns Hopkins University, Baltimore, MD

**Speaker:**
KATAYOUN REZVANI, MD, PhD, The University of Texas, MD Anderson Cancer Center, Houston, TX

*Natural Killer Cells: A New Frontier for Cancer Immunotherapy*

### TUESDAY

**Announcement of Awards: William Dameshek Prize and Henry M. Stratton Medals**

<table>
<thead>
<tr>
<th>Day</th>
<th>Time</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tuesday</td>
<td>8:45 a.m. – 9:00 a.m.</td>
<td>Hall A</td>
</tr>
</tbody>
</table>

**Chair:**
ROBERT BRODSKY, MD, President, American Society of Hematology, Johns Hopkins University, Baltimore, MD

**Late-Breaking Abstracts Session**

<table>
<thead>
<tr>
<th>Day</th>
<th>Time</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tuesday</td>
<td>9:00 a.m. – 10:30 a.m.</td>
<td>Hall A</td>
</tr>
</tbody>
</table>

**Co-Chairs:**
JEAN M. CONNORS, MD, Dana-Farber Cancer Institute, Boston, MA
AMY E. DEZERN, MD, Johns Hopkins University, Baltimore, MD

**Presidential Symposium**

<table>
<thead>
<tr>
<th>Day</th>
<th>Time</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tuesday</td>
<td>11:00 a.m. – 12:30 p.m.</td>
<td>Hall A</td>
</tr>
</tbody>
</table>

*The Complement System and Targeted Therapies*

**Chair:**
ROBERT BRODSKY, MD, President, American Society of Hematology, Johns Hopkins University, Baltimore, MD

### Ernest Beutler Lecture and Prize

<table>
<thead>
<tr>
<th>Day</th>
<th>Time</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Monday</td>
<td>1:30 p.m. – 2:30 p.m.</td>
<td>Hall A</td>
</tr>
</tbody>
</table>

**Non-Replacement Therapy in Hemophilia Management: The Evolution of FVIII Mimetics from Basic Science to Clinical Translation**

**Chair:**
ROBERT BRODSKY, MD, President, American Society of Hematology, Johns Hopkins University, Baltimore, MD

**Speakers:**
TAKEHISA KITAZAWA, DMV, PhD, Chugai Pharmaceutical, Totsuka-Ku, Japan
JOYCE MAHLANGU, MBBCh, MMEd, University of the Witwatersrand, Johannesburg, South Africa

**Best of ASH 🌟**

<table>
<thead>
<tr>
<th>Day</th>
<th>Time</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tuesday</td>
<td>12:30 p.m. – 2:00 p.m.</td>
<td>Hall A</td>
</tr>
</tbody>
</table>

**Co-Chairs:**
ELIZABETA NEMETH, PhD, University of California, Los Angeles, Los Angeles, CA
KOJO S.J. ELENITOB-JOHNSON, MD, Memorial Sloan Kettering Cancer Center, New York, NY

### Saturday–Tuesday

GENERAL SESSIONS

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>9–12 Dec</td>
<td>9:00 a.m. – 10:00 a.m.</td>
<td>Hall A</td>
</tr>
</tbody>
</table>

**Chair:**
ROBERT BRODSKY, MD, President, American Society of Hematology, Johns Hopkins University, Baltimore, MD

**Speaker:**
KATAYOUN REZVANI, MD, PhD, The University of Texas, MD Anderson Cancer Center, Houston, TX

*Natural Killer Cells: A New Frontier for Cancer Immunotherapy*
**SPECIAL INTEREST SESSIONS**

These smaller sessions provide the opportunity for ASH's various communities to focus on specific topics of interest.

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

---

**FRIDAY**

**Training Directors’ Workshop**
(for in-person participants)

<table>
<thead>
<tr>
<th>Friday</th>
<th>9:00 a.m. – 12:00 p.m.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Indigo 204</td>
<td></td>
</tr>
<tr>
<td>Hilton San Diego Bayfront</td>
<td></td>
</tr>
</tbody>
</table>

**Chair:**
SANJAY MOHAN, MD, MSCI, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN

**Speakers:**

TAMARA J. DUNN, MD, Stanford University, Stanford, CA

Diversity, Equity, and Inclusion Considerations & Recruitment

MARTHA ARELLANO, MD, Emory University School of Medicine, Atlanta, GA

Diversity, Equity, and Inclusion Considerations & Recruitment

---

**ASH Wellness Studio, Sails Pavilion**
(for in-person participants)

<table>
<thead>
<tr>
<th>Time</th>
<th>Activity</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00 a.m. - 7:45 a.m.</td>
<td>ASH Yoga (ASH Park @ the Plaza)</td>
</tr>
<tr>
<td>9:05 a.m. - 9:15 a.m.</td>
<td>What’s Restoring You</td>
</tr>
<tr>
<td>9:15 a.m. - 9:25 a.m.</td>
<td>An Oasis in Chaos</td>
</tr>
<tr>
<td>11:05 a.m. - 11:15 a.m.</td>
<td>Fix the Way You Sit</td>
</tr>
<tr>
<td>11:20 a.m. - 11:30 a.m.</td>
<td>Life-Saving Lessons from Plant-Based Eaters</td>
</tr>
<tr>
<td>11:35 a.m. - 11:45 a.m.</td>
<td>Feel Better in Your Body</td>
</tr>
<tr>
<td>1:35 p.m. - 1:45 p.m.</td>
<td>Finding Stillness in the Busyness</td>
</tr>
<tr>
<td>1:45 p.m. - 1:55 p.m.</td>
<td>The Real Purpose of Your Purpose</td>
</tr>
<tr>
<td>3:35 p.m. - 3:45 p.m.</td>
<td>Workday Tension Timeout</td>
</tr>
<tr>
<td>3:45 p.m. - 3:55 p.m.</td>
<td>Eating With a Full Mind or Mindfully</td>
</tr>
</tbody>
</table>

---

**Health Equity Studio, Sails Pavilion**

<table>
<thead>
<tr>
<th>Time</th>
<th>Activity</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:00 a.m. - 9:30 a.m.</td>
<td>Outcome Disparities in Hematologic Diseases: The Important of Social Determinants of Health</td>
</tr>
<tr>
<td>11:00 a.m. - 11:30 a.m.</td>
<td>Community Partnerships: An Essential Component to Advance Health Equity</td>
</tr>
<tr>
<td>1:30 p.m. - 2:00 p.m.</td>
<td>How to Support LGBTQIA Patients, Trainees, and Colleagues: A Whole Person Perspective</td>
</tr>
<tr>
<td>3:30 p.m. - 4:00 p.m.</td>
<td>Using Research to Advance Equity in the LGBTQIA+ Space</td>
</tr>
</tbody>
</table>

---

of interest to PhD attendees. CME credit is not offered.
**SPECIAL INTEREST SESSIONS**

Friday – Monday 8–11 Dec 2023

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

---

### Blood Journals Studio, Halls G-H

(for in-person participants)

- **10:00 a.m. - 11:00 a.m.** Meet the Blood Advances Editors
- **2:00 p.m. - 3:30 p.m.** Distinguished Abstract Achievement Awards Ceremony
- **5:00 p.m. - 5:30 p.m.** Meet the Blood VTH Editor-in-Chief

---

**SATURDAY**

#### Special Session on Sickle Cell Disease Centers

**Saturday** 9:30 a.m. – 11:00 a.m.

**Hall A**

San Diego Convention Center

**Co-Chairs:**

- **Payal Desai**, MD, Atrium Health, Charlotte, NC
- **Julie Kanter**, MD, University of Alabama at Birmingham, Birmingham, AL

**Speakers:**

- **Sophie Lanzkron**, MD, Johns Hopkins Medical Institute, Baltimore, MD
  - *Maximizing Revenue from an Infusion Center*
- **Julie Kanter**, MD, University of Alabama at Birmingham, Birmingham, AL
  - *Partnering With Your Hospital On 340B*
- **Alexis Kristine Leonard**, MD, St. Jude Children’s Research Hospital, Germantown, TN
  - *Getting Ready to Provide Genetic Therapies*

---

#### ASH Grassroots Network Lunch

(for in-person participants)

**Saturday** 11:15 a.m. – 12:15 p.m.

**Marina Ballroom DE**

Marriott Marquis San Diego Marina

**Chair:**

**Jennifer Holter-Chakraborty**, MD, University of Oklahoma Stephenson Cancer Center, Oklahoma City, OK

**Blood Presents: How to get Published in a Peer Review Journal**

(for in-person participants)

**Saturday** 11:15 a.m. – 12:15 p.m.

**Room 24**

San Diego Convention Center

**Panelists:**

- **Nancy Berliner**, MD, Brigham and Women’s Hospital, Boston, MA

---

**Special Session on Sickle Cell Disease Centers**

**Saturday** 9:30 a.m. – 11:00 a.m.

**Hall A**

San Diego Convention Center

**Co-Chairs:**

- **Payal Desai**, MD, Atrium Health, Charlotte, NC
- **Julie Kanter**, MD, University of Alabama at Birmingham, Birmingham, AL

**Speakers:**

- **Sophie Lanzkron**, MD, Johns Hopkins Medical Institute, Baltimore, MD
  - *Maximizing Revenue from an Infusion Center*
- **Julie Kanter**, MD, University of Alabama at Birmingham, Birmingham, AL
  - *Partnering With Your Hospital On 340B*
- **Alexis Kristine Leonard**, MD, St. Jude Children’s Research Hospital, Germantown, TN
  - *Getting Ready to Provide Genetic Therapies*

---

#### Special Symposium on Quality - Identifying and Addressing Underuse in Hematologic Care

**Saturday** 2:00 p.m. – 3:30 p.m.

**Room 11**

San Diego Convention Center

**Co-Chairs:**

- **Ming Y Yeong Lim**, MBBS, Chir, University of Utah, Salt Lake City, UT
- **Jacob Cogan**, MD, University of Minnesota, Minneapolis, MN

**Speakers:**

- **Geoffrey Barnes**, MD, MSc, University of Michigan, Ann Arbor, MI
  - *IVC Filter Retrieval*
- **Alexandra Power-Hays**, MD, Cincinnati Children’s Hospital, Cincinnati, OH
  - *Hydroxyurea in Sickle Cell Disease*
- **Allison Burnett**, PhD, University of New Mexico Health Sciences Center, Albuquerque, NM
  - *Patient Education Prior to Anticoagulation*

---

#### Promoting Minorities in Hematology (PMH) Oral Presentations

(for in-person participants)

**Saturday** 6:30 p.m. – 9:00 p.m.

**Marina Ballrooms D-F**

Marriott Marquis San Diego Marina

---

#### Promoting Minorities in Hematology (PMH) MRI Anniversary Reception

(for in-person participants)

**Saturday** 8:00 p.m. – 9:00 p.m.

**Marian Ballroom G**

Marriott Marquis San Diego Marina
SPECIAL INTEREST SESSIONS

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

ASH Wellness Studio, Sails Pavilion (non-CME)
(for in-person participants)

9:05 a.m. - 9:15 a.m.  How to Quiet the Mind Chatter
9:15 a.m. - 9:25 a.m.  Family First – 7 Steps to Living Well
11:05 a.m. - 11:15 a.m.  The Real Purpose of Your Purpose
11:20 a.m. - 11:30 a.m.  Straight Spine, Big Smile
11:35 a.m. - 11:45 a.m.  Stress Doesn’t Exist
4:05 p.m. – 4:15 p.m.  The Greatest Medicine...The Right Tribe!
4:15 p.m. - 4:25 p.m.  Fix the Way You Sit

Health Equity Studio, Sails Pavilion (non-CME)

9:00 a.m. - 9:30 a.m.  Systemic Racism in Hematology
11:00 a.m. - 11:30 a.m.  Legally Intentional: Microlearning Session on Systemic Racism
1:30 p.m. - 2:00 p.m.  Epidemiology of Social Determinants of Health: Inequities and Outcomes of Hematologic Diseases
4:00 p.m. - 4:30 p.m.  Community Partnerships: An Essential Component to Advance Health Equity

Blood Journals Studio, Halls G-H (non-CME)
(for in-person participants)

10:00 a.m. - 11:00 a.m.  Meet the Blood Advances Editors
5:30 p.m. - 6:00 p.m.  Meet the Blood Neoplasia Editor-in-Chief

SUNDAY

Medical Educators’ Symposium

Sunday  7:30 a.m. – 9:30 a.m.
Sapphire Ballroom AB
Hilton San Diego Bayfront

Chair:
PALLAWI TORKA, MD, Memorial Sloan Kettering Cancer Center, New York, NY

 Speakers:
ANGELA C. WEYAND, MD, University of Michigan, Ann Arbor, MI
General Session 1: Utilizing Social Media in Learning

ALFRED I. LEE, MD, PhD, Yale University School of Medicine, New Haven, CT
General Session 2: Making the Most of Virtual Teaching

SCOTT MOERDLER, MD, Children’s Hospital at Montefiore, New Brunswick, NJ
General Session 2: Making the Most of Virtual Teaching

ALEXANDER A. BOUCHER, MD, University of Minnesota Medical School, Plymouth, MN
General Session 3: Diversity, Equity, and Inclusion in Educational Material Development

ERIN G. REID, MD, MS, Moores University of California, San Diego Cancer Center, La Jolla, CA
Breakout 1: Technology and Medical Education: Remote Learning

RITA PASCHAL, MD, University of Alabama at Birmingham Medical Center, Birmingham, AL
Breakout 2: How to be a Good Mentor

ALEXANDER A. BOUCHER, MD, University of Minnesota Medical School, Plymouth, MN
Breakout 3: DEI and Implicit Bias in Case Development

ARIELA L. MARSHALL, MD, Dana-Farber Cancer Institute, Inc., Philadelphia, PA
Breakout 4: Teaching Across the Learner Spectrum and Integrating APPs

ALICE MA, MD, FACP, University of North Carolina at Chapel Hill, Chapel Hill, NC
Breakout 5: Giving Good Feedback to Trainees

of interest to PhD attendees.  CME credit is not offered.
2023 ASH Guideline Implementation Champions

Sunday 9:30 a.m. – 11:00 a.m.
Room 7
San Diego Convention Center

Co-Chairs:
Rachel P. Rosovsky, MD, MPH, Massachusetts General Hospital, Boston, MA
Amy Billett, MD, Dana-Farber Cancer Institute, Wilmington, DE

Speakers:
Christina Marie Ruiz, MD, University of California San Diego School of Medicine, San Diego, CA
Improving the Outpatient Pain Management Plan for Patients with Sickle Cell Disease with Innovative Pain Action Plan
Gabriella Nguyen, MD, Children’s Health, University of Texas Southwestern, Dallas, TX
Steering Change with Compass: Clinical Pathway to Optimize the Management of Pediatric Acute Stroke in Sickle Cell Disease

Maternal Health: Fertility Preservation in Hematology Care

Sunday 9:30 a.m. – 11:00 a.m.
Ballroom 20AB
San Diego Convention Center

Chair:
Sarah O’Brien, MD, MSc, Nationwide Children’s Hospital, Columbus, OH

Speakers:
Erica Marsh, MD, MSCI, FACOG, University of Michigan, Ann Arbor, MI
Fertility Health Equity and the Fertility Preservation Process
Alison Loren, MD, MSCE, University of Pennsylvania, Philadelphia, PA
Fertility Care for Patients with Hematologic Conditions
Mindy Christianson, MD, MBA, Cleveland Clinic, Cleveland, OH
Fertility Care for Physicians

Special Scientific Session on Race and Science: Bench to Bedside to the Community

Sunday 9:30 a.m. – 11:00 a.m.
Hall A
San Diego Convention Center

Co-Chairs:
Elizabeth Nemeth, PhD, University of California, Los Angeles, Los Angeles, CA
Alison R. Walker, MD, MPH, MBA, The Ohio State University Medical Center, Powell, OH
Nadine J. Barrett, PhD, MS, MA, Duke University School of Medicine, Durham, NC

Speakers:
Shonta Chambers, MSW, Patient Advocate Foundation, Hampton, VA
Community and Patient Advocate Perspective
Saad Z. Usmani, MD, Memorial Sloan Kettering Cancer Center, New York, NY
Clinical Trial Perspective
Nicole Gormley, MD, Food and Drug Administration, Bethesda, MD
Regulatory Perspective
Alisa S. Wolberg, PhD, University of North Carolina at Chapel Hill, Chapel Hill, NC
Basic Science Perspective

Blood Advances Presents: How to Peer Review a Scientific Paper

Sunday 11:15 a.m. – 12:15 p.m.
Room 24
San Diego Convention Center

ASH Clinicians in Practice (ACIP) Lunch - How Can We Provide Sustainable Care to Hematology Patients?

Sunday 11:15 a.m. – 12:30 p.m.
Marina Ballroom DE
Marriott Marquis San Diego Marina

Chair:
Chancellor Donald, MD, Tulane University School of Medicine, New Orleans, LA

Speakers:
Aaron Goodman, MD, University of California, San Diego, San Diego, CA
Financial Toxicity: How to Determine Value of Hematology Treatments for Patients?
**SPECIAL INTEREST SESSIONS**

**71**

**Friday – Monday**

8-11 Dec 2023

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

---

**How can Artificial Intelligence Improve the Practice of Hematology in Providing Sustainable Care in Pediatrics?**

**Shannon Walker**, MD, Vanderbilt University, Nashville, TN

**Benjamin F. Tillman**, MD, Vanderbilt University, Nashville, TN

**David Andorsky**, MD, Rocky Mountain Cancer Centers, Boulder, CO

**Can Guidelines and Pathways Help Determine Value of Treatments for Hematology Patients?**

---

**Health Equity Rounds Lunch**

(for in-person participants)

**Sunday**

11:15 a.m. – 12:15 p.m.

Sapphire Ballroom CD

Hilton San Diego Bayfront

**Moderator:**

**Yvonne Efepera**, MD, Ohio Health, Columbus, OH

**Speakers:**

**Shakira J. Grant**, MBBS, MSCR, University of North Carolina at Chapel Hill, Chapel Hill, NC

**Health Workforce Diversity and Equity**

**Srinivas Devarakonda**, MD, The Ohio State University, Columbus, OH

**Health Workforce Diversity and Equity**

---

**Blood and Beyond**

**Sunday**

4:30 p.m. – 6:00 p.m.

Room 24

San Diego Convention Center

**Co-Chairs:**

**Nancy Berliner**, MD, Brigham and Women’s Hospital, Boston, MA

**Alison R. Walker**, MD, Moffitt Cancer Center, Tampa FL

---

**How can Artificial Intelligence Improve the Practice of Hematology in Providing Sustainable Care?**

---

**Un-walling Health and Well-Being: Shared destinies at the San Diego-Tijuana Border**

Considering the intersection of diversity, equity and inclusion, migration and social policy, Fonna Forman and Teddy Cruz will discuss the eco-social impacts of increasing migration across the US-Mexico border region, and how the UCSD Center on Global Justice is responding to the challenge in Tijuana. This includes the construction of emergency housing and the coordination of education, vocational training, employment, cultural activity, and health services.

---

**Systems-Based Hematology Education and Networking Session: Hematology E-Consultation**

**Sunday**

4:30 p.m. – 6:30 p.m.

Room 30

San Diego Convention Center

**Chair:**

**Marc Stuart Zumberg**, MD, University of Florida, Gainesville, FL

**Speakers:**

**Sandhya R. Panch**, MD, Fred Hutchinson Cancer Center, Seattle, WA

Start up, Resource Allocation, Insurance, and Work Flow for Hematology E-Consultation

**Surbhi Shah**, MD, Mayo Clinic, Scottsdale, AZ

Lessons Learned in Hematology E-Consultation: Advantages, Disadvantages, and Applicability to Other Academic Centers and Smaller Institutions

---

**of interest to PhD attendees. CME credit is not offered.**
MONDAY

Wake Up to DEI Networking Breakfast (for in-person participants)

Monday 7:00 a.m. – 8:30 a.m.  
Marina Ballroom  
Marriott Marquis San Diego Marina

AI in Hematology: Where Do You Stand in 2023?

Monday 10:30 a.m. – 12:00 p.m.  
San Diego Convention Center

Chair:  
TORSTEN HAIFERLACH, MD, PhD, Munich Leukemia Laboratory, Munich, Germany

Speakers:  
WEIDA TONG, PhD, National Center for Toxicological Research, US Food and Drug Administration, Jefferson, AR  
Can AI Be Used in Drug Discovery?  
YATES COLEY, PhD, Kaiser Permanente Washington Health Research Institute, Seattle, WA

Health Equity Studio, Sails Pavilion

8:15 a.m. - 8:45 a.m.  
How to Support LGBTQIA Patients, Trainees, and Colleagues: A Whole Person Perspective

10:00 a.m. - 10:30 a.m.  
Using Research to Advance Equity in the LGBTQIA+ Space

12:00 p.m. - 12:30 p.m.  
Systemic Racism in Hematology

1:00 p.m. - 1:30 p.m.  
Legally Intentional: Microlearning Session on Systemic Racism

Blood Journals Studio, Halls G-H

10:00 a.m. - 11:00 a.m.  
Meet the Blood Advances Editors

11:00 a.m. - 12:00 p.m.  
Blood Advances in a Different Vein: Live

12:00 p.m. - 1:00 p.m.  
The ABCs of Publishing for Authors

3:00 p.m. - 4:00 p.m.  
Meet the Blood Editors

ASH Wellness Studio, Sails Pavilion

(for in-person participants)

7:00 a.m. - 7:45 a.m.  
ASH Yoga (ASH Park @ the Plaza)

10:05 a.m. - 10:15 a.m.  
What’s Restoring You

10:15 a.m. - 10:25 a.m.  
Eating With a Full Mind or Mindfully

12:05 p.m. - 12:15 p.m.  
Feel Better in Your Body

12:20 p.m. - 12:30 p.m.  
Workday Tension Timeout

12:35 p.m. - 12:45 p.m.  
An Oasis in Chaos

2:35 p.m. - 2:45 p.m.  
Protective Power of Plants

AI Ethics: More Complex Than What You Think

MATTHEW LUNGEN, MD, MPH, Microsoft+Nuance Communications, Burlington, MA  
The Application of Artificial Intelligence in Medical Imaging: Lessons Learned from Radiology, Ophthalmology and Oncology

TORSTEN HAIFERLACH, MD, PhD, Munich Leukemia Laboratory, Munich, Germany  
The Future Is Now: AI in the Hematology Clinic

ASH Guidelines on Acute Lymphoblastic Leukemia (ALL) in Adolescents and Young Adults

Monday 10:30 a.m. – 12:00 p.m.  
Grand Hall C Manchester  
Grand Hyatt San Diego

Chair:  
MATTHEW C. CHEUNG, MD, MSc, Sunnybrook Odette Cancer Centre, Toronto, ON, Canada
SPECIAL INTEREST SESSIONS

8-11 Dec 2023

Thursday – Monday

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

Speakers:

WENDY STOCK, MD, The University of Chicago, Chicago, IL
Initial Therapy for ALL in Adolescents and Young Adults

JULIE WOLFSON, MD, MSHS, The University of Alabama at Birmingham, Birmingham, AL
Initial Therapy for ALL in Adolescents and Young Adults

KRISTEN M. O’DWYER, MD, University of Rochester Medical Center, Rochester, NY
Management of Remission and Relapse of ALL in Adolescents and Young Adults

SUMIT GUPTA, MD, PhD, Hospital for Sick Children, Toronto, ON, Canada
Management of Remission and Relapse of ALL in Adolescents and Young Adults

Junior Faculty Career Development Session

Monday 10:30 a.m. – 12:00 p.m.
Room 25
San Diego Convention Center

Chair:
SANJAY MOHAN, MD, MSCI, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN

Speakers:

OVERIMPE ADESINA, MD, MS, University of California, Davis, Sacramento, CA
Individual Career Development Awards- K23/K08

CASSANDRA JOSEPHSON, Children’s Healthcare of Atlanta, Atlanta, GA
Individual Career Development Awards- K07

SRINIVAS DEVARAKONDA, MD, The Ohio State University, Columbus, OH
Funding Your Medical Education Research

ASH Guidelines on Venous Thromboembolism (VTE): What’s New

Monday 4:30 p.m. – 6:00 p.m.
Room 28 A-D, San Diego Convention Center

Chair:
ADAM CUKER, MD, MS, University of Pennsylvania, Philadelphia, PA

Speakers:

SASKIA MIDDELDORP, MD, PhD, Academic Medical Center, Nijmegen, Netherlands
ASH Guidelines on Thrombophilia

DEBORAH SIEGAL, MD, MSc, University of Ottawa, Ottawa, Ontario, Canada
Next Steps for ASH Guidelines on Use of Anticoagulation in Patients with COVID-19

SUELY M. REZENDE, MD, PhD, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil
Updates on Adaptation of ASH VTE Guidelines for Latin America

ASH Hemostasis and Thrombosis Community Networking Reception (for in-person participants)

Monday 6:00 p.m. – 7:30 p.m.
East Terrace (Upper Level), San Diego Convention Center

ASH and the ASH Research Collaborative: Advancing Progress in Sickle Cell Disease (for in-person participants)

Monday 6:15 p.m. – 8:15 p.m.
Room 28 A-D & Plaza Terrace, San Diego Convention Center

Women In Hematology Networking Event (for in-person participants)

Monday 7:30 p.m. – 9:30 p.m.
Coronado Ballroom & Terrace, Manchester Grand Hyatt, San Diego

Moderators:
ARIELA L. MARSHALL, MD, Dana-Farber Cancer Institute, Inc., Rochester, MN
TAMARA J. DUNN, MD, Stanford University, Stanford, CA

ASH Choosing Wisely® Campaign: 2023 ASH Choosing Wisely Champions

Monday 12:15 p.m. – 1:15 p.m.
Room 7
San Diego Convention Center

Chair:
MING Y. YEONG LIM, MBBCHIR, University of Utah, Salt Lake City, UT

Speakers:

VILMARIE RODRIGUEZ, MD, Nationwide Children’s Hospital, The Ohio State University, Columbus, OH
Rebida: Reduction of Blood Transfusions for Iron Deficiency Anemia

ALESSANDRA FERRAJOLI, MD, University of Texas MD Anderson Cancer Center, Houston, TX
Usefulness of a Treatment Algorithm for the Management of Abnormal Uterine Bleeding in Patients with Hematological Malignancies
Panelists:
ALEXIS A. THOMPSON, MD, MPH, Children's Hospital of Philadelphia, Philadelphia, PA
IFEYINWA OSUNKWOD, MD, Novo Nordisk, Waltham, MA
KONSTANZE DÖHNER, University Hospital of Ulm, Ulm, Germany

Speakers:
VILMARIE RODRIGUEZ, MD, Nationwide Children’s Hospital, The Ohio State University, Columbus, OH
Rebida: Reduction of Blood Transfusions for Iron Deficiency Anemia
ALESSANDRA FERRAJOLI, MD, University of Texas MD Anderson Cancer Center, Houston, TX
Usefulness of a Treatment Algorithm for the Management of Abnormal Uterine Bleeding in
AYMAN ALHEJAZI, MD, Ministry of National Guard-Health Affairs, Riyadh, Saudi Arabia
Outpatient Versus Inpatient Delivery of Intensive Chemotherapy for Patients with Hematological Neoplasms: A 5-Year Experience from a Tertiary Center

ASH Guidelines on Venous Thromboembolism (VTE): What’s New

ASH Hemostasis and Thrombosis Community Networking Reception (for in-person participants)
Monday 6:00 p.m. – 7:30 p.m.
Room 28A-D, San Diego Convention Center

ASH and the ASH Research Collaborative: Advancing Progress in Sickle Cell Disease (for in-person participants)
Monday 6:00 p.m. – 8:00 p.m.
Room 28E & Plaza Terrace, San Diego Convention Center

Women in Hematology Networking Event (for in-person participants)
Monday 7:30 p.m. – 9:30 p.m.
Coronado Ballroom & Terrace, Manchester Grand Hyatt San Diego
ASH provides a variety of high-quality educational, career-development, and networking opportunities to help trainees make the most of their meeting experience. The following activities have been identified as most relevant to the unique interests of undergraduates, medical and graduate students, residents, and fellows. These activities are open only to individuals with a blue trainee badge or by invitation.

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

FRIDAY

ASH-a-Palooza

Friday 12:45 p.m. – 5:00 p.m.
Petco Park

This is ASH’s premier trainee event complete with micro-learning sessions, mentorship opportunities, and more! It is only open to trainees wearing a blue badge. Blood Buddies are one-on-one, ten-minute sessions to discuss career tracks and seek advice for faculty members.

ASH Talk Opening Song and Welcome

Friday 12:45 p.m. – 1:00 p.m.
Sections 112 and 114
Petco Park

Speaker:
RAYNE H. ROUCE, MD, Clinical Care Center-Texas Children’s Hospital, Houston, TX

ASH Talk #1 - Imposter Syndrome/DEI/Pay Disparities

Friday 1:00 p.m. – 1:20 p.m.
Sections 112 and 114
Petco Park

Chair:
MAYA ABDALLAH, MD, Boston University, Boston, MA

Speaker:
JULIE SILVER, MD, Harvard Medical School, Boston, MA

Blood Buddies (In-Person)

Friday 1:30 p.m. – 2:00 p.m., 2:40 p.m. – 3:10 p.m., 4:35 p.m. – 5:00 p.m.
Petco Park, Sections 122 and 124

Adult Clinical Classical Hematology

MOREY BLINDER, MD, Washington University, Saint Louis, MO

MARC CARRIER, MD, The Ottawa Hospital, Ottawa, ON, Canada

JULIE KANTER, MD, University of Alabama At Birmingham, Birmingham, AL

ALICE MA, MD, University of North Carolina at Chapel Hill, Chapel Hill, NC

SANA SAIF UR REHMAN, MD, Washington University in St. Louis, St. Louis, MO

Adult Clinical Malignant Hematology

JULIE E CHANG, MD, University of Wisconsin, Madison, WI

ALISON W. LOREN, MD, Perelman Center for Advanced Medicine, Philadelphia, PA

MATTHEW L. ULRICKSON, MD, MD Anderson Medical Center/Banner Health, Gilbert, AZ

ALISON R. WALKER, MD, MPH, MBA, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL

AMY YUAN WANG, MD, MPH, University of Chicago, Chicago, IL

BMT Peds and Adult

EMILY K. CURRAN, MD, University of Chicago, Cincinnati, OH

HANY ELMARIAH, MD, MS, Moffitt Cancer Center, Tampa, FL

of interest to PhD attendees. CME credit is not offered.
**Diversity, Equity, and Inclusion (DEI)**

- Deepa Jagadeesh, MD, Cleveland Clinic, Solon, OH
- Sajad Khazal, MD Anderson Medical Center, Houston, TX
- Satyajit Kosuri, MD, University of Chicago, Chicago, IL
- Kristin M. Page, MD, Medical College of Wisconsin, Milwaukee, WI
- Reshma Ramlal, MD, University of Kentucky, Lexington, KY
- Santosh L. Saraf, MD, University of Illinois, Chicago, IL
- Adrianna Vlachos, MD, Steven and Alexandra Cohen Children's Medical Center, New York, NY

**Medical Education**

- Alex A. Boucher, MD, University of Minnesota Medical School, Plymouth, MN
- Caroline Cromwell, MD, Mount Sinai School of Medicine, New York, NY
- Usha Perepu, MBBS, MRCP, University of Iowa, Iowa City, IA
- Alexandra P. Wolanskyj-Spinner, MD, Mayo Clinic, Rochester, MN
- Ida Wong-Sefidan, MD, University of California San Diego, San Diego, CA

**Pediatric Clinical Malignant Hematology**

- Aimee C. Talleur, MD, St. Jude Children's Research Hospital, Memphis, TN
- Kara M. Kelly, MD, Roswell Park Cancer Center, Buffalo, NY
- Leslie Kersun, MD, MSEd, Children's Hospital of Philadelphia, Swarthmore, PA
- Jennifer McNeer, MD, MS, University of Utah, Salt Lake City, UT
- Andrew E. Place, MD, PhD, Dana-Farber Cancer Institute, Inc., Boston, MA
- Rayne Roche, MD, Texas Children's Hospital, Houston, TX

**Pediatric Clinical Classical Hematology**

- E. Leila Jerome Clay, MD, Novo Nordisk, Tampa, FL
- Melanie E. Fields, MD, The Washington University, Saint Louis, MO
- Lewis Hsu, MD, PhD, University of Illinois, Chicago, IL
- Seethal A. Jacob, MD, MS, Riley Hospital For Children, Indianapolis, IN
- Akshat Jain, MD, MPH, North Shore LIJ, Redlands, CA
- Jeffrey D. Levensburger, DO, The University of Alabama, Birmingham, AL

**Quality Improvement**

- Adam F. Binder, MD, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA
- Rachel F. Grace, MD, The Children's Hospital Corporation, Boston, MA
- Allison A. King, MD, PhD, MPH, Washington University, St. Louis, MO
- Jordan K. Schaefer, MD, University of Michigan, Ann Arbor, MI

**Blood Drops**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:30 p.m. – 1:40 p.m.</td>
<td>Diversity, Equity, and Inclusion</td>
<td>Left Field Concourse, Petco Park</td>
</tr>
<tr>
<td>1:50 p.m. – 2:00 p.m.</td>
<td>Hematology Opportunities for the Next Generation (HONORS)</td>
<td>Left Field Concourse, Petco Park</td>
</tr>
<tr>
<td>1:50 p.m. – 2:00 p.m.</td>
<td>Malignant Hematology</td>
<td>Left Field Concourse, Petco Park</td>
</tr>
</tbody>
</table>

**MEJ**

- Pamela B. Allen, MD, Emory University, Decatur, GA

**PhD**

- Wei Tong, PhD, Children's Hospital of Philadelphia, Philadelphia, PA
TRAINEE ACTIVITIES

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

**Research Training Award Fellows (RTAF)**
RAMZI ABBOUD, MD, Washington University School of Medicine, Clayton, MO

**Sickle Cell Disease**
LUKE R. SMART, MD, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH

**Quality Improvement**
MING Y. YEONG LIM, MBBSCHIR, University of Utah, Salt Lake City, UT

**Wellness**
JACQUELINE C. BARRIENTOS, MD, MS, Mount Sinai Medical Center, Miami Beach, Florida

**ASH Talk #2 - Approaches to Team Management**

<table>
<thead>
<tr>
<th>Friday</th>
<th>2:10 p.m. – 2:30 p.m.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Sections 112 and 114</td>
</tr>
<tr>
<td></td>
<td>Petco Park</td>
</tr>
</tbody>
</table>

**Chair:**
MAYA ABDALLAH, MD, Boston University, Boston, MA

**Speaker:**
IFEYINWA OSUNKWO, MD, Novo Nordisk Rare Disease, Waltham, MA

**Blood Drops**

<table>
<thead>
<tr>
<th>Friday</th>
<th>2:40 p.m. – 2:50 p.m., 3:00 p.m. – 3:10 p.m.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Left Field Concourse</td>
</tr>
<tr>
<td></td>
<td>Petco Park</td>
</tr>
</tbody>
</table>

**Diversity, Equity, and Inclusion**
ALISON W. LOREN, MD, Perelman Center for Advanced Medicine, Philadelphia, PA

**Hematology Opportunities for the Next Generation (HONORS)**
GEORGIOS E. CHRISTAKOPOULOS, MD, University of Minnesota Medical School, Masonic Children’s Hospital, Memphis, TN

**Malignant Hematology**
HIRA MIAN, MD, McMaster University, Hamilton, ON, Canada

**PhD**
ZE ZHENG, MBBS, PhD, Medical College of Wisconsin, Milwaukee, WI

**Physician-Scientist Award (Phy-Sci)**
CHRISTINA SNIDER, MD, Cleveland Clinic Lerner College of Medicine, Nashville, TN

**Quality Improvement**
ELIZABETH J. SHPALL, MD, The University of Texas MD Anderson Cancer Center, Houston, TX

**Scholar**
STEPHEN S. CHUNG, MD, UT Southwestern Medical Center, Dallas, TX

**Sickle Cell Disease**
DEEPIKA S. DARBARI, MD, Children’s National Center for Cancer and Blood Disorders, Washington, DC

**Translational Research Training in Hematology (TRTH)**
ANNA M. EIRING, PhD, Texas Tech University Health Science Center, El Paso, TX

**Wellness**
LESLIE R. ELLIS, MD, MSHPED, Wake Forest University School of Medicine, Winston Salem, NC

**President’s Remarks**

<table>
<thead>
<tr>
<th>Friday</th>
<th>3:20 p.m. – 3:30 p.m.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Sections 112 and 114</td>
</tr>
<tr>
<td></td>
<td>Petco Park</td>
</tr>
</tbody>
</table>

**Blood Wars - Jeopardy!**

<table>
<thead>
<tr>
<th>Friday</th>
<th>3:30 p.m. – 4:15 p.m.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Sections 112 and 114</td>
</tr>
<tr>
<td></td>
<td>Petco Park</td>
</tr>
</tbody>
</table>

**Blood Drop**

<table>
<thead>
<tr>
<th>Friday</th>
<th>4:35 p.m. – 4:45 p.m., 4:50 p.m. – 5:00 p.m.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Left Field Concourse</td>
</tr>
<tr>
<td></td>
<td>Petco Park</td>
</tr>
</tbody>
</table>

**CRTI**
SURBHI SIDANA, MD, Stanford University, Stanford, CA

**Diversity, Equity, and Inclusion**
ALISON R. WALKER, MD, MPH, MBA, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL

**Malignant Hematology**
KAH POH (MELISSA) LOH, MBCh BAO, MS, University of Rochester Medical Center, Rochester, NY

**MMSAP**
NATASHA STANLEY, DO, Children’s Hospital of Philadelphia, Philadelphia, PA

of interest to PhD attendees.  **CME credit is not offered.**
PhD
HEATHER O'LEARY, PhD, Northeast Ohio Medical University, Rootstown, OH

Physician-Scientist Award (Phy-Sci)
ALEXANDER F. M. CRAIG, MPHIL, Stanford University Medical Center, Stanford, CA

Quality Improvement
ALLISON A. KING, MD, PhD, MPH, Washington University in St. Louis, St. Louis, MO

SATURDAY

Career Development Lunch

Saturday  11:15 a.m. – 12:15 p.m.  Hilton San Diego Bayfront  Sapphire Ballroom ABCD

This session will provide an intimate venue for trainees to meet with leaders in hematology to discuss careers in the wide array of practice areas within hematology, including basic, clinical, and translational research, PhD careers, careers in industry settings, and careers in private and clinical practice.

A boxed lunch is provided. There will be one hematology leader, assigned with a topic, at a table where trainees are welcome to eat lunch and chat about that topic.

Adult and Pediatric BMT
DARIA V BABUSHKOV, MD, PhD, University of Pennsylvania, Merion Station, PA

SHARON SAVAGE, MD, National Cancer Institute, NIH, Bethesda, MD

KRIS MICHAEL MAHADEO, MD, MD Anderson Medical Center, Houston, TX

ADRIANNA VLACHOS, MD, Steven and Alexandra Cohen Children’s Medical Center of New York, New Hyde Park, NY

Adult Clinical Classical Hematology
OYEBIMPE ADESINA, MD, MS, University of California Davis, Mountain View, CA

BETH MARTIN-KOOL, MD, Stanford University, Palo Alto, CA

ANNA L. PARKS, MD, University of Utah, Salt Lake City, UT

LAYLA VAN DOREN, MD, Yale School of Medicine, New Haven, CT

Sickle Cell Disease
JEFFREY D. LEBENSBURGER, DO, The University of Alabama, Birmingham, AL

Wellness
RONAK H. MISTRY, DO, Vanderbilt University Medical Center, Nashville, TN

Adult Clinical Malignant Hematology
BRANDON BLUE, MD, Moffitt Cancer Center, Tampa, FL

KIERON DUNLEAVY, MD, Georgetown University, Washington, DC

MARLISE R. LUSKIN, MD, Dana-Farber Cancer Institute, Boston, MA

KENDRA SWEET, MD, Moffitt Cancer Center, Tampa, FL

Clinical Careers in Hematology (Private Practice Careers)
JOHN M. BURKE, MD, Rocky Mountain Cancer Centers, Aurora, CO

KAREN CHEE, MD, University of California, San Francisco, CA

PAUL FISHKIN, MD, Illinois Cancer Care, Peoria, IL

EMILY MEIER, MD, MSc, Pfizer, South San Francisco, CA

Geriatric Hematology
CHARITY I. OYEDEJI, MD, Duke University, Durham, NC

ASHLEY E. ROSKO, MD, The Ohio State University, Columbus, OH

Global Hematology
LUIS ENRIQUE MALPICA CASTILLO, MD, University of Texas MD, Anderson cancer Center, Pearland, TX

DIEGO VILA CLE, MD, Medical School of Ribeirao Preto, Ribeirao Preto, Brazil

ADLETTE INATI, MD, Rafik Hariri University Hospital, Tripoli, Lebanon

Government Careers (NIH and FDA)
ANGELO DE CLARO, MD, Food and Drug Administration, Silver Spring, MD

LAUREL MENAPACE, MD, Sanofi, Washington, DC

WILLIAM MERRITT, Germantown, MD
TRAINEE ACTIVITIES

Industry Careers
Gregory J. Kato, MD, University of Pittsburgh Medical Center, Pittsburgh, PA
Ifeinywa Osunkwo, MD, Novo Nordisk Rare Disease, Waltham, MA
Weli Sun, MD, PhD, Janssen Pharmaceutical, Los Angeles

Laboratory and Translational Hematology
Eugene Khandros, MD, PhD, Children’s Hospital of Philadelphia, Philadelphia, PA
Bridget Marcellino, MD, PhD, Mount Sinai School of Medicine, New York, NY
Seongseok Yum, MD, PhD, University of Arizona, Tucson, AZ

Lifespan Hematology
Seethal A Jacob, MD, MS, Riley Hospital for Children, Indianapolis, IL
Julie Kanter, MD, University of Alabama, Birmingham, AL

Maternal Health
Ariela L. Marshall, MD, Mayo Clinic, Rochester, MN
Bethany T. Samuelson Bannow, MD, Oregon Health and Science University, Portland, OR

Medical Educators in Hematology
Tamara J. Dunn, MD, Stanford University, Stanford, CA
Annie Im, MD, University of Pittsburgh Medical Center, Pittsburgh, PA

Medical Informatics & Artificial Intelligence
Lars Bullinger, MD, Charité Universitätsmedizin Berlin, Berlin, Germany
Roni Shouval, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY

Pediatric Clinical Hematology
Alex A Boucher, MD, University of Minnesota, Minneapolis, MN
Peter Gordon, MD, PhD, Masonic Cancer Center, University of Minnesota, Minneapolis, MN
Kara M. Kelly, MD, Roswell Park Comprehensive Cancer Center, Buffalo, NY
Guy Young, MD, University of Southern California Keck School of Medicine, Children’s Hospital of Los Angeles, Los Angeles, CA

PhD Careers
Gabriel Ghiaur, MD, PhD, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD
Andrew Volk, PhD, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH

Systems-Based Hematology
Harriet A. Bering, MD, Harvard Vanguard Medical Associates, Lexington, MA
Nathan T. Connell, MD, MPH, Brigham and Woman’s Hospital, Boston, MA

SUNDAY – MONDAY

Trainee Didactic Sessions
Offered during lunch on Sunday and Monday, the Trainee Didactic Sessions are designed to offer trainees an overview of timely and relevant career-oriented issues.

Trainee Didactic Session: A Road Less Traveled - Careers Outside of Academia

Chair:
Ifeinywa Osunkwo, MD, Novo Nordisk, Waltham, MA

Speakers:
Amber Yates, MD, Agios Pharmaceuticals, Houston, TX
Timothy Kubal, MD, MBA, Moffitt Cancer Center, Tampa, FL

Sunday 11:15 a.m. – 12:15 p.m.
Room 33
San Diego Convention Center
<table>
<thead>
<tr>
<th>Trainee Didactic Session: Show Me the Money - Funding Your Research</th>
<th>Trainee Didactic Session: What to Ask for in an Interview</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Monday</strong>&lt;br&gt;12:15 p.m. – 1:15 p.m.&lt;br&gt;Room 31&lt;br&gt;San Diego Convention Center</td>
<td><strong>Monday</strong>&lt;br&gt;12:15 p.m. – 1:15 p.m.&lt;br&gt;Room 33&lt;br&gt;San Diego Convention Center</td>
</tr>
<tr>
<td><strong>Chair:</strong>&lt;br&gt;Ifeinwa Osunkwo, MD, Novo Nordisk, Waltham, MA</td>
<td><strong>Chair:</strong>&lt;br&gt;Ifeinwa Osunkwo, MD, Novo Nordisk, Waltham, MA</td>
</tr>
<tr>
<td><strong>Speakers:</strong>&lt;br&gt;Ifeinwa Osunkwo, MD, Novo Nordisk, Waltham, MA&lt;br&gt;Cassandra Josephson, MD, Johns Hopkins University, St Petersburg, FL</td>
<td><strong>Speakers:</strong>&lt;br&gt;Alison R. Walker, MD, MPH, MBA, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL&lt;br&gt;Z.F. Zheng, MBBS, PhD, Medical College of Wisconsin, Milwaukee, WI</td>
</tr>
<tr>
<td><strong>Trainee Didactic Session: The International Trainee Journey</strong></td>
<td>Non-CME</td>
</tr>
<tr>
<td><strong>Sunday</strong>&lt;br&gt;11:15 a.m. – 12:15 p.m.&lt;br&gt;Room 31&lt;br&gt;San Diego Convention Center</td>
<td><strong>Trainee Didactic Session: The International Trainee Journey</strong></td>
</tr>
<tr>
<td><strong>Chair:</strong>&lt;br&gt;Ifeinwa Osunkwo, MD, Novo Nordisk, Waltham, MA</td>
<td>Non-CME</td>
</tr>
<tr>
<td><strong>Speakers:</strong>&lt;br&gt;Eloisa Riva, MD, MEd, Hospital Britânico, Montevideo, Uruguay&lt;br&gt;Andres Gomez-De Leon, MD, Universidad Autónoma de Nuevo León, Nuevo Leon, Mexico</td>
<td>CME credit is not offered.</td>
</tr>
</tbody>
</table>

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.
Biomea Fusion is developing BMF-219, an investigational, oral, covalent menin inhibitor, currently being evaluated in multiple clinical trials. We are enrolling patients with known menin inhibitor sensitive mutations in various heme malignancies, KRAS mutant solid tumors, as well as adults with diabetes.

A COVALENT small molecule is a synthetic compound that forms a permanent bond to its target protein and offers a number of potential advantages over conventional non-covalent drugs, including greater target selectivity, lower drug exposure, and the ability to drive a deeper, more durable response.

Biomea Fusion is a clinical stage biopharmaceutical company focused on the discovery and development of novel covalent small molecules to treat patients with genetically defined cancers and metabolic diseases. 

Visit us at the 2023 ASH Annual Meeting Booth #3223.

To learn more about Biomea Fusion’s covalent menin inhibitor (BMF-219) clinical trials, contact us at 1-844-245-0490, clinicaltrials@biomeafusion.com or visit clinicaltrials.gov.
The Education Program will be held from Saturday, December 9 – Monday, December 11. A question-and-answer period will occur following the conclusion of all the session's presentations. Chapters based on these sessions will be published in Hematology 2023, the ASH Education Program.

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

Education Program Co-Chairs:

Jean M. Connors, MD, Dana-Farber Cancer Institute, Boston, MA
Amy E. DeZern, MD, Johns Hopkins University, Baltimore, MD

### Acquired Hemophilia A Diagnosis and Management

<table>
<thead>
<tr>
<th>Day</th>
<th>Time</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saturday</td>
<td>9:30 a.m. – 10:45 a.m.</td>
<td>Room 28 A-D San Diego Convention Center</td>
</tr>
</tbody>
</table>

Chair: Andreas Tiede, MD, Hannover Medical School, Hannover, Germany

Speakers:
Séan Platt, MSc, CSci, FIBMS, Barts Health NHS Trust, London, England
Diagnosis and Laboratory Monitoring of Acquired Hemophilia A

Andreas Tiede, MD, Hannover Medical School, Hannover, Germany
Immunotherapy of Acquired Hemophilia A

Rebecca Kruse-Jarres, MD, MPH, Puget Sound Blood Center, Seattle, WA
The Role of Emicizumab in Acquired Hemophilia A

### Are We Personalizing MDS Therapy in 2023?

<table>
<thead>
<tr>
<th>Day</th>
<th>Time</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saturday</td>
<td>9:30 a.m. – 10:45 a.m.</td>
<td>Marriott Grand Ballroom 5-6 Marriott Marquis San Diego Marina</td>
</tr>
</tbody>
</table>

Chair: David A. Sallman, MD, H. Lee Moffitt Cancer Center, Tampa, FL

Speakers:
Renata Xian, MD, Johns Hopkins University, Baltimore, MD
How to Classify Risk Based On Clinical and Molecular Modeling: Integrating molecular markers in the risk assessment of myelodysplastic syndrome

Marie Sebert, MD, PhD, Institution, Paris, France
Next-Generation Therapy for Lower Risk MDS

David A. Sallman, MD, H. Lee Moffitt Cancer Center, Tampa, FL
Frontline Treatment Options for Higher Risk MDS: Can We Move Past Azacitidine?

### CAR T Cells in ALL: Bridge or Definitive Therapy?

<table>
<thead>
<tr>
<th>Day</th>
<th>Time</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saturday</td>
<td>9:30 a.m. – 10:45 a.m.</td>
<td>Room 6B San Diego Convention Center</td>
</tr>
</tbody>
</table>

Chair: Alice Bertaina, MD, PhD, Stanford University, Palo Alto, CA

Speakers:
Nirali N. Shah, M.D., National Institutes of Health, Bethesda, MD
Long-Term Follow-Up of CD19-CAR T-Cell Therapy in Children and Young Adults With B-ALL

Alice Bertaina, MD, PhD, Stanford University, Palo Alto, CA
Stem Cell Transplantation for ALL: You’ve Always Got a Donor, Why Not Always Use It?

Stephen Gottschalk, MD, St. Jude’s Children’s Research Hospital, Memphis, TN
Preventing Relapse after CD19-CAR T-cell Therapy for Pediatric ALL: Role of Transplant and Enhanced CAR T cells

### How Do We Calibrate Cellular Therapy for Lymphoma in 2023?

<table>
<thead>
<tr>
<th>Day</th>
<th>Time</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saturday</td>
<td>9:30 a.m. – 10:45 a.m.</td>
<td>Room 6CF San Diego Convention Center</td>
</tr>
</tbody>
</table>

Chair: Manali K. Kamdar, MD, MBBS, University of Colorado, Denver, CO

Speakers:
Anna Maria Sureda Balari, MD, PhD, Institut Catala D’Oncologia, Barcelona, Spain
CAR T-Cell Therapy in Aggressive Lymphomas—Identifying Prognostic and Predictive Markers
**Saturday-Monday**

**EDUCATION SESSIONS**

**09–11 Dec 2023**

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

---

**Loretta J. Nastoupil, MD, MD Anderson Cancer Center, Houston, TX**

**Management of Aggressive Lymphoma After CAR T-Cell Therapy Failure**

---

**Manali K. Kamdar, MD, MBBS, University of Colorado, Denver, CO**

**Selection of Bispecific Antibody Therapies or CAR T-Cell Therapy in Relapsed Lymphomas**

---

**What are Treatment Options for Patients with Relapsed, Refractory or Persistent AML?**

**Saturday** 9:30 a.m. – 10:45 a.m.  
Pacific Ballroom Salons 15-17  
Marriott Marquis San Diego Marina

**Chair:**  
**Alison R. Walker, MD, MPH, MBA, The Ohio State University Medical Center, Powell, OH**

**Speakers:**  
**Jacqueline Cloos, PhD, VU University Medical Center, Amsterdam, Netherlands**  
**Understanding Differential Technologies for Detection of MRD and How to Incorporate into Clinical Practice**  
**Marion Subklewe, MD, Ludwig-Maximilians-University of Munich, Muenchen, Bavaria, Germany**  
**Novel Immunotherapies in the Treatment of AML, Is There a Hope?**  
**Alison R. Walker, MD, MPH, MBA, The Ohio State University Medical Ctr., Powell, OH**  
**Novel Therapies upon Failure of HMA + Venetoclax**

---

**How Do We Extend Survival for Patients with Chronic Lymphocytic Leukemia (CLL) in 2023?**

**Saturday** 2:00 p.m. – 3:15 p.m.  
Ballroom 20CD  
San Diego Convention Center

**Chair:**  
**Chaitra S. Ujjani, MD, Seattle Cancer Care Alliance/Fred Hutchinson Cancer Research Center, Seattle, WA**

**Speakers:**  
**Chaitra S. Ujjani, MD, Seattle Cancer Care Alliance/Fred Hutchinson Cancer Research Center, Seattle, WA**  
**Dual Targeted Regimens for the Front-line Treatment of CLL**

---

**Inherited Bone Marrow Failure Syndromes - From Pediatrics to Adult**

**Saturday** 2:00 p.m. – 3:15 p.m.  
Room 24  
San Diego Convention Center

**Chair:**  
**Emma M. Groarke, MD, National Institutes of Health, Bethesda, MD**

**Speakers:**  
**Emma M. Groarke, MD, National Institutes of Health, Bethesda, MD**  
**When to Consider Inherited Marrow Failure Syndromes in Adults**  
**Timothy S. Olson, MD, PhD, Children’s Hospital of Philadelphia, Merion Station, PA**  
**Management of Fanconi Anemia Beyond Childhood**  
**Marena R. Niewisch, MD, Hannover Medical School, Hannover, Germany**  
**Clinical Manifestations of Telomere Biology Disorders in Adults**

---

**Ongoing Challenges in the Management of VTE**

**Saturday** 2:00 p.m. – 3:15 p.m.  
Room 29  
San Diego Convention Center

**Chair:**  
**Kenneth A. Bauer, MD, Beth Israel Deaconess Medical Center, Boston, MA**

**Speakers:**  
**Kenneth A. Bauer, MD, Beth Israel Deaconess Medical Center, Boston, MA**  
**Talk #1 The Do’s, Don’ts, and Nuances of Thrombophilia Testing**  
**Cecilia Becattini, MD, University of Perugia, Perugia, Italy**  
**Provoked vs Minimally Provoked vs Unprovoked VTE—Does it Matter?**
KEITH R. MCCRAE, MD, Cleveland Clinic, Cleveland, OH
*How to Diagnose and Manage Antiphospholipid Syndrome*

### Transfusion Support in Sickle Cell Disease

**Saturday 2:00 p.m. – 3:15 p.m.**
**Room 28 A-D**
**San Diego Convention Center**

**Chair:**
FRANCE PIENNE, MD, PhD, Université Paris-Est Créteil Hospital, Creteil, France

**Speakers:**
ANOOSHA HABIBI, MD, Henri-Mondor University Hospital- UPEC, Creteil Cedex, France
*Managing Pregnancy in Patients with Sickle Cell Disease from a Transfusion Perspective*

SHANNON KELLY, Vitalant Research Institute (formerly Blood Systems Research Institute), San Francisco, CA
*Suppressing HbS With Chronic Exchange Transfusions*

FRANCE PIENNE, MD, PhD, Université Paris-Est Créteil Hospital, Creteil, France
*Alloimmunization and Hyperhemolysis in Sickle Cell Disease*

### Graft Versus Host Disease: Is an Ounce of Prevention Worth a Pound of Cure?

**Saturday 4:00 p.m. – 5:15 p.m.**
**San Diego Ballroom AB**
**Marriott Marquis San Diego Marina**

**Chair:**
MUNA QAYED, MD, Emory University, Atlanta, GA

**Speakers:**
KIRK R. SCHULTZ, B.C. Children’s Hospital, Vancouver, BC, Canada
*Planning GVHD Preemptive Therapy: Risk factors, Biomarkers, and Prognostic Scores*

MUNA QAYED, MD, Emory University, Atlanta, GA
*Novel Approaches to Acute GVHD Prevention*

IDORENYI AMANAM, MD, City of Hope, Duarte, CA
*Chronic GVHD: Review Advances in Prevention, Novel Endpoints and Targeted Strategies*

### Hematologic Toxicity of Immunotherapies

**Saturday 4:00 p.m. – 5:15 p.m.**
**Room 6DE**
**San Diego Convention Center**

**Chair:**
FREDERICK L. LOCKE, MD, Moffitt Cancer Center, Tampa, FL

**Speakers:**
FREDERICK L. LOCKE, MD, Moffitt Cancer Center, Tampa, FL
*CAR-T*

MICHAEL KROLL, MD, MD Anderson Cancer Center, Houston, TX
*Checkpoint Inhibitors*

MARTIN HUTCHINGS, MD, PhD, Rigshospitalet, Copenhagen, Denmark
*Bispecific Antibody Therapies*

### How is the Management Paradigm Evolving for Hodgkin Lymphoma in 2023?

**Saturday 4:00 p.m. – 5:15 p.m.**
**Ballroom 20CD**
**San Diego Convention Center**

**Chair:**
ANDREW M. EVENS, DO, MBA, MMSc, Rutgers Cancer Institute New Jersey, New Brunswick, NJ

**Speakers:**
ANDREW M. EVENS, DO, MBA, MMSc, Rutgers Cancer Institute New Jersey, New Brunswick, NJ
*Hodgkin Lymphoma Treatment for Older Persons in the Modern Era*

SAIRAH AHMED, MD, The University of Texas M D Anderson Cancer Center, Houston, TX
*Management of Limited Stage Hodgkin Lymphoma*

NATALIE S. GROVER, MD, University of North Carolina, Chapel Hill, NC
*The Optimal Management of Relapsed and Refractory Hodgkin Lymphoma: Post-Brentuximab and Checkpoint Inhibitor Failure*
### Why Am I Getting Paged at 2AM?
**Microangiopathic Emergencies**

<table>
<thead>
<tr>
<th>Saturday</th>
<th>4:00 p.m. – 5:15 p.m.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Room 29</td>
<td>San Diego Convention Center</td>
</tr>
</tbody>
</table>

**Chair:**

Shruti Chaturvedi, MBBS, Johns Hopkins University School of Medicine, Baltimore, MD

**Speakers:**

Jennifer Jury McIntosh, DO, Medical College of Wisconsin, Milwaukee, WI  
*Labor and Delivery: DIC, HELLP, Pre-eclampsia*

Shruti Chaturvedi, MBBS, Johns Hopkins University School of Medicine, Baltimore, MD  
*Medical Consult—aHUS, TTP—How to Distinguish and What to Do*

Beverley Jane Hunt, MD, FMCPATH, FRCP, King’s College, London, England  
*Consumptive Coagulopathy in the ICU*

### Hemostasis in Patients with Severe Liver Disease

<table>
<thead>
<tr>
<th>Sunday</th>
<th>9:30 a.m. – 10:45 a.m.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Room 31</td>
<td>San Diego Convention Center</td>
</tr>
</tbody>
</table>

**Chair:**

Lara N. Roberts, MD, MBBS, King’s College Hospital, London, England

**Speakers:**

Ton Lishman, PhD, University Medical Centre Groningen, Groningen, Netherlands  
*How to Assess Hemostasis in Patients with Severe Liver Disease*

Lara N. Roberts, MD, MBBS, King’s College Hospital, London, England  
*How to Manage Hemostasis in Patients with Liver Disease During Interventions*

Walter Ageno, MD, University of Insubria, Varese, Italy  
*How to Manage Splanchnic Vein Thrombosis in Patients with Liver Disease*

### Goldilocks and Transplant Timing in Inherited Marrow Failure Syndromes: Too Early, Too Late, Just Right?

<table>
<thead>
<tr>
<th>Sunday</th>
<th>9:30 a.m. – 10:45 a.m.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Room 11</td>
<td>San Diego Convention Center</td>
</tr>
</tbody>
</table>

**Chair:**

Suneet Agarwal, MD, PhD, Children’s Hospital Boston, Boston, MA

**Speakers:**

Kristen E. Schratz, MD, Johns Hopkins Hospital, Baltimore, MD  
*Clonal Evolution in Inherited Marrow Failure Syndromes Predicts Disease Progression*

Suneet Agarwal, MD, PhD, Children’s Hospital Boston, Boston, MA  
*Minimal Intensity Conditioning Strategies for Bone Marrow Failure – Is It Time for “Preventative” Transplants?*

Kasiani Myers, MD, Cincinnati Children’s Hospital, Cincinnati, OH  
*Post-transplant Complications in Patients With Marrow Failure Syndromes—Are We Improving Long-Term Outcomes?*

### How Do We Enhance Results in Rare Hematologic Malignancies?

<table>
<thead>
<tr>
<th>Sunday</th>
<th>9:30 a.m. – 10:45 a.m.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Room 29</td>
<td>San Diego Convention Center</td>
</tr>
</tbody>
</table>

**Chair:**

Anita D’Souza, MD, MS, The Medical College of Wisconsin Inc, Milwaukee, WI

**Speakers:**

Oussama Abla, MD, Hospital for Sick Children, Toronto, ON, Canada  
*Langerhans Cell Histiocytosis: Promises and Caveats of Targeted Therapies in High-risk and CNS Disease*

Deepti H. Radia, MD, FRCPATH, Guy’s and St. Thomas’ Hospital, London, United Kingdom  
*Mastocytosis Demystified*

Anita D’Souza, MD, MS, The Medical College of Wisconsin Inc, Milwaukee, WI  
*Amyloid Consults Do Not Have to be Vexing*
How Do We Improve Outcomes in Relapsed and Refractory Multiple Myeloma in 2023?

**Sunday** 9:30 a.m. – 10:45 a.m.
Seaport Ballroom EFGH
Manchester Grand Hyatt San Diego

**Chair:**
FRANCESCA GAY, MD, PhD, University of Torino, Torino, Italy

**Speakers:**
FRANCESCA GAY, MD, PhD, University of Torino, Torino, Italy
A Rational Approach to Functionally High-Risk Myeloma
MONIQUE A. HARTLEY-BROWN, MD, Dana-Farber Cancer Institute, Boston, MA
Considerations for Next Therapy After ANTI CD38 Monoclonal Antibodies Used as First Line
ADAM D. COHEN, The Trustees of The University of Pennsylvania, Philadelphia, PA
Options at the Time of Relapse After ANTI BCMA Therapy

**The Iron Revolution!**

**Sunday** 9:30 a.m. – 10:45 a.m.
Room 28 A-D
San Diego Convention Center

**Chair:**
THOMAS G. DELOUGHERY, MD, Oregon Health and Science University, Portland, OR

**Speakers:**
THOMAS G. DELOUGHERY, MD, Oregon Health and Science University, Portland, OR
Sex, Lies, and Iron Deficiency: A Call to Change Ferritin Reference Ranges
MICHAEL AUERBACH, MD, Auerbach Hem-Onc Associates, Inc., Baltimore, MD
IV Iron Formulations and Use in Adults
JACQUELYN POWERS, MD, Baylor College of Medicine/Texas Children’s Hospital, Houston, TX
Intravenous Iron Therapy in Pediatrics: Who Should Get It and When Is the Right Time?

What Are the Advances in Myeloproliferative Neoplasms Affecting Management?

**Sunday** 9:30 a.m. – 10:45 a.m.
Marriott Grand Ballroom 5-6
Marriott Marquis San Diego Marina

**Chair:**
JEANNE PALMER, MD, Mayo Clinic - Arizona, Scottsdale, AZ

**Speakers:**
DOUGLAS TREMBLAY, MD, Icahn School of Medicine at Mount Sinai, New York, NY
Cytoreduction for ET and PV: Who, What, When, and How?
HARINDER GILL, MD, MBBS, FRCP, FRCPATH, The University of Hong Kong, Hong Kong
Evolving landscape of JAK Inhibition in Myelofibrosis: Monotherapy and Combinations
JEANNE PALMER, MD, Mayo Clinic, Arizona, Scottsdale, AZ
Are Transplant Indications Changing for MF?

Have We Optimized Therapy Yet for Patients with AML?

**Sunday** 4:30 p.m. – 5:45 p.m.
Room 6CF
San Diego Convention Center

**Chair:**
TARA L. LIN, MD, The University of Kansas Medical Center, Westwood, KS

**Speakers:**
CHRISTOPH RÖLLIG, MD, MSc, University Hospital Dresden, Dresden, Germany
Improving Long-Term Outcomes with Intensive Induction Chemotherapy for Patients with AML
TARA L. LIN, MD, The University of Kansas Medical Center, Westwood, KS
The Approach of HMA + ven With or Without BMT for All patients
JUSTIN M. WATTS, MD, Miami, Coral Gables, FL
The Future Paradigm of HMA + ven or Targeted Inhibitor Approaches: Sequencing or Triplet Combinations in AML Therapy
Hematologists and the Care of Pregnant Women

**Sunday**  4:30 p.m. – 5:45 p.m.
Room 25
San Diego Convention Center

**Chair:**  
**Fionnuala Ni Ainle**, MD, PhD, Mater Misericordiae University Hospital, University College Dublin, Dublin, Ireland

**Speakers:**  
**Adam K. Lewkowitz**, MD, Brown University School of Medicine, Women & Infants Hospital in Rhode Island, Providence, RI
*Identifying and Treating Iron Deficiency in Pregnancy*

**Andra H. James**, MD, Duke University School of Medicine, Durham, NC
*Management of Pregnant Women Who Have Bleeding Disorders*

**Fionnuala Ni Ainle**, MD, PhD, Mater Misericordiae University Hospital, University College Dublin, Dublin, Ireland
*Prevention, Diagnosis and Management of PE & DVT in Pregnant Women*

**Energizing the Red Cell: Novel Therapies for Hereditary Hemolytic Anemias**

**Sunday**  4:30 p.m. – 5:45 p.m.
Hall A
San Diego Convention Center

**Chair:**  
**Richard M. Kaufman**, MD, Brigham and Women’s Hospital, Boston, MA

**Speakers:**  
**Mindy Goldman**, MD, Canadian Blood Services, Ottawa, ON, Canada
*MSM and Blood Donation: Shifting to Individualized Risk Assessment*

**Darja Karpova**, MD, Washington University in St. Louis, Saint Louis, MO
*Clonal Hematopoiesis in Frequent Whole Blood Donors*

**Richard M. Kaufman**, MD, Brigham and Women’s Hospital, Boston, MA
*T-cell Lymphopenia in Frequent Platelet Donors*

**How Do We Tackle Remaining Clinical Challenges in CML?**

**Sunday**  4:30 p.m. – 5:45 p.m.
San Diego Ballroom AB
Marriott Marquis San Diego Marina

**Chair:**  
**Naranie Shanmuganathan**, MBBS, FRACP, FRCPA, PhD, Royal Adelaide Hospital and SA Pathology, Adelaide, Australia

**Speakers:**  
**Naranie Shanmuganathan**, MBBS, FRACP, FRCPA, PhD, Royal Adelaide Hospital and SA Pathology, Adelaide, Australia
*Accelerated phase CML--de Novo and Transformed*

**Simona Soverini**, PhD, University of Bologna School of Medicine, Castel Maggiore, Bologna, Italy
*Resistance Mutations in CML and How We Approach Them*

**Massimo Breccia**, Hematology-Sapienza University, Rome, Italy
*Atypical CML-Diagnosis and Treatment*

**Energizing the Red Cell: Novel Therapies for Hereditary Hemolytic Anemias**

**Monday**  10:30 a.m. – 11:45 a.m.
Room 28 A-D
San Diego Convention Center

**Chair:**  
**Rachael F. Grace**, MD, The Children’s Hospital Corporation, Boston, MA

**Speakers:**  
**Rachael F. Grace**, MD, The Children’s Hospital Corporation, Boston, MA
*PK Activators in Pyruvate Kinase Deficiency*

**Eduard J. Van Beers**, MD, PhD, University Medical Centre Utrecht, Utrecht, Netherlands
*PK Activators for Sickle Cell Disease*

**Kevin H.M. Kuo**, MD, FRCP, MSc, University of Toronto, Toronto, ON, Canada
*PK Activators for Thalassemia*
EDUCATION SESSIONS

89
Saturday – Monday
09–11 Dec 2023

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

How Do We Apply T-Cell Redirection Therapy for Multiple Myeloma? CAR T-Cells and Bispecific Antibodies

Monday 10:30 a.m. – 11:45 a.m.
Seaport Ballroom ABCD
Manchester Grand Hyatt San Diego

Chair:
NIZAR J. BAHLIS, MD, University of Calgary, Alberta, Canada

Speakers:
NIZAR J. BAHLIS, MD, University of Calgary, Alberta, Canada
Current Use of Bispecific Antibodies to Treat Multiple Myeloma
SHAM MAILANKODY, MBBS, Memorial Sloan Kettering Cancer Center, New York, NY
Current Use of CAR T-Cells to Treat Multiple Myeloma
SURBHI SIDANA, MD, Stanford University, Stanford, CA
Managing Side Effects: Guidance for Use of Immunotherapies in Multiple Myeloma

Not Kids Anymore and Not Adults Yet: How Do We Treat Adolescent and Young Adult (AYA) Patients With ALL?

Monday 2:45 p.m. – 4:00 p.m.
Grand Hall B
Manchester Grand Hyatt San Diego

Chair:
TAMARA P. MILLER, MD, MSCE, Emory University, Decatur, GA

Speakers:
JOHN C. MOLINA, MD, MEd, , Shaker Heights, OH
Leveraging Health Care Technology to Improve Health Outcomes and Reduce Outcome Disparities in AYA Leukemia
TAMARA P. MILLER, MD, MSCE, Emory University, Decatur, GA
Adolescent and Young Adults (AYA) Versus Pediatric Patients: Survival, Risks and Barriers to Enrollment
EMILY K. CURRAN, MD, University of Cincinnati, Cincinnati, OH
Acute Lymphoblastic Leukemia in Young Adults: Which Treatment?

What Makes a Good Transplant Recipient? Putting the Puzzle Pieces Together

Monday 2:45 p.m. – 4:00 p.m.
Ballroom 20AB
San Diego Convention Center

Chair:
RONI SHOUVAL, MD, PhD, Memorial Sloan-Kettering, New York, NY

Speakers:
REENA JAYANI, MD, Vanderbilt University Medical Center, Nashville, TN
How Old Is Too Old? Frailty and Geriatric Assessments of Older Patients Undergoing Allogeneic HCT
RONI SHOUVAL, MD, PhD, Memorial Sloan-Kettering, New York, NY
The Sum of the Parts: What We Can and Cannot Learn from Comorbidity Scores in Allogeneic Transplantation
ASMITA MISHRA, MD, MBA, Moffitt Cancer Center, Tampa, FL
Approaches to Optimize Outcomes in Transplant Recipients

Alphabet Soup - Challenging Consults on the Pediatric Units

Monday 4:30 p.m. – 5:45 p.m.
Room 11
San Diego Convention Center

Chair:
NICOLE KUCINE, MD, MS, Weill Cornell Medical College, New York, NY

Speakers:
ASHISH KUMAR, MD, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH
Inflamed – HLH, MAS, or Something Else?
NICOLE KUCINE, MD, MS, Weill Cornell Medical College, New York, NY
Too Many White Cells – TAM, JMML, or Something Else?
CLIFFORD M. TAKEMOTO, MD, St Jude’s Children’s Research Hospital, Memphis, TN
Where Have All the Platelets Gone – HIT, DIC, or Something Else?
### Hematologists as Lifesavers: Inpatient Hematology Emergencies

<table>
<thead>
<tr>
<th>Day</th>
<th>Time</th>
<th>Venue</th>
</tr>
</thead>
<tbody>
<tr>
<td>Monday</td>
<td>4:30 p.m. – 5:45 p.m.</td>
<td>Marriott Grand Ballroom 5-6, Marriott Marquis San Diego Marina</td>
</tr>
</tbody>
</table>

**Chair:**
STEVEN FEIN, MD, MPH, Heme Onc Call, Miami, FL

**Speakers:**

- MARTIN S. TALLMAN, MD, Northwestern University, Highland Park, IL
  *How to Avoid Early Mortality in APL*
- STEVEN FEIN, MD, MPH, Heme Onc Call, Miami, FL
  *How to manage ITP with life-threatening bleeding*
- ADI ZOREF-LORENZ, MD, Hematology Institute, Meir Medical Center, Kfar Saba, Israel
  *Inpatient Recognition and Management of HLH*

### How Can We Manage High-Risk Hematologic Malignancies in the Community?

<table>
<thead>
<tr>
<th>Day</th>
<th>Time</th>
<th>Venue</th>
</tr>
</thead>
<tbody>
<tr>
<td>Monday</td>
<td>4:30 p.m. – 5:45 p.m.</td>
<td>Grand Hall B, Manchester Grand Hyatt San Diego</td>
</tr>
</tbody>
</table>

**Chair:**
DIPTI PATEL-DONNELLY, MD, Virginia Cancer Specialists, McLean, VA

**Speakers:**

- DIPTI PATEL-DONNELLY, MD, Virginia Cancer Specialists, McLean, VA
  *Acute Leukemias and Complicated Lymphomas: Pearls to Optimize Management When Patients Stay Local*
- JESUS G. BERDEJA, MD, Sarah Cannon Center For Blood Cancers, Nashville, TN
  *Multiple Myeloma: A Paradigm for Blending Community and Academic Care*
- RUEMU EJEFAYA BIRRIRAY, MD, Hem.-Onc. of Indiana, PC, Indianapolis, IN
  *Clinical Research in the Community*

### Improving Outcomes for Individuals with Sickle Cell Disease: Are We Moving the Needle?

<table>
<thead>
<tr>
<th>Day</th>
<th>Time</th>
<th>Venue</th>
</tr>
</thead>
<tbody>
<tr>
<td>Monday</td>
<td>4:30 p.m. – 5:45 p.m.</td>
<td>Room 29, San Diego Convention Center</td>
</tr>
</tbody>
</table>

**Chair:**
COURTNEY FITZHugh, National Institutes of Health (Hematology), Bethesda, MD

**Speakers:**

- KENNETH I. ATAGA, MD, University of Tennessee Health Sciences Center, Memphis, Nashville, TN
  *Using Disease Modifying Therapies in Sickle Cell Disease*
- ADETOLA A. KASSIM, MBBS, MS, Vanderbilt University Medical Center, Nashville, TN
  *The Range of Haploidentical Transplant Protocols in Sickle Cell Disease: All Haplos Are Not Created Equally*
- JOHN F. TISDALE, MD, National Institutes of Health Molecular & Clinical Hematology, Bethesda, MD
  *Gene Therapy for Sickle Cell Disease*
We invite you to attend the sessions below at the **Blood Journals Studio**

or stop by to meet journal staff during the poster hall hours

**LOCATED IN THE POSTER HALL, G-H**

<table>
<thead>
<tr>
<th>TIME*</th>
<th>SATURDAY, DECEMBER 9</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00 AM</td>
<td>Meet the <strong>Blood Advances</strong> Editors</td>
<td>Alisa Wolberg, PhD; Constantine Tam, MBBS, MD</td>
<td></td>
</tr>
<tr>
<td>2:00 PM</td>
<td><strong>Distinguished Abstract Achievement Award Ceremony</strong></td>
<td>Lisa Baumann Kreuziger, MD, MS. Versiti, Menomonee Falls, WI; Harvey Roweth, PhD,BSc. Brigham and Women's Hospital, Boston, MA; Marie Hollenhorst, MD, PhD. Brigham and Women's Hospital, Boston, MA, Harvard Medical School, Boston, MA Organized by: <strong>ASH SCIENTIFIC AFFAIRS</strong></td>
<td></td>
</tr>
<tr>
<td>4:00 PM</td>
<td>**ASH Poster Walk on Hemostasis and Thrombosis hosted by <strong>Blood Vessels, Thrombosis &amp; Hemostasis (VTH)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5:00 PM</td>
<td>Meet the <strong>Blood VTH</strong> Editor-in-Chief</td>
<td>Keith McCrae, MD, Editor-in-Chief, Blood VTH</td>
<td></td>
</tr>
</tbody>
</table>

**SUNDAY, DECEMBER 10**

<table>
<thead>
<tr>
<th>TIME</th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00 AM</td>
<td>Meet the <strong>Blood</strong> Editors</td>
<td>Helen Heslop, MD; Bertie Göttgens, DPhil</td>
<td></td>
</tr>
<tr>
<td>4:30 PM</td>
<td><strong>ASH Poster Walk on the Progression of Clonal Hematopoiesis to Hematologic Neoplasms:</strong> Biology, Risk Stratification and Therapeutic Interventions hosted by <strong>Blood Neoplasia</strong></td>
<td>Klaus Metzeler, MD. University of Leipzig, Germany Organized by: <strong>ASH SCIENTIFIC AFFAIRS</strong></td>
<td></td>
</tr>
<tr>
<td>5:30 PM</td>
<td>Meet the <strong>Blood Neoplasia</strong> Editor-in-Chief</td>
<td>Jonathan Licht, MD. Editor-in-Chief, Blood Neoplasia</td>
<td></td>
</tr>
</tbody>
</table>

**MONDAY, DECEMBER 11**

<table>
<thead>
<tr>
<th>TIME</th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00 AM</td>
<td>Meet the <strong>Blood Advances</strong> Editors</td>
<td>Geoffrey R. Hill, MD, FRCPA, FRACP: Olatoyosi Odenike, MD</td>
<td></td>
</tr>
<tr>
<td>11:00 AM</td>
<td><strong>Best Practices for Peer Review: ASH Clinical News interviews Blood Advances Editors</strong></td>
<td>Aaron T. Gerds, MD, ASH Clinical News Editor-in-Chief Catherine M. Bollard, MD. Editor-in-Chief, Blood Advances; Andrew S. Weyrich, PhD. Deputy Editor, Blood Advances</td>
<td></td>
</tr>
<tr>
<td>12:00 PM</td>
<td><strong>The ABCs of Publishing for Authors: The Hematologist interviews the Blood Editors</strong></td>
<td>Shaji Kumar, MD. Editor-in-Chief, The Hematologist; Nancy Berliner, MD, Editor-in-Chief, Blood; Andrew Roberts, MBBS, PhD. Deputy Editor, Blood</td>
<td></td>
</tr>
<tr>
<td>3:00 PM</td>
<td>Meet the <strong>Blood</strong> Editors</td>
<td>Erica Wood, MBBS: Philippe Armand, MD, PhD</td>
<td></td>
</tr>
</tbody>
</table>

* Pacific Daylight Time (PDT)
These sessions are intended to provide an in-depth review on specific scientific topics. This year, speakers will discuss current challenges and controversies in two exciting topics, addressing the current state of knowledge, translational and clinical applications, and future directions.

Each 90-minute session will be presented once in a small-venue format on either Sunday or Monday and will include ample time for audience questions and participation. These sessions are restricted to medical and research professionals only; no businesspersons or media will be admitted.

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

**SUNDAY**

**Debate: PCC or Andexanet alfa for Managing Bleeding in Patients on Oral Xa Inhibitors?**

**Sunday**
4:30 p.m. – 5:45 p.m.
Room 29, San Diego Convention Center

**Chair:**
DAVID GARCIA, MD, University of Washington, Seattle, WA

**Speakers:**
SAM SCHULMAN, MD, PHD, McMaster University, Hamilton, Ontario, Canada
PCC Should Be Used to Reverse Xai Anticoagulants

DEBORAH SEIGAL, MD, MSc, University of Ottawa, Ottawa, Ontario, Canada
Andexanet Should Be Used to Reverse Xai Anticoagulants

**Where the Bench Meets the Bedside: Laboratory Correlates in Clinical Trials**

**Sunday**
4:30 p.m. – 5:45 p.m.
Room 6A, San Diego Convention Center

**Chair:**
JUSTIN TAYLOR, MD, University of Miami, Miami, FL

**Speakers:**
VALERIA SANTINI, AOU Careggi-University of Florence, Firenze, Italy
Laboratory Scientists Don't Care

JUSTIN TAYLOR, MD, University of Miami, Miami, FL
Clinicians Don't Care

**MONDAY**

**Managing Previvorship in Hematology: Clinical Approaches to CCUS and MBL**

**Monday**
2:45 p.m. – 4:00 p.m.
Room 7, San Diego Convention Center

**Chair:**
GREGORY A. ABEL, MD, MPH, DFCI, Boston, M

**Speakers:**
ZHUOER XIE, MD, MS, Lutz, FL
CCUS is Increasingly Significant in Clinical Practice

PAOLO GHIA, MD, PhD, Vita-Salute San Raffaele University, Milano, Italy
Monoclonal B-cell Lymphocytosis: at a Crossroad Between Disease and Senescence
### What is a “Normal” Neutrophil Count?
The Duffy Red Cell Antigen, Ancestry, Genetics and Evolution

**Monday**  2:45 p.m. – 4:00 p.m.
Hall A, San Diego Convention Center

**Chair:**
**MAUREEN OKAM ACHBE,** MD, MPH, Hematology Division
Brigham and Women’s, Boston, MA

**Speakers:**
**LAUREN E. MERZ,** MD, MSc, Dana-Farber Cancer Institute, Boston, MA
**Duffy-null Associated Neutrophil Counts--What is Normal**

**JOHN MARK SLOAN,** MD, Boston Medical Center, Boston, MA
**Clinical Implications of the Duffy Antigen**

---

### Who are the Alternatives for Cellular Therapies?
Engineering and Retargeting Other Effector Lymphocytes

**Monday**  2:45 p.m. – 4:00 p.m.
Room 11, San Diego Convention Center

**Chair:**
**DEAN ANTHONY LEE,** MD, PhD, The Research Institute at Nationwide Children’s Hospital, Columbus, OH

**Speakers:**
**CARLOS A. RAMOS,** MD, The Methodist Hospital, Houston, TX
**Off-the-shelf αβ- or NK-T Cells for Cancer Therapy**

**JONATHAN P. H. FISHER,** University College London, London, United Kingdom
**Engineering T cells: A New Tool for Cancer Immunotherapy**
HOW I TREAT: BRINGING SCIENCE TO CLINICAL DILEMMAS

These sessions will provide an opportunity for a small number of attendees to meet with a clinical expert in a setting that fosters interaction. ASH has invited experts from around the world to facilitate informal discussions, allowing participants to present their questions and gain new perspectives on specific disease topics. A boxed breakfast will be provided.

Tickets are restricted to medical professionals only and will be available on site on a first-come, first-served basis; no businesspersons or media will be admitted. Only one ticket per person is allowed. Tickets may be purchased on site during registration hours beginning Thursday, December 7, at the Ticketed Sessions Counter in Building A, Level 1, Hall A1.

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

SATURDAY

<table>
<thead>
<tr>
<th>Acquired Hemophilia A Diagnosis and Management (for in-person participants)</th>
<th>Advances in Myeloproliferative Neoplasms Affecting Management (for in-person participants)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Saturday 8:00 a.m. – 9:00 a.m.</strong></td>
<td><strong>Saturday 8:00 a.m. – 9:00 a.m.</strong></td>
</tr>
<tr>
<td>Aqua Salon AB Hilton San Diego Bayfront</td>
<td>Aqua Salon D Hilton San Diego Bayfront</td>
</tr>
</tbody>
</table>

**Speaker:**

Acquired Hemophilia A Diagnosis and Management:

Annette Tiede, MD, Hannover Medical School, Hannover, Germany

Adolescent and Young Adult (AYA) Patients with Acute Lymphoblastic Leukemia (ALL) (for in-person participants):

John C. Molina, MD, ME, National Cancer Institute, Shaker Heights, OH

Advances in Myeloproliferative Neoplasms Affecting Management:

Jeanne Palmer, MD, Mayo Clinic, Scottsdale, AZ

Hematologists and the Care of Pregnant Women (for in-person participants):

Fionnuala Ní Ainle, MD, PhD, Mater Misericordiae University Hospital, University College Dublin, Dublin, Ireland

Tickets are restricted to medical professionals only and will be available on site on a first-come, first-served basis; no businesspersons or media will be admitted. Only one ticket per person is allowed. Tickets may be purchased on site during registration hours beginning Thursday, December 7, at the Ticketed Sessions Counter in Building A, Level 1, Hall A1.
Patients with Acute Myeloid Leukemia (for in-person participants)

Saturday 8:00 a.m. – 9:00 p.m.  
Aqua Salon C  
Hilton San Diego Bayfront

Speaker:  
CHRISTOPH ROLLIG, MD, MSc, University Hospital, Dresden, Germany

SUNDAY

Cellular Therapy for Lymphoma (for in-person participants)

Sunday 8:00 a.m. – 9:00 a.m.  
Aqua Salon D  
Hilton San Diego Bayfront

Speaker:  
LORETTA J. NASTOUPIL, MD, MD Anderson Cancer Center, Houston, TX

Early Management of Acute Promyelocytic Leukemia (APML) (for in-person participants)

Sunday 8:00 a.m. – 9:00 a.m.  
Aqua Salon F  
Hilton San Diego Bayfront

Speaker:  
MARTIN TALLMAN, MD, Northwestern University Feinberg School of Medicine, Highland Park, IL

Ongoing Challenges in the Management of VTE (for in-person participants)

Sunday 8:00 a.m. – 9:00 a.m.  
Aqua Salon AB  
Hilton San Diego Bayfront

Speaker:  
KENNETH A. BAUER, MD, Beth Israel Deaconess Medical Center, Boston, MA

T-Cell Redirection Therapy for Multiple Myeloma (for in-person participants)

Sunday 8:00 a.m. – 9:00 a.m.  
Aqua Salon E  
Hilton San Diego Bayfront

Speaker:  
SURBHI SIDANA, MD, Stanford University, Stanford, CA
For adults with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.

LIFT PLATELETS. NO SWEAT.

**No food-type restrictions:** Patients can take Doptelet with any food (food required); no administration concerns with minerals like calcium or magnesium.¹

**No liver monitoring:** Doptelet does not require additional liver-function monitoring; no significant hepatotoxicity seen in Doptelet clinical trials.¹,²

**No injections:** Doptelet can be taken anytime, anywhere, without adding trips to the doctor [platelet monitoring required].¹

INDICATION
DOPTELET® (avatrombopag) is indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment.

IMPORTANT SAFETY INFORMATION

**WARNINGS AND PRECAUTIONS**
Thrombotic/Thromboembolic Complications. DOPTELET is a thrombopoietin (TPO) receptor agonist and TPO receptor agonists have been associated with thrombotic complications in patients with chronic liver disease (0.4%; 1/274) in DOPTELET-treated patients and thromboembolic complications in patients with chronic immune thrombocytopenia (9/128) in DOPTELET-treated patients. Portal vein thrombosis has been reported in patients with chronic liver disease, and thromboembolic events (arterial and venous) have been reported in patients with chronic immune thrombocytopenia treated with TPO receptor agonists.

Consider the potential increased thrombotic risk when administering DOPTELET to patients with known risk factors for thromboembolism, including genetic prothrombotic conditions.

DOPTELET should not be administered to patients with chronic liver disease or chronic immune thrombocytopenia in an attempt to normalize platelet counts. Monitor platelet counts, and for signs and symptoms of thromboembolic events and institute treatment promptly.

**Serious Adverse Reactions**
Serious adverse reaction that occurred more frequently in patients treated with DOPTELET (9%; 12/128) compared to placebo (5%; 1/22) was headache, occurring in 1.6% (2/128).

Adverse Reactions
The most common adverse reactions (≥10%) in patients with chronic immune thrombocytopenia were headache, fatigue, confusion, epistaxis, upper respiratory tract infection, arthralgia, gingival bleeding, petechiae, and nasopharyngitis.

Postmarketing Experience
Following the approval of DOPTELET, hypersensitivity reactions involving the immune system, including, but not limited to, pruritus, rash, choking sensation, swollen face, and swollen tongue have been reported.

These are not all the possible risks associated with DOPTELET. Please see Full Prescribing Information for DOPTELET at www.doptelethcp.com

To report suspected adverse reactions, contact Sobi North America at 1-866-773-5274 or FDA at 1-800-FDA-1088.

Please see Brief Summary of Full Prescribing Information on the adjacent page.

Visit us at LiftPlatelets.com, or scan the QR code:


Doptelet is a registered trademark of Akari, Inc. Sobi is a trademark of Swedish Orphan Biovitrum AB (publ) ©2022 Sobi, Inc. - All rights reserved. PP-13394 01/2022
**BRIEF SUMMARY OF PRESCRIBING INFORMATION**

**DOPELET® (eptafolopag) tablets, for oral use**

1. **INDICATIONS AND USAGE**

1.1 Treatment of Thrombocytopenia in Patients with Chronic Liver Disease (CLD)

DOPELET is indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure.

1.2 Treatment of Thrombocytopenia in Patients with Chronic Immune Thrombocytopenia (ITP)

DOPELET is indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment.

4. **CONTRAINDICATIONS**

None.

5. **WARNINGS AND PRECAUTIONS**

5.1 Thrombotic/Thromboembolic Complications

DOPELET is a thrombotic (TPP) receptor agonist, and TPPI receptor agonists have been associated with thrombotic and thromboembolic complications in patients with chronic liver disease or chronic immune thrombocytopenia. In patients with chronic liver disease, thromboembolic events (portal vein thrombosis) occurred in 0.4% (1/274) of patients receiving DOPELET. In patients with chronic immune thrombocytopenia, thromboembolic events (posterior cerebral) occurred in 7% (9/128) of patients receiving DOPELET.

Consider the potential increased thrombotic risks when administering DOPELET to patients with known risk factors for thrombembolism, including genetic prothrombin conditions (e.g., Factor V Leiden, Prothrombin 20210A, Antithrombin deficiency or Protein C or S deficiency).

DOPELET should not be administered to patients with chronic liver disease or chronic immune thrombocytopenia in an attempt to normalize platelet counts. Monitor platelet counts and follow the dosing guidelines to achieve targeted platelet counts (see Dosage and Administration (2.2)). Monitor patients receiving DOPELET for signs and symptoms of thromboembolic events and institute treatment promptly.

6. **ADVERSE REACTIONS**

The following clinically significant adverse reactions are discussed in detail in other sections of the labeling:

- Thrombotic/Thromboembolic Complications [see Warnings and Precautions (5.1)]

6.1 Clinical Trial Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

**Patients with Chronic Liver Disease**

The safety of DOPELET was evaluated in two international, identical, single-center, randomized, double-blind, placebo-controlled trials, ADAPT-1 and ADAPT-2, in which 430 patients with chronic liver disease and thrombocytopenia received either DOPELET (n=274) or placebo (n=156) daily for 5 days prior to a scheduled procedure, and had a post-dose safety assessment. Patients were divided into two groups based on their mean platelet count at baseline:

- Low Baseline Platelet Count Cohort (less than 50 x 10^9/L) who received DOPELET 60 mg once daily for 5 days
- High Baseline Platelet Count Cohort (40 to less than 50 x 10^9/L) who received DOPELET 40 mg once daily for 5 days

The majority of patients were males (65%) and median subject age was 58 years (range 19-88 years of age). The racial and ethnic distribution was White (60%), Asian (33%), Black (3%) and Other (3%).

The most common adverse reactions (those occurring in ≥5% of patients) in the ADAPT-1 and ADAPT-2 trials are summarized in Table 5.

**Table 5: Adverse Reactions With a Frequency ≥5% in Patients with Chronic Liver Disease Treated with DOPELET - Pooled Data ADAPT-1 and ADAPT-2**

<table>
<thead>
<tr>
<th>Adverse Reaction</th>
<th>Low Baseline Platelet Count Cohort (≤40 x 10^9/L)</th>
<th>High Baseline Platelet Count Cohort (40 to ≤50 x 10^9/L)</th>
<th>Combined Baseline Platelet Count Cohorts (&gt;50 x 10^9/L)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>DOPELET (n=274)</td>
<td>Placebo (n=156)</td>
<td>DOPELET (n=274)</td>
</tr>
<tr>
<td>Pyrexia</td>
<td>4%</td>
<td>6%</td>
<td>4%</td>
</tr>
<tr>
<td>Abdominal Pain</td>
<td>8%</td>
<td>8%</td>
<td>8%</td>
</tr>
<tr>
<td>Nausea</td>
<td>8%</td>
<td>8%</td>
<td>8%</td>
</tr>
<tr>
<td>Headache</td>
<td>4%</td>
<td>4%</td>
<td>4%</td>
</tr>
<tr>
<td>Fatigue</td>
<td>4%</td>
<td>4%</td>
<td>4%</td>
</tr>
<tr>
<td>Edema Peripheral</td>
<td>3%</td>
<td>2%</td>
<td>3%</td>
</tr>
</tbody>
</table>

For the Low Baseline Platelet Count Cohort, the incidence of serious adverse reactions was 7% (11/159) in the 60 mg DOPELET treatment group. For the High Baseline Platelet Count Cohort, the incidence of serious adverse reactions was 5% (9/185) in the 40 mg DOPELET treatment group. The most common serious adverse reaction reported with DOPELET was hyponatremia. Two DOPELET-treated patients (3.7%) developed hyponatremia.

Adverse reactions resulting in discontinuation of DOPELET were anemia, pyrexia, and myalgia; each was reported in a single (0.4%) patient in the DOPELET (60 mg) treatment group.

**Patients with Chronic Immune Thrombocytopenia**

The safety of DOPELET was evaluated in four clinical trials in patients with chronic immune thrombocytopenia: two Phase 3 trials (one randomized, double-blind, placebo-controlled trial, and one randomized, double-blind, active-controlled trial) and two Phase 2 trials (one randomized, double-blind, placebo-controlled, dose-ranging trial, and one open-label extension trial) in 161 patients with chronic immune thrombocytopenia in both the double-blind and open-label extension phases.

The pooled safety data from these four clinical trials includes 128 patients who received 2.5 to 40 mg of DOPELET once daily for a median duration of exposure of 29.1 weeks and had 1 post-dose safety assessment. The majority of patients were female (63%) and median subject age was 50.5 years (range 18-88 years of age). The racial and ethnic distribution was White (84%), Black (6%), Asian (6%) and Other (6%).

The most common adverse reactions (those occurring in ≥10% of patients) in the DOPELET-treated patients across the pooled safety data from the four trials are summarized in Table 6.

**Table 6: Adverse Reactions With a Frequency ≥10% in Patients with Chronic Immune Thrombocytopenia Treated with DOPELET - Pooled Data from Clinical Trials**

<table>
<thead>
<tr>
<th>Adverse Reaction</th>
<th>DOPELET (n=128) %</th>
<th>Placebo (n=22) %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Headache</td>
<td>34</td>
<td>14</td>
</tr>
<tr>
<td>Fatigue</td>
<td>28</td>
<td>9</td>
</tr>
<tr>
<td>Vomiting</td>
<td>26</td>
<td>10</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>15</td>
<td>5</td>
</tr>
<tr>
<td>Upper respiratory tract infection</td>
<td>15</td>
<td>5</td>
</tr>
<tr>
<td>Arthralgia</td>
<td>13</td>
<td>0</td>
</tr>
<tr>
<td>Gastrointestinal bleeding</td>
<td>13</td>
<td>0</td>
</tr>
<tr>
<td>Petechiae</td>
<td>11</td>
<td>9</td>
</tr>
<tr>
<td>Nausea</td>
<td>10</td>
<td>0</td>
</tr>
</tbody>
</table>

The incidence of serious adverse reactions was 9% (12/128) in the DOPELET treatment group. Serious adverse reactions reported in more than 1 individual DOPELET-treated patient included headache, occurring in 1.6% (2/128).

Adverse reactions resulting in discontinuation of DOPELET were reported in more than 1 patient included headache, occurring in 1.6% (2/128).

6.2 Postmarketing Experience

The following adverse reactions have been identified during post approval use of DOPELET. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

**Drug Interactions**

7.1 Effect of Other Drugs on DOPELET in Patients with Chronic Immune Thrombocytopenia

**Moderate or Strong Dual Inhibitors of CYP2C9 and CYP3A4**

Concomitant use with a moderate or strong dual inhibitor of CYP2C9 and CYP3A4 increases eptafolopag AUC [see Clinical Pharmacology (12.3)], which may increase the risk of DOPELET toxicities. Reduce the starting dosage of DOPELET when used concomitantly with a moderate or strong dual inhibitor of CYP2C9 and CYP3A4 (see Table 4) [see Dosage and Administration (2.5)].

In patients starting moderate or strong dual inhibitors of CYP2C9 and CYP3A4 while receiving DOPELET, monitor platelet counts and adjust DOPELET dose as necessary (see Table 3) [see Dosage and Administration (2.5)].

**Moderate or Strong Dual Inhibitors of CYP2C9 and CYP3A4**

Concomitant use with a moderate or strong dual inhibitor of CYP2C9 and CYP3A4 decreases eptafolopag AUC [see Clinical Pharmacology (12.3)], which may reduce DOPELET efficacy. Increase the recommended starting dosage of DOPELET when used concomitantly with a moderate or strong dual inhibitor of CYP2C9 and CYP3A4 (see Table 4) [see Dosage and Administration (2.5)].
In patients starting moderate or strong dual inductors of CYP2C9 and CYP3A4 while receiving DOPELETT, monitor platelet counts and adjust DOPELETT dose as necessary (see Table 3) [see Dosage and Administration (2.2)].

**Patients with Chronic Liver Disease**

No dosage adjustments are required for patients with chronic liver disease.

**8 USE IN SPECIFIC POPULATIONS**

**8.1 Pregnancy**

**Risk Summary**

Based on findings from animal reproduction studies, DOPELETT may cause fetal harm when administered to a pregnant woman (see Data). The available data on DOPELETT in pregnant women are insufficient to inform a drug-associated risk of adverse developmental outcomes in humans. In animal reproduction studies, oral administration of avatrombopag resulted in adverse developmental outcomes when administered during organogenesis in rabbits and during organogenesis and the lactation period in rats. However, these findings were observed at exposures based on an AUC substantially higher than the AUC observed in patients at the maximum recommended dose of 60 mg once daily. Advise pregnant women of the potential risk to a fetus. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.

**Data**

**Animal Data**

In embryo-fetal development studies, avatrombopag was administered during organogenesis at doses of 100, 300, and 1000 mg/kg/day in rats and doses of 100, 300, and 600 mg/kg/day in rabbits. Minimal decreases in fetal weights were observed in rats at the maternally toxic dose of 1000 mg/kg/day with exposures 19 times the human exposure based on AUC. Spontaneous abortions were observed at all doses tested in rabbits and were associated with decreased body weights and food consumption at 300 and 600 mg/kg/day; exposures at the lowest dose of 100 mg/kg/day were 10 times the AUC in patients at the maximum recommended dose of 60 mg once daily. There were no embryo-fetal effects in rats administered avatrombopag at doses up to 200 mg/kg/day (33 times the human exposure based on AUC) or rabbits administered avatrombopag at doses up to 600 mg/kg (60 times the human exposure based on AUC).

In pre- and postnatal development studies in rats, avatrombopag was administered during both the organogenesis and lactation periods at doses ranging from 5 to 600 mg/kg/day. Doses of 100, 300, and 600 mg/kg/day caused maternal toxicity leading to total litter losses, decreased body weight in pups, and increased pup mortality, with the majority of the pup mortality occurring postnatally days 14 to 21. At a dose of 50 mg/kg/day that did not produce clear maternal toxicity, avatrombopag caused increased pup mortality from postnatal days 4 to 21, and mortality continued through postnatal day 25. The 50 mg/kg/day dose also decreased pup weight gain in the pups, resulting in a delay in sexual maturation. There were no effects on behavioral or reproductive functions in the offspring. The 50 mg/kg/day dose resulted in maternal exposures 43 times and pup exposures approximately 3 times the AUC observed in patients at the maximum recommended dose of 60 mg once daily.

**8.2 Lactation**

**Risk Summary**

There is no information regarding the presence of avatrombopag in human milk, the effects on the breastfed child, or the effects on milk production. Avatrombopag was present in the milk of lactating rats. When a drug is present in animal milk, it is likely the drug will be present in human milk. Due to the potential for serious adverse reactions in a breastfed child from DOPELETT, breastfeeding is not recommended during treatment with DOPELETT and for at least 2 weeks after the last dose (see Clinical Considerations).

**Clinical Considerations**

**Minimizing Exposure**

A lactating woman receiving DOPELETT for brief periods, such as prior to an invasive procedure, should interrupt breastfeeding and pump and discard breast milk during treatment and for 2 weeks after the last dose of DOPELETT in order to minimize exposure to a breastfed child. Advise lactating women receiving chronic DOPELETT therapy not to breastfeed during treatment with DOPELETT and for at least 2 weeks after the last dose.

**8.4 Pediatric Use**

Safety and effectiveness in pediatric patients have not been established.

In a 10-week juvenile toxicology study in rats, avatrombopag was administered at doses ranging from 20 to 300 mg/kg/day. There was no test article-related mortality and there were no clinical signs at doses up to 300 mg/kg/day. In the somatic, dose-dependent degeneration, regenerative hyperplasia, and atrophy of the glandular epithelium occurred at 100 and 300 mg/kg/day; exposures at 100 mg/kg/day in male rats were 14 times the AUC in patients at the highest recommended dose of 60 mg once daily. An increased incidence of background foci of mineralization was also observed in the kidneys of females at 300 mg/kg/day (female rat exposure was 50 times the human exposure based on AUC at the 60 mg daily dose).

**8.5 Geriatric Use**

Clinical studies of DOPELETT did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience does not identify differences in responses between the elderly and younger patients.

**10 OVERDOSAGE**

In the event of overdose, platelet count may increase excessively and result in thrombotic or thromboembolic complications. Closely monitor the patient and platelet count. Treat thrombotic complications in accordance with standard of care.

No antidote for DOPELETT overdose is known. Hemodialysis is not expected to enhance the elimination of DOPELETT because DOPELETT is only approximately 6% renally excrated and is highly bound to plasma proteins.

**17 PATIENT COUNSELING INFORMATION**

Advise the patient or caregiver to read the FDA-approved patient labeling (Patient Information).

Prior to treatment, patients should fully understand and be informed of the following risks and considerations for DOPELETT:

**Risks**

**Thrombotic/Thromboembolic Complications**

DOPELETT is a thrombopoietin (TPO) receptor agonist and TPO receptor agonists have been associated with thrombotic and thromboembolic complications in patients with chronic liver disease or chronic immune thrombocytopenia. Portal vein thrombosis has been reported in patients with chronic liver disease treated with TPO receptor agonists. Various thromboembolic complications (arterial and venous) have been reported in patients treated with DOPELETT [see Warnings and Precautions (5.1)].

**Drug Interactions**

DOPELETT may be affected by other drugs and may require a dose adjustment when co-administered with other drugs; therefore, advise patients to report the use of any other prescription or nonprescription medications or dietary supplements [see Dosage and Administration (2.3), Drug Interactions (7)].

**Pregnancy**

Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to inform their prescriber of a known or suspected pregnancy [see Use in Specific Populations (8.1)].

**Lactation**

Advise women not to breastfeed during treatment with DOPELETT and for at least 2 weeks after the last dose [see Use in Specific Populations (8.2)].

**Rx Only**

Please see package insert for Full Prescribing Information at www.DopelethalCP.com.

This Brief Summary is based on Dopelet (avatrombopag) Prescribing Information R00802 R6 July 2021

DOPELETT is a registered trademark of AkaRx, Inc. Manufactured for AkaRx, Inc., Durham, North Carolina 27707

Sobi is a trademark of Swedish Orphan BiBV 12 (publ) © 2021 Sobi, Inc.

For more information, go to www.DOPELETT.com or call 1-855-454-3887.

PP-13400 11/21
Blood Neoplasia joins Blood and Blood Advances in the Blood Journals portfolio, expanding our journal footprint. This new specialty journal will publish open access original research and will focus on hematologic malignancies, including leukemia, lymphoma, multiple myeloma, Waldenström macroglobulinemia, myeloproliferative neoplasms, minimal residual disease, and precursor conditions to neoplasia. The journal is open for submissions.

With a long publishing history that exemplifies superior quality and reach, the Blood Journals portfolio, anchored by our high-impact flagship, Blood, is a natural home for research in specialty areas of hematology.

WHY SUBMIT?

Blood Neoplasia helps place your research within the reputable and highly visible Blood Journals portfolio. By publishing within these journals, you align your research with the long-trusted ASH and Blood brands.

BENEFITS TO AUTHORS:

- ASH & Blood Portfolio Brand Visibility
- Fast Peer Review
- Seamless Transfers
- Speed to Publication
- Open Science

ASH is the home for hematology. Long embraced by the hematology community, the Blood Journals are a sought-after platform for researchers to advance their work. Expansion gives more authors an opportunity to be published in a Blood journal.

Submit your paper now
The Scientific Program features sessions developed by the Society’s 18 Scientific Committees. The sessions highlight emerging areas of science in the field of hematology and address topics referenced in ASH’s Agenda for Hematology Research.

Sessions will be held Saturday, December 9, through Monday, December 11. Following the didactic lectures, there will be a panel discussion at the end of the session, during which questions from the audience will be entertained. There will be no Q&A after each individual speaker’s presentation.

Scientific Program Co-Chairs:
Kojo S.J. Elenitoba-Johnson, MD, Memorial Sloan Kettering Cancer Center, New York, NY
Elizabeta Nemeth, PhD, University of California, Los Angeles, Los Angeles, CA

Mechanisms of Genetic Rescue in Inherited Bone Marrow Failure Syndromes

Saturday 9:30 a.m. – 10:45 a.m.
Room 7
San Diego Convention Center

Scientific Committee on Bone Marrow Failure
Chair:
Marcin W. Wlodarski, MD, PhD, St. Jude Children’s Research Hospital, Memphis, TN

Speakers:
Jean Soulier, MD, Hôpital Saint-Louis, Paris, France
Revertant Mosaicism in Fanconi Anemia

Alyssa Kennedy, MD, PhD, Boston Children’s Hospital, Boston, MA
Clonal Hematopoiesis in Shwachman Diamond Syndrome

Sushree S. Sahoo, PhD, St. Jude Children’s Research Hospital, Memphis, TN
Somatic Genetic Rescue in SAMD9 and SAMD9L Syndromes

Next Generation of Gene-Based Therapies for Bleeding Disorders

Saturday 9:30 a.m. – 10:45 a.m.
Room 31
San Diego Convention Center

Scientific Committee on Hemostasis
Chair:
Denise E. Sabatino, PhD, Children’s Hospital of Philadelphia, Philadelphia, PA

Speakers:
Leah Sabin, PhD, Regeneron Pharmaceuticals, Goldens Bridge, NY
Novel Approaches for Gene-Based Therapies

Lindsey A. George, MD, University Medical Centre Hamburg-Eppendorf, Haddenfield, NJ
Novel Variants of Coagulation Factors for Improved Gene Therapy

Jeroen Eikenboom, MD, PhD, Leiden University Medical Center, Leiden, Netherlands
SiRNA-Mediated/Novel Strategies to Treat Bleeding

The Evolution of Multiple Myeloma: From Inside-Out

Saturday 9:30 a.m. – 10:45 a.m.
Grand Hall C
Manchester Grand Hyatt San Diego

Scientific Committee on Plasma Cell Neoplasia
Chair:
Nina Shah, MD, AstraZeneca, San Francisco, CA

Speakers:
Marta Chesi, PhD, Mayo Clinic Arizona, Scottsdale, AZ
The Big Myc – What We Know About Myc Signaling in Myelomagenesis

Eugenio Morelli, MD, Dana Farber Cancer Institute, Boston, MA
Alternate Code: The Role of Non-Coding RNAs in Multiple Myeloma
Saturday–Monday

SCIENTIFIC SESSIONS

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

TOM CUPEDO, PhD, Erasmus University Medical Center, Rotterdam, Netherlands
Fertile Soil: The Contribution of the Non-Immune Microenvironment in the Development of Multiple Myeloma

Co-Operativity in the Pathogenesis of Myeloid Malignancies

Saturday 2:00 p.m. – 3:15 p.m.
Marriott Grand Ballroom 11-13
Marriott Marquis San Diego Marina

Scientific Committee on Myeloid Neoplasia

Chair:
SAAR GILL, MD, PhD, University of Pennsylvania, Philadelphia, PA

Speakers:
SEISHI OGAWA, MD, PhD, Kyoto University, Kyoto, Japan
Interplay Between Chromosomal Alterations and Gene Mutations
LINDE A. MILES, PhD, Cincinnati Children's Hospital, Cincinnati, OH
Single Cell Mutation Analysis of Clonal Evolution and Its Clinical Implications
MARK A. DAWSON, MD, PhD, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
Beyond Somatic Mutations in the Pathogenesis of Myeloid Neoplasia

Emerging Methodologies to Investigate Platelet Biology

Saturday 2:00 p.m. – 3:15 p.m.
Room 25
San Diego Convention Center

Scientific Committee on Megakaryocytes and Platelets

Chair:
HERVE FALET, PhD, Versiti Blood Research Institute, Milwaukee, WI

Speakers:
ANITA ECKLY, PhD, Inserm-Université De Strasbourg, Strasbourg, France
High-Resolution 3D Imaging of Megakaryocytes
FLORIAN GAERTNER, MD, PhD, Institute of Science and Technology Austria, Klosterneuburg, Austria
Dynamic Live Imaging of Platelets

ANDREW D. JOHNSON, PhD, National Heart, Lung, and Blood Institute, Bethesda, MD
Next Generation Sequencing in Platelet Biology

Spatial Genomic & Epigenomic Profiling in Hematology

Saturday 2:00 p.m. – 3:15 p.m.
Marriott Grand Ballroom 8-9
Marriott Marquis San Diego Marina

Scientific Committee on Epigenetics and Genomics

Chair:
DINESH S. RAO, MD, PhD, University of California, Los Angeles, CA

Speakers:
FEI CHEN, PhD, Broad Institute of MIT, Boston, MA
Spatial Mapping of Immune Cells & Clonal Heterogeneity in Tissues
ELHAM AZIZI, PhD, Columbia University, New York, NY
Understanding the Spatial-contextual Regulatory Mechanisms That Shape Cellular Identity and Heterogeneity
RONG FAN, PhD, Yale School of Engineering and Applied Science, New Haven, CT
Spatial Mapping of Chromatin and Proteomes

Iron and Heme in Stem Cell Maintenance and Erythropoiesis

Saturday 4:00 p.m. – 5:15 p.m.
Room 24
San Diego Convention Center

Scientific Committee on Iron and Heme

Chair:
LAURA SILVESTRI, PhD, San Raffaele Scientific Institute, Università Vita-Salute, Milan, Italy

Speakers:
DACHUAN ZHANG, PhD, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Iron and Heme Shape the Hematopoietic Stem Cell Fate and the Erythron Function
ANNAMARIA APRILE, PhD, Ospedale San Raffaele, Milan, Italy
Iron and Hematopoietic Stem Cell in Ineffective Erythropoiesis

of interest to PhD attendees. CME credit is not offered.
**Mechanistic Role(s) of Neutrophil Extracellular Traps in Thrombosis**

<table>
<thead>
<tr>
<th>Saturday</th>
<th>4:00 p.m. – 5:15 p.m.</th>
<th>Room 31</th>
<th>San Diego Convention Center</th>
</tr>
</thead>
</table>

**Scientific Committee on Thrombosis & Vascular Biology**

**Chair:** Rafal Pawlinski, PhD, University of North Carolina, Chapel Hill, NC

**Speakers:**
- Kimberly Martinod, PhD, KU Leuven, Leuven, Belgium
  *Neutrophil Extracellular Traps and Thrombosis in Different Disease States*
- Evi X. Stavrou, MD, University Hospitals Cleveland Medical Center, Cleveland, OH
  *Role of Neutrophils in In Vivo Models of Thrombosis*
- Ioannis Mitroulis, MD, PhD, Democritus University of Thrace, Alexandroupolis, Greece
  *Role of Immune Cells in the Pathophysiology of Thrombosis*

**Single Cell Omics and High Resolution Imaging to Unravel the Role of the Niche in Stress and Ageing Hematopoiesis**

<table>
<thead>
<tr>
<th>Saturday</th>
<th>4:00 p.m. – 5:15 p.m.</th>
<th>Marriott Grand Ballroom 8-9</th>
<th>Marriott Marquis San Diego Marina</th>
</tr>
</thead>
</table>

**Scientific Committee on Hematopoiesis**

**Chair:** Marieke Essers, PhD, HI-STEM GgmbH, Heidelberg, Germany

**Speakers:**
- Tiago C. Luis, PhD, University of Oxford, Oxford, United Kingdom
  *Niche Regulation of HSCs in Homeostasis and Emergency Hematopoiesis*
- Maria C. Florian, PhD, The Bellvitge Institute for Biomedical Research, Barcelona, Spain
  *Ageing in the Hematopoietic Stem Cells Niche*

**The Long Non-Coding Road, RNA and Signaling, and Regulation of Globin Gene Expression.**

<table>
<thead>
<tr>
<th>Saturday</th>
<th>4:00 p.m. – 5:15 p.m.</th>
<th>Room 25</th>
<th>San Diego Convention Center</th>
</tr>
</thead>
</table>

**Scientific Committee on Red Cell Biology**

**Chair:** Jane A. Little, MD, University of North Carolina at Chapel Hill, Chapel Hill, NC

**Speakers:**
- Mitchell J. Weiss, MD, PhD, St. Jude Children’s Research Hospital, Memphis, TN
  *Understanding Fetal Hgb Regulation: HIF1alpha and LNC RNA*
- Ann Dean, PhD, National Institutes of Health, Bethesda, MD
  *Understanding Fetal Hgb Regulation: LNC RNA*
- Gerd A. Blobel, MD, PhD, Children’s Hospital of Philadelphia, Philadelphia, PA
  *Mechanisms of Developmental Globin Gene Expression Control Revealed via Functional CRISPR Screens*

**JOINT SESSION: Lymphomagenesis - What Normal Immunology, Abnormal Immunology, and Genomics Can Teach Us About Lymphoma Biology and Novel Therapeutic Strategies**

<table>
<thead>
<tr>
<th>Saturday</th>
<th>4:00 p.m. – 5:35 p.m.</th>
<th>Ballroom 20AB</th>
<th>Marriott Marquis San Diego Marina</th>
</tr>
</thead>
</table>

**Scientific Committee on Hematopathology & Clinical Laboratory Hematology & Scientific Committee on Lymphoid Neoplasia**

**Co-Chairs:** Parul Bhargava, MD, University of California San Francisco, Redwood City, CA
- Caron A. Jacobson, MD, MMSc, Dana-Faber Cancer Institute, Boston, MA
SCIENTIFIC SESSIONS

Saturday–Monday 09–11 Dec 2023

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

**Speakers:**

**Aswin Sekar,** MD, PhD, Dana-Farber Cancer Institute, Boston, MA  
*Mutations in Healthy Humans Associated with Lymphoid Malignancies*

**Laura Pasqualucci,** MD, Columbia University, New York, NY  
*Aberrant Germinal Center Expansion and Lymphomagenesis*

**Christian Munz,** PhD, University of Zurich, Zurich, Switzerland  
*Infections and Lymphomagenesis*

**Mandeep Singh,** PhD, University of New South Wales, Sydney, Australia  
*Immune Dysregulation and Lymphomagenesis*

**JOINT SESSION: Ontogeny and Myeloid Disorders of Childhood**

- **Saturday 4:00 p.m. – 5:35 p.m.**
  - Marriott Grand Ballroom 5-6
  - Marriott Marquis San Diego Marina

*Scientific Committee on Myeloid Biology & Scientific Committee on Stem Cells and Regenerative Medicine*

**Co-Chairs:**

**Eirini Papapetrou,** MD, PhD, Icahn School of Medicine at Mount Sinai, New York, NY

**Jeffrey Magee,** MD, PhD, Washington University School of Medicine, Saint Louis, MO

**Speakers:**

**Shannon McKinney-Freeman,** PhD, St. Jude Children’s Research Hospital, Memphis, TN  
*Normal Hematopoietic Ontogeny*

**Jan-Henning Klussmann,** MD, Goethe University Frankfurt, Frankfurt, Germany  
*Ontogeny and Malignant Disorders of Childhood*

**Alan B. Cantor,** MD, PhD, Boston Children’s Hospital, Boston, MA  
*Ontogeny and Inherited Myeloid Disorders*

**Anna E. Beaudin,** PhD, University of Utah, Salt Lake City, UT  
*Microenvironmental Contributions to Fetal/Neonatal Blood Development and Diseases*

**JOINT SESSION: Genome Engineering for Enhanced Blood Cancer Immunotherapy**

- **Sunday 9:30 a.m. – 11:05 a.m.**
  - Room 6CF
  - San Diego Convention Center

*Scientific Committee on Immunology and Host Defense & Scientific Committee on Transplantation Biology & Cellular Therapies*

**Co-Chairs:**

**Todd A. Feinberg,** MD, PhD, Washington University School of Medicine, Saint Louis, MO

**Carl June,** MD, University of Pennsylvania, Philadelphia, PA

**Speakers:**

**Alexander Marson,** MD, PhD, University of California, San Francisco, San Francisco, CA  
*Decoding and Rewriting Immune Cells to Advance Immune Responses to Cancer*

**Dan S Kaufman,** MD, PhD, University of California San Diego, La Jolla, CA  
*Engineering Alternative Immune Cells as Blood Cancer Immunotherapy*

**Chiara Bonini,** MD, Ospedale San Raffaele, Milano, Italy  
*TCR Engineering of Immune Cells to Enhance Responses to Blood Cancers*

**Carl June,** MD, University of Pennsylvania, Philadelphia, PA  
*Applying Genome Engineering to Enhance CAR T Cell Responses to Blood Cancers*
<table>
<thead>
<tr>
<th>Pre- and Post-Thrombus: Risk Factors of Clotting and Post-Thrombosis Syndrome</th>
<th>Interplay of Coagulation and Complement in Transfusion Medicine</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Monday</strong> 10:30 a.m. – 11:45 a.m.</td>
<td><strong>Monday</strong> 2:45 p.m. – 4:00 p.m.</td>
</tr>
<tr>
<td>Room 31</td>
<td>Room 29</td>
</tr>
<tr>
<td>San Diego Convention Center</td>
<td>San Diego Convention Center</td>
</tr>
</tbody>
</table>

*Scientific Committee on Blood Disorders in Childhood*

**Chair:** Nadasha Archer, MD, Dana-Farber/Boston Children's Cancer and Blood Disorder Center, Boston, MA

**Speakers:**

- Jordan Shavit, MD, PhD, University of Michigan, Ann Arbor, MI
  - Genetics of Thrombosis
- Pavel Davison-Castillo, MD, University of Colorado, Denver, Denver, CO
  - The Role of Inflammation in Thrombosis
- Suzan Williams, MD, Hospital for Sick Children, Toronto, ON, Canada
  - Post-Thrombotic Syndrome

*Scientific Committee on Transfusion Medicine*

**Chair:** Sean Stowell, MD, Harvard University, Boston, MA

**Speakers:**

- Satheesh Chonat, MD, Children’s Healthcare of Atlanta, Atlanta, GA
  - The Role of Complement in Bystander Hemolysis
- Rick Kapur, MD, PhD, Sanquin Research, Utrecht, Netherlands
  - Complement and TRALI
- Debin Wang, PhD, The Blood Research Institute, Milwaukee, WI
  - Role of Complement in HIT
ASH® Clinical Practice Guidelines

Evidence-based guidelines covering the prevention, diagnosis, and treatment of blood disorders.

The American Society of Hematology (ASH) Clinical Practice Guidelines support clinicians and their patients with hematologic conditions to make decisions about diagnostic and treatment options based on a systematic review of the best available evidence. The guidelines are published in ASH’s open access scientific journal Blood Advances.

The guidelines are monitored annually for currency by experts. ASH will revise its guidelines when there is new evidence that could substantially change published recommendations.

Mobile Access to Guidelines and Pocket Guides

ASH Guidelines App: Easily access all ASH guideline recommendations from the convenience of your smartphone or tablet.

ASH Pocket Guides App: Get interactive versions of all the Society’s clinical pocket guides right on your smartphone or tablet, as well as various tools and calculators to aid in clinical decision making.

hematology.org/guidelines

Sickle Cell Disease (SCD)
- Stem Cell Transplantation
- Cardiopulmonary and Kidney Disease
- Transfusion Support
- Cerebrovascular Disease
- Management of Acute and Chronic Pain

Venous Thromboembolism (VTE)
- Treatment
- Prophylaxis in Medical Patients
- Prevention in Surgical Patients
- Diagnosis
- Anticoagulation Therapy
- Heparin-Induced Thrombocytopenia (HIT)
- Pregnancy
- Pediatrics
- Cancer Thrombophilia Testing
- VTE Guidelines Adapted for Latin America
- Anticoagulation in Patients with COVID-19

Immune Thrombocytopenia (ITP)

Von Willebrand Disease (VWD)
- Diagnosis
- Management

Acute Myeloid Leukemia (AML)
- Treatment of Newly Diagnosed Acute Myeloid Leukemia in Older Adults

Coming Soon:
- Aplastic Anemia
- Acute Lymphoblastic Leukemia in Adolescents and Young Adults
- Amyloidosis
The Scientific Symposia features transformative basic, translational, and clinical research poised to advance the field of hematology. There will be a panel discussion at the end of each session, during which questions from the audience will be entertained. There will be no Q&A after each individual speaker’s presentation.

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

SATURDAY

Alternative Immune Effector Cells

<table>
<thead>
<tr>
<th>Saturday</th>
<th>2:00 p.m. – 3:15 p.m.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Room 6DE</td>
<td>San Diego Convention Center</td>
</tr>
</tbody>
</table>

Chair: Fabiana Perna, MD, PhD, Moffitt Cancer Center, Indianapolis, IN

Speakers:
Evan Weber, PhD, Children’s Hospital of Philadelphia, Philadelphia, PA
Optimizing Use of Immune Effector Cells
Marie Bleakley, MD, PhD, Fred Hutchinson Cancer Research Center, Seattle, WA
Advances in TCR Based Therapeutics for Hematologic Malignancies

SUNDAY

The Impact of the Microbiota on Immunotherapy of Hematological Malignancies

<table>
<thead>
<tr>
<th>Sunday</th>
<th>9:30 a.m. – 10:45 a.m.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Room 25</td>
<td>San Diego Convention Center</td>
</tr>
</tbody>
</table>

Chair: Marco Ruella, MD, University of Pennsylvania, Philadelphia, PA

Speakers:
Ami S. Bhatt, MD, PhD, Stanford University, Stanford, CA
Microbiota and the Development of Hematological Malignancies
Marcel R.M. van den Brink, MD, PhD, Memorial Sloan Kettering Cancer Center, New York
Microbiota’s Impact on Stem Cell Transplant Outcomes and GVHD
Kate A. Markley, MBBS, PhD, FRACP, MPH, Fred Hutchinson Cancer Center, Seattle, WA
The Role of the Microbiota on Hemopoiesis and Immune Reconstitution after Therapy

Understanding Sickle Cell Pathophysiology

<table>
<thead>
<tr>
<th>Sunday</th>
<th>9:30 a.m. – 10:45 a.m.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Room 3</td>
<td>San Diego Convention Center</td>
</tr>
</tbody>
</table>

Chair: Payal Desai, MD, Wake Forest University, Charlotte, NC

Speakers:
Enrico M Novelli, MD, University of Pittsburgh Medical Center, Pittsburgh, PA
The Role of Heme in Acute and Chronic Sickle Cell Complications
Lucia De Franceschi, MD, University of Verona & AOUI Verona, Policlinico GB Rossi, Verona, Italy
The Role of Complement Activation in Complications of Sickle Cell Disease
Jeffrey Chalmers, PhD, The Ohio State University, Columbus, OH
Novel Testing Techniques in SCD
MONDAY

Multi-Omics Driven Precision Hematology

Monday 2:45 p.m. – 4:00 p.m.
Room 30
San Diego Convention Center

Chair:
PAMELA S. BECKER, MD, PhD, City of Hope, Duarte, CA

Speakers:
JUN J. YANG, PhD, St. Jude Children’s Research Hospital, Memphis, TN
Innovations in Precision Medicine Approaches to Hematologic Malignancies: Beyond NextGen Sequencing

MIKA KONTRO, MD, PhD, Helsinki University Hospital and University of Helsinki, Helsinki, Finland
Functional Screening for Precision Medicine Approaches in Acute Myeloid Leukemia

PAMELA S. BECKER, MD, PhD, City of Hope, Duarte, CA
Precision Medicine Approaches to Rare Blood Disorders

Special Symposium on the Basic Science in Hemostasis and Thrombosis

Monday 4:30 p.m. – 6:00 p.m.
Room 30
San Diego Convention Center

Chair:
PAMENSA A. ABATE, PhD, Children’s Hospital of Philadelphia, Philadelphia, PA
HERVE FALET, PhD, Versiti Blood Research Institute, Milwaukee, WI
Rafal Pawlinski, PhD, University of North Carolina, Chapel Hill, NC

Co-Chairs:
DENISE E. SABATINO, PhD, Children’s Hospital of Philadelphia, Philadelphia, PA
HERVE FALET, PhD, Versiti Blood Research Institute, Milwaukee, WI
Rafal Pawlinski, PhD, University of North Carolina, Chapel Hill, NC

Speakers:
CATERINA CASARI, PhD, University Paris-Saclay, Le Kremlin-Bicetre, France
Antibody-Based Strategies As Potential New Treatments for Von Willebrand Disease

MATTHEW J. FLYK, PhD, University of North Carolina, Chapel Hill, NC
Novel Mechanisms for Targeting Fibrin(ogen) to Suppress Thrombosis

MARIE LORDEPINIDZE, Research Center, Montreal Heart Institute, Montreal, Quebec, Canada
Platelets As Biomarkers and Vectors of Neuroactive Agents
The Scientific Spotlight sessions are crowdsourced from the hematology community and cover niche topic areas that are of interest to specific communities.

Sessions will be held Sunday, December 10, through Monday, December 11. Following the didactic lectures, there will be a panel discussion at the end of the session, during which questions from the audience will be entertained. There will be no Q&A after each individual speaker’s presentation.

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

### SUNDAY

#### Immunometabolism as a Tool to Advance Cell Therapy

<table>
<thead>
<tr>
<th>Sunday</th>
<th>4:30 p.m. – 5:45 p.m.</th>
<th>Room 11</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>San Diego Convention Center</td>
</tr>
</tbody>
</table>

**Co-Chairs:**

GREG DELGOFFE, PhD, University of Pittsburgh Medical Center, Pittsburgh, PA

MAY DAHER, MD, The University of Texas MD Anderson Cancer Center, Houston, TX

**Speakers:**

MAY DAHER, MD, The University of Texas MD Anderson Cancer Center, Houston, TX

Metabolic Reprogramming to Enhance the Antitumor Activity of Adoptive Cell Therapy

GREG DELGOFFE, PhD, University of Pittsburgh Medical Center, Pittsburgh, PA

Intersection of Metabolism and Immunity in Cancer

#### Tackling Greater Burden of Multiple Myeloma in African American Patients

<table>
<thead>
<tr>
<th>Sunday</th>
<th>4:30 p.m. – 5:45 p.m.</th>
<th>Room 6B</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>San Diego Convention Center</td>
</tr>
</tbody>
</table>

**Co-Chairs:**

YVONNE EFEBERA, MD, OhioHealth, Columbus, OH

SRINIVAS DEVARAKONDA, MD, Louisiana State University Health, Columbus, OH

**Speakers:**

YVONNE EFEBERA, MD, OhioHealth, Columbus, OH

Interplay of Healthcare Access and Outcomes in Multiple Myeloma

SRINIVAS DEVARAKONDA, MD, Louisiana State University Health, Columbus, OH

Redesigning Clinical Trials in Multiple Myeloma - Need of the Hour

δ of interest to PhD attendees.
MONDAY

Advances in Genomics: Tools Finally Opening the Molecular Secrets of Burkitt Lymphoma

**Monday** 10:30 a.m. – 11:45 a.m.
Grand Hall D
Manchester Grand Hyatt, San Diego

**Co-Chairs:**
RYAN MORIN, PhD, Simon Fraser University, Burnaby, British Columbia, Canada
LUDMILA PROKUNINA-OLSSON, PhD, National Cancer Institute, Bethesda, MD

**Speakers:**
RYAN MORIN, PhD, Simon Fraser University, Burnaby, British Columbia, Canada
Divide and Conquer: The Emerging Molecular Subdivisions of BL

LUDMILA PROKUNINA-OLSSON, PhD, National Cancer Institute, Bethesda, MD
Genome-wide Association Study of Burkitt Lymphoma: Insights About Host Genetic Architecture and Risk

The Mysteries of Factor XI

**Monday** 2:45 p.m. – 4:00 p.m.
Room 31
San Diego Convention Center

**Co-Chairs:**
DAVID GAILANI, MD, Vanderbilt University, Nashville, TN
OPHIRA SALOMON, MD, Tel Aviv University, Tel Hashomer, Israel

**Speakers:**
DAVID GAILANI, MD, Vanderbilt University, Nashville, TN
Mechanistic Understanding of Factor XI inhibitors

OPHIRA SALOMON, MD, Tel Aviv University, Tel Hashomer, Israel
Conundrums of Factor XI Deficiency
Leaders in Cellular Therapy Care & Research

The physician scientists at the University of Chicago Medicine are world renowned for cellular therapy research and clinical care. As leaders in stem cell transplantation, cellular therapies, and clinical trials, they continue to discover breakthrough treatments and therapeutic approaches for patients.

OUTCOMES & QUALITY

• The 2020, 2021 and 2022 CIBMTR* Annual report results showed that UChicago Medicine had the best one-year outcomes in Chicago and the highest relative to their predicted outcomes.

• Our pediatric program at Comer Children's Hospital also ranked highly, with actual survival numbers surpassing predicted outcomes.

SOLID TUMOR & BLOOD CANCER TRIALS

• Our portfolio of clinical trials for patients with hematologic malignancies is one of the largest in the country.

• We have some of the latest Phase I and II trials and our portfolio also has extensive solid tumor cell therapy trials, which are showing promising results. These targeted therapies have wide applicability across various tumor types.

TRANSPLANT OPTIMIZATION PROGRAM FOR OLDER ADULTS

• The Transplant Optimization Program (TOP) at UChicago Medicine plays a vital role in addressing hematopoietic cell transplantation treatment options for older adults.

• For patients that are at least 60 years old, our TOP clinic provides a personalized supportive care plan including a multidisciplinary team approach that fosters more successful outcomes.

AYA EXPERTS

• Adolescents and young adults (AYA) often confront different personal, psychosocial and medical challenges.

• Our nationally known AYA team includes pediatric and adult hematologists/oncologists, dedicated nurse practitioners, social workers, psychologists and physical therapists who work collaboratively to provide a comprehensive, one-stop model of care for young adults (ages 15-39) in significant life transition.

JONAS CENTER FOR CELLULAR THERAPY

• Physicians and scientists at the David and Etta Jonas Center for Cellular Therapy are working to develop novel cellular therapy products for hematologic malignancies and solid tumors. This team is aided by the state-of-the-art Advanced Cellular Therapeutics Facility (ACTF).

• The ACTF is a 10,000 square feet facility dedicated to both manufacturing cells for existing therapies, but also for developing and scaling up new cellular therapies from investigator-initiated and pharmaceutical company sponsored clinical trials for blood cancers, solid tumors, and benign conditions such as sickle cell disease.

SPECIALIZED HIGH-RISK CLINICS

• Our newly launched High-Risk Lymphoma and Complex Leukemias Clinics provide the full spectrum of treatments for the most complex cases, including options not widely available at most hospitals.

• These aggressive cancers require prompt, focused care from a team of highly skilled interdisciplinary specialists, which is why we created these clinics to meet the unique needs of patients.

Learn more at UChicagoMedicine.org/cellular-therapy
SCIENTIFIC WORKSHOPS

The Scientific Workshops are interactive discussions of the latest scientific developments in a particular field of hematology. All registered ASH annual meeting attendees are welcome to attend these workshops at no additional fee.

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

**Scientific Workshop on Defining Goals and Utilizing Tools for Enhancing Diversity, Equity and Inclusion (DEI) in Clinical Trials in Hematology**

**2:00 p.m. – 5:00 p.m.**

**Room 33**

San Diego Convention Center

**Co-Chair:**

**Arushi Khurana,** MBBS, Virginia Commonwealth University, Rochester, MN

**Alan E. Mast,** MD, PhD, Blood Center of Wisconsin, Milwaukee, WI

2:00 p.m. – 2:05 p.m. Opening Remarks
2:05 p.m. – 3:00 p.m. Current State and Anticipated Barriers in Increasing DEI in Hematology Clinical Trials
3:00 p.m. – 3:55 p.m. Setting Realistic Goals for DEI in Hematology Trials
3:55 p.m. – 4:45 p.m. Tools for Enhancing DEI in Hematology Trials
4:45 p.m. – 4:55 p.m. Keynote Address: Road Map to Increase DEI in Clinical Trials
4:55 p.m. – 5:00 p.m. Closing Remarks

**Scientific Workshop on Diagnostic Techniques in Classical and Malignant Hematology**

**2:00 p.m. – 5:00 p.m.**

**Room 28 A-D**

San Diego Convention Center

**Co-Chairs:**

**Piers Blombery,** PhD, MBBS, Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia

**Bruno Fattizzo,** MD, Fondazione IRCCS Ca’ Granda - Ospedale Maggiore Policlinico Milano, Italy

**Torsten Haferlach,** MD, PhD, MLL Munich Leukemia Laboratory, Munich, Germany

**Irina Murakhovskaya,** MD, Montefiore Medical Center, Brooklyn, NY

2:00 p.m. – 2:05 p.m. Opening Remarks
2:05 p.m. – 3:20 p.m. Diagnostic Testing in Classical Hematologic Disorders
3:20 p.m. – 4:25 p.m. Translational Molecular Diagnostics
4:25 p.m. – 4:55 p.m. Molecular Hematology Case-Based Discussion
4:55 p.m. – 5:00 p.m. Closing Remarks

**Scientific Workshop on Germline Predisposition to Hematopoietic Malignancies and Bone Marrow Failure**

**2:00 p.m. – 5:00 p.m.**

**Room 29**

San Diego Convention Center

**Co-Chairs:**

**Lucy Godley,** MD, PhD, University of Chicago Medical Center, Chicago, IL

**Marcin W. Lodarski,** MD, PhD, St. Jude Children’s Research Hospital, Memphis, TN

2:00 p.m. – 2:01 p.m. Opening Remarks
2:01 p.m. – 2:42 p.m. Preclinical Development of Model Systems and Organisms
2:42 p.m. – 2:58 p.m. Special Focus on Telomeropathies and Somatic Rescue - Part 1
2:58 p.m. – 3:14 p.m. Special Focus on Telomeropathies and Somatic Rescue - Part 2
3:14 p.m. – 3:30 p.m. Special Focus on Telomeropathies and Somatic Rescue - Part 3
3:37 p.m. – 4:18 p.m. Germline Predisposition That Intersects With Lymphoid Malignancies, Solid Tumors, and DNA Repair Pathways
4:18 p.m. – 4:59 p.m.  How Scientific Advances Impact Clinical Predictive Models and Recommendations
4:59 p.m. – 5:00 p.m.  Closing Remarks

Scientific Workshop on Hematology and Aging

2:00 p.m. – 5:00 p.m.
Room 11
San Diego Convention Center

Co-Chairs:
ASHLEY E ROSKO, MD, The Ohio State University, Columbus, OH
MEGAN WEIVODA, PhD, Mayo Clinic, Rochester, MN

2:00 p.m. – 2:05 p.m.  Opening Remarks
2:05 p.m. – 2:45 p.m.  Biomarkers of Biological Aging in Hematologic Malignancies
2:45 p.m. – 3:20 p.m.  Gauging Response of BiTes and CAR-T in Aging Adults
3:30 p.m. – 4:20 p.m.  Mechanisms of Microbiome-Immune Cross talk in Hematologic Disorders
4:20 p.m. – 4:58 p.m.  Mechanisms By Which Cell Stress Drives Aging vs Malignant Adaptation
4:58 p.m. – 5:00 p.m.  Closing Remarks

Scientific Workshop on the Interplay between Coagulation and Malignancy

2:00 p.m. – 5:00 p.m.
Room 25
San Diego Convention Center

Co-Chairs:
LISA BAUMANN KREUZIGER, MD, MS, Versiti, Menomonee Falls, WI
JEFFREY I. ZWICKER, MD, Beth Israel Deaconess Medical Center Harvard Medical School, Boston, MA

2:00 p.m. – 2:05 p.m.  Opening Remarks
2:05 p.m. – 2:50 p.m.  Coagulation Alterations in Hematologic Malignancies
2:50 p.m. – 3:45 p.m.  Mechanisms of Thrombosis in Brain Tumors
4:00 p.m. – 4:55 p.m.  Role of Neuroendocrine Tumors in Cancer Associated Thrombosis
4:55 p.m. – 5:00 p.m.  Closing Remarks

Scientific Workshop on Myeloid Development

2:00 p.m. – 5:00 p.m.
Room 6CF
San Diego Convention Center

Co-Chairs:
PATRICIA ERNST, PhD, University of Colorado Denver, Aurora, CO
ULRICH STEIDL, MD, PhD, Albert Einstein College of Medicine-Montefiore Health System, Bronx, NY

2:00 p.m. – 2:03 p.m.  Opening Remarks
2:03 p.m. – 2:45 p.m.  Stem Cell Biology
2:45 p.m. – 3:33 p.m.  Signaling and Development
3:33 p.m. – 4:15 p.m.  Myeloid Malignancies
4:15 p.m. – 4:57 p.m.  Gene Regulation in Myeloid Differentiation
4:57 p.m. – 5:00 p.m.  Closing Remarks
### Scientific Workshop on Therapy Resistance Mechanisms in Blood Malignancies

**2:00 p.m. – 5:00 p.m.**  
**Room 7**  
**San Diego Convention Center**

**Co-Chairs:**  
Christina Glytsou, PhD, Rutgers University, Newark, NJ  
Panagiotis Ntziachristos, PhD, Ghent University, Ghent, Belgium  
Daniel T. Starczynowski, PhD, University of Cincinnati College of Medicine, Cincinnati, OH

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>2:00 p.m.</td>
<td>Opening Remarks</td>
<td></td>
</tr>
<tr>
<td>2:01 p.m.</td>
<td>Epigenetic and Chromatin Mechanisms Implicated in Therapy Resistance</td>
<td></td>
</tr>
<tr>
<td>2:45 p.m.</td>
<td>Post-Transcriptional Mechanisms Controlling Therapy Response</td>
<td></td>
</tr>
<tr>
<td>3:29 p.m.</td>
<td>Post-Translational Underpinnings of Therapy Response and Resistance to Therapy</td>
<td></td>
</tr>
<tr>
<td>4:14 p.m.</td>
<td>Metabolic Mechanisms and Mitochondria Biology Behind Therapy Resistance</td>
<td></td>
</tr>
<tr>
<td>4:59 p.m.</td>
<td>Closing Remarks</td>
<td></td>
</tr>
</tbody>
</table>

### Scientific Workshop on Viruses in Hematology: Emerging Challenges and Therapeutic Vulnerabilities

**2:00 p.m. – 5:00 p.m.**  
**Room 8**  
**San Diego Convention Center**

**Co-Chairs:**  
Maher K. Gandhi, PhD, University of Queensland Diamantina Institute, Brisbane, QLD, Australia  
Helen Elisabeth Heslop, MD, DSc (Hon), Baylor College of Medicine, Houston, TX  
Rayne Rouce, MD, BS, Texas Children’s Hospital, Houston, TX  
Keri Toner, MD, Children’s National Hospital, Washington, DC

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>2:00 p.m.</td>
<td>Opening Remarks</td>
<td></td>
</tr>
<tr>
<td>2:03 p.m.</td>
<td>Background to Virally Driven Lymphoproliferative Disorders</td>
<td></td>
</tr>
<tr>
<td>2:43 p.m.</td>
<td>Emerging Vulnerabilities in Special Populations</td>
<td></td>
</tr>
<tr>
<td>3:33 p.m.</td>
<td>The Landscape of Viral Reactivation After Transplantation</td>
<td></td>
</tr>
<tr>
<td>4:13 p.m.</td>
<td>Anti-Viral Cellular Immunotherapies</td>
<td></td>
</tr>
<tr>
<td>4:53 p.m.</td>
<td>Closing Remarks</td>
<td></td>
</tr>
</tbody>
</table>
2023 ASH Annual Meeting Webcasts

Get access to more than 400 hours of recorded content from the 2023 ASH Annual Meeting, including oral abstract sessions.

WEBCAST PACKAGES AVAILABLE FOR PURCHASE

<table>
<thead>
<tr>
<th>Included Sessions</th>
<th>WEBCAST PACKAGES</th>
<th>Poster Presentations</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Invited Program</td>
<td>Invited Program</td>
</tr>
<tr>
<td>Education Program*</td>
<td>✔</td>
<td>✔</td>
</tr>
<tr>
<td>Scientific Program</td>
<td>✔</td>
<td>✔</td>
</tr>
<tr>
<td>General Sessions</td>
<td>✔</td>
<td>✔</td>
</tr>
<tr>
<td>Special-Interest Sessions</td>
<td>✔</td>
<td>✔</td>
</tr>
<tr>
<td>Trainee Didactic Sessions</td>
<td>✔</td>
<td>✔</td>
</tr>
<tr>
<td>Oral Abstract Sessions*</td>
<td>✔</td>
<td></td>
</tr>
</tbody>
</table>

Please note that webcast packages do not include the poster sessions.

WEBCAST PURCHASE PRICING

<table>
<thead>
<tr>
<th>Registration Category</th>
<th>BEST VALUE</th>
<th>Invited Program</th>
<th>Education Program Only</th>
<th>Scientific Program Only</th>
<th>Poster Presentations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Active or International Member</td>
<td>$450</td>
<td>$350</td>
<td>$250</td>
<td>$250</td>
<td>$99</td>
</tr>
<tr>
<td>Non-Member</td>
<td>$650</td>
<td>$550</td>
<td>$350</td>
<td>$350</td>
<td>$125</td>
</tr>
<tr>
<td>Associate, International Associate, Medical Student, Graduate Student, or Resident Member</td>
<td>$225</td>
<td>$175</td>
<td>$120</td>
<td>$120</td>
<td>$25</td>
</tr>
<tr>
<td>Non-Member in Training</td>
<td>$225</td>
<td>$175</td>
<td>$120</td>
<td>$120</td>
<td>$25</td>
</tr>
<tr>
<td>Allied Health Professional</td>
<td>$650</td>
<td>$550</td>
<td>$350</td>
<td>$350</td>
<td>$25</td>
</tr>
<tr>
<td>Honorary/Emeritus Member</td>
<td>$225</td>
<td>$175</td>
<td>$120</td>
<td>$120</td>
<td>$25</td>
</tr>
</tbody>
</table>

SPECIAL CONFERENCE PRICES

ASH STORE — SAILS PAVILION, UPPER LEVEL
ASH POSTER WALKS

ASH Poster Walks as of October 24, 2023.

The ASH Poster Walks highlight posters selected for the Annual Meeting that showcase emerging science in hematology. Two of the Poster Walks will take place as in-person sessions in the Blood Journals Studio during the Annual Meeting, while four will take place virtually following the Annual Meeting.

ASH Poster Walks are not offered for CME credit.

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

CME credit is not offered.

SATURDAY

ASH Poster Walk on Hemostasis and Thrombosis hosted by Blood VTH (for in-person participants)

4:00 p.m. – 5:00 p.m.
Halls G-H - Blood Journals Studio
San Diego Convention Center

Co-Chairs:
MARIE HOLLENHORST, MD, PhD, Brigham and Women’s Hospital, Boston, MA
Harvard Medical School, Boston, MA

LISA BAUMANN KREUZIGER, MD,MS, Versiti, Menomonee Falls, WI

ASH Poster Walk on the Progression of Clonal Hematopoiesis to Hematologic Neoplasms: Biology, Risk Stratification and Therapeutic Interventions hosted by Blood Neoplasia (for in-person participants)

4:30 p.m. – 5:30 p.m.
Halls G-H - Blood Journals Studio
San Diego Convention Center

Chair:
KAUS METZLER, MD, University of Leipzig, Germany, Leipzig, Germany

ASH Poster Walk on Genetic Mutations in Myeloma and Leukemia

10:00 a.m. – 11:00 a.m.
Virtual Program

Chair:
KARUN NEUPANE, MD, MBBS, Jacobi Medical Center/Albert Einstein College of Medicine, Bronx, NY

ASH Poster Walk on What’s Hot in Sickle Cell Disease Clinical Research in 2023

5:00 p.m. – 6:00 p.m.
Virtual Program

Chair:
ELIZABETH KLINGS, MD, Boston University, Boston, MA

SUNDAY

ASH Poster Walk on Diversity, Equity and Inclusion (DEI) in Hematology

10:00 a.m. – 11:00 a.m.
Virtual Program

Co-Chairs:
ELNA SAAH, MD, Emory School of Medicine, Atlanta, GA

ASH Poster Walk on Time to Examine Time Toxicity in Hematology

5:00 p.m. – 6:00 p.m.
Virtual Program

Chair:
RAHUL BANERJEE, MD, Fred Hutchinson Cancer Center, Seattle, WA

THURSDAY

ASH Poster Walk on Hemostasis and Thrombosis hosted by Blood VTH (for in-person participants)

4:00 p.m. – 5:00 p.m.
Halls G-H - Blood Journals Studio
San Diego Convention Center

Co-Chairs:
MARIE HOLLENHORST, MD, PhD, Brigham and Women’s Hospital, Boston, MA
Harvard Medical School, Boston, MA

LISA BAUMANN KREUZIGER, MD,MS, Versiti, Menomonee Falls, WI

ASH Poster Walk on the Progression of Clonal Hematopoiesis to Hematologic Neoplasms: Biology, Risk Stratification and Therapeutic Interventions hosted by Blood Neoplasia (for in-person participants)

4:30 p.m. – 5:30 p.m.
Halls G-H - Blood Journals Studio
San Diego Convention Center

Chair:
KAUS METZLER, MD, University of Leipzig, Germany, Leipzig, Germany

ASH Poster Walk on Genetic Mutations in Myeloma and Leukemia

10:00 a.m. – 11:00 a.m.
Virtual Program

Chair:
KARUN NEUPANE, MD, MBBS, Jacobi Medical Center/Albert Einstein College of Medicine, Bronx, NY

ASH Poster Walk on What’s Hot in Sickle Cell Disease Clinical Research in 2023

5:00 p.m. – 6:00 p.m.
Virtual Program

Chair:
ELIZABETH KLINGS, MD, Boston University, Boston, MA

ASH Poster Walk on Diversity, Equity and Inclusion (DEI) in Hematology

10:00 a.m. – 11:00 a.m.
Virtual Program

Co-Chairs:
ELNA SAAH, MD, Emory School of Medicine, Atlanta, GA

ASH Poster Walk on Time to Examine Time Toxicity in Hematology

5:00 p.m. – 6:00 p.m.
Virtual Program

Chair:
RAHUL BANERJEE, MD, Fred Hutchinson Cancer Center, Seattle, WA
Share Your Expertise Treating R/R AML With a FLT3 Mutation

What should your patient’s next step be?

Compare your approach at
BOOTH 2311

AML=acute myeloid leukemia; FLT3=FMS-like tyrosine kinase 3; R/R=relapsed or refractory.
MEET THE SCIENTIST

These sessions will provide an opportunity for a small number of attendees to meet with a scientific expert in a setting that fosters interaction. ASH has invited experts from around the world to facilitate informal discussions, allowing participants to present their questions and gain new perspectives. A boxed breakfast will be provided.

Tickets are restricted to medical professionals only and will be available on site on a first-come, first-served basis; no businesspersons or media will be admitted. Only one ticket per person is allowed. Tickets may be purchased on site during registration hours beginning Thursday, December 7, at the Ticketed Sessions Counter in Building A, Level 1, Hall A1.

Ticket Prices (per session)

- Active or Interna Member: $75
- Non-Member: $75
- Associate, International Associate, Resident, or Graduate/Medical Student, or honorary/Emeritus Member: $50
- Non-Member in Training: $50
- Allied Health Professional: $50
- Attention Trainees!

A number of tickets for these sessions will be reserved for trainees. Proof of status as an Associate, International Associate, Resident, or Graduate/Medical Student member, or Non-Member in Training will be required to purchase a ticket.

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

SATURDAY

**Genome Engineering for Enhanced Blood Cancer Immunotherapy (for in-person participants)**

**Saturday**

8:00 a.m. – 9:00 a.m.
Aqua 314
Hilton San Diego Bayfront

**Speaker:**
CARI JUNE, MD, University of Pennsylvania, Philadelphia, PA
*Genome Engineering for Enhanced Blood Cancer Immunotherapy*

**Improving Outcomes for Individuals with Sickle Cell Disease: Are We Moving the Needle (for in-person participants)**

**Saturday**

8:00 a.m. – 9:00 a.m.
Aqua 313
Hilton San Diego Bayfront

**Speaker:**
ADETOA A. KASSIM, MBBS, MS, Vanderbilt University Medical Center, Nashville, TN
*Improving Outcomes for Individuals with Sickle Cell Disease: Are We Moving the Needle*

**Lymphomagenesis - What Normal Immunology, Abnormal Immunology and Genomics Can Teach Us About Lymphoma Biology and Novel Therapeutic Strategies (for in-person participants)**

**Saturday**

8:00 a.m. – 9:00 a.m.
Aqua 300
Hilton San Diego Bayfront

**Speaker:**
LAURA PASQUALUCCI, MD, Columbia University, New York, NY
*Lymphomagenesis - What Normal Immunology, Abnormal Immunology and Genomics Can Teach Us About Lymphoma Biology and Novel Therapeutic Strategies*
### SUNDAY

#### Mechanisms of Genetic Rescue in Inherited Bone Marrow Failure Syndromes (for in-person participants)

**Sunday**  
8:00 a.m. – 9:00 a.m.  
Aqua 314  
Hilton San Diego Bayfront

**Speaker:**  
**Jean Soulier,** MD, University of Paris, Saint-Louis Hospital, Paris, France  
*Mechanisms of Genetic Rescue in Inherited Bone Marrow Failure Syndromes*

#### Natural Killer Cells: A New Frontier for Cancer Immunotherapy (for in-person participants)

**Sunday**  
8:00 a.m. – 9:00 a.m.  
Aqua 300  
Hilton San Diego Bayfront

**Speaker:**  
**Katayoun Rezvani,** MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX  
*Natural Killer Cells: A New Frontier for Cancer Immunotherapy*

#### Research in Complications Sickle Cell Disease (for in-person participants)

**Sunday**  
8:00 a.m. – 9:00 a.m.  
Aqua 313  
Hilton San Diego Bayfront

**Speaker:**  
**Oyebi MP Adesina,** MD, MS, University of California, Mountain View, CA  
*Research in Complications Sickle Cell Disease*

#### The Long Non-Coding Road, RNA and Signaling, and Regulation of Globin Gene Expression (for in-person participants)

**Sunday**  
8:00 a.m. – 9:00 a.m.  
Aqua 311  
Hilton San Diego Bayfront

**Speaker:**  
**Mitchell Weiss,** MD, PhD, St. Jude Children’s Research Hospital, Memphis, TN  
*The Long Non-Coding Road, RNA and Signaling, and Regulation of Globin Gene Expression*
2023 SCIENTIFIC CATEGORIES

For the 65th ASH Annual Meeting, abstracts were submitted in 66 different scientific categories in 9 larger topics. For your ease in finding the oral and poster abstracts on topics of interest to you, the abstract program has been organized by category number. Oral Abstract Sessions’ titles begin with the category number and name. They are listed in the Program-at-a-Glance by date, time, and then by category number. The In-Person and Virtual Poster Hall is arranged by category number.

100s—Red Cell Physiology and Disorders
101 Red Cells and Erythropoiesis, Excluding Iron
102 Iron Homeostasis and Biology
112 Thalassemia and Globin Gene Regulation
113 Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias: Basic and Translational
114 Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological

200s—Leukocytes, Inflammation, and Immunology
201 Granulocytes, Monocytes, and Macrophages
203 Lymphocytes and Acquired or Congenital Immunodeficiency Disorders

300s—Hemostasis, Thrombosis, and Vascular Wall Biology
301 Vasculature, Endothelium, Thrombosis and Platelets: Basic and Translational
311 Disorders of Platelet Number or Function: Clinical and Epidemiological
321 Coagulation and Fibrinolysis: Basic and Translational
322 Disorders of Coagulation or Fibrinolysis: Clinical and Epidemiological
331 Thrombotic Microangiopathies/Thrombocytopenias and COVID-19-related Thrombotic/Vascular Disorders: Clinical and Epidemiological
332 Thrombosis and Anticoagulation: Clinical and Epidemiological

400s—Transfusion Medicine
401 Blood Transfusion

500s—Hematopoiesis
501 Hematopoietic Stem and Progenitor Cells and Hematopoiesis: Basic and Translational
503 Clonal Hematopoiesis, Aging and Inflammation
506 Bone Marrow Microenvironment
508 Bone Marrow Failure: Acquired
509 Bone Marrow Failure and Cancer Predisposition Syndromes: Congenital

600s—Hematologic Malignancy
602 Myeloid Oncogenesis: Basic
603 Lymphoid Oncogenesis: Basic
604 Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms
605 Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms
612 Acute Lymphoblastic Leukemias: Clinical and Epidemiological
613 Acute Myeloid Leukemias: Clinical and Epidemiological
614 Acute Lymphoblastic Leukemias: Therapies, Excluding Transplantation and Cellular Immunotherapies
615 Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies
616 Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies
617 Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis
618 Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis
621 Lymphomas: Translational—Molecular and Genetic
622 Lymphomas: Translational—Non-Genetic
623 Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological
624 Hodgkin Lymphomas and T/NK cell Lymphomas: Clinical and Epidemiological
626 Aggressive Lymphomas: Prospective Therapeutic Trials
627 Aggressive Lymphomas: Clinical and Epidemiological
631 Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational
632 Chronic Myeloid Leukemia: Clinical and Epidemiological
634 Myeloproliferative Syndromes: Clinical and Epidemiological
636 Myelodysplastic Syndromes—Basic and Translational
637 Myelodysplastic Syndromes—Clinical and Epidemiological
641 Chronic Lymphocytic Leukemias: Basic and Translational
642 Chronic Lymphocytic Leukemia: Clinical and Epidemiological
651 Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational
652 Multiple Myeloma: Clinical and Epidemiological
653 Multiple Myeloma Prospective Therapeutic Trials
654 MGUS, Amyloidosis and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological

700s—Transplantation and Adoptive Cell Therapies
701 Experimental Transplantation: Basic and Translational
703 Cellular Immunotherapies: Basic and Translational
704 Cellular Immunotherapies: Early Phase and Investigational Therapies
705 Cellular Immunotherapies: Late Phase and Commercially Available Therapies
711 Cell Collection and Processing
721 Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities
722 Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution
723 Allogeneic Transplantation: Long-term Follow-up and Disease Recurrence
731 Autologous Transplantation: Clinical and Epidemiological
732 Allogeneic Transplantation: Disease Response and Comparative Treatment Studies

800s—Gene Therapies, Chemical Biology, and Emerging Diagnostics
801 Gene Therapies
802 Chemical Biology and Experimental Therapeutics
803 Emerging Tools, Techniques and Artificial Intelligence in Hematology

900s—Health Services, Quality Improvement, and Outcomes Research
901 Health Services and Quality Improvement—Non-Malignant Conditions
902 Health Services and Quality Improvement—Lymphoid Malignancies
903 Health Services and Quality Improvement—Myeloid Malignancies
904 Outcomes Research—Non-Malignant Conditions
905 Outcomes Research—Lymphoid Malignancies
906 Outcomes Research—Myeloid Malignancies
Breakthrough Discoveries. Life-Changing Results.

City of Hope® is renowned for rapidly translating hematologic breakthroughs into lifesaving treatment. A leader in treating blood cancers and improving outcomes for patients, we deliver world-class, personalized care to patients from all over the United States and the world.

Visit us at Booth 2204 during the 2023 ASH Annual Meeting.
The Oral Abstract Sessions will be held Saturday, December 9, through Monday, December 11. Each abstract presentation will be followed immediately by a question-and-answer period with the presenter.

The Plenary Scientific Session will be held Sunday, September 10, from 2:00–4:00 p.m. The Oral Abstract Sessions are not offered for CME credit.

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

All Grand Halls, Seaport Ballrooms, and the Harbor Ballroom are in the Manchester Grand Hyatt

All Pacific Ballrooms and San Diego Ballrooms are in the Marriott Marquis San Diego Marina

### SATURDAY

<table>
<thead>
<tr>
<th>Time</th>
<th>Oral Abstract Sessions</th>
</tr>
</thead>
</table>
| 9:30 a.m. – 11:00 a.m. | 101. Red Cells and Erythropoiesis, Excluding Iron: Red Cells: Emerging Gene Regulatory Mechanisms in Erythroid Differentiation (7–12) Room 25  
113. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias: Basic and Translational: Emerging Therapies for Sickle Cell Disease (13–18) Room 29  
321. Coagulation and Fibrinolysis: Basic and Translational: Coagulation Protein: Molecular Insights and Molecular Therapies (19–24) Room 33  
322. Disorders of Coagulation or Fibrinolysis: Clinical and Epidemiological: Out of the Box: Acquired, Vascular and Other Neglected Bleeding Disorders (25–30) Room 30  
604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Personalized and Combinatorial Approaches to Target Vulnerabilities in Myeloid Malignancies (43–48) Ballroom 20CD  
605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Novel Therapeutic Approaches in Lymphoma and Multiple Myeloma (49–54) Grand Hall D  
|               | 617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Risk Refinement and Therapy Response (61–66) Pacific Ballroom Salons 24-26  
627. Aggressive Lymphomas: Clinical and Epidemiological: Real World Data on Outcomes and Treatment-Related Toxicity in B Cell NHL (67–72) Seaport Ballroom EFGH  
634. Myeloproliferative Syndromes: Clinical and Epidemiological: Rare Myeloproliferative Neoplasms: Unveiling Promising Pathways and Novel Therapies (73–78) Ballroom 20AB  
641. Chronic Lymphocytic Leukemias: Basic and Translational: Molecular Determinants of CLL and Richter Transformation (79–84) Grand Hall B  
651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Spatial Dissection and Multiomics Analysis of the Multiple Myeloma Tumor and Immune Microenvironment (85–90) Harbor Ballroom  
652. Multiple Myeloma: Clinical and Epidemiological: T Cell Redirecting Therapy Outcomes and Associated Complications (91–96) Seaport Ballroom ABCD |
|               | 703. Cellular Immunotherapies: Basic and Translational: Overcoming Challenges in CAR-T Therapies Through Biological Insights (97–102) Room 6DE  
705. Cellular Immunotherapies: Late Phase and Commercially Available Therapies: Cellular Therapy for B Cell Lymphomas: Prospective Clinical Trials and Real World Data (103–108) Room 6A  
ORAL ABSTRACT SESSIONS

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited. All Grand Halls, Seaport Ballrooms, and the Harbor Ballroom are in the Manchester Grand Hyatt. All Pacific Ballrooms and San Diego Ballrooms are in the Marriott Marquis San Diego Marina.

803. Emerging Tools, Techniques and Artificial Intelligence in Hematology: Reading the Blood: Generative and Discriminative AI in Hematology (121–126)
San Diego Ballroom AB

904. Outcomes Research – Non-Malignant Conditions: Across the Age Spectrum: Thromboembolism Outcomes in Adult and Pediatric Patients (133–138)
Pacific Ballroom Salons 18-19

902. Health Services and Quality Improvement – Lymphoid Malignancies: Making a Splash In Outcomes Data (127–132)
Marriott Grand Ballroom 2-4

101. Red Cells and Erythropoiesis, Excluding Iron: Red Cells: Erythropoiesis in Stress and Disease (139–144)
Room 33

114. Sickle cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: Hot Topics in Clinical Care and Genomic Factors (145–150)
Room 31

203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: Decoding the Complex Landscape of Human Immunity: Insights From Genetic Mutations to Cellular Heterogeneity (151–156)
San Diego Ballroom AB

Room 6A

617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Biomarkers and Therapeutics (163–168)
Pacific Ballroom Salons 24-26

621. Lymphomas: Translational – Molecular and Genetic: Microenvironment and Methylome in Lymphoma and Misc. (169–174)
Ballroom 20AB

622. Lymphomas: Translational – Non-Genetic: Illuminating the Tumor Microenvironment and Immune Landscape in Lymphoma (175–180)
Seaport Ballroom ABCD

Grand Hall B

627. Aggressive Lymphomas: Clinical and Epidemiological: Diagnostic and Prognostic Implications in the Care of Patients With Aggressive Lymphomas (187–192)
Grand Hall C

Pacific Ballroom Salons 18-19

642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Analysis and Treatment of High Risk and Treatment of Relapsed CLL or Richter Transformation (199–204)
Grand Hall D

653. Multiple Myeloma: Prospective Therapeutic Trials: Smoldering and Newly Diagnosed Myeloma (205–210)
Harbor Ballroom

Room 30

901. Health Services and Quality Improvement – Non-Malignant Conditions: Sickle Cell Disease Across the Spectrum (247–252)
Pacific Ballroom Salons 15-17

902. Health Services and Quality Improvement – Lymphoid Malignancies: Innovative Care in CAR-T Therapy (253–258)
Marriott Grand Ballroom 2-4

903: Health Services and Quality Improvement – Myeloid Malignancies: From Blood to Bombs: Identifying and Addressing Barriers to Care for Myeloid Malignancies (259–264)
Hall A

905. Outcomes Research – Lymphoid Malignancies: Outcomes Research in Lymphoma/CLL: Biomarkers, Dosing Strategies, and Big-Data (265–270)
Pacific Ballroom Salons 21-22
## ORAL ABSTRACT SESSIONS

**Saturday–Monday**

### Saturday, December 9, 2023

#### 4:00 p.m. – 5:30 p.m.  
**Oral Abstract Sessions**  

**Room 28 A-D**

<table>
<thead>
<tr>
<th>Session Title</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>114. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: Building on Momentum in Disease-Modifying Therapeutics for Sickle Cell Disease (271–276)</td>
<td>Room 28 A-D</td>
</tr>
<tr>
<td>301. Vascularulture, Endothelium, Thrombosis and Platelets: Basic and Translational: The Multimodal Platelet; Discovery of Novel Platelet Functions and Applications From Cancers to Thrombocytopenias (277–282)</td>
<td>Room 33</td>
</tr>
<tr>
<td>322. Disorders of Coagulation or Fibrinolysis: Clinical and Epidemiological: Beyond the Numbers: Non-Factor Factors in Bleeding Disorder Care (283–288)</td>
<td>Room 30</td>
</tr>
<tr>
<td>617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Immunologic and Metabolic Biomarkers of Disease Control (289–294)</td>
<td>Room 6CF</td>
</tr>
<tr>
<td>623. Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Prospective and Real-World Outcomes of Novel Therapies in Indolent Lymphomas and MCL (295–300)</td>
<td>Seaport Ballroom ABCD</td>
</tr>
<tr>
<td>636. Myelodysplastic Syndromes – Basic and Translational: Molecular Drivers and Therapeutic Implications (313–318)</td>
<td>Pacific Ballroom Salons 21-22</td>
</tr>
<tr>
<td>705. Cellular Immunotherapies: Late Phase and Commercially Available Therapies: Prediction and Management of CAR-T Cell Related Toxicity (355–360)</td>
<td>Room 6B</td>
</tr>
<tr>
<td>723. Allogeneic Transplantation: Long-Term Follow-Up and Disease Recurrence: Basic and Translational: Optimizing Post-Transplant Outcomes (361–366)</td>
<td>Room 11</td>
</tr>
<tr>
<td>903. Health Services and Quality Improvement – Myeloid Malignancies: Looking Below the Surface at Patient Level Predictors of Outcomes in Myeloid Malignancies (373–378)</td>
<td>Pacific Ballroom Salons 15-17</td>
</tr>
</tbody>
</table>

### Sunday, December 10, 2023

#### 9:30 a.m. – 11:00 a.m.  
**Oral Abstract Sessions**  

**Room 30**

<table>
<thead>
<tr>
<th>Session Title</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Clinical Practice, Natural History, and Patient Reported Outcomes (391–396)</td>
<td>Room 30</td>
</tr>
</tbody>
</table>

---

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

All Grand Halls, Seaport Ballrooms, and the Harbor Ballroom are in the Manchester Grand Hyatt.

All Pacific Ballrooms and San Diego Ballrooms are in the Marriott Marquis San Diego Marina.

CME credit is not offered.
Grand Hall B

617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis:
Minimal Residual Disease and Therapy Response (421–426)
Marriott Grand Ballroom 8-9

Grand Hall C

Seaport Ballroom ABCD

Grand Hall D

632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Treatment-Free Remission and Prognostication (445–450)
Pacific Ballroom Salons 21-22

651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Characterizing Response and Resistance to CAR-T and TCEs (451–456)
Harbor Ballroom

12:00 p.m. – 1:30 p.m. Oral Abstract Sessions

301. Vasculature, Endothelium, Thrombosis and Platelets: Basic and Translational: Insights Into the Role of Endothelium in Cardiovascular Disease and Thrombosis (499–504)
Room 28 A-D

322. Disorders of Coagulation or Fibrinolysis: Clinical and Epidemiological: Bleeding Disorder Management Throughout the Lifespan (505–510)
Room 29

506. Bone Marrow Microenvironment: Bone Marrow Microenvironment in Health and Disease (511–516)
Room 11

Grand Hall B

621. Lymphomas: Translational – Molecular and Genetic: Signaling Pathways and MRD in Lymphoma (523–528)
Harbor Ballroom

4:30 p.m. – 6:00 p.m. Oral Abstract Sessions

112. Thalassemia and Globin Gene Regulation: Finding New Pathways to Treat Thalassemia (553–558)
Room 31

113. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias: Basic and Translational: Pathophysiology of Sickle Hemoglobinopathies: From Mice to Humans (559–564)
Room 33

Grand Hall B

117. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis:
Minimal Residual Disease and Therapy Response (421–426)
Marriott Grand Ballroom 8-9

Grand Hall C

Seaport Ballroom ABCD

Grand Hall D

632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Treatment-Free Remission and Prognostication (445–450)
Pacific Ballroom Salons 21-22

651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Characterizing Response and Resistance to CAR-T and TCEs (451–456)
Harbor Ballroom
### ORAL ABSTRACT SESSIONS

**Saturday–Monday**

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

All Grand Halls, Seaport Ballrooms, and the Harbor Ballroom are in the Manchester Grand Hyatt. All Pacific Ballrooms and San Diego Ballrooms are in the Marriott Marquis San Diego Marina.

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30 a.m. – 12:00 p.m.</td>
<td>Oral Abstract Sessions [Non-CME]</td>
<td>Marriott Grand Ballroom 11-13</td>
</tr>
</tbody>
</table>

#### ORAL ABSTRACT SESSIONS

- **602. Myeloid Oncogenesis: Basic: Chemical and Genetic Approaches for Targeting Leukemic Stem Cells (577–582)**
  - Marriott Grand Ballroom 11-13
- **604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Therapeutic Implications of Leukemia Stem Cells and Differentiation in Myeloid Malignancies (583–588)**
  - Pacific Ballroom Salons 18-19
  - Pacific Ballroom Salons 24-26
- **618. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Targeted Therapies and The Immune Microenvironment (595–600)**
  - Grand Hall D
  - Grand Hall C
  - Grand Hall B
  - Ballroom 20AB
  - Ballroom 20CD
- **631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Stromal-Immune and Signaling Context (703–708)**
  - Room 6DE
  - Room 6A
- **623. Mantle Cell, Follicular and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Prospective Clinical Trials in Mantle Cell Lymphoma Incorporating Novel Agents (733–738)**
  - Grand Hall B
- **631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Stromal-Immune and Signaling Context (739–744)**
  - Ballroom 20AB
  - Marriott Grand Ballroom 11-13
  - Pacific Ballroom Salons 15-17
  - Room 6B
  - Room 6A
  - Pacific Ballroom Salons 21-22
- **642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Frontline Treatment With Targeted Agents in Patients With Chronic Lymphocytic Leukemia (631–636)**
  - Seaport Ballroom ABCD
  - Harbor Ballroom
- **652. Multiple Myeloma: Clinical and Epidemiological: Novel Biomarkers for Treatment Guidance in Multiple Myeloma (643–648)**
  - Seaport Ballroom EFGH
  - Marriott Grand Ballroom 8-9
  - Marriott Grand Ballroom 5-6
- **604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Therapeutic Implications of Leukemia Stem Cells and Differentiation in Myeloid Malignancies (661–666)**
  - Marriott Grand Ballroom 11-13
  - Seaport Ballroom ABCD
- **604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Therapeutic Implications of Leukemia Stem Cells and Differentiation in Myeloid Malignancies (691–696)**
  - Marriott Grand Ballroom 2-4
  - Ballroom 20AB
- **602. Myeloid Oncogenesis: Basic: Chemical and Genetic Approaches for Targeting Leukemic Stem Cells (577–582)**
  - Marriott Grand Ballroom 11-13
- **604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Therapeutic Implications of Leukemia Stem Cells and Differentiation in Myeloid Malignancies (583–588)**
  - Pacific Ballroom Salons 18-19
  - Pacific Ballroom Salons 24-26
- **618. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Targeted Therapies and The Immune Microenvironment (595–600)**
  - Grand Hall D
  - Grand Hall C
  - Grand Hall B
  - Ballroom 20AB
  - Ballroom 20CD
- **602. Myeloid Oncogenesis: Basic: Chemical and Genetic Approaches for Targeting Leukemic Stem Cells (577–582)**
  - Marriott Grand Ballroom 11-13
- **604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Therapeutic Implications of Leukemia Stem Cells and Differentiation in Myeloid Malignancies (583–588)**
  - Pacific Ballroom Salons 18-19
  - Pacific Ballroom Salons 24-26
- **618. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Targeted Therapies and The Immune Microenvironment (595–600)**
  - Grand Hall D
  - Grand Hall C
  - Grand Hall B
  - Ballroom 20AB
  - Ballroom 20CD
- **602. Myeloid Oncogenesis: Basic: Chemical and Genetic Approaches for Targeting Leukemic Stem Cells (577–582)**
  - Marriott Grand Ballroom 11-13
- **604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Therapeutic Implications of Leukemia Stem Cells and Differentiation in Myeloid Malignancies (583–588)**
  - Pacific Ballroom Salons 18-19
  - Pacific Ballroom Salons 24-26
- **618. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Targeted Therapies and The Immune Microenvironment (595–600)**
  - Grand Hall D
  - Grand Hall C
  - Grand Hall B
  - Ballroom 20AB
  - Ballroom 20CD
634. Myeloproliferative Syndromes: Clinical and Epidemiological: Treatment and Outcomes in MPNs (745–750) Ballroom 20CD

651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Advancing Therapies in Multiple Myeloma and Waldenström’s Macroglobulinemia (751–756) Harbor Ballroom

652. Multiple Myeloma: Clinical and Epidemiological: Immunological Effects of Sustained Responses in Multiple Myeloma (757–762) Seaport Ballroom EFGH


704. Cellular Immunotherapies: Early Phase and Investigational Therapies: Novel Approaches to Enhance Cellular Therapies and Immune Responses in Leukemias and Lymphomas (769–774) Room 6CF

722. Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Advancements in GVHD Management (775–780) Marriott Grand Ballroom 8-9


901. Health Services and Quality Improvement – Non-Malignant Conditions: Improving Care in Sickle Cell Disease Via Technologies and Medical Education (787–792) Marriott Grand Ballroom 2-4
<table>
<thead>
<tr>
<th>4:30 p.m. – 6:00 p.m.</th>
<th>Oral Abstract Sessions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Room 31</td>
<td>705. Cellular Immunotherapies: Late Phase and Commercially Available Therapies: Cellular Therapy for Multiple Myeloma, B-cell Acute Lymphoblastic Leukemia and B Cell Lymphomas: Clinical Trial and Real World Evidence (1027–1032)  Room 6CF</td>
</tr>
<tr>
<td>Room 33</td>
<td>721. Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities: Expanding the Donor Pool (1039–1044)  Ballroom 20AB</td>
</tr>
<tr>
<td>Room 24</td>
<td>801. Gene Therapies: The Long and the Short of Clinical Trials in Blood Disorders (1051–1056)  Hall A</td>
</tr>
<tr>
<td>Room 7</td>
<td>905. Outcomes Research – Lymphoid Malignancies: Balancing Efficacy, Safety and Tolerability, and Quality of Life in Patients With Multiple Myeloma (1063–1068)  Marriott Grand Ballroom 2-4</td>
</tr>
<tr>
<td>Grand Hall C</td>
<td>617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Response Predictors to Targeted Therapies and Transplant (973–978)  Pacific Ballroom Salons 15-17</td>
</tr>
</tbody>
</table>
The Hematology ASH Education Program 2023 provides review articles from the Education Program at the 2023 ASH Annual Meeting. In this publication, each chapter relates to a different session presented at the meeting, spanning the spectrum from basic discovery and disease pathogenesis to the clinical application at the bedside.
The Poster Hall will be open for in-person and Virtual attendees. The Poster Hall is located in the San Diego Convention Center, Halls G-H. Presenters will stand beside their posters during the evening Presentation times. Virtual poster presentations will be shared via a brief PowerPoint presentation with accompanying audio. The Virtual Poster Hall will allow attendees to browse a new set of posters starting at 9:00 a.m. (Pacific time) each day, as well as access posters from previous days on the virtual platform.

The Poster Hall hours are as follows:
- Saturday, December 09: 9:00 a.m. – 7:30 p.m.
- Sunday, December 10: 9:00 a.m. – 8:00 p.m.
- Monday, December 11: 9:00 a.m. – 8:00 p.m.

Poster Sessions are not offered for CME credit.

SATURDAY, DECEMBER 9, 2023

9:00 a.m. – 7:30 p.m.  Poster Session I – Viewing

5:30 p.m. – 7:30 p.m.  Poster Session I – Presentations

Halls G-H, San Diego Convention Center

101. Red Cells and Erythropoiesis, Excluding Iron: Poster I (1069–1087)
102. Iron Homeostasis and Biology: Poster I (1088–1098)
112. Thalassemia and Globin Gene Regulation: Poster I (1099–1107)
113. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias: Basic and Translational: Poster I (1108–1123)
114. Sickle cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: Poster I (1124–1142)
201. Granulocytes, Monocytes, and Macrophages: Poster I (1160–1172)
203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: Poster I (1173–1185)
301. Vasculature, Endothelium, Thrombosis and Platelets: Basic and Translational: Poster I (1186–1205)
311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Poster I (1206–1226)
321. Coagulation and Fibrinolysis: Basic and Translational: Poster I (1227–1235)
322. Disorders of Coagulation or Fibrinolysis: Clinical and Epidemiological: Poster I (1236–1256)
332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Poster I (1266–1285)

501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis: Basic and Translational: Poster I (1296–1314)
503. Clonal Hematopoiesis, Aging and Inflammation: Poster I (1315–1327)
506. Bone Marrow Microenvironment: Poster I (1328–1337)
508. Bone Marrow Failure: Acquired: Poster I (1338–1354)
509. Bone Marrow Failure and Cancer Predisposition Syndromes: Congenital: Poster I (1355–1366)
602. Myeloid Oncogenesis: Basic: Poster I (1367–1394)
603. Lymphoid Oncogenesis: Basic: Poster I (1395–1409)
613. Acute Myeloid Leukemias: Clinical and Epidemiological: Poster I (1469–1496)
615. Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster I (1513–1535)
617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster I (1556–1599)
POSTER PRESENTATIONS
Saturday-Monday
09–11 Dec 2023

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

CME credit is not offered. Poster Presentations
311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Poster II (2577–2597)
322. Disorders of Coagulation or Fibrinolysis: Clinical and Epidemiological: Poster II (2608–2628)
332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Poster II (2637–2658)
401. Blood Transfusion: Poster II (2659–2668)
501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis: Basic and Translational: Poster II (2669–2687)
503. Clonal Hematopoiesis, Aging and Inflammation: Poster II (2688–2699)
506. Bone Marrow Microenvironment: Poster II (2700–2710)
508. Bone Marrow Failure: Acquired: Poster II (2711–2727)
509. Bone Marrow Failure and Cancer Predisposition Syndromes: Congenital: Poster II (2728–2738)
602. Myeloid Oncogenesis: Basic: Poster II (2739–2766)
603. Lymphoid Oncogenesis: Basic: Poster II (2767–2781)
604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Poster II (2782–2807)
605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Poster II (2808–2826)
612. Acute Lymphoblastic Leukemias: Clinical and Epidemiological: Poster II (2827–2839)
613. Acute Myeloid Leukemias: Clinical and Epidemiological: Poster II (2840–2867)
615. Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster II (2884–2905)
616. Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster II (2906–2925)
617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster II (2926–2968)
618. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster II (2969–2984)
621. Lymphomas: Translational—Molecular and Genetic: Poster II (2985–3006)
622. Lymphomas: Translational—Non-Genetic: Poster II (3007–3021)
623. Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster II (3022–3055)
624. Hodgkin Lymphomas and T/NK cell Lymphomas: Clinical and Epidemiological: Poster II (3056–3084)
626. Aggressive Lymphomas: Prospective Therapeutic Trials: Poster II (3085–3104)
627. Aggressive Lymphomas: Clinical and Epidemiological: Poster II (3105–3144)
631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Poster II (3145–3163)
632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Poster II (3164–3180)
634. Myelodysplastic Syndromes—Basic and Translational: Poster II (3212–3225)
635. Myelodysplastic Syndromes – Clinical and Epidemiological: Poster II (3226–3253)
641. Chronic Lymphocytic Leukemias: Basic and Translational: Poster II (3254–3265)
642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster II (3266–3288)
651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Poster II (3289–3323)
652. Multiple Myeloma: Clinical and Epidemiological: Poster II (3324–3376)
653. Multiple Myeloma: Prospective Therapeutic Trials: Poster II (3377–3396)
654. MGUS, Amyloidosis and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster II (3397–3416)
701. Experimental Transplantation: Basic and Translational: Poster II (3417–3430)
703. Cellular Immunotherapies: Basic and Translational: Poster II (3431–3464)
704. Cellular Immunotherapies: Early Phase and Investigational Therapies: Poster II (3465–3493)
705. Cellular Immunotherapies: Late Phase and Commercially Available Therapies: Poster II (3494–3519)
711. Cell Collection and Processing: Poster II (3520–3524)
721. Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities: Poster II (3525–3550)
722. Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Poster II (3551–3576)
723. Allogeneic Transplantation: Long-term Follow-up and Disease Recurrence: Poster II (3577–3591)
731. Autologous Transplantation: Clinical and Epidemiological: Poster II (3592–3603)
732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster II (3604–3622)
801. Gene Therapies: Poster II (3623–3633)
802. Chemical Biology and Experimental Therapeutics: Poster II (3634–3642)
803. Emerging Tools, Techniques and Artificial Intelligence in Hematology: Poster II (3643–3670)
901. Health Services and Quality Improvement - Non-Malignant Conditions: Poster II (3671–3701)
902. Health Services and Quality Improvement - Lymphoid Malignancies: Poster II (3702–3719)
903. Health Services and Quality Improvement – Myeloid Malignancies: Poster II (3720–3733)
904. Outcomes Research—Non-Malignant Conditions: Poster II (3734–3759)
905. Outcomes Research—Lymphoid Malignancies: Poster II (3760–3798)
All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

701. Experimental Transplantation: Basic and Translational: Poster III (4786–4799)

703. Cellular Immunotherapies: Basic and Translational: Poster III (4800–4834)

704. Cellular Immunotherapies: Early Phase and Investigational Therapies: Poster III (4835–4863)

705. Cellular Immunotherapies: Late Phase and Commercially Available Therapies: Poster III (4864–4889)

711. Cell Collection and Processing: Poster III (4890–4894)

721. Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities: Poster III (4895–4921)

722. Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Poster III (4922–4947)

723. Allogeneic Transplantation: Long-term Follow-up and Disease Recurrence: Poster III (4948–4961)

731. Autologous Transplantation: Clinical and Epidemiological: Poster III (4962–4974)

732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster III (4975–4993)

801. Gene Therapies: Poster III (4994–5004)

802. Chemical Biology and Experimental Therapeutics: Poster III (5005–5013)

803. Emerging Tools, Techniques and Artificial Intelligence in Hematology: Poster III (5014–5040)

901. Health Services and Quality Improvement - Non-Malignant Conditions: Poster III (5041–5071)

902. Health Services and Quality Improvement - Lymphoid Malignancies: Poster III (5072–5090)

903. Health Services and Quality Improvement –Myeloid Malignancies: Poster III (5091–5105)

904. Outcomes Research—Non-Malignant Conditions: Poster III (5106–5131)

905. Outcomes Research—Lymphoid Malignancies: Poster III (5132–5170)

906. Outcomes Research—Myeloid Malignancies: Poster III (5171–5191)
Select Inclusion Criteria\(^{1,2}\)*

For both cohorts:
- Patients ≥18 years of age with a diagnosis of CML-CP
- No previous accelerated phase or blast crisis
- No T315I mutation at any time prior to study entry

For 2L patient cohort:
- Warning or failure with 1L TKI therapy at the time of screening
  - Warning is defined as:
    - BCR::ABL\(^1\)IS >1% to 10% 6 months after treatment initiation
    - BCR::ABL\(^1\)IS >0.1% to 1% 12 months after treatment initiation
  - Treatment failure with/resistance to 1L TKI is defined as:
    - BCR::ABL\(^1\)IS >10% if 1L treatment duration between 6 and 12 months
    - BCR::ABL\(^1\)IS >1% if 1L treatment duration is longer than 12 months
    - Loss of MMR beyond 12 months after treatment initiation\(^2\)
  - Treatment intolerance of 1L TKI and BCR::ABL\(^1\)IS >0.1% at screening\(^2\)

For 1L patient cohort:
- Patients with newly diagnosed CML-CP (treatment with 1 prior TKI [imatinib, dasatinib, nilotinib, or bosutinib] for ≤4 weeks is allowed)

This Phase II trial will evaluate the efficacy and safety of asciminib monotherapy as 2L and 1L therapy for patients with CML-CP, starting at 80 mg QD with dose escalation from 80 mg QD to 200 mg QD or 200 mg QD to 200 mg BID in patients who do not achieve response milestones at 6 and 12 months\(^{1,2}\)

### Study Design\(^2\)

**Study duration:** 24 months

**Primary endpoint:** MMR at 12 months in 2L cohort

**2L cohort**
- Asciminib 80 mg QD
  - N = 92

**1L cohort**
- Asciminib 80 mg QD
  - N = 60-90

If a new mutation is detected by exploratory NGS assay without treatment failure, the patient may continue on the study at the same dose (unless meeting dose escalation criteria) or discontinue from the study treatment as per the investigator’s decision.

**Abbreviations:** 1L, first line; 2L, second line; ABL1, Abelson tyrosine kinase 1; BCR, breakpoint cluster region; BID, twice daily; CML-CP, chronic myeloid leukemia in chronic phase; IS, International Scale; MMR, major molecular response (BCR::ABL\(^1\)IS ≤0.1%); NGS, next-generation sequencing; QD, once daily; TKI, tyrosine kinase inhibitor.

\(^*\) For complete eligibility criteria, please see ClinicalTrials.gov.

\(^{a}\) For those patients who experience any grade 3 or 4 toxicity, or persistent grade 2 toxicity unresponsive to optimal management, the dose escalation mentioned above will not apply, and those patients will be continued on asciminib at the most current dosage.

\(^{b}\) Based on investigator’s clinical judgment of prospect treatment benefit. Patients switching to investigator’s choice will be taken off study.

**References:**

Compound(s) are either investigational or being studied for a new use(s). Efficacy and safety have not been established and there is no guarantee that they will become commercially available for the use(s) under investigation.
Friday Satellite Symposia (FSS) will take place on Friday, December 8, 2023, preceding the ASH annual meeting. ASH appreciates its corporate and nonprofit partners for their participation in FSS. The Society values its partnerships and the supportive role that members of the community play in an effort to provide hematologists with quality educational programs. Satellite Symposia are not CME-accredited through ASH and are planned solely by the sponsoring organizations. Each symposium lists a contact person for accreditation information. An ASH meeting badge is not needed to attend these symposia.

FRIDAY MORNING SYMPOSIA
7:00 A.M. – 10:00 A.M.

Advances in the Treatment Paradigm of Myeloid Malignancies: From Biology to Clinical Practice (for in-person participants)

7:00 a.m. – 10:00 a.m.
Room 6CF
San Diego Convention Center

This program is provided by the Cleveland Clinic, The Aplastic Anemia and MDS International Foundation.

Chair:
SUDIPTO MUKHERJEE, MD, PhD, MPH, Cleveland Clinic, Cleveland, OH

Speakers:
UMA M. BORATE, MBBS, MS, The Ohio State University Comprehensive Cancer Center, Columbus, OH
MARCO DAVILA, MD, PhD, Roswell Park Comprehensive Cancer Center, Buffalo, NY
AUSTIN KULASEKARARAJ, MD, PhD, MPH, King’s College Hospital, London, United Kingdom
ESTHER NATALIE OLIVA, MD, Grande Ospedale Metropolitano Bianchi Melacrino Morelli, Reggio Calabria, Italy
KRISTEN MARIE PETTIT, MD, C.S. Mott Children’s Hospital, Ann Arbor, MI
ABHAY SINGH, MD, MPH, Cleveland Clinic, Cleveland, OH

Contact: Kristin Bower
Email: bowerk@ccf.org

Applying the Latest Evidence and NCCN Guideline Recommendations in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

7:00 a.m. – 10:00 a.m.
Pacific Ballroom Salons 21-22
Marriott Marquis San Diego Marina

This program is provided by the National Comprehensive Cancer Network in partnership with Clinical Care Options, LLC and supported by educational grants from AstraZeneca, BeiGene, and Lilly.

Chair:
BRIAN T. HILL, MD, PhD, Cleveland Clinic, Cleveland, OH

Speakers:
DANIELLE M. BRANDER, MD, Duke Cancer Center, Durham, NC
DEBORAH M. STEPHENS, DO, University of Utah, Salt Lake City, UT

Contact: Ishana Fleurant
Email: Ifleurant@clinicaloptions.com
BEYOND THE GUIDELINES: Clinical Investigator Perspectives on the Management of Patients with Follicular, Mantle Cell and Hodgkin Lymphoma (Part 1 of a 4-part CME-accredited Symposia Series)

7:00 a.m. – 10:00 a.m.  
Grand Ballroom  
Omni San Diego

This program is provided by Research To Practice and supported by educational grants from AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Genentech, a member of the Roche Group, Genmab US Inc, Merck, and Seagen Inc.

Chair: Neil Love, MD, Research To Practice, Key Biscayne, FL

Speakers:
Jeremy S. Abramson, MD, Massachusetts General Hospital Cancer Center, Boston, MA  
Stephen M. Ansell, MD, PhD, Mayo Clinic, Rochester, MN  
Nancy L. Bartlett, MD, Washington University School of Medicine, Saint Louis, MO  
Jonathan B. Cohen, MD, MS, Winship Cancer Institute, Emory University, Atlanta, GA  
Jonathan W. Friedberg, MD, MMSc, University of Rochester, Rochester, NY  
Brad S. Kahl, MD, Washington University School of Medicine in St. Louis, Saint Louis, MO

Contact: Sylvia Eriksen  
Email: meetings@researchtopractice.com

Medical Crossfire® Novel BTKi Strategies Transforming Aggressive and Indolent B-Cell Malignancies

7:00 a.m. – 10:00 a.m.  
Room 6B  
San Diego Convention Center

This program is provided by Physicians Education Resources, LLC and supported by Lilly, Merck & Co., Inc., and Pharmacyclics.

Chair: Ian W. Flinn, MD, PhD, Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN

Speakers:
Catherine C. Coombs, MD, University of California Irvine, Irvine, CA  
Paolo Strati, MD, University of Texas MD Anderson Cancer Center, Houston, TX  
Steven P. Treon, MD, PhD, FRCP, Dana-Farber Cancer Institute, Boston, MA  
Michael Wang, MD, University of Texas MD Anderson Cancer Center, Houston, TX

Contact: Kelly Donald  
Email: kdonald@mjhevents.com

Myelodysplastic Syndromes 2023: What’s New?

7:00 a.m. – 10:00 a.m.  
San Diego Ballroom AB  
Marriott Marquis San Diego Marina

This program is provided and supported by MDS Foundation, Inc.

Co-Chairs:
Rena Buckstein, MD, FRCPC, Sunnybrook Health Sciences Centre, Toronto, ON, Canada  
Moshe Mittelman, MD, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel

Speakers:
Mario Cazzola, MD, University of Pavia, Pavia, Italy  
Matteo Giovanni Della Porta, MD, Cancer Center IRCCS Humanitas Research Hospital, Milan, Italy

Aditi Shastri, MD, Albert Einstein College of Medicine, Bronx, NY

Contact: Leigh Anne Bongiovanni  
Email: leighanne.bongiovanni@peerview.com

Exploring Unmarked Territory in MDS: Taking Command and Enhancing Care with Team-Based Diagnosis and Treatment for Lower- and Higher-Risk Disease

7:00 a.m. – 10:00 a.m.  
Ballroom 20CD  
San Diego Convention Center

This program is provided by PVI, PeerView Institute for Medical Education and supported by Bristol Myers Squibb, Geron Corporation, Karyopharm Therapeutics, and Novartis Pharmaceuticals.

Speakers:
Rory M. Shallis, MD, Yale School of Medicine and Yale Cancer Center, Killingworth, CT
Overcoming Racial Disparities in Multiple Myeloma Outcomes and Clinical Trials: How We are Moving Care Forward Today

7:00 a.m. – 10:00 a.m.
Room 6A
San Diego Convention Center

This program is provided by Physicians’ Education Resource, LLC and supported by Regeneron Pharmaceuticals, Inc., Sanofi, and Takeda Pharmaceuticals U.S.A., Inc.

Chair:
Irene M. Ghobrial, MD, Dana-Farber Cancer Institute, Boston, MA

Speaker:
Craig Emmett Cole, MD, Michigan State University, East Lansing, MI

FRIDAY EARLY AFTERNOON SYMPOSIA:
11:00 A.M. – 2:00 P.M.

A Master Class in Personalized Myelofibrosis Care: Applying New Evidence and Novel Therapeutic Strategies to Improve Outcomes

11:00 a.m. – 2:00 p.m.
San Diego Ballroom AB
Marriott Marquis San Diego Marina

This program is provided by Clinical Care Options, LLC and supported by educational grants from CTI Biopharma, Geron Corporation, GSK, and Karyopharm Therapeutics.

Raising the BCMA Standard in Multiple Myeloma: Strategies for Enhanced Care With Potent CAR-T and Bispecific Options

7:00 a.m. – 10:00 a.m.
Pacific Ballroom Salons 15-17
Marriott Marquis San Diego Marina

This program is sponsored by PVI, PeerView Institute for Medical Education and supported by Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Pfizer, and Regeneron Pharmaceuticals, Inc.

Chair:
Nikhil C. Munshi, MD, Jerome Lipper Multiple Myeloma Center, Harvard Medical School, Boston, MA

Speakers:
Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Sorbonne University, Paris, France
Krishna Patel, MD, Msc, University of Texas MD Anderson Cancer Center, Houston, TX

Contact: Leigh Anne Bongiovanni
Email: leighanne.bongiovanni@peerview.com

Speakers:
Jean-Jacques Kiladjian, MD, PhD, Hospital Saint-Louis, Paris, France
Abdulrahem Yacoub, MD, The University of Kansas, Leawood, KS

Contact: Ishana Fleurant
Email: Ifleurant@clinicaloptions.com
An MCL Quiz Game: Experts Review New and Emerging Therapies to Optimize Clinical Outcomes

11:00 a.m. – 2:00 p.m.
Pacific Ballroom Salons 21-22
Marriott Marquis San Diego Marina

This program is provided by Clinical Care Options, LLC and supported by an educational grant from AstraZeneca.

Chair:
John P. Leonard, MD, Weill Cornell Medicine, New York, NY

Speakers:
Ann LaCasce, MD, Dana-Farber Cancer Institute, Boston, MA
Matthew A. Lunning, DO, FACP, University of Nebraska, Omaha, NE

Contact: Ishana Fleurant
Email: ifleurant@clinicaloptions.com

BEYOND THE GUIDELINES: Clinical Investigator Perspectives on the Management of Patients with Diffuse Large B-Cell Lymphoma (Part 2 of a 4-part CME-accredited Symposia Series)

11:00 a.m. – 2:00 p.m.
Grand Ballroom
Omni San Diego

This program is provided by Research To Practice and supported by educational grants from ADC Therapeutics, Genentech, a member of the Roche Group, Incyte Corporation, Kite, A Gilead Company, and Regeneron Pharmaceuticals Inc.

Chair:
Neil Love, MD, Research To Practice, Key Biscayne, FL

Speakers:
Michael Dickinson, MBBS, D. Med Sci, FRACP, FRCPA, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, VIC, Australia
Grzegorz S. Nowakowski, MD, Mayo Clinic, Rochester, MN
Gilles Salles, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY

CAR T-Cell Therapies in Relapsed/Refractory Multiple Myeloma: Evaluating the Evidence for Optimal Integration

11:00 a.m. – 2:00 p.m.
Room 30 A-E
San Diego Convention Center

This program is provided by Answers in CME and supported by educational grants from Bristol Myers Squibb and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

Speakers:
Sikander Ailawadhi, MD, Mayo Clinic, Jacksonville, FL
Ajai Chari, MD, University of California, San Francisco, San Francisco, CA

Contact: Caitlan Bose
Email: caitlan.bose@answersincme.com

Controlling and Conquering CLL: Guidance on Modern Targeted Options, Innovative Combinations, and Sequential Management

11:00 a.m. – 2:00 p.m.
Ballroom 20CD
San Diego Convention Center

This program is provided by PVI, PeerView Institute for Medical Education and supported by AbbVie, AstraZeneca, Lilly, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

Chair:
Prof. John G. Gribben, MD, DSc, Barts Cancer Institute, Barts and The London School of Medicine, Queen Mary, University of London, London, United Kingdom

Speakers:
John N. Allan, MD, Weill Cornell Medicine, New York, NY
Experts Address the Hottest Topics in AML: Considerations on FLT3, IDH1/2, TP53, Maintenance, Novel Combinations and Beyond!

11:00 a.m. – 2:00 p.m.
Room 6A
San Diego Convention Center

This program is provided by Physicians’ Education Resource, LLC., and supported by Rigel Pharmaceuticals, Inc., Syndax Pharmaceuticals, Inc., Jazz Pharmaceuticals, Inc., Gilead Sciences, Inc., Daiichi Sankyo, Inc., and Curis, Inc.

Chair:
NAVAL DAWER, MD, University of Texas MD Anderson Cancer Center, Houston, TX

Speakers:
COURTNEY D. DI NARDO, MD, MSc, University of Texas MD Anderson Cancer Center, Houston, TX
AMIR T. FATHI, MD, Massachusetts General Hospital, Boston, MA
GAIL J. ROBOZ, MD, Weill Cornell Medicine and The New York-Presbyterian Hospital, New York, NY
ETYAN M. STEIN, MD, Memorial Sloan Kettering Cancer Center, New York, NY

Contact: Kelly Donald
Email: kdonald@mjhevents.com

Medical Crossfire®: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?

11:00 a.m. – 2:00 p.m.
Pacific Ballroom Salons 24-26
Marriott Marquis San Diego Marina

This program is provided by Physicians’ Education Resource and supported by American Regent, Inc.

Chair:
GEORGE M. RODGERS, MD, PhD, University of Utah Medical Center, Salt Lake City, UT

Speaker:
SIDARTH ANAND, MD, UCLA HEALTH, LOS ANGELES, CA
PATRICIA A. LOCANTORE-FORD, MD, Pennsylvania Hospital, Philadelphia, PA

Contact: Kelly Donald
Email: kdonald@mjhevents.com

Medical Crossfire®: Bridging Expert Guidance and Evidence-Based Recommendations in the Treatment of AYA and Adult ALL

11:00 a.m. – 2:00 p.m.
Marriott Grand Ballroom 11-13
Marriott Marquis San Diego Marina

This program is provided by Physicians’ Education Resource, LLC and supported by Amgen, US Inc., Servier Pharmaceuticals, and Takeda Oncology.

Chair:
ELIAS JABBOUR, MD, University of Texas MD Anderson Cancer Center, Houston, TX

Speakers:
LIA GORE, MD, University of Colorado Cancer Center, Aurora, CO
More Than a Disease: Exploring the Patient Journey for Chronic Immune Thrombocytopenia

11:00 a.m. – 2:00 p.m.
Marriott Grand Ballroom 2-4
Marriott Marquis San Diego Marina

This program is provided by Medscape Oncology and supported by an independent educational grant from Argenx US, Inc., Sanofi, and Novartis Oncology.

Chair: Spero Cataland, MD, Ohio State University Comprehensive Cancer Center, Columbus, OH

Speakers: Srikanth Nagalla, MBBS, Miami Cancer Institute, Miami, FL
Marie Scully, MD, University College London, London, England

Contact: Harmony Washington
Email: hwashington@medscapelive.com

Multiple Myeloma: Clinical Challenges for the Community Clinician

11:00 a.m. – 2:00 p.m.
Marriott Grand Ballroom 5-6
Marriott Marquis San Diego Marina

This program is provided by Medscape Oncology and supported by Bristol Myers Squibb, Janssen, Sanofi, Karyopharm, and Legend.

Chair: C. Ola Landgren, MD, PhD, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL

Speakers: Luciano Costa, MD, PhD, University of Alabama at Birmingham, Birmingham, AL
Nisha S. Joseph, MD, Winship Cancer Institute of Emory University, Atlanta, GA

Contact: Cathy Zehr
Email: cathy.zehr@catalystmeded.com
# Satellite Symposia

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

## Show Me the Data™: How Do We Navigate the Latest Evidence on Novel Therapies, Combinations, and Clinical Trials Across MPN Care in the Context of Current Treatment Algorithms?

**11:00 a.m. – 2:00 p.m.**

**Room 6B**

San Diego Convention Center

*This program is provided by Physicians’ Education Resource, LLC and supported by Geron Corporation, Incyte Corporation, Protagonist Therapeutics, and PharmaEssentia USA.*

**Chair:**

Andrew T. Kuykendall, MD, Moffitt Cancer Center, Tampa, FL

**Speakers:**

Gabriela S. Hobbs, MD, Massachusetts General Hospital, Boston, MA  
Barbara Mora, MD, Ospedale ASST Sette Laghi, University of Insurbia, Varese, Italy  
Naveen Pemmaraju, MD, University of Texas MD Anderson Cancer Center, Houston, TX

Contact: Kelly Donald  
Email: kdonald@mjhevents.com

---

## Untangling Amyloidosis 2023: Diagnosis, Prognosis, Selection of Individualized Therapy, and Management of Difficult Clinical Complications

**11:00 a.m. – 2:00 p.m.**

**Ballroom 20AB**

San Diego Convention Center

*This program is provided by Karmanos Cancer Institute and supported by Prothena, Amyloidosis Foundation Amyloidosis Support Group.*

**Chair:**

Jeffrey A. Zonder, MD, Karmanos Cancer Institute, Detroit, MI

**Speakers:**

Rafat Abonour, MD, Indiana University School of Medicine, Indianapolis, IN  
Giada Bianchi, MD, Brigham and Women’s Hospital, Boston, MA  
Eli Muchtar, MD, Mayo Clinic, Rochester, MN  
Laura Obici, MD, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy

Contact: Christiane Houde  
Email: houdec@karmanos.org

---

## FRIDAY LATE AFTERNOON SYMPOSIA: 3:00 P.M. – 6:00 P.M.

### A Rare Day in the Community Hematology Clinic: Interesting Cases in Classical Hematology

**3:00 p.m. – 6:00 p.m.**

**Marriott Grand Ballroom 11-13**  
**Marriott Marquis San Diego Marina**

*This program is provided by Medscape Oncology and supported by Agios and Novartis Oncology.*

**Chair:**

Morag Griffin, FRCPATH, MRCP, St James’s University Hospital, Leeds, United Kingdom

**Speaker:**

Michael R. DeBaun, MD, MPH, Vanderbilt University Medical Center, Nashville, TN

Contact: Harmony Washington  
Email: hwashington@medscapelive.com

---

### Achieving “Next-Level” Care in AML: Conversations on Targeted Platforms, Emerging Immunotherapies, and Implications for Precision Medicine

**3:00 p.m. – 6:00 p.m.**

**Pacific Ballroom Salons 15-17**  
**Marriott Marquis San Diego Marina**

*This program is provided by PVI, PeerView Institute for Medical Education and supported by AbbVie, Actinium Pharmaceuticals, Astellas, Kura Oncology, Inc., and Syndax.*

**Chair:**

Sergio A. Giralt, MD, FACP, Weill Cornell Medical College, Memorial Sloan Kettering Cancer Center, New York, NY
**Friday**  

**SATELLITE SYMPOSIA**  

*All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.*

---

**Speakers:**  
**PINKAL DESAI**, MD, MPH, Weill Cornell Medicine, The New York Presbyterian Hospital, New York, NY  
**GHAYAS C. ISSA**, MD, University of Texas MD Anderson Cancer Center, Houston, TX  
**TAPAN M. KADIA**, MD, University of Texas MD Anderson Cancer Center, Houston, TX  
**SELINA M LUGER**, MD, FRCP, Perelman School of Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA

Contact: Leigh Anne Bongiovanni  
Email: leighanne.bongiovanni@peerview.com

---

**Advances in Autoimmune Hemolytic Anemia: Targeting the Complement Cascade in Cold Agglutinin Disease**

**3:00 p.m. – 6:00 p.m.**  
**San Diego Ballroom AB**  
**Marriott Marquis San Diego Marina**

*This program is provided by Clinical Care Options, LLC and supported by Sanofi.*

**Chair:**  
**CATHERINE BROOME**, MD, Georgetown University, Washington, DC

**Speakers:**  
**DAVID DINGLI**, MD, Mayo Clinic, Rochester, MN  
**DEVA SHARMA**, MD, Vanderbilt University School of Medicine, Nashville, TN

Contact: Ishana Fleurant  
Email: Ifleurant@clinicaloptions.com

---

**Advances in Precision Medicine for Relapsed/Refractory Diffuse Large B-Cell Lymphoma Care**

**3:00 p.m. – 6:00 p.m.**  
**Room 30 A-E**  
**San Diego Convention Center**

*This program is provided by RMEI Medical Education, LLC and supported by an educational grant from Genmab US, Inc. and AbbVie.*

**Chair:**  
**JOSHUA BRODY**, MD, Icahn School of Medicine at Mount Sinai, New York, NY

---

**Advancing cTTP Care Through Integration of the Latest Clinical Evidence**

**3:00 p.m. – 6:00 p.m.**  
**Ballroom 20AB**  
**San Diego Convention Center**

*This program is provided by PRIME Education, LLC and supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.*

**Speakers:**  
**AZRA BOROGOVAC**, MD, City of Hope National Medical Center, Irvine, CA  
**CHRISTINA HAAG, PHARM.D**, University of Illinois at Chicago College of Pharmacy, Chicago, IL  
**LONG ZHENWANG**, MD, PhD, University of Kansas Medical Center, Kansas City, KS

Contact: Eryn Litvinas  
Email: e.litvinas@primeinc.org

---

**AL Amyloidosis: Advancements and Future Trends on Diagnosis and Individualized Treatment Approaches**

**3:00 p.m. – 6:00 p.m.**  
**Pacific Ballroom Salons 21-22**  
**Marriott Marquis San Diego Marina**

*This program is provided by Clinical Care Options, LLC and supported by educational grants from Alexion Pharmaceuticals, Janssen Biotech Inc., administered by Janssen Scientific Affairs LLC, and Prothena.*

**Chair:**  
**ANGELA DISPENZIERI**, MD, Mayo Clinic, Rochester, MN

**Speaker:**  
**ASHUTOSH D. WECHELEKAR**, MBBS, DM, FRCP, FRCPATH, University College London Hospitals, London, United Kingdom

Contact: Ishana Fleurant  
Email: Ifleurant@clinicaloptions.com
Amplifying New and Emerging Clinical Evidence in the Treatment and Management of Myelodysplastic Syndrome

3:00 p.m. – 6:00 p.m.
Room 6DE
San Diego Convention Center

This program is provided by PRIME Education, LLC and supported by Gilead Sciences, Inc.

Chair:
AMER M. ZEIDAN, MBBS, MHS, Yale University, New Haven, CT

Speakers:
DOUGLAS BURGOYNE, PHARM.D, FAMCP, University of Utah, Salt Lake City, UT
RAMI S. KOMROKJI, MD, Moffitt Cancer Center, Tampa, FL

Contact: Eryn Litvinas
Email: e.litvinas@primeinc.org

An Expert Guide to What’s New and What’s Next for Novel Targeted Therapies in Relapsed/Refractory Follicular Lymphoma

3:00 p.m. – 6:00 p.m.
Pacific Ballroom Salons 18-19
Marriott Marquis San Diego Marina

This program is provided by Clinical Care Options, LLC and supported by educational grants from Genentech, a member of the Roche Group, Genmab, Ipsen Biopharmaceuticals, Inc., and Regeneron Pharmaceuticals, Inc.

Chair:
JULIE M. VOSE, MD, MBA, University of Nebraska Medical Center, Omaha, NE

Speakers:
PETER MARTIN, MD, Weill Cornell Medical College, New York, NY
SONALI M. SMITH, University of Chicago, Chicago, IL

Contact: Ishana Fleurant
Email: ifleurant@clinicaloptions.com

BEYOND THE GUIDELINES: Clinical Investigator Perspectives on the Management of Patients with Chronic Lymphocytic Leukemia (Part 3 of a 4-part CME-accredited Symposia Series)

3:00 p.m. – 6:00 p.m.
Grand Ballroom
Omni San Diego

This program is provided by Research To Practice and supported by educational grants from AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Bristol Myers Squibb, and Lilly.

Chair:
NEIL LOVE, MD, Research To Practice, Key Biscayne, FL

Speakers:
FARRUKH T. AWAN, MD, The University of Texas, Dallas, TX
MATTHEW S. DAVIDS, MD, MMSc, Dana-Farber Cancer Institute, Inc., Boston, MA
STEPHEN J. SCHUSTER, MD, University of Pennsylvania, Philadelphia, PA
WILLIAM G. WIERDA, MD, PhD, University of Texas MD Anderson Cancer Center, Houston, TX
JENNIFER A. WOYACH, MD, The Ohio State University Comprehensive Cancer Center, Columbus, OH

Contact: Sylvia Eriksen
Email: meetings@researchtopractice.com

Case Challenges in Myelofibrosis for the Community Clinician

3:00 p.m. – 6:00 p.m.
Marriott Grand Ballroom 5-6
Marriott Marquis San Diego Marina

This program is provided by Medscape Oncology and supported by CTI Biopharma Corp.

Chair:
RUBEN A. MESA, MD, Atrium Health Levine Cancer Institute, Charlotte, NC

Speakers:
ANGELA G. FLEISCHMAN, MD, PhD, University of California, Irvine, Irvine, CA
RAAJIT K. RAMPAL, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY

Contact: Harmony Washington
Email: hwashington@medscapelive.com
Changing the Path of Myelofibrosis: Exploring How We Can Do More for Our Patients

3:00 p.m. – 6:00 p.m.
Marriott Grand Ballroom 8-9
Marriott Marquis San Diego Marina

This program is provided by Medscape Oncology and supported by Morphosys.

Chair:
John Mascarenhas, MD, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY

Speakers:
Claire N Harrison, Guy’s and St. Thomas’ NHS Foundation Trust, London, United Kingdom
Ronald Hoffman, MD, Tisch Cancer Institute, New York, NY
Ann Mullally, MD, Dana-Farber Cancer Institute, Boston, MA

Contact: Harmony Washington
Email: hwashington@medscapelive.com

Comprehensive Approaches to Creating Successful Sickle Cell Management Plans Across Patients’ Lifespans

3:00 p.m. – 6:00 p.m.
Room 6B
San Diego Convention Center

This program is provided by Physicians’ Education Resource, LLC and supported by Vertex Pharmaceuticals.

Chair:
Biree Andemariam, MD, University of Connecticut Health, Farmington, CT

Speakers:
Lydia H. Pecker, MD, Johns Hopkins University School of Medicine, Baltimore, MD
Nirmish Shah, MD, Duke University Medical Center, Durham, NC

Contact: Kelly Donald
Email: kdonald@mjhevents.com

Complement Wheel: Optimizing Care for Patients with aHUS, HSCT-TMA, and PNH

3:00 p.m. – 6:00 p.m.
Marriott Grand Ballroom 2-4
Marriott Marquis San Diego Marina

This program is provided by Medscape Oncology and supported by Alexion Pharmaceuticals, Inc.

Chair:
Irene Weitz, MD, Keck School of Medicine of USC, Los Angeles, CA

Speakers:
Vincent T. Ho, MD, Harvard Medical School, Boston, MA
David J Kuter, MD, DPhIl, Massachusetts General Hospital, Boston, MA

Contact: Harmony Washington
Email: hwashington@medscapelive.com

Putting Your Stamp on the Next Generation of Care in CML – Improving Outcomes from Frontline to R/R Treatment Settings

3:00 p.m. – 6:00 p.m.
Pacific Ballroom Salons 24-26
Marriott Marquis San Diego Marina

This program is provided by Physicians’ Education Resource, LLC and supported by Novartis Pharmaceuticals Corporation.

Chair:
Jorge Cortes, MD, Augusta University, Augusta, GA

Speakers:
Andreas Hochhaus, MD, Universitätsklinikum Jena, Jena, Germany
Amanda Rodriguez, PA-C, Moffitt Cancer Center, Tampa, FL

Contact: Kelly Donald
Email: kdonald@mjhevents.com
Real-World Applications of Asparaginase Formulations in ALL and LBL from Pediatric/AYA to Adult Treatment: Maximizing Clinical Benefits Through Multidisciplinary Care

3:00 p.m. – 6:00 p.m.
Room 6A
San Diego Convention Center

This program is provided by Physicians’ Education Resource, LLC and supported by Jazz Pharmaceuticals, Inc and Servier Pharmaceuticals.

Chair:
RACHEL E. RAU, MD, Texas Children’s Hospital/Baylor College of Medicine, Houston, TX

Speakers:
LAUREN HUANG, DNP, ARNP, PNP-PC, Seattle Children’s Hospital, Seattle, WA
LUKE MAESE, DO, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT
ETAN ORGEL, MD, Keck School of Medicine of USC, Los Angeles, CA

Contact: Kelly Donald
Email: kdonald@mjhevents.com

Toward a Brighter Future for Preventing COVID-19 in Patients With Hematologic Malignancies: Leveraging the Power of Current Strategies and Next-Generation Agents

3:00 p.m. – 6:00 p.m.
Ballroom 20CD
San Diego Convention Center

This program is provided by PVI, PeerView Institute for Medical Education and supported by AstraZeneca LP.

Chair:
SHMUEL SHOHAM, MD, Johns Hopkins University School of Medicine, Baltimore, MD

Speakers:
GHADY HAIDAR, MD, University of Pittsburgh, University of Pittsburgh Medical Center, Pittsburgh, PA
CAROL ANN HUFF, MD, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins School of Medicine, Baltimore, MD

Contact: Leigh Anne Bongiovanni
Email: leighanne.bongiovanni@peerview.com

FRIDAY EVENING SYMPOSIA:
7:00 P.M. – 10:00 P.M.

BEYOND THE GUIDELINES: Clinical Investigator Perspectives on the Management of Patients with Multiple Myeloma (Part 4 of a 4-part CME-accredited Symposia Series)

7:00 p.m. – 10:00 p.m.
Grand Ballroom
Omni San Diego

This program is provided by Research To Practice and supported by educational grants from Abbvie Inc, GSK, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Karyopharm Therapeutics, Legend Biotech, Regeneron Pharmaceuticals Inc, and Sanofi.

Chair:
NEIL LOVE, MD, Research To Practice, Key Biscayne, FL

Speakers:
AMRITA KRISHNAN, MD, City of Hope, Irvine, CA
SAGAR LONIAL, MD, Winship Cancer Institute, School of Medicine, Emory University, Atlanta, GA
ROBERT Z. ORLOWSKI, MD, PHD, University of Texas MD Anderson Cancer Center, Houston, TX
NOOPOOR RAJE, MD, Massachusetts General Hospital Cancer Center, Boston, MA
PAUL G. RICHARDSON, MD, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

Contact: Sylvia Eriksen
Email: meetings@researchtopractice.com
**Friday**

<table>
<thead>
<tr>
<th>Satellite Symposia</th>
<th>08 Dec 2023</th>
</tr>
</thead>
</table>

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

### Evolving Paradigms: Novel Approaches and Best Practices for Hodgkin Lymphoma

**7:00 p.m. – 10:00 p.m.**

**Marriott Grand Ballroom 11-13**  
Marriott Marquis San Diego Marina

_This program is provided by Medscape Oncology and supported by Bristol Myers Squibb, and Seagen._

**Chair:**  
ALEX F. HERRERA, MD, City of Hope, Duarte, CA

**Speakers:**  
PHILIPPE ARMAND, MD, PhD, Dana-Farber Cancer Institute, Boston, MA  
CARLA CASULO, MD, University of Rochester, Rochester, NY

Contact: Harmony Washington  
Email: hwashington@medscapelive.com

### How Do We Treat GvHD Today... And Tomorrow? Treatment Algorithms for Key Decision Points in Prophylaxis Care, Acute, and Chronic Disease

**7:00 p.m. – 10:00 p.m.**  
Pacific Ballroom Salons 24-26  
Marriott Marquis San Diego Marina

_This program is provided by Physicians’ Education Resource, LLC and supported by Incyte Corporation, ST Shared Services LLC, a Mallinckrodt company, and Equillium Bio._

**Chair:**  
COREY CUTLER, Dana-Farber Cancer Institute, Boston, MA

**Speakers:**  
HANNAH CHOE, MD, The Ohio State University Wexner Medical Center, Columbus, OH  
CARRIE L. KITKO, MD, Vanderbilt University, Nashville, TN  
MIGUEL-ANGEL PERALES, MD, Memorial Sloan Kettering Cancer Center, New York, NY

Contact: Kelly Donald  
Email: kdonald@mjhevents.com
PRODUCT THEATERS

Product Theaters as of October 19, 2023.
Check the mobile app for an updated list of Product Theaters.

Product Theaters feature exhibitor presentations on the clinical benefit or scientific research relating to the development of an approved pharmaceutical product and may include information on new uses, combinations, or therapies for the approved product. The Product Theater sessions offered at the times listed below will be solely promotion in nature; therefore, continuing medical education credits will not be offered.

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

SATURDAY

**Sponsored by Johnson & Johnson**

**Frontline Treatment of Newly Diagnosed, Transplant-Ineligible Multiple Myeloma Across Patient Types**

**11:30 a.m. – 12:30 p.m.**
Room 3
San Diego Convention Center

This presentation is intended for U.S. based registered meeting attendees.

For in-person participants only.

Speaker:
Vipin Khare, MD, Johnson & Johnson

**Sponsored by Bristol Myers Squibb**

**Learn More About a CAR T Cell Therapy for Relapsed/Refractory Multiple Myeloma (RRMM)**

**11:30 a.m. – 12:30 p.m.**
Room 2
San Diego Convention Center

This presentation is intended for U.S. based registered meeting attendees.

**For in-person participants only.**

Speakers:
Amani Kitali, MBA, MPH, PMP, Bristol Myers Squibb
Josephine Machado, MSN, APN-C, AOCNP, Bristol Myers Squibb

**Sponsored by Blueprint Medicines**

**The FIRST and ONLY Therapy Approved for Adults with Indolent Systemic Mastocystosis (ISM)**

**11:30 a.m. – 12:30 p.m.**
Room 4
San Diego Convention Center

This presentation is intended for U.S. based registered meeting attendees.

For in-person participants only.

Speaker:
Daniel Shaheen, PharmD, Blueprint Medicines
SUNDAY

**Sponsored by Pfizer**

**A Treatment Option for Relapsed or Refractory Multiple Myeloma from Pfizer**

8:00 a.m. – 9:00 a.m.  
Room 2  
San Diego Convention Center

This presentation is intended for U.S. based registered meeting attendees.  
For in-person participants only.  
**Speaker:**  
Caroline Hoang, PhD, Pfizer

**Sponsored by BioLineRx, Inc.**

**APHEXDA (motixafortide): Learn about this new FDA approved treatment option**

8:00 a.m. – 9:00 a.m.  
Room 3  
San Diego Convention Center

This presentation is intended for U.S. based registered meeting attendees.  
For in-person participants only.  
**Speaker:**  
Ella Sorani, PhD, BioLineRx, Inc.

**Sponsored by Pharming Healthcare Inc.**

**Could there be a Link Between Autoimmune Cytopenias, Lymphadenopathy, and Splenomegaly? A Physician’s Perspective and a Patient’s Experience**

8:00 a.m. – 9:00 a.m.  
Room 4  
San Diego Convention Center

This presentation is intended for U.S. based registered meeting attendees.  
For in-person participants only.  
**Speaker:**  
Anurag Relan, MD, Pharming Healthcare Inc.

**Sponsored by AbbVie Oncology**

**Exploring Time Off Treatment with a BCL-2 Inhibitor**

8:00 a.m. – 9:00 a.m.  
Room 5B  
San Diego Convention Center

This presentation is intended for U.S. based registered meeting attendees.  
For in-person participants only.  
**Speakers:**  
Jalaja Potluri, MD, AbbVie  
Ahmed Kotb, MD, AbbVie

**Sponsored by Genmab and AbbVie**

**Unveiling a Subcutaneous Therapy for 3L+ DLBCL**

8:00 a.m. – 9:00 a.m.  
Room 5A  
San Diego Convention Center

This presentation is intended for U.S. based registered meeting attendees.  
For in-person participants only.  
**Speaker:**  
Samantha Brodkin, DO, MS, Genmab

**Sponsored by Apellis Pharmaceuticals**

**A Complement Inhibitor for PNH**

11:30 a.m. – 12:30 p.m.  
Room 5B  
San Diego Convention Center

This presentation is intended for U.S. based registered meeting attendees.  
For in-person participants only.  
This session will include a patient perspective provided by Louis Hernandez.  
**Speakers:**  
Peter Hillmen, MD, Apellis Pharmaceuticals  
Mary Rowan, RN, BSN, Apellis Pharmaceuticals
<table>
<thead>
<tr>
<th>Time</th>
<th>Location</th>
<th>Event Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:30 a.m. – 12:30 p.m.</td>
<td>Room 5A</td>
<td><strong>Dated by Pfizer</strong></td>
</tr>
<tr>
<td></td>
<td>San Diego Convention Center</td>
<td>A Discussion on a Treatment Option for Sickle Cell Disease</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>For in-person participants only.</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Speaker:</strong> Kim Smith-Whitley, MD, Pfizer</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Janssen invites you to learn about a treatment for adult patients with RRMM who have received at least four prior lines of therapy, including a PI, IMiD, and anti-CD38 monoclonal antibody</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>11:30 a.m. – 12:30 p.m.</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Room 1B</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>San Diego Convention Center</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>This presentation is intended for U.S. based registered meeting attendees.</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>For in-person participants only.</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Speaker:</strong> Anthony Vaganos, MBiotech, GSK</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Sponsored by AstraZeneca</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Long-term Clinical Trial Results for CALQUENCE in the Treatment of All Patients with CLL/SLL</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>11:30 a.m. – 12:30 p.m.</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Room 3</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>San Diego Convention Center</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>This presentation is intended for U.S. based registered meeting attendees.</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>For in-person participants only.</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Speaker:</strong> Vikram Shetty, MD, AstraZeneca</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Sponsored by Bristol Myers Squibb</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Treatment Options in Relapsed Refractory Multiple Myeloma: Clinical Data and Patient Cases</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>11:30 a.m. – 12:30 p.m.</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Room 1A</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>San Diego Convention Center</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>This presentation is intended for U.S. based registered meeting attendees.</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>For in-person participants only.</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Speaker:</strong> Pavit Singh, PharmD, RPh, MBA, Bristol Myers Squibb</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Learn more about a new FDA-approved treatment, OJJAARA (momelotinib)</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>11:30 a.m. – 12:30 p.m.</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Room 4</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>San Diego Convention Center</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>For in-person participants only.</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Speaker:</strong> Anthony Vaganos, MBiotech, GSK</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Sponsored by AstraZeneca</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Long-term Clinical Trial Results for CALQUENCE in the Treatment of All Patients with CLL/SLL</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>11:30 a.m. – 12:30 p.m.</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Room 3</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>San Diego Convention Center</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>For in-person participants only.</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Speaker:</strong> Vikram Shetty, MD, AstraZeneca</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Sponsored by Bristol Myers Squibb</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Treatment Options in Relapsed Refractory Multiple Myeloma: Clinical Data and Patient Cases</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>11:30 a.m. – 12:30 p.m.</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Room 1A</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>San Diego Convention Center</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>This presentation is intended for U.S. based registered meeting attendees.</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>For in-person participants only.</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Speaker:</strong> Pavit Singh, PharmD, RPh, MBA, Bristol Myers Squibb</td>
</tr>
</tbody>
</table>
MONDAY

**Sponsored by Johnson & Johnson**

**A new, first-in-class treatment for RRMM patients**

<table>
<thead>
<tr>
<th>Time</th>
<th>Room</th>
<th>San Diego Convention Center</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 a.m. – 9:00 a.m.</td>
<td>Room 5B</td>
<td></td>
</tr>
</tbody>
</table>

This presentation is intended for U.S. based registered meeting attendees.
For in-person participants only.

**Speaker:**

Saurabh N. Patel, MD, Johnson & Johnson

**Sponsored by Sanofi**

**Achieving Higher Factor VIII Levels in Hemophilia A**

<table>
<thead>
<tr>
<th>Time</th>
<th>Room</th>
<th>San Diego Convention Center</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 a.m. – 9:00 a.m.</td>
<td>Room 3</td>
<td></td>
</tr>
</tbody>
</table>

This presentation is intended for U.S. based registered meeting attendees.
For in-person participants only.

This session will include a patient perspective provided by David, living with Hemophilia A and Sanofi Peer Ambassador.

**Speakers:**

Peter Chen, PhD, Sanofi
Ekta Seth Chhabra, PhD, Sanofi

**Sponsored by Genentech**

**An Advancement in Frontline DLBCL and A Fixed-Duration Treatment Option for 3L+ Diffuse Large B-Cell Lymphoma**

<table>
<thead>
<tr>
<th>Time</th>
<th>Room</th>
<th>San Diego Convention Center</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 a.m. – 9:00 a.m.</td>
<td>Room 1B</td>
<td></td>
</tr>
</tbody>
</table>

For in-person participants only.

**Speaker:**

Jamie H. Hirata, PharmD, Genentech

**Sponsored by Gamida Cell**

**Latest Advancement in Allogeneic Hematopoietic Cell Transplantation**

<table>
<thead>
<tr>
<th>Time</th>
<th>Room</th>
<th>San Diego Convention Center</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 a.m. – 9:00 a.m.</td>
<td>Room 5A</td>
<td></td>
</tr>
</tbody>
</table>

This presentation is intended for U.S. based registered meeting attendees.
For in-person participants only.

**Speaker:**

Ronit Simantov, MD, Gamida Cell

**Sponsored by Bristol Myers Squibb**

**An FDA approved treatment option for anemia in LR-MDS**

<table>
<thead>
<tr>
<th>Time</th>
<th>Room</th>
<th>San Diego Convention Center</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:15 p.m. – 1:15 p.m.</td>
<td>Room 3</td>
<td></td>
</tr>
</tbody>
</table>

This presentation is intended for U.S. based registered meeting attendees.
For in-person participants only.

**Speaker:**

Christina Hughes, PhD, Bristol Myers Squibb

**Sponsored by Johnson & Johnson and Legend Biotech**

**CARVYKTI® Product Summary for Healthcare Providers**

<table>
<thead>
<tr>
<th>Time</th>
<th>Room</th>
<th>San Diego Convention Center</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:15 p.m. – 1:15 p.m.</td>
<td>Room 1B</td>
<td></td>
</tr>
</tbody>
</table>

This presentation is intended for U.S. based registered meeting attendees.
For in-person participants only.

**Speaker:**

Lisa Kallenbach, MD, MPA, Johnson & Johnson
Sponsored by Sanofi

Outcomes and Economic Impact of Treatment with CABLIVI® (caplacizumab-yhdp)

12:15 p.m. – 1:15 p.m.
Room 4
San Diego Convention Center

For in-person participants only.

Speakers:
RAHUL BOHRA, MSc, PhD, Sanofi
ALIX ARNAUD, MSc, Sanofi
Industry Theaters as of October 19, 2023.
Check the mobile app for an updated list of Industry Theaters.

Industry Theater presentations are company developed presentations that highlight medical devices, medical technology, non-FDA approved pharmaceutical products, investigational products or devices in pipeline or clinical trial phases, and patient treatment resources. The Industry Theater sessions offered at the times listed below will be solely promotion in nature; therefore, continuing medical education credits will not be offered.

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

### SATURDAY

**Sponsored by AbbVie (Pharmacyclics)**

**BTK Mutations and the Emergence of Treatment Resistance: Changing the CLL Landscape**

<table>
<thead>
<tr>
<th>Time</th>
<th>Room</th>
<th>Venue</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:30 a.m. – 12:30 p.m.</td>
<td>5A</td>
<td>San Diego Convention Center</td>
</tr>
</tbody>
</table>

For in-person participants only.

**Speaker:**

James P. Dean, MD, PhD, AbbVie

**Sponsored by AstraZeneca**

**COVID-19: Protecting Vulnerable Populations**

<table>
<thead>
<tr>
<th>Time</th>
<th>Room</th>
<th>Venue</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:30 a.m. – 12:30 p.m.</td>
<td>5B</td>
<td>San Diego Convention Center</td>
</tr>
</tbody>
</table>

For in-person participants only.

**Speaker:**

Ketul Patel, PhD, AstraZeneca

**Sponsored by GSK**

**GSK Oncology: Breaking Barriers for Patients with Multiple Myeloma**

<table>
<thead>
<tr>
<th>Time</th>
<th>Room</th>
<th>Venue</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:30 a.m. – 12:30 p.m.</td>
<td>1B</td>
<td>San Diego Convention Center</td>
</tr>
</tbody>
</table>

For in-person participants only.

**Speakers:**

Tania Small, MD, GSK Collegeville PA

Julian Perez Ronco, MD, MBH, MPH, GSK

**Sponsored by Genentech, A Member of the Roche Group**

**Quality of Life, Burden of Illness, and Treatment Burden in Paroxysmal Nocturnal Hemoglobinuria: A Current Perspective on C5 Inhibitors**

<table>
<thead>
<tr>
<th>Time</th>
<th>Room</th>
<th>Venue</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:30 a.m. – 12:30 p.m.</td>
<td>1A</td>
<td>San Diego Convention Center</td>
</tr>
</tbody>
</table>

This presentation is intended for U.S. based registered meeting attendees.

For in-person participants only.

**Speaker:**

John Pasi, MD, PhD, Genentech
SUNDAY

**Sponsored by X4 Pharmaceutical**

**Classical Hematology: Looking into the Future**

8:00 a.m. – 9:00 a.m.
Room 1B
San Diego Convention Center

This presentation is intended for U.S. based registered meeting attendees.
For in-person participants only.
Speaker:  
**Christophe Arbet-Engels**, MD, PhD, X4 Pharmaceutical

**Sponsored by Vertex Pharmaceuticals Inc.**

**The disease burden of transfusion dependent beta-thalassemia and approaches to cell and genetic therapy**

8:00 a.m. – 9:00 a.m.
Room 1A
San Diego Convention Center

This presentation is intended for U.S. based registered meeting attendees.
For in-person participants only.
Speakers:
  - **Aric Parnes**, MD, Vertex Pharmaceuticals Inc.
  - **Tony Botano**, PhD, Vertex Pharmaceuticals Inc.
  - **Nnenna Ukachi**, MD, MPH, Vertex Pharmaceuticals Inc.

MONDAY

**Sponsored by AstraZeneca**

**Emerging AstraZeneca Hematology Pipeline**

12:15 p.m. – 1:15 p.m.
Room 5B
San Diego Convention Center

For in-person participants only.
Speakers:
  - **Alan Yong**, MD, AstraZeneca
  - **Richard Hermann**, MD, AstraZeneca
  - **Vikram Shetty**, MD, AstraZeneca

**Sponsored by Gilead and Kite Oncology**

**Gilead and Kite Oncology Pipeline**

12:15 p.m. – 1:15 p.m.
Room 1A
San Diego Convention Center

This presentation is intended for U.S. based registered meeting attendees.
For in-person participants only.
Speakers:
  - **Carol O’Hear**, MD, PhD, Gilead and Kite Oncology
  - **Rolando Enoch**, MS, Gilead and Kite Oncology
  - **Frank Neumann**, MD, PhD, Gilead and Kite Oncology
  - **Chris McDonald**, MBA, Gilead and Kite Oncology

**Sponsored by Agios Pharmaceuticals, Inc.**

**In Pursuit of Healthier Red Blood Cells: The RISE UP Phase 2/3 Clinical Trial of Mitapivat in Sickle Cell Disease**

12:15 p.m. – 1:15 p.m.
Room 5A
San Diego Convention Center

For in-person participants only.
This session will include a patient perspective provided by Golie Lorenzo Green.
Speakers:
  - **Ahmar U Zaidi**, MD, Agios Pharmaceuticals
  - **Sarah Gheuens**, MD, PhD, Agios Pharmaceuticals
COMPANY SHOWCASES

Check the mobile app for an updated list of Company Showcases.

Company Showcase presentations are 15-minute promotional presentations that provide an overview of the companies’ services, pipeline products, clinical trials, or mission-based initiatives for a company, non-profit organization, or contract/clinical research organization. The Company Showcase sessions offered at the times listed below will be solely promotion in nature; therefore, continuing medical education credits will not be offered.

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

SATURDAY

Sponsored by Galapagos

Galapagos’ 7 Day Vein-to-Vein Point-of-Care CAR-T Manufacturing Model (non-CME)

<table>
<thead>
<tr>
<th>1:30 p.m. – 1:45 p.m.</th>
<th>Room 5A</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>San Diego Convention Center</td>
</tr>
</tbody>
</table>

For in-person participants only.

Speakers:
- Ruiz Astigarraga, MSc, Galapagos
- Jacqueline Vink-Korndorffer, MSc, Galapagos

Sponsored by GRAIL LLC

Showcase on Galleri®, a Multi-Cancer Early Detection Test (non-CME)

<table>
<thead>
<tr>
<th>1:30 p.m. – 1:45 p.m.</th>
<th>Room 5B</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>San Diego Convention Center</td>
</tr>
</tbody>
</table>

This presentation is intended for U.S. based registered meeting attendees.

For in-person participants only.

Speaker:
- Rita Shaknovich, MD, PhD, GRAIL, LLC

Sponsored by Precision NanoSystems

Genetic Engineering of T Cells and CD34+ HSPCs using RNA-Lipid Nanoparticle for Cell and Gene Therapies (non-CME)

<table>
<thead>
<tr>
<th>3:30 p.m. – 3:45 p.m.</th>
<th>Room 5B</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>San Diego Convention Center</td>
</tr>
</tbody>
</table>

For in-person participants only.

Speaker:
- Angela Zhang, PhD, Precision NanoSystems

Sponsored by Syndax Pharmaceuticals

Reimagining Cancer Care at Syndax: Clinical Development of Targeted Therapies (non-CME)

<table>
<thead>
<tr>
<th>3:30 p.m. – 3:45 p.m.</th>
<th>Room 5A</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>San Diego Convention Center</td>
</tr>
</tbody>
</table>

For in-person participants only.

Speakers:
- Neil Gallagher, MD, PhD, Syndax Pharmaceuticals
- Kate Madigan, MD, Syndax Pharmaceuticals
SUNDAY

Sponsored by Halia Therapeutics

Halia Therapeutics- Targeting the Chronic Inflammatory Bone Marrow Microenvironment

4:00 p.m. – 4:15 p.m.
Room 5B
San Diego Convention Center

This presentation is intended for U.S. based registered meeting attendees.
For in-person participants only.

Speakers:
David Bearss, PhD, Halia Therapeutics
Alan List, MD, Halia Therapeutics
<table>
<thead>
<tr>
<th>Exhibitors</th>
<th>Booth Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>AbbVie</td>
<td>309</td>
</tr>
<tr>
<td>Acrotech Biopharma</td>
<td>2100</td>
</tr>
<tr>
<td>Actinium Pharmaceuticals</td>
<td>2033</td>
</tr>
<tr>
<td>Adaptive Biotechnologies Corporation</td>
<td>2129</td>
</tr>
<tr>
<td>ADC Therapeutics</td>
<td>1325</td>
</tr>
<tr>
<td>Agios Pharmaceuticals</td>
<td>133</td>
</tr>
<tr>
<td>Aixial</td>
<td>2450</td>
</tr>
<tr>
<td>Allogene Therapeutics</td>
<td>3205</td>
</tr>
<tr>
<td>Alpine Immune Sciences</td>
<td>3443</td>
</tr>
<tr>
<td>American Association for Cancer Research</td>
<td>200</td>
</tr>
<tr>
<td>American Society for Transplantation and Cellular Therapy (ASTCT)</td>
<td>2120</td>
</tr>
<tr>
<td>American Society of Gene and Cell Therapy (ASGCT)</td>
<td>11</td>
</tr>
<tr>
<td>American Society of Hematology</td>
<td>1215, Virtual</td>
</tr>
<tr>
<td>American Society of Pediatric Hematology Oncology (ASPHO)</td>
<td>23</td>
</tr>
<tr>
<td>Amgen</td>
<td>833</td>
</tr>
<tr>
<td>Amyloidosis Foundation</td>
<td>2056</td>
</tr>
<tr>
<td>Amyloidosis Support Groups</td>
<td>37</td>
</tr>
<tr>
<td>Apellis Pharmaceuticals</td>
<td>615, 714</td>
</tr>
<tr>
<td>Aplastic Anemia and MDS International Foundation, Inc.</td>
<td>2130</td>
</tr>
<tr>
<td>AplusA</td>
<td>1849</td>
</tr>
<tr>
<td>Applied Cells</td>
<td>3447</td>
</tr>
<tr>
<td>Aptitude Health</td>
<td>2257</td>
</tr>
<tr>
<td>Aptose Biosciences Inc.</td>
<td>505</td>
</tr>
<tr>
<td>ArccellX</td>
<td>748</td>
</tr>
<tr>
<td>argenx</td>
<td>3318</td>
</tr>
<tr>
<td>ARUP Laboratories</td>
<td>2453</td>
</tr>
<tr>
<td>Ascentage Pharma</td>
<td>3355</td>
</tr>
<tr>
<td>Association for Value-Based Cancer Care</td>
<td>16</td>
</tr>
<tr>
<td>Association of PAs in Oncology</td>
<td>Virtual</td>
</tr>
<tr>
<td>Association of Public Health Laboratories</td>
<td>29</td>
</tr>
<tr>
<td>Astellas Pharma US, Inc.</td>
<td>2311</td>
</tr>
<tr>
<td>Astex Pharmaceuticals, Inc.</td>
<td>1549</td>
</tr>
<tr>
<td>AstraZeneca</td>
<td>1433</td>
</tr>
<tr>
<td>Atara Biotherapeutics, Inc.</td>
<td>1456</td>
</tr>
</tbody>
</table>
AVM Biotechnology LLC
Bayer
Beam Therapeutics
Beckman Coulter Life Sciences
BeiGene USA
Binaytara Foundation
Binding Site, Inc.
Bio Products Laboratory USA, Inc. 2022, 2026
Biognosys
BioIVT
BioLineRx, Inc.
BioMarin Pharmaceutical Inc.
Biomea Fusion, Inc
BioSkryb Genomics
BioSpyder
Blood Cancers Today / Mashup Media
Blue Spark Technologies, Inc.
bluebird bio 743, 756
Blueprint Medicines
BostonGene
Brazilian Association of Hematology, Hemotherapy And Cell Therapy (AHHH) 40
Bristol Myers Squibb 2609, Virtual
Cardinal Health
Caribou Biosciences, Inc.
Cellular Highways Ltd
Centessa Pharmaceuticals
Certara
Children's Hospital of Philadelphia 3348
CIBMTR (Center for International Blood & Marrow Transplant Research) 2118
Citius Pharmaceuticals
City of Hope Comprehensive Cancer Center
Cleveland Clinic Taussig Cancer Institute
Clinical Advances in Hematology and Oncology 2801
CLL Society 7, Virtual
Cogent Biosciences
College of American Pathologists
Cooley’s Anemia Foundation Virtual
CRISPR Therapeutics
Cryoport Systems
CSL Behring
Curis, Inc.
Cytiva
<table>
<thead>
<tr>
<th>Company Name</th>
<th>Booth Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>D2V Clinical, Inc.</td>
<td>3446</td>
</tr>
<tr>
<td>Daiichi Sankyo</td>
<td>2819</td>
</tr>
<tr>
<td>Dana-Farber Cancer Institute</td>
<td>2900</td>
</tr>
<tr>
<td>DAVA Oncology</td>
<td>1156, 1157</td>
</tr>
<tr>
<td>Diagenode, Inc.</td>
<td>2132</td>
</tr>
<tr>
<td>Diamond Blackfan Anemia Canada</td>
<td>19</td>
</tr>
<tr>
<td>Diamond Blackfan Anemia Foundation Inc.</td>
<td>20</td>
</tr>
<tr>
<td>Doximity</td>
<td>2355</td>
</tr>
<tr>
<td>Edenbridge Pharmaceuticals, LLC</td>
<td>2016</td>
</tr>
<tr>
<td>Editas Medicine</td>
<td>2152</td>
</tr>
<tr>
<td>Elsevier</td>
<td>2605</td>
</tr>
<tr>
<td>Emmaus Medical, Inc.</td>
<td>3305</td>
</tr>
<tr>
<td>Emmes Company LLC</td>
<td>2356</td>
</tr>
<tr>
<td>Enable Injections</td>
<td>405</td>
</tr>
<tr>
<td>EpiCypher</td>
<td>3442</td>
</tr>
<tr>
<td>Eurasian Hematology Oncology Group</td>
<td>39</td>
</tr>
<tr>
<td>Eurofins Viracor</td>
<td>3405</td>
</tr>
<tr>
<td>European Hematology Association</td>
<td>2449</td>
</tr>
<tr>
<td>Flagship Biosciences</td>
<td>3349</td>
</tr>
<tr>
<td>Flatiron Health</td>
<td>3156</td>
</tr>
<tr>
<td>Florida Cancer Specialists &amp; Research Institute</td>
<td>3145</td>
</tr>
<tr>
<td>Food And Drug Administration - Center for Biologics Evaluation And Research</td>
<td>34</td>
</tr>
<tr>
<td>Foresight Diagnostics</td>
<td>2014</td>
</tr>
<tr>
<td>Fortrea</td>
<td>3242</td>
</tr>
<tr>
<td>Foundation for Sickle Cell Disease Research</td>
<td>5</td>
</tr>
<tr>
<td>Foundation for the Accreditation of Cellular Therapy (FACT)</td>
<td>12</td>
</tr>
<tr>
<td>Foundation for Women &amp; Girls with Blood Disorders</td>
<td>21</td>
</tr>
<tr>
<td>Foundation Medicine</td>
<td>3203</td>
</tr>
<tr>
<td>Fred Hutchinson Cancer Center</td>
<td>3337</td>
</tr>
<tr>
<td>Fulcrum Therapeutics</td>
<td>752</td>
</tr>
<tr>
<td>Fugent Oncology</td>
<td>3345</td>
</tr>
<tr>
<td>Galapagos</td>
<td>3419</td>
</tr>
<tr>
<td>Gamida Cell</td>
<td>2653, 2752</td>
</tr>
<tr>
<td>Genentech</td>
<td>333</td>
</tr>
<tr>
<td>Genmab</td>
<td>3029</td>
</tr>
<tr>
<td>Genmab - Patient Support Services</td>
<td>2945</td>
</tr>
<tr>
<td>Genomic Testing Cooperative</td>
<td>3315</td>
</tr>
<tr>
<td>GenPath</td>
<td>142</td>
</tr>
<tr>
<td>GenScript ProBio USA Inc</td>
<td>2155</td>
</tr>
<tr>
<td>Geron Inc.</td>
<td>1251</td>
</tr>
<tr>
<td>Gilead and Kite Oncology</td>
<td>1415</td>
</tr>
<tr>
<td>Global Pediatric MDS Initiative</td>
<td>31</td>
</tr>
<tr>
<td>EXHIBITORS</td>
<td></td>
</tr>
<tr>
<td>--------------------------------------------------------------------------</td>
<td>---</td>
</tr>
<tr>
<td>GRAIL</td>
<td>1326</td>
</tr>
<tr>
<td>GSK</td>
<td>1814</td>
</tr>
<tr>
<td>Gundersen Health System</td>
<td>4</td>
</tr>
<tr>
<td>Halia Therapeutics</td>
<td>2254</td>
</tr>
<tr>
<td>Harborside</td>
<td>3253</td>
</tr>
<tr>
<td>Haymarket Oncology</td>
<td>2614</td>
</tr>
<tr>
<td>HCU Network America</td>
<td>Virtual</td>
</tr>
<tr>
<td>Healgen Scientific LLC</td>
<td>754</td>
</tr>
<tr>
<td>HealthTree Foundation</td>
<td>24</td>
</tr>
<tr>
<td>HealthWell Foundation</td>
<td>32</td>
</tr>
<tr>
<td>HEMA Biologics</td>
<td>1853</td>
</tr>
<tr>
<td>Hemophilia Federation of America (HFA)</td>
<td>17</td>
</tr>
<tr>
<td>Horizon Therapeutics</td>
<td>3416</td>
</tr>
<tr>
<td>Hospital Information Services for Jehovah’s Witnesses (USA)</td>
<td>33</td>
</tr>
<tr>
<td>Ichnos Sciences</td>
<td>305</td>
</tr>
<tr>
<td>ICON plc</td>
<td>3249</td>
</tr>
<tr>
<td>Imaging Endpoints II, LLC</td>
<td>104</td>
</tr>
<tr>
<td>Incyte Corporation</td>
<td>1233</td>
</tr>
<tr>
<td>Intermountain Health</td>
<td>3303</td>
</tr>
<tr>
<td>International Myeloma Foundation</td>
<td>3351</td>
</tr>
<tr>
<td>International Myeloma Society</td>
<td>2</td>
</tr>
<tr>
<td>International Society on Thrombosis and Haemostasis (ISTH)</td>
<td>8</td>
</tr>
<tr>
<td>Intrinsic LifeSciences</td>
<td>2020</td>
</tr>
<tr>
<td>Invivoscribe, Inc.</td>
<td>349</td>
</tr>
<tr>
<td>iProcess Global Research Inc</td>
<td>3438</td>
</tr>
<tr>
<td>Ipsen Biopharmaceuticals</td>
<td>1453</td>
</tr>
<tr>
<td>IQVIA Biotech</td>
<td>2151</td>
</tr>
<tr>
<td>Italian Society of Hematology</td>
<td>1449</td>
</tr>
<tr>
<td>JAMA Network</td>
<td>301</td>
</tr>
<tr>
<td>Johnson &amp; Johnson Innovative Medicine</td>
<td>1033, 1225, 1324</td>
</tr>
<tr>
<td>Jazz Pharmaceuticals, Inc.</td>
<td>2419</td>
</tr>
<tr>
<td>John Theurer Cancer Center</td>
<td>401</td>
</tr>
<tr>
<td>Kaiser Permanente/ The Southeast Permanente Medical Group</td>
<td>3445</td>
</tr>
<tr>
<td>Karyopharm Therapeutics Inc.</td>
<td>733</td>
</tr>
<tr>
<td>Kindstar Globalgene (HK) Limited</td>
<td>3448</td>
</tr>
<tr>
<td>Kura Oncology</td>
<td>2701</td>
</tr>
<tr>
<td>Kyan Technologies PTE LTD</td>
<td>3457</td>
</tr>
<tr>
<td>Kyowa Kirin, Inc.</td>
<td>1949</td>
</tr>
<tr>
<td>Labcorp Oncology</td>
<td>2753</td>
</tr>
<tr>
<td>Larvol</td>
<td>3347</td>
</tr>
<tr>
<td>Legend Biotech</td>
<td>3005</td>
</tr>
<tr>
<td>Leukemia Research Foundation</td>
<td>1</td>
</tr>
<tr>
<td>Exhibitor</td>
<td>Booth</td>
</tr>
<tr>
<td>-----------------------------------------------</td>
<td>-------</td>
</tr>
<tr>
<td>Loxo@Lilly</td>
<td>2729, Virtual</td>
</tr>
<tr>
<td>Lunaphore Technologies</td>
<td>3453</td>
</tr>
<tr>
<td>Machaon Diagnostics, Inc.</td>
<td>3055</td>
</tr>
<tr>
<td>Mallinckrodt Pharmaceuticals</td>
<td>3412</td>
</tr>
<tr>
<td>Mayo Clinic Laboratories</td>
<td>3415</td>
</tr>
<tr>
<td>Mayo Clinic Referring Provider Office</td>
<td>2041</td>
</tr>
<tr>
<td>MD Anderson Cancer Center</td>
<td>122</td>
</tr>
<tr>
<td>MDOutlook</td>
<td>3219</td>
</tr>
<tr>
<td>Mechatronics Instruments B.V.</td>
<td></td>
</tr>
<tr>
<td>Med Learning Group</td>
<td>755, 2545</td>
</tr>
<tr>
<td>Medexus Pharma</td>
<td>2502</td>
</tr>
<tr>
<td>Medidata, a Dassault Systèmes company</td>
<td>2142</td>
</tr>
<tr>
<td>Medpace Inc.</td>
<td>136</td>
</tr>
<tr>
<td>Medscape Oncology &amp; Hematology</td>
<td>2340</td>
</tr>
<tr>
<td>Melinta Therapeutics</td>
<td>3257</td>
</tr>
<tr>
<td>Menarini Silicon Biosystems</td>
<td>555</td>
</tr>
<tr>
<td>Menarini Stemline</td>
<td>1047</td>
</tr>
<tr>
<td>Merck &amp; Co., Inc.</td>
<td>2111</td>
</tr>
<tr>
<td>Miltenyi Biotec</td>
<td>3329</td>
</tr>
<tr>
<td>Mission Bio</td>
<td>2015</td>
</tr>
<tr>
<td>MJH Life Sciences</td>
<td>2019</td>
</tr>
<tr>
<td>MLM Medical Labs</td>
<td>604</td>
</tr>
<tr>
<td>Moffitt Cancer Center</td>
<td>655</td>
</tr>
<tr>
<td>MorphoSys</td>
<td>2405</td>
</tr>
<tr>
<td>Multiple Myeloma Research Foundation</td>
<td>22</td>
</tr>
<tr>
<td>National Comprehensive Cancer Network (NCCN)</td>
<td>13</td>
</tr>
<tr>
<td>National Heart, Lung, and Blood Institute</td>
<td>2401</td>
</tr>
<tr>
<td>NeoGenomics Laboratories</td>
<td>851</td>
</tr>
<tr>
<td>NMDP</td>
<td>2112</td>
</tr>
<tr>
<td>Northside Hospital</td>
<td>2105</td>
</tr>
<tr>
<td>Northwell Health</td>
<td>2029</td>
</tr>
<tr>
<td>Notable Labs</td>
<td>2454</td>
</tr>
<tr>
<td>Novartis</td>
<td>2429</td>
</tr>
<tr>
<td>Novo Nordisk</td>
<td>619</td>
</tr>
<tr>
<td>NURIX</td>
<td>821</td>
</tr>
<tr>
<td>Omeros Corporation</td>
<td>2305</td>
</tr>
<tr>
<td>ONO PHARMA</td>
<td>243</td>
</tr>
<tr>
<td>OPTOLANE Technologies, Inc.</td>
<td>2027</td>
</tr>
<tr>
<td>Ossium Health, Inc.</td>
<td>300</td>
</tr>
<tr>
<td>OxyDial Inc</td>
<td>2501</td>
</tr>
<tr>
<td>Parexel</td>
<td>449</td>
</tr>
<tr>
<td>Pfizer</td>
<td>1832</td>
</tr>
<tr>
<td>Company Name</td>
<td>Booth Number</td>
</tr>
<tr>
<td>--------------------------------------------</td>
<td>--------------</td>
</tr>
<tr>
<td>PharmaEssentia Corporation</td>
<td>2915</td>
</tr>
<tr>
<td>Pharming Healthcare, Inc.</td>
<td>2250</td>
</tr>
<tr>
<td>Platelet Disorder Support Association</td>
<td>10</td>
</tr>
<tr>
<td>PlatformQ Health</td>
<td>116</td>
</tr>
<tr>
<td>Precision for Medicine</td>
<td>649</td>
</tr>
<tr>
<td>Precision NanoSystems</td>
<td>2255</td>
</tr>
<tr>
<td>Premier Research</td>
<td>2148</td>
</tr>
<tr>
<td>ProPharma Group</td>
<td>3343</td>
</tr>
<tr>
<td>Protagonist Therapeutics, Inc</td>
<td>2122</td>
</tr>
<tr>
<td>PROTEINA Co., LTD.</td>
<td>3455</td>
</tr>
<tr>
<td>Proteintech</td>
<td>2852</td>
</tr>
<tr>
<td>Prothena</td>
<td>400</td>
</tr>
<tr>
<td>PSI CRO</td>
<td>3352</td>
</tr>
<tr>
<td>Q2 Solutions</td>
<td>2548</td>
</tr>
<tr>
<td>Rapid Novor Inc.</td>
<td>1548</td>
</tr>
<tr>
<td>Rare Disease Therapeutics, Inc.</td>
<td>1355</td>
</tr>
<tr>
<td>Recordati Rare Diseases</td>
<td>2500</td>
</tr>
<tr>
<td>Recordati Rare Diseases – Medical</td>
<td>3001</td>
</tr>
<tr>
<td>Regeneron Pharmaceuticals</td>
<td>633</td>
</tr>
<tr>
<td>Rigel Pharmaceuticals</td>
<td>2805</td>
</tr>
<tr>
<td>Roswell Park Comprehensive Cancer Center</td>
<td>3411</td>
</tr>
<tr>
<td>Rutgers Cancer Institute of New Jersey/RWJBarnabas Health</td>
<td>3150</td>
</tr>
<tr>
<td>Sanofi</td>
<td>915</td>
</tr>
<tr>
<td>Sanofi</td>
<td>3429</td>
</tr>
<tr>
<td>Sarah Cannon Research Institute</td>
<td>2104</td>
</tr>
<tr>
<td>Seagen</td>
<td>117, 355</td>
</tr>
<tr>
<td>Sebia</td>
<td>2455</td>
</tr>
<tr>
<td>Secura Bio Inc.</td>
<td>3321</td>
</tr>
<tr>
<td>SeQure Dx</td>
<td>3449</td>
</tr>
<tr>
<td>Servier Pharmaceuticals</td>
<td>1347</td>
</tr>
<tr>
<td>Shanghai Model Organisms Center</td>
<td>2550</td>
</tr>
<tr>
<td>Shield Therapeutics</td>
<td>2745</td>
</tr>
<tr>
<td>Shwachman-Diamond Syndrome Foundation</td>
<td>27</td>
</tr>
<tr>
<td>Sight Diagnostics</td>
<td>1357</td>
</tr>
<tr>
<td>Silence Therapeutics</td>
<td>3057</td>
</tr>
<tr>
<td>Sobi, Inc.</td>
<td>105, 2028</td>
</tr>
<tr>
<td>Society for Immunotherapy of Cancer (SITC)</td>
<td>18</td>
</tr>
<tr>
<td>Society of Hematologic Oncology</td>
<td>2552</td>
</tr>
<tr>
<td>Spark Therapeutics, Inc.</td>
<td>549</td>
</tr>
<tr>
<td>Stanford Cancer Institute</td>
<td>3436</td>
</tr>
<tr>
<td>Star Therapeutics</td>
<td>2157</td>
</tr>
<tr>
<td>STARCELL Technologies</td>
<td>118</td>
</tr>
<tr>
<td>Company</td>
<td>Number</td>
</tr>
<tr>
<td>---------------------------------------------</td>
<td>--------</td>
</tr>
<tr>
<td>Sumitomo Pharma Oncology</td>
<td>143</td>
</tr>
<tr>
<td>Sutro Biopharma</td>
<td>302</td>
</tr>
<tr>
<td>Sutter Health – Bay Area</td>
<td>3244</td>
</tr>
<tr>
<td>Syndax Pharmaceuticals, Inc.</td>
<td>2400</td>
</tr>
<tr>
<td>Syneos Health</td>
<td>1555</td>
</tr>
<tr>
<td>Syros</td>
<td>2804</td>
</tr>
<tr>
<td>Taiho</td>
<td>827, 2141</td>
</tr>
<tr>
<td>Takeda Hematology</td>
<td>2321</td>
</tr>
<tr>
<td>Takeda Oncology</td>
<td>2229</td>
</tr>
<tr>
<td>Team Telomere</td>
<td>30</td>
</tr>
<tr>
<td>Telo Genomics</td>
<td>404</td>
</tr>
<tr>
<td>Tempus Labs, Inc.</td>
<td>3051</td>
</tr>
<tr>
<td>The Japanese Society of Hematology</td>
<td>9</td>
</tr>
<tr>
<td>The Leukemia &amp; Lymphoma Society</td>
<td>2705</td>
</tr>
<tr>
<td>The MDS Foundation, Inc.</td>
<td>3</td>
</tr>
<tr>
<td>Theradex Oncology</td>
<td>815</td>
</tr>
<tr>
<td>ThermoFisher</td>
<td>727</td>
</tr>
<tr>
<td>ThinkCyte, Inc.</td>
<td>140</td>
</tr>
<tr>
<td>Trinity Biotech</td>
<td>3000</td>
</tr>
<tr>
<td>Turkish Society of Hematology</td>
<td>6</td>
</tr>
<tr>
<td>TwinStrand Biosciences</td>
<td>3143</td>
</tr>
<tr>
<td>U.S. Department of State Bureau of Medical Services</td>
<td>38</td>
</tr>
<tr>
<td>UC San Diego Hemophilia and Thrombosis Treatment Center</td>
<td>25</td>
</tr>
<tr>
<td>UCI Health</td>
<td>28</td>
</tr>
<tr>
<td>University of Chicago – Data for the Common Good</td>
<td>41</td>
</tr>
<tr>
<td>Vaniem Group</td>
<td>3149</td>
</tr>
<tr>
<td>Vertex Pharmaceuticals Inc.</td>
<td>715, 841</td>
</tr>
<tr>
<td>Viracta Therapeutics</td>
<td>504</td>
</tr>
<tr>
<td>wAIHA Warriors</td>
<td>36</td>
</tr>
<tr>
<td>Waldenstrom’s Macroglobulinemia Foundation</td>
<td>15</td>
</tr>
<tr>
<td>Wolters Kluwer</td>
<td>2301</td>
</tr>
<tr>
<td>Worldwide Clinical Trials</td>
<td>3313</td>
</tr>
<tr>
<td>X4 Pharmaceuticals</td>
<td>501, 1957</td>
</tr>
<tr>
<td>Xcene Research</td>
<td>2515</td>
</tr>
</tbody>
</table>
CD47-Blocking Agents:

Emerging Checkpoint Inhibitor Approach in Hematologic Malignancies

CD47 signaling has been shown to inhibit phagocytosis and promotes tumor cell immune evasion

1. CD47, or integrin-associated protein, is a cell-surface ligand expressed at low levels by nearly all cells of the body.
2. CD47 signaling can be overexpressed in various hematologic malignancies and expressed by cells within the tumor microenvironment.
3. Its interaction with signal regulatory protein (SIRP)α on phagocytic cells sends an inhibitory “Don’t eat me” signal that is known to prevent phagocytosis of the tumor cell.
4. Overexpression of CD47 is thus often associated with poor clinical outcomes.

CD47 blockade may enhance phagocytosis and may promote antitumor activity

1. CD47-blocking agents can bind to CD47 on tumor cells and prevent it from delivering its inhibitory signal to phagocytic cells.
2. Some CD47-blocking agents in development include an Fc region from human IgG, which may potentially generate a prophagocytic signal.

CD47 blockade may promote both innate and adaptive immunity

1. Upon engulfment, the antigen-presenting cell (APC) presents antigens from the engulfed tumor cells, potentially leading to T-cell activation and tumor cell lysis.

VISIT US AT BOOTH #1832 TO LEARN MORE

CD, cluster of differentiation; Fc, fragment crystallizable; FcγR, Fc gamma receptor; IgG, immunoglobulin G.

This document contains medical information concerning a mechanism still under investigation.
DISCOVER THE CURRENT
OF CALQUENCE

Follow the current to the latest long-term efficacy and safety data, now with up to ~6 years of median follow-up*1

Visit Booth #1433
at the 2023 ASH Annual Meeting

*At median 74.5-month follow-up (range: 0.0-89.0 months).1